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Abstract 
Antimicrobial resistance (AMR) presents a global threat to human and animal 
health. Southeast Asia (SEA) is seen as a potential hotspot for the emergence and 
dissemination of new resistance mechanisms. The World Health Organization 
highlights research on multi-drug resistant Gram-negative bacteria 
(Enterobacteriaceae, Acinetobacter and Pseudomonas spp) as a critical priority. 
 
This study reports findings from Brunei Darussalam. A molecular epidemiological 
surveillance study conducted using contemporary MDR Escherichia coli, Klebsiella 
pneumoniae, A. baumannii and P. aeruginosa of human and avian (farmed 
poultry) origin. Resistance to carbapenems and polymyxins was investigated using 
phenotypic (susceptibility, serotyping) and genotypic (PCR, sequencing, typing) 
methods. A selective bacterial culture media was developed and evaluated as a 
screening media for polymyxin-resistant (PR) strains. Immunochromatographic 
assays were used in the rapid identification of novel resistance determinants 
(OXA-48-like, MCR-1). Pathogenicity, fitness and virulence was correlated with 
host strain background and the carriage of AMR plasmids by resistant isolates.  
 
Carbapenem-resistant (CR) A. baumannii were prevalent amongst hospital 
isolates and produced OXA-23 carbapenemases, similar to those reported 
worldwide. CR K. pneumoniae (CRKP) with plasmid encoded OXA-232 
carbapenemase were found as part of a hospital outbreak. All identified as 
members of sequence type 231, a hi-risk epidemic clone in SEA. In separate point 
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prevalence studies, polymyxin resistant E. coli were found in 58% of poultry and 
41.7% of human faecal samples. All produced phosphoethanolamine transferases 
encoded by mcr genes supported by diverse plasmid backbones (IncHI2, IncI2, 
IncX4) and host strain sequence types (n= 40).  Additionally, a novel variant, mcr-
1.8, localised on a 63,056 bp IncI2 conjugative plasmid was identified and 
characterized in E. coli O88:H31 ST101. PR strains were co-resistant to quinolones, 
aminoglycosides and phenicols. CTX-M β-lactamases (CTX-M-3 and CTX-M-65) 
were found in 2 strains but none co-produced a carbapenemase. 
 
Comparison of human and avian MCR producing E. coli revealed only 6 sequence 
types were common to both humans and poultry. Polymyxin resistant strains 
harboured multiple virulence factors (VF) but no Avian Pathogenic (APEC) or Shiga 
Toxin (STEC) producing strains were found. Virulence of human and poultry 
isolates assessed in a Galleria mellonella infection model showed differences in 
survival rates that did not correlate with virulence score. When virulence of 
polymyxin resistant transconjugants (TC) was assessed only one which encoded 
MCR-1.8 exhibited heightened virulence. Growth kinetics showed no obvious 
differences despite plasmid acquisition. 
 
This study demonstrates the high rate of resistance to carbapenems and 
polymyxins in critical Gram-negative bacteria in Brunei Darussalam. Plasmid-
mediated polymyxin resistance in E. coli was found to be endemic in poultry and 
highly prevalent in the human samples studied. Unlike carbapenem resistance, 
polymyxin resistance was not associated with any predominant clone and did not 
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readily correlate with virulence properties of the strain. However, given the high 
background rates, enhanced surveillance for MCR-1 within more virulent 
Enterobacterial backgrounds is warranted, particularly in Southeast Asia 
countries.  
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Chapter 1 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
31 
1.1 Antimicrobial Resistance (AMR) 
1.1.1 Antimicrobial resistance (AMR): an end of the antibiotic era? 
Antimicrobial resistance (AMR) poses a major threat to public health in the 21st 
century (Woolhouse and Farrar, 2014). According to a Lord Jim O’Neill, a leading 
UK economist, tasked with analyzing the global problem of rising drug resistance, 
whereby in 2050 the attributable number of deaths caused by AMR every year is 
predicted to rise to 10 million people (O’Neill, 2014). AMR deaths will exceed 
diseases caused by cancer, cholera, diabetes, diarrheal disease, measles, tetanus 
and road traffic accidents (O’Neill, 2014). The World Health Organization (WHO) 
further emphasized that AMR threatens the ability to treat common infectious 
diseases, resulting in prolonged illness, disability and death (WHO, 2018). 
 
A highly diverse collection of genes encoding resistance to antibiotics (β-lactam, 
tetracycline and glycopeptide) have been found from an ancient DNA of 30,000-
year-old Beringian permafrost sediments samples, this shows that antibiotic use 
and misuse favor resistance through selection pressure (D'Costa et al., 2011). The 
first synthetic antibiotic used systemically and paved the way for the antibiotic 
revolution in medicine was sulfonamide drugs (Skold, 2000). However, in the late 
1930s, sulfonamide resistance was reported (Skold, 2000). In the late 1940s, the 
naturally occurring antibiotic benzylpenicillin (Penicillin G) discovered by Sir 
Alexander Fleming in 1928, recovered from the mold Penicillium notatum was also 
short lived due to resistance (Piddock, 2012; Sengupta et al., 2013). Since then, 
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resistance has developed in every major class of antibiotics (polymyxins, 
tetracyclines, carbapenems, cephalosporins, tigecyclines) (Figure 1). 
 
The AMR crisis is further magnified with the movement of resistance genes 
through plasmid-mediated horizontal gene transfer (HGT) between different 
bacterial species which increases the variety of bacterial populations possessing 
multidrug-resistant (MDR) potential (Holmes et al., 2016). The various mechanism 
of HGT for which exchange of genetic information takes place includes 
transformation (extracellular donor DNA taken up recipient bacterium), 
transduction (donor DNA packaged in bacteriophage infects the recipient 
bacterium) and conjugation (through mating the donor bacterium transfer DNA to 
the recipient) (Carroll et al., 2016). In addition, the spread of bacteria carrying 
resistance genes through vertical transfer (from mother to daughter cells) are also 
known as clones (Woodford et al., 2011). More importantly are the high-risk 
clones which are able to disseminate resistance gene globally (Woodford et al., 
2011). 
 
 
 
 
 
 
 
33 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Timeline of antibiotic introduced and the development of resistance. R- resistance. Adapted from (CDC, 2013). 
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1.1.2 AMR a global problem 
With increasing numbers of carbapenem-resistant pathogen, in 2017 the 
coordinating group of the Member States (Israel, Switzerland, Sweden, 
Netherlands, South Africa, France, USA and Austria) were tasked by the WHO after 
their request to develop a global priority pathogen list (Table 1) of antibiotic-
resistant bacteria to help in prioritizing the research and development (R&D) of 
new and effective antibiotic treatments (WHO, 2017a). The criteria for 
prioritization was as follows; all-cause mortality, healthcare and community 
burden, prevalence of resistance, 10-year trend of resistance, transmissibility, 
preventability in hospital and community settings, treatability and current pipeline 
(WHO, 2017a).
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1. Critical priority 
i. Acinetobacter baumannii, carbapenem-resistant 
ii. Pseudomonas aeruginosa, carbapenem-resistant 
iii. Enterobacteriaceae, carbapenem-resistant, 3rd generation cephalosporin-
resistant 
 
2. High priority 
i. Enterococcus faecium, vancomycin-resistant 
ii. Staphylococcus aureus, methicillin-resistant, vancomycin intermediate 
and resistant 
iii. Helicobacter pylori, clarithromycin-resistant  
iv. Campylobacter, fluoroquinolone-resistant 
v. Salmonella spp., fluoroquinolone-resistant  
vi. Neisseria gonorrhoeae, 3rd generation cephalosporin-resistant, 
fluoroquinolone-resistant 
 
3. Medium priority 
i. Streptococcus pneumoniae, penicillin-non-susceptible 
ii. Haemophilus influenza, ampicillin-resistant  
iii. Shigella spp., fluoroquinolone-resistant 
Table 1. Global priority pathogen lists of antibiotic-resistant bacteria for Research 
& Development of new antibiotics. Adapted from (WHO, 2017a) 
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1.1.3 AMR in Southeast Asia (SEA)  
There are 10-member states of ASEAN (Association of Southeast Asian Nation) 
Brunei Darussalam, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, 
Singapore, Thailand and Vietnam (Figure 2). Most of these states are still under-
developed and surveillance for antimicrobial resistance can be challenging due to 
limited microbiology tools.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Map of Southeast Asia (SEA) and the ASEAN member states; A) Brunei 
Darussalam, B) Cambodia, C) Indonesia, D) Laos, E) Malaysia, F) Myanmar, G) 
Philippines, H) Singapore, I) Thailand and J) Vietnam. Map taken from ASEAN UP, 
www.aseanup.com 
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As of May 2016, there are only four countries with established National 
Antimicrobial Surveillance Programmes; Singapore, Thailand, Malaysia and the 
Philippines (Hsu et al., 2017). The highest rates of carbapenem resistance in Gram-
negative bacteria in Southeast Asia are reported in Acinetobacter baumannii 
followed by Enterobacteriaceae (Hsu et al., 2017). However, AMR data for the East 
Malaysian states (Sabah and Sarawak) and Indonesian state (Kalimantan) in the 
Borneo island are unknown. 
 
1.1.4 Brunei Darussalam at a glance 
Brunei Darussalam (capital, Bandar Seri Begawan) is situated on the island of 
Borneo flanked between Sabah and Sarawak (Malaysian states) (Figure 3). As of 
2018, Brunei’s population is approximately 433, 517, with a total area of 5,765 
square kilometers (2,226 sq mi). Brunei Darussalam comprises of four districts 
namely; Brunei-Muara, Tutong, Kuala Belait and Temburong. All districts have 
their own hospitals and laboratory services (PMO). However, due to limited 
capacity in terms of services provided by the district hospitals, Raja Isteri Pengiran 
Anak Hajah Saleha (RIPAS) Hospital (main hospital, located in Brunei-Muara 
district) is the main center for most of the medical and laboratory services offered 
to patients.
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Figure 3. Map of Brunei Darussalam consisting of four districts; A) Brunei-Muara, 
B) Tutong, C) Belait and D) Temburong. Map available at ArcGIS, www.arcgis.com. 
 
1.1.4.1 AMR in Brunei Darussalam  
Little is known about AMR in Brunei Darussalam. However, like many other 
countries, Hospitals in Brunei are threatened with infections caused by pathogens 
in the WHO critical lists, causing a public health threat. Despite limited information 
on AMR in Brunei, monitoring and reporting of these resistant pathogens are 
routinely done by the Microbiology Laboratory Services in RIPAS Hospital using the 
WHONET 5.4 system (a Microsoft Windows-based database software for the 
C 
D 
B 
A 
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entry, reporting, and analysis of microbiology laboratory test results (O'Brien et 
al., 2001). Although, the WHONET program is excellent for entry, analysis and 
reporting of resistant data, the software is not intended to function as a complete 
patient management system (O'Brien et al., 2001). 
 
1.2 Gram-negative pathogens 
Gram-negative pathogens of interest in this study includes the Non-fermenters 
(Acinetobacter baumannii, Pseudomonas aeruginosa) and Enterobacteriaceae 
(Escherichia coli, Klebsiella pneumoniae). These pathogens can cause a multitude 
of infections such as urinary tract infection, intra-abdominal infection, nosocomial 
pneumonia, septicemia and meningitis (CDC, 2011). 
 
The importance of Gram-negative pathogens was highlighted in a study done by 
de Kraker and colleagues where it was predicted that there would be an increase 
in Gram-negative third generation cephalosporin-resistant E. coli (G3CREC) 
surpassing Gram-positive methicillin-resistant Staphylococcus aureus (MRSA) 
bacteremias (de Kraker et al., 2011). Data were analysed from the European 
Antibiotic Resistance Surveillance System (EARSS) from 2005-2009 (de Kraker et 
al., 2011) . 
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1.2.1 Structure of Gram-Negative Bacteria 
Gram-negative bacteria (GNB) have a unique structure.  They have multiple layers 
of membranes that protects them from foreign attack (immune system, 
antibiotics) before reaching the cytoplasm. The first outer layer is the capsule, 
followed by the outer membrane, a thin layer of peptidoglycan layer and an inner 
cytoplasmic cell membrane. Other features of GNB structure includes flagella, pili, 
nucleoid, ribosomes and plasmids (Figure 4). Magnified structure of GNB cell wall 
is shown in Figure 5. 
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Figure 4.  Overview structure of Gram-negative bacteria. Adapted from (Carroll et al., 2016) 
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1.2.2 Mobile Genetic Elements (MGE) in bacteria 
Mobile Genetic Elements are important for the exchange of genetic information 
between bacteria, between species, on a chromosome or between chromosome 
(Carroll et al., 2016). This includes plasmid, transposon, insertion element, 
integron and gene cassette. 
 
1.2.2.1 Plasmid  
Plasmids play an important role in the dissemination of antimicrobial resistance 
and present one of the most difficult challenges (Carattoli, 2013). Plasmids are 
small circular DNA that is able to self-replicate in a host cell (Carattoli et al., 2005). 
Plasmids vary in sizes from a few to more than several hundred kilobases (kb) 
found in nearly all bacterial species (Waters, 1999). Plasmids contain genes 
essential for initiation and control of replication and accessory genes that may be 
useful to their bacterial hosts such as antimicrobial resistance or virulence genes 
(Amabile-Cuevas and Chicurel, 1992; Bergstrom et al., 2000; Thomas, 2000). In 
addition, plasmids are classified based on incompatibility (Inc) groups (Novick, 
1987). Incompatibility grouping is based on the procedure by conjugation or 
transformation, of a plasmid of an “unknown” Inc group into a strain carrying a 
plasmid of a known Inc group (Carattoli et al., 2005). 
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If the plasmids, currently present in the bacteria are eliminated, the incoming 
plasmid is assigned to its same Inc group (Datta and Hedges, 1971). “Incompatible” 
is when the plasmids have the same replication control, whereas plasmids with 
different replication controls are “compatible” (Carattoli et al., 2005). Hence, on 
this basis two plasmids cannot be propagated in the same cell line belonging to 
the same Inc group (Datta and Hughes, 1983; Couturier et al., 1988). Examples of 
these Inc groups includes Inc HI1, HI2, I2, I, X, Y, FIA, FIB, P and N (Carattoli et al., 
2005). 
 
1.2.2.2 Transposons 
Transposons are DNA sequences containing several genes, including those 
necessary for their migration from one genetic locus to another (Carroll et al., 
2016). And during their migration, they create insertion mutations (Carroll et al., 
2016). 
 
1.2.2.3 Insertion elements (IS) 
Insertion elements are short transposons (0.75-2.0 kbp long) producing insertion 
mutations (Carroll et al., 2016). In addition, they carry enzymes needed to 
promote their own transposition to another genetic locus but cannot replicate on 
their own (Carroll et al., 2016). 
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1.2.2.4 Integron 
An integron is a genetic element that possesses a site, attI, at which additional 
DNA (in the form of gene cassettes) is able to integrate by site-specific 
recombination (Bennett, 1999). It also encodes an enzyme, integrase, that 
mediates these site-specific recombination events (Bennett, 1999). 
 
1.2.2.5 Gene cassette 
Gene cassettes are discrete mobile genetic elements that may exist as free, 
circular, non-replicating DNA molecules when moving from one genetic site to 
another, (Collis and Hall, 1992) but which are normally found as linear sequences 
that constitute part of a larger DNA molecule, such as a plasmid or bacterial 
chromosome (Bennett, 1999). In addition, gene cassettes normally contain only a 
single gene and an additional short sequence (called a 59-base element), that 
functions as a specific recombination site (Hall et al., 1991). The size of the 
cassettes are small, normally in the order of 500–1000bp (Bennett, 1999). 
Furthermore, genes that are carried on gene cassettes usually lack promoters 
(region of DNA where transcription is initiated and encoded proteins to be 
expressed at high levels) (Carroll et al., 2016) and are expressed from a promoter 
on the integron (Wiedemann et al., 1986; Collis and Hall, 1995).  
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Figure 5. Gram-negative bacteria cell wall structure. Adapted from (Carroll et al., 2016) 
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1.3 Important WHO Gram-negative critical pathogen lists 
1.3.1 Acinetobacter baumannii 
The genus Acinetobacter was first described in 1911 by a Dutch microbiologist, 
Beijerinck isolated from a soil sample, which was named Micrococcus 
calcoaceticus (Henriksen, 1973). Acinetobacter baumannii (A. baumannii) are 
Gram-negative, strictly aerobic, non-fastidious, non-motile and non-fermenting 
coccobacilli bacteria where the genus is a member of the order 
Gammaproteobacteria and belongs to the family Moraxellaceae (Peleg et al., 
2008; Evans et al., 2013). More recently, twitching motility has been reported in 
A. baumannii mediated by type IV pili by the action of extension and retraction of 
the pili (Vijayakumar et al., 2016). A. baumannii has been classified as one of the 
ESKAPE organism (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter species) causing nosocomial infections and effectively “escaping” 
the effects of antibacterial drugs (Boucher et al., 2009). 
 
A. baumannii can cause a diverse range of infections (respiratory tract, urinary 
tract, bloodstream, skin and soft tissue, device-related) and are frequently 
isolated from immunocompromised patients hospitalised in the intensive care 
unit (ICU) (Potron et al., 2015). In the United States (1986-2003) between 5% and 
10% of all ICU-acquired pneumonia and 1.6% of ICU-urinary tract infection (UTI) 
was caused by A. baumannii (Gaynes et al., 2005). In another large study done on 
nosocomial bloodstream infection (BSI) in the US hospitals (1995-2002), A. 
 
 
47 
baumannii was found to be the 10th most common etiologic agent accountable for 
1.3% of all monomicrobial nocosomial BSI (Wisplinghoff et al., 2004). The overall 
crude mortality from A. baumannii BSI was 34% to 43.4% in the ICU, compared to 
16.3% outside the ICU (Peleg et al., 2008). Of greater concern, higher mortality in 
post-neurosurgical A. baumannii meningitis with mortality as high as 70%, (Peleg 
et al., 2008) usually seen in patients with an external ventricular drainage setup 
after neurosurgery (Metan et al., 2007). However, the direct effects of A. 
baumannii on mortality appear less well defined (Peleg et al., 2008). 
 
1.3.2 Pseudomonas aeruginosa 
In the 1850s, Sédillot observed a blue-green discharge frequently present and 
associated with infection in surgical wound dressings (Lyczak et al., 2000). The 
non-fluorescence bluish pigment is pyocanin, where only Pseudomonas 
aeruginosa (P. aeruginosa) produces this pigment (Carroll et al., 2016). P. 
aeruginosa is a motile, non-fermenting, opportunistic Gram-negative bacteria 
belonging to the family Pseudomonadaceae, (Alhazmi, 2015) which also belongs 
to the ESKAPE pathogen group (Boucher et al., 2009). In the 1960s, P. aeruginosa 
has emerged as an important human pathogen (Doggett, 1979).  By 1961, this 
organism can cause both severe acute and chronic infections (Freeman, 1916).  
 
In 2006-2007, the National Healthcare Safety Network (NHSN) in the United States 
reported that 8% of all hospital-associated infections were due to P. aeruginosa, 
3% causing central line-associated bloodstream infections, 6% of surgical site 
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infections, 10% of catheter-associated urinary tract infection and 16% of 
ventilator-associated pneumonia (VAP) infections (Hidron et al., 2008). The major 
predisposing factors to the acquisition of P. aeruginosa in hospitals are mechanical 
ventilation, antibiotic therapy, surgery, and chemotherapy (Thuong et al., 2003). 
 
Nosocomial bacteremia leading to sepsis associated with P. aeruginosa accounts 
for mortality greater than 50% ( Whitecar et al., 1970; Fishman and Armstrong, 
1972) and as high as 70% in febrile neutropenic patients (Bodey et al., 1985). P. 
aeruginosa gains access to the blood stream from the local site of infection by 
breaking down epithelial and endothelial tissue barriers (Kurahashi et al., 1999). 
In order to evade bactericidal activity of the serum complement, P. aeruginosa 
produces smooth LPS; full-length O side-chain of the bacteria. (Hancock et al., 
1983; Pier and Ames, 1984) 
 
In Cystic fibrosis (CF), 90% of individuals suffering become infected with P. 
aeruginosa during their lifetime (Alhazmi, 2015). This pathogen is the leading 
cause of morbidity and mortality among those patients and a dominant pathogen 
present in chronic lung infection in CF (Alhazmi, 2015). CF is an autosomal 
recessive genetic disorder caused by a mutation in a gene on chromosome 7 
known as CFTR (cystic fibrosis transmembrane conductance regulator) (Alhazmi, 
2015). The most common mutation is in the ΔF508 (or F508del), which is a three-
nucleotide deletion of a phenylalanine residue and subsequent defective 
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intracellular processing of the CFTR protein that is an important chloride channel 
(Bobadilla et al., 2002). CF affects 1:2,500 in the Caucasian population (Ratjen and 
Doring, 2003) and mortality are due to lung disease (Bobadilla et al., 2002). 
 
1.3.3 Klebseilla pneumoniae 
Klebsiella pneumoniae was first described by Carl Friedlander in 1882 as a 
bacterium isolated from the lungs of patients who had died from pneumonia 
(Freidlander, 1882). Klebsiella pneumoniae (K. pneumoniae) is a Gram-negative, 
lactose-fermenting, non-motile, aerobic, rod-shaped bacterium with a prominent 
capsule and belongs to the family Enterobacteriaceae (Carroll et al., 2016) also 
part of the ESKAPE pathogen group (Boucher et al., 2009). They have large 
polysaccharide capsule and lacks motility (Carroll et al., 2016). Klebsiella species 
are found ubiquitously in nature, including in plants, animals, and humans (Carroll 
et al., 2016). 
 
These pathogens are an opportunistic hospital-acquired infection (HAI) causing 
several types of infections in humans, including respiratory tract infections, 
urinary tract infections (UTIs), and bloodstream infections, (Podschun and 
Ullmann, 1998) infecting the critically ill and immunocompromised patients.  
Furthermore, K. pneumoniae are found in the respiratory tract and faeces of about 
5% of normal individuals (Carroll et al., 2016). In the 1980s and 1990s community-
acquired hypervirulent K. pneumoniae has emerged from the Asian Pacific Rim 
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causing pyogenic liver abscess affecting Asian males and this was mostly 
associated with the K1 encapsulated strains (Martin and Bachman, 2018). 
 
Klebsiella species have been identified as the third leading cause of HAIs in the 
United States (9.9%) behind Clostridium difficile and Staphylococcus aureus (Magill 
et al., 2014) and the second leading cause of bloodstream infections (BSI) caused 
by Gram-negative bacteria, behind only E. coli (Podschun and Ullmann, 1998; 
Magill et al., 2014). Hospital-acquired K. pneumoniae BSI is associated with the 
primary underlying cancer disease, while liver abscess and diabetes mellitus are 
highly associated among community-acquired (CA) K. pneumoniae BSI (Kang et al., 
2006). 
 
1.3.4 Escherichia coli 
Escherichia coli (E. coli) was first isolated by Theodor Escherich from an infant stool 
sample in 1886 and named Bacterium coli commune (the common colon bacillus) 
(Shulman et al., 2007). E. coli is fascinatingly diverse bacteria adapted to diverse 
environmental conditions and lifestyles (Hufnagel et al., 2015). They are 
facultatively anaerobic Gram-negative rods belonging to the family 
Enterobacteriaceae and member of the normal intestinal flora (Hufnagel et al., 
2015). There are a total of over 15,000 genes that make up the E. coli pangenome 
(Touchon et al., 2009; Kaas et al., 2012). Hence, due to the genomic plasticity of 
various E. coli isolates allows this bacterium the ability to proliferate and survive 
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in an array of environments (Kaper et al., 2004; Tenaillon et al., 2010). A major 
niche of E. coli is found in the lower intestinal tract of mammals, birds and reptiles 
(Smith, 1965a). 
 
E. coli becomes pathogenic when it reaches tissue outside of the normal intestinal 
such as urinary tract, biliary tract and other sites in the abdominal cavity (Carroll 
et al., 2016). Approximately, 90% of first UTI in young women are caused by E. coli 
(Carroll et al., 2016). Most of UTI involving the bladder or kidney are caused by a 
small number of O antigen types with virulence factors facilitating colonization 
and subsequent clinical infections (Carroll et al., 2016). Other associated disease 
caused by E. coli are diarrheal diseases that are common worldwide (Carroll et al., 
2016). There are seven groups of E. coli pathotypes classified by their 
pathogenicity profiles (clinical disease, virulence factors and phylogenetic 
profiles); Enteropathogenic E. coli (EPEC), Enterotoxigenic E. coli (ETEC), Shiga 
toxin-producing E. coli (STEC), Enteroinvasive E. coli (EIEC), Enteroaggregative E. 
coli (EAEC), Diffusely Adherent E. coli (DAEC) and Adherent Invasive E. coli (AIEC) 
(Clements et al., 2012). In developing countries ETEC, EPEC and EAEC contributes 
to infantile diarrhoea with potentially fatal consequences when untreated 
(Clements et al., 2012). In contrast, in developed countries these infections are 
mild and self-limiting (Clements et al., 2012). EHEC and more recently EAEC and 
STEC are associated with food poisoning outbreaks in developed countries 
(Clements et al., 2012). While AIEC is associated with Crohn’s disease but does not 
cause diarrhoeal disease (Croxen and Finlay, 2010). 
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Pathogenic E. coli strains are identified in the environment, food or clinical 
samples, and for understanding epidemiology, serotyping based on antigens is one 
of the requirements (Wang et al., 2010). Serotyping method is based on its O 
(somatic), H (flagellar) and K (capsular) surface antigen profiles (Kauffman, 1944) 
which exist in many combinations, and their combinations make specific serotypes 
(Nataro and Kaper, 1998). The O-antigen is a component of the thermostable LPS 
found in the cell wall of E. coli (Orskov et al., 1977). An important virulence factors 
which play a major role in the pathogen-host interactions (DebRoy et al., 2011). 
The H-antigen is the flagellar filament of E. coli and it is made up of a single protein, 
flagellin (Wang et al., 2010). The importance of H-antigen in E. coli is in the typing 
because strains causing epidemic diarrheal diseases can be differentiated from the 
normal stool flora by its unique O:H antigenic combinations (Evans and Evans, 
1996). As with the capsular (K) antigens in E. coli, they have virulence capabilities 
of resisting phagocytosis by the host leucocytes (Glynn and Howard, 1970). 
 
Another important determinant for pathogenic E. coli is by grouping them 
according to their phylotypes. E. coli are composed of four main phylogenetic 
groups (A, B1, B2 and D2) (Clermont et al., 2000). Phylo-groups B2 or D strains are 
responsible for extra-intestinal infection than members of A or B1 (Picard et al., 
1999; Johnson and Stell, 2000). Assigning E. coli isolates to these groups are 
determined by PCR assay to detect the genes chuA and yjaA and a DNA fragment 
 
 
53 
TspE4.C2, later characterized as a putative lipase esterase gene (Gordon et al., 
2008).  
 
1.4 Definitions of multidrug-resistant (MDR), extensively drug-
resistant (XDR) and pandrug-resistant (PDR) 
Resistant bacteria are categorized based on their antibiotic resistance profiles. 
MDR is when bacteria are non-susceptible to at least one agent in three or more 
antimicrobial categories (Magiorakos et al., 2012). While XDR bacteria are non-
susceptible to at least one agent in all but two or fewer antimicrobial categories 
(Magiorakos et al., 2012). PDR bacteria are non-susceptible to all agents in all 
antimicrobial categories (Magiorakos et al., 2012). These definitions were 
proposed based on a joint initiative by the European Centre for Disease Prevention 
and Control (ECDC) and Centers for Disease Control and Prevention (CDC) 
(Magiorakos et al., 2012). 
 
1.5 Antimicrobial agents 
1.5.1 Definition 
Antimicrobial agents are a natural or synthetic compound that kill or inhibit the 
growth of microorganisms (fungi, virus, bacteria) (Carroll et al., 2016). In the 
context of an antibiotic, it is a chemical substance that prevents bacterial growth 
by inhibiting the cell from dividing (bacteriostatic) or by killing them (bactericidal) 
(Carroll et al., 2016).  
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1.5.2 Overview of the mode of actions of antibiotics 
Summary of the mode of action of antibiotics is shown in Figure 6. 
 
1.5.2.1 Inhibitors of cell wall synthesis 
The cell wall of bacteria is made of peptidoglycan (long sugar polymers) (Kahne et 
al., 2005). The peptidoglycan undergoes cross-linking of the glycan strands by the 
action of transglycosidase while the peptide chains extend from the sugars in the 
polymers to form cross-links from one peptide to another (Kahne et al., 2005). In 
the presence of PBPs (penicillin binding proteins), the D-alanly-alanine portion of 
peptide chain is cross linked by glycine residues (Reynolds, 1989). The cross-linking 
aids in strengthening the cell wall (Kapoor et al., 2017). 
 
The primary target of β-lactam antibiotics are the PBPs where during the 
interaction of the PBP with the β-lactam ring, prevents the peptidoglycan being 
synthesised (Kapoor et al., 2017). This leads to the disruption of the peptidoglycan 
layer and lysis of bacterium (Džidic et al., 2008). 
 
Gylcopeptide antibiotics binds to the D-alanly D-alanine portion of the peptide 
side chain of the precursor peptidoglycan subunit (Kapoor et al., 2017). For 
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example, vancomycin (large drug molecule) will prevent the binding of D-alanyl 
subunit with the PBP, hence inhibiting cell wall synthesis (Grundmann et al., 2006; 
Džidic et al., 2008). 
 
1.5.2.2 Inhibitors of cell membrane function 
Cell membranes are important barriers that segregate and regulate the intra- and 
extracellular flow of substances (Kapoor et al., 2017). A disruption or damage to 
this structure could result in leakage of important solutes essential for the cell’s 
survival (Kapoor et al., 2017). Because this structure is found in both eukaryotic 
and prokaryotic cells, the action of this class of antibiotics is often poorly selective 
and can often be toxic for systemic use in the mammalian host (Kapoor et al., 
2017). Most clinical usage is therefore limited to topical applications, for 
examples; polymyxin B and colistin (Kapoor et al., 2017). 
 
1.5.2.3 Inhibitors of protein synthesis 
The process of utilising information in bacterial DNA to synthesise an RNA 
molecule referred to mRNA (messenger RNA) is known as transcription (Kapoor et 
al., 2017). And in translation, the ribosome synthesis proteins present in mRNA 
(Kapoor et al., 2017). The bacterial 70S ribosome is composed of two 
ribonucleoprotein subunits, which are the 30S and 50S subunits (Yoneyama and 
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Katsumata, 2006). Hence, these subunits are targeted by antibiotics inhibiting 
protein synthesis (Vannuffel and Cocito, 1996; Johnston et al., 2002). 
 
For example, the action of tetracyclines (doxycycline, minocycline or 
chlortetracycline) on the 30S subunit of the ribosome (Kapoor et al., 2017). These 
antibiotics act upon the conserved sequences of the 16S rRNA of the 30S 
ribosomal subunit to prevent binding to tRNA to the A site ( Wise, 1999; Yoneyama 
and Katsumata, 2006). 
 
With the 50S subunit, chloramphenicol interacts with the conserved sequences of 
the peptidyl transferase cavity of the 23S rRNA of the 50S subunit, thus inhibiting 
protein synthesis by preventing binding of tRNA to the A site of the ribosome 
(Vannuffel and Cocito, 1996; Yoneyama and Katsumata, 2006). 
 
1.5.2.4 Inhibitors of nucleic acid synthesis 
 Fluoroquinolones (FQ) antibiotics inhibit the bacterial enzyme DNA gyrase 
(Kapoor et al., 2017). The function of this enzyme to nick the double-stranded 
DNA, introduces supercoiling and then reseals the nicked ends (Kapoor et al., 
2017). This process is necessary to prevent excessive positive supercoiling of the 
strands when they separate to allow replication or transcription which are carried 
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out by two A subunits and two B subunits of the DNA gyrase (Kapoor et al., 2017). 
A subunit carries out nicking of DNA, B subunit introduces negative supercoils and 
then the strand is resealed back by A subunit (Kapoor et al., 2017). The FQ will 
bind to the A subunit with high infinity and interfere with its strand cutting and 
resealing function (Kapoor et al., 2017). 
 
1.5.2.5 Inhibitors of other metabolic processes 
Both sulfonamides and trimethoprim inhibit distinct steps in the folic acid pathway 
(Kapoor et al., 2017). However, the combination of both drugs acts as a distinct 
step on the same biosynthetic pathways that shows synergy and a reduced 
mutation rate for resistance (Yoneyama and Katsumata, 2006). Sulfonamides will 
competitively inhibit dihydropteroate synthase with higher affinity for the enzyme 
than the natural substrate, p-amino benzoic acid (PABA) (Kapoor et al., 2017). 
While trimethoprim act at a later stage of folic acid synthesis and inhibits enzyme 
dihydrofolate reductase (Kapoor et al., 2017). 
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Figure 6. Mechanism of actions of antibiotics on bacteria. Taken from (Brooks and Brooks, 2014)  
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1.5.3 Overview of antibiotic resistance mechanisms 
Summary of antibiotic resistance mechanisms is shown in Figure 7. 
 
1.5.3.1 Enzymatic inactivation of antibiotic 
The most common mechanism of antibiotic resistance (Courvalin et al., 2010). The 
production of enzymes can either be intrinsic (encoded by the chromosomal gene 
carried by the bacteria) or acquired through horizontal gene transfer (plasmid or 
transposons) (Courvalin et al., 2010). For example ß-lactamase enzymes which 
hydrolyse ß-lactam ring of ß-lactam antibiotics. (Courvalin et al., 2010)  
 
1.5.3.2 Target modification 
1.5.3.2.1 Enzymatic 
Polymyxin resistance is an example of target modification by the overproduction 
of phosphoethanolamine transferase enzymes (Courvalin et al., 2010). The 
enzyme causes modification of the LPS (lipopolysaccharide) by attaching to L-
Ara4N (4-amino-4-deoxy-L-arabinose) or 2-aminoethanol residue of the 
phosphate group on the LPS, hence preventing polymyxin penetration and binding 
(Nummila et al., 1995). 
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1.5.3.2.2 Mutational  
Mutations can be spontaneous causing amino acid changes or nucleotide 
substitution (Courvalin et al., 2010). With quinolone resistance, type II 
topoisomerase is targeted, which is composed of DNA gyrase (DNA replication) 
and topoisomerase IV subunits (chromosomal segregation during cell division) 
(Courvalin et al., 2010). Mutations in the genes encoding these subunits have been 
reported; gyrA and gyrB in DNA gyrase subunit while parC and parE in 
topoisomerase IV subunit (Courvalin et al., 2010).  
 
1.5.3.2.3 Antibiotic sequestration and target protection  
Sequestration of antibiotic by bacteria neutralizes the effect of the drug (Courvalin 
et al., 2010). This mechanism of resistance has been observed with third 
generation cephalosporin (C3G) in “derepressed” mutants of Gram-negative 
bacilli overproducing chromosomal cephalosporinase AmpC, due to the relative 
stability of beta-lactams to the enzyme (Sanders and Sanders, 1985). 
 
With regards to target protection, bacteria produce a protein that can protect the 
target from interacting with antibiotics (Courvalin et al., 2010). For example, with 
tetracycline, the Tet(O) and Tet(M) proteins can displace tetracycline from the 
ribosomal A site (aminoacyl-tRNA), allowing protein synthesis to continue 
normally (Connell et al., 2003). 
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1.5.3.2.4 Loss of membrane permeability and active efflux 
Loss of membrane permeability has been seen in fosfomycin resistance due to a 
deficiency in glycerol-3-phosphate active transport system which this antibiotic 
uses to enter the cytoplasm, leading to impermeability (Arca et al., 1997). While 
in P. aeruginosa, defect and synthesis in the porin, OprD (facilitating diffusion of 
basic amino acids and gluconate) due to mutations can prevent the entry of 
imipenem causing resistance (Dib et al., 1995; Pai et al., 2001). 
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Figure 7. Summary of the mechanism of antibiotic resistance. Red colour represents antibiotics. Yellow colour channels are drug entry 
ports/porins. Taken from (Andersen et al., 2015). 
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1.6 Antibiotics and mechanisms of resistance   
1.6.1 Carbapenem 
Carbapenems (doripenem, ertapenem, imipenem and meropenem) possess the 
broadest spectrum of activity and greatest potency against Gram-positive and 
Gram-negative bacteria (Papp-Wallace et al., 2011). They work by inactivating the 
PBP (penicillin binding proteins), enzymes with an essential role in cell wall 
synthesis, leading to cell death (Vollmer et al., 2008; Yao et al., 2012). Carbapenem 
are often used as antibiotic of last-resort when patients with infections become 
gravely ill or are suspected of harbouring resistant bacteria (Bradley et al., 1999; 
Paterson, 2000; Paterson, 2002; Paterson and Bonomo, 2005; Torres et al., 2007). 
 
1.6.1.1 Carbapenem and other β-lactam antibiotic resistance mechanisms 
The most important mechanism of carbapenem resistance is the production of β-
lactamases (carbapenemases) (Munita and Arias, 2016). β-lactamases are 
classified according to their ambler classification based on their amino acid 
homology which includes Class A, B, C and D β-lactamases (Ambler, 1980; Jaurin 
and Grundström, 1981). Most important are the class A, B and D carbapenemases 
(Munita and Arias, 2016). These enzymes can be found on the bacterial 
chromosome or plasmids (Palzkill, 2013). 
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There are more than 1000 different β-lactamases described 
(www.lahey.org/studies) and from the new current website 
http://www.laced.uni-stuttgart.de/ (TEM, SHV and class B enzymes) and National 
Centre for  Biotechnology Information, NCBI 
https://www.ncbi.nlm.nih.gov/pathogens/isolates#/refgene/  
 
1.6.1.1.1 Class A β-lactamases  
An important property of Class A β-lactamases is the presence of a serine residue 
in the catalytic site, which is also shared with class C and D enzymes (Munita and 
Arias, 2016). Most class A enzymes are inhibited by clavulanic acid and they can 
hydrolyse monobactams but not cefoxitin and cefotetan (Munita and Arias, 2016). 
 
There is a wide range of proteins having different catalytic activities with Class A 
enzymes, extending from penicillinases (TEM-1, SHV-1), Extended-spectrum β-
lactamases, ESBLs (CTX-M) to carbapanemases (KPC) prevalent in several Gram-
negative species carried on plasmids (Munita and Arias, 2016). However, three are 
typically chromosomally encoded which includes IMI [imipenem-hydrolyzing 
enzyme], SME [Serratia marcescens enzyme] and NMC [not-metallo-enzyme 
carbapenemase] (Queenan and Bush, 2007). 
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KPC, a clinically important class A enzyme was first reported in 1996 from K. 
penumoniae isolate, recovered from a patient in North Carolina, USA (Yigit et al., 
2001). Although KPC carbapenemases are predominantly found in Klebsiella spp, 
and they have also been reported in other gram-negatives, including 
Enterobacter spp., E. coli, Proteus mirabilis, Salmonella spp (Munita and Arias, 
2016) and in non-lactose fermenters such as P. aeruginosa (Poirel et al., 2010b). 
There are a total of 37 KPC-like variants to date 
https://www.ncbi.nlm.nih.gov/pathogens/isolates#/refgene/,  most of them are 
located in plasmids harboring transposable elements (e.g. Tn4401) or in 
association with insertion sequences like ISKpn6 and ISKpn7 (Nordmann et al., 
2009). Hence, causing dissemination of variants. Interestingly, most of the 
endemic outbreaks of KPC and international outbreaks belongs to clonal 
expansion of strains of K. pneumoniae belonging to clonal complex 258 (CC258) 
and more specifically to sequence type, ST258 (Cuzon et al., 2010; Logan and 
Weinstein, 2017). These strains harbours blaKPC-2 or blaKPC-3 gene located on a Tn3-
based transposon, Tn4401 (Kitchel et al., 2009; Cuzon et al., 2011). In terms of the 
propagation of blaKPC, it is a complex process (Logan and Weinstein, 2017). There 
are two distinct genetic clades (I and II) found in a circulating ST258 K. pneumoniae 
(Logan and Weinstein, 2017). In addition, several sequence types have been found 
to carry blaKPC associated with a variety of plasmids (Patel and Bonomo, 2013; 
Carattoli, 2009; Chen et al., 2014). 
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Another clinically important class A enzyme is the CTX-M (cefotaxime-Munich) 
ESBLs (Extended Spectrum b-lactamases) that have been reported worldwide, 
typically found in K. pneumoniae, E. coli and other Enterobacteriaceae (Munita 
and Arias, 2016). CTX-M-1 was the first enzyme of clinical origin that was 
described in enterobacterial strains isolated in Europe in the late 1980s (Bonnet, 
2004). The sources of CTX-M determinants are chromosomal genes resident in 
members of the genus Kluyvera which is part of an environmental species with 
little or no pathogenic activity against humans (Rossolini et al., 2008). The 
precursor of genes encoding CTX-M-1 and CTX-M-2 group have been found in 
strains of Kluyvera ascorbata (Bonnet, 2004; Rodriguez et al., 2004). As for the 
precursor of genes encoding CTX-M-8 and CTX-M-9 group, it has been detected in 
strains of Kluyvera georgina (Bonnet, 2004; Olson et al., 2005). However, the 
original sources of genes encoding members of the CTX-M-25 and CTX-M-49 
subgroups are currently unidentifiable, but most likely comprise other members 
of the genus Kluyvera (Rossolini et al., 2008). 
 
In contrast to other Amber class A ESBLs such as TEM-3, this enzyme did not 
derived from TEM or SHV, it was likely acquired from Kluyvera spp. (an 
environmental bacterium and non-pathogenic) through horizontal gene transfer 
(Bonnet, 2004).  
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CTX-M enzymes are mostly associated with the insertional sequence, ISEcp1 and 
transposon, Tn402-like which mobilise the enzymes (Poirel et al., 2005). This is 
captured on broad-range conjugative plasmids or phage-like sequences that 
serves a vehicle for dissemination (Poirel et al., 2005). Other different IS that have 
been identified upstream of the blaCTX-Ms genes includes ISCR1, IS10, and IS26 
(Canton et al., 2012). 
 
1.6.1.1.2 Class B β-lactamases 
Class B metallo-β-lactamases (MBLs) have a broad substrate spectrum and have 
the ability to catalyze the hydrolysis of virtually all β-lactam antibiotics except for 
monobactams (Palzkill, 2013). They are known as metallo-β-lactamases because 
they utilize a metal ion (most usually Zinc) as a cofactor (instead of a serine 
residue) for the nucleophilic attack of the β-lactam ring (Munita and Arias, 2016). 
Class B MBLs are not readily inhibited by mechanism-based inhibitors such as 
clavulanate, sulbactam, or tazobactam that are effective against serine-based, 
class A β-lactamases (Perez-Llarena and Bou, 2009; Drawz and Bonomo, 2010). 
Apart from serine-based ezymes, MBLs are inactivated by metal chelators such as 
EDTA (Ethylene Diamine Tetra Acetic acid) (Drawz and Bonomo, 2010). 
 
MBLs discovered forty years ago did not cause any serious problem for antibiotic 
therapy as they  were located in the chromosome of non-pathogenic bacteria (Lim 
et al., 1988; Walsh et al., 1994). However, during the 1990’s the situation changed 
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with the spread of IMP- and VIM-type MBL in Gram-negative pathogens, including 
Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii 
(Laraki et al., 1999; Lauretti et al., 1999). 
 
The IMP- and VIM-type enzymes are encoded as gene cassettes and reside with 
other resistance genes within integron structures that are associated with 
transposons and can insert into bacterial chromosome or within plasmids (Laraki 
et al., 1999; Cornaglia et al., 2011). 
 
IMP, VIM, SPM and NDM are the most of the clinically important MBLs (Munita 
and Arias, 2016). In the early 1990s, IMP-type enzymes were first reported in 
Japan in S. marcescens (Munita and Arias, 2016). Since then, there are currently 
79 IMP-like variants 
(https://www.ncbi.nlm.nih.gov/pathogens/isolates#/refgene/). IMP-type 
enzymes have been described worldwide in Enterobacteriaceae Pseudomonas 
spp., and Acinetobacter spp, among other organisms (Munita and Arias, 2016). In 
addition, blaIMP genes have been identified on large-size plasmids and forming part 
of Class 1 integron (Poirel et al., 2007). As with VIM-type enzymes, it was first 
described in the late 1990s in Verona, Italy and have since disseminated 
throughout the globe (Munita and Arias, 2016). VIM-type enzymes were initially 
found in Pseudomonas aeruginosa; however, its association with Class 1 integron, 
along with reports in locating them in different types of Mobile Genetic Element 
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(MGE) has led to their dissemination to many different bacterial species and major 
concern worldwide (Munita and Arias, 2016). Among the VIM variants described 
to date, VIM-2 is the most widely distributed enzyme, with reports from Europe, 
Asia, Africa, and the Americas (Cornaglia et al., 2011). 
 
More recent of the MBLs was the NDM-type enzyme reported in 2008 (Munita 
and Arias, 2016). NDM-type enzyme was identified in Klebsiella pneumoniae 
isolate recovered from a Swedish patient who had been previously admitted to a 
hospital in New Delhi, India (Munita and Arias, 2016). This enzyme was designated 
NDM-1, in reference to its origin (Kumarasamy et al., 2010). NDM-1 shares little 
amino acid identity, for example 32% with VIM-1, however, its hydrolytic profile 
is very similar to other members of Ambler class B enzymes (Munita and Arias, 
2016). Since the first description of NDM-1, eight variants of this enzyme have 
been identified (NDM-1 to -8) (Dortet et al., 2014c). 
 
The blaNDM gene has been found in several types of plasmids and it is readily 
transferable among different species of Gram-negative (Munita and Arias, 2016). 
This gene is also associated with the presence of insertion sequences such as the 
ISAba125, but not usually related to integron-like structures (Nordmann et al., 
2011b). In addition, NDM-type MBL genes have been present in several epidemic 
clones, this includes K. pneumoniae ST11 and ST147 and Escherichia coli ST131 
and ST101, which are known to harbor other β-lactamase genes and antibiotic 
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resistance determinants (Walsh, 2010; Patel and Bonomo, 2013; Dortet et al., 
2014c). 
 
Hence it is a public health concern, as the blaNDM gene has shown to be readily 
transmissible among different types of Gram-negative organisms, spreading to 
many countries in a short period and becoming one of the most feared resistance 
determinants in several parts of the world (Cornaglia et al., 2011). 
 
Interestingly, in the Indian subcontinent (India and Pakistan), the blaNDM genes are 
not only found disseminated among nosocomial pathogens but in community-
associated isolates (Munita and Arias, 2016). Several reports have found this gene 
in the soil and drinking water for human consumption, suggesting that its ability 
to disseminated through the human microbiota (Walsh et al., 2011). 
 
1.6.1.1.3 Class C β-lactamases 
The most clinically relevant class C enzyme is AmpC, which is a cephalosporinase 
that is generally chromosomally-mediated (Munita and Arias, 2016). AmpC b-
lactamases will hydrolyze narrow-, broad-, and expanded-spectrum 
cephalosporins and cephamycins and resist inhibition by clavulanate, sulbactam, 
and tazobactam (Thomson, 2010). When this enzyme is hyperproduced, it may 
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cause resistance to penicillins, aztreonam, cephamycins, and narrow-, broad-, and 
expanded-spectrum cephalosporins (Thomson, 2010). 
 
Plasmid-mediated AmpC b-lactamases have been detected in some isolates of 
Klebsiella spp., Salmonella spp., C. freundii, E. aerogenes, P. mirabilis, and E. coli 
(Jacoby, 2009) and are typically associated with multidrug resistance (Thomson, 
2010). The most commonly encountered plasmid-mediated AmpC b-lactamases 
belong to the ACT, ACC, CFE, CMY, DHA, FOX, LAT, MIR and MOX families (Jacoby, 
2009; Thomson, 2010). While chromosomal AmpC has been identified in E. 
cloacae, E. aerogenes, C. freundii, S. marcescens, Providencia sp., Morganella 
morganii, and P. aeruginosa, among others (Munita and Arias, 2016). 
 
The expression of ampC is generally inducible, controlled by complex regulatory 
mechanisms (Munita and Arias, 2016). For example, in Enterobacter spp, AmpR 
(transcriptional regulator of the LysR family) will act as a repressor of the 
transcription of blaAmpC (Munita and Arias, 2016). Usually, under non-inducing 
conditions (absence of β-lactams), AmpR will bind to peptidoglycan precursors 
(UDP-MurNAc pentapeptides) and the interaction of AmpR with its cognate 
promoter does not occur hence, resulting in the absence of blaAmpC transcription 
(Munita and Arias, 2016). 
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On the contrary, the presence of β-lactams will alter cell wall homeostasis 
resulting in accumulation of peptidoglycan byproducts such as anhydro-
muropeptides that compete for the same AmpR binding site with the UDP-
MurNAc pentapeptides (Munita and Arias, 2016). Due to this competition for the 
same binding site, AmpR is released and is able to interact with the blaAmpC 
promoter, activating transcription of the gene (Jacobs et al., 1997; Johnson et al., 
2013). 
 
AmpD is another mechanism by which ampC is overexpressed, a cytosolic amidase 
that recycles muropeptides (Munita and Arias, 2016). AmpC overexpression 
occurs when AmpD effectively reduces the concentration of anhydro-UDP-
MurNAc tri-, tetra- and pentapeptides preventing displacement of UDP-MurNAc 
pentapeptide from AmpR (Munita and Arias, 2016). Additionally, mutations 
in ampD are often seen in isolates that constitutively overproduce AmpC; hence, 
the clinical efficacy of cephalosporins is affected (Munita and Arias, 2016). 
Cefepime is not a good substrate for AmpC enzymes, but high-level production of 
AmpC may markedly increase cefepime MICs (Schmidtke and Hanson, 2006; 
Jacoby, 2009). 
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1.6.1.1.4 Class D β-lactamases 
The Class D β-lactamases have emerged as a prominent resistance mechanism 
against β-lactam antibiotics that previously had efficacy against infections caused 
by pathogenic bacteria, especially by Acinetobacter baumannii and the 
Enterobacteriaceae (Antunes and Fisher, 2014). 
 
Class D β-lactamases include a wide range of enzymes that were initially 
differentiated from the class A penicillinases due to their ability to hydrolyse 
cloxacillin and oxacillin faster than benzylpenicillin (Bush et al., 1995). Class D β-
lactamases are usually not inhibited by clavulanic acid, tazobactam and 
sulbactam, whereas their activities may be inhibited in vitro by sodium chloride 
(NaCl) (Poirel et al., 2010a) and more efficiently by avibactam (Docquier and 
Mangani, 2018). 
 
There are many OXA variants with over 779 variants currently recognised 
(https://www.ncbi.nlm.nih.gov/pathogens/isolates#/refgene/).  OXA β-lactamase 
genes are found on both the chromosomes as well as the plasmids of diverse 
bacterial species such as Acinetobacter, Shewanella, Pseudomonas, and 
Burkholderia (Sanschagrin et al., 1995; Poirel et al., 2010a). In addition, most of 
chromosomal Class D β-lactamases have now been transferred to plasmids which 
pose a greater clinical threat (Bush, 2013a; Bush, 2013b). 
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Examples of the OXA variants are their ability to degrade third generation 
cephalosporins (ESBLs) (OXA-11 in P. aeruginosa) and carbapenems (OXA-23 
detected in A. baumannii from Scotland) (Munita and Arias, 2016).  
 
Additionally, OXA-23 identified in A. baumannii was isolated from Scotland (Poirel 
et al., 2010a) and found to be plasmid mediated after its transfer to 
Acinetobacter junii (Scaife et al., 1995). The genetic structures which are involved 
in the mobilization includes transposon and insertion elements (Munita and Arias, 
2016). For example, the blaOXA-23 gene originating from the chromosome of A. 
radioresistens may be mobilized onto plasmids diffusing into A. baumannii by 
the involvement of a composite transposon Tn2006, formed by two ISAba1 
elements (Corvec et al., 2007; Mugnier et al., 2009).  
 
Since then, OXA-23-positive A. baumannii strains have spread globally, to 
locations including France (Corvec et al., 2007), Bulgaria (Stoeva et al., 2008), Iran 
(Feizabadi et al., 2008), the United Arab Emirates (Mugnier et al., 2008), Tunisia 
(Mansour et al., 2008), Brazil (Dalla-Costa et al., 2003), and Australia (Valenzuela 
et al., 2007).  
 
Another example is OXA-48, a widely disseminated class D carbapenemases which 
were originally described in 2001 in Turkey from a multidrug resistant isolate of K. 
pneumoniae (Munita and Arias, 2016). The blaOXA-48 gene has been associated with 
insertion sequence IS1999 in K. pneumoniae (Poirel et al., 2004). In addition, the 
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blaOXA-48 gene was part of composite transposon Tn1999, made of two copies of 
IS1999, with the copy located upstream of blaOXA-48 providing promoter sequences 
for blaOXA-48 expression (Aubert et al., 2006). 
 
Many other types of OXA enzymes have been described that are often found in a 
wide range of MGEs (Munita and Arias, 2016). In other instances, the OXA-
containing MGE inserts in the chromosome, resulting in core-genome genes 
encoding OXA enzymes (Munita and Arias, 2016). For example, OXA-51 enzyme is 
found intrinsic to Acinetobacter baumannii isolates (Evans and Amyes, 2014). This 
enzyme is naturally found in the chromosome of this isolates (Evans and Amyes, 
2014). 
 
More importantly, successful intra- and interspecies transmission of these genes 
have been described with enzymes such as OXA-23 and OXA-58, currently 
disseminated globally (Munita and Arias, 2016). 
 
Summary of all the ß-lactamases mentioned above are shown in Table 2. 
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Molecular classification of 
ß-lactamases 
Example Remarks 
A KPC-like Carbapenemase 
CTX-M-like ESBL 
SHV-1-like 
TEM-1-like 
Penicillinases 
IMI 
NMC 
SME 
Chromosomally encoded 
B IMP-like 
NDM-like 
SPM-like 
VIM-like 
Carbapenemases 
C AmpC Chromosomally encoded 
ACT-like 
ACC-like 
CFE-like 
CMY-like 
DHA-like 
FOX-like 
 LAT-like 
MIR-like 
MOX-like 
Plasmid encoded 
D OXA-11-like ESBL 
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OXA-23-like Carbapenemase 
OXA-48-like Carbapenemase 
Table 2. Molecular classification of ß-lactamases. 
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1.6.2 Polymyxin: an old antibiotic repurposed 
Polymyxins are a family of nonribosomal lipopeptide nonapeptides, isolated from 
Bacillus polymyxa in 1947 (Walsh and Wencewicz, 2016). Polymyxin B and E 
(colistin) were used against Gram-negative bacterial infections for decades, 
however, due to neurotoxicity and nephrotoxicity, this led to their replacement 
with subsequent generations of less toxic antibiotics (Walsh and Wencewicz, 
2016). 
 
The recent emergence of multidrug-resistant Gram-negative organisms including 
the rise of carbapenem resistance had led to the repurposing of polymyxins 
antibiotic (Walsh and Wencewicz, 2016). 
 
Colistin disrupts membrane integrity through displacement of cations like Mg2+ 
and Ca2+ in the outer membrane (Falagas and Kasiakou, 2005). The 
lipopolysaccharide (LPS) is therefore destabilized, consequently increasing the 
permeability of the bacterial membrane, leading to leakage of the cytoplasmic 
content and ultimately causing cell death (Falagas and Kasiakou, 2005; Li et al., 
2006a)  
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1.6.2.1 Polymyxin Resistance mechanisms 
1.6.2.1.1 Chromosomal-mediated  
Most mechanisms conferring resistance to colistin are directed against 
modifications of the lipid A moiety of lipopolysaccharide (LPS), which is the 
primary target of colistin (Baron et al., 2016). Mechanisms that are associated 
with colistin resistance across different bacterial genera may be different, but 
more often than not the majority always follow the common pathway of lipid A 
modifications with 4-amino-4-deoxy-L-arabinose (L-Ara4N) and/or 
phosphoethanolamine (PEtN) (Baron et al., 2016). 
 
Resistance mechanisms described to date involve lipopolysaccharide (LPS) 
modification, particularly through derivatization of lipid A phosphate moieties 
with a sugar or ethanolamine (Wright et al., 2015). These modifications reduce 
the electrostatic affinity between the cationic colistin and anionic LPS (Wright et 
al., 2015). Mutations in the transcriptional regulatory systems controlling these 
LPS modifications are a common genetic mechanism leading to colistin resistance 
(Wright et al., 2015). For example, the PhoPQ and PmrAB two-component 
regulatory systems (TCRS) regulate expression of the gene (pmrC) that codes for 
the addition of phosphoethanolamine (pETN) and genes encoding biosynthesis 
and lipid A transfer of 4-amino-4-deoxy-L-arabinose (L-ara4N) (pmrHFIJKLM) 
(Wright et al., 2015). Other regulatory components in this pathway include PmrD 
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and MgrB, two connector proteins that convey feedback between the PmrAB and 
PhoPQ TCRS (Lippa and Goulian, 2009; Cannatelli et al., 2013; Luo et al., 2013; 
Lopez-Camacho et al., 2014) (Error! Reference source not found.). Mutations in p
mrAB, phoPQ, and mgrB have been identified as mechanisms conferring colistin 
resistance in several Gram-negative pathogens, including K. pneumoniae (Adams 
et al., 2009; Beceiro et al., 2011; Lesho et al., 2013; Cannatelli et al., 2014; Jayol et 
al., 2014; Kim et al., 2014). 
 
Recently, mutations in the crrB gene, belonging to a third two-component system 
(named CrrAB for Colistin Resistance Regulation) (Figure 8) are involved in LPS 
modifications, have also been associated with colistin resistance (Wright et al., 
2015; Cheng et al., 2016). Mutations in the crrB gene is responsible for the 
increase of the crrC gene transcription, which in turns regulates the expression of 
the pmrC gene and the pmrHFIJKLM operon, through the PmrAB two-component 
system (Cheng et al., 2016). The expression of these genes leads to the addition 
of cationic groups on the LPS and consequently to colistin resistance (Jayol et al., 
2017). 
 
1.6.2.1.2 Plasmid-mediated  
The encoded MCR-1 protein is a member of the phosphoethanolamine 
transferase enzyme family, mcr-1 gene acquisition results in the addition of 
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phosphoethanolamine to lipid A (Figure 8), and consequently results in a more 
cationic LPS and reduction in polymyxin affinity (Poirel et al., 2017). Detailed 
plasmid-mediated colistin resistance mechanism would be further discussed in 
Chapter 4.  
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Figure 8. Two-component systems (TCSs) for colistin resistance in bacteria. Activation of the TCSs, stimulates the transcription of 
lipopolysaccharide (LPS) modification loci arnBCADTEF (pmrHFIJKLM) and pmrC, which leads to the synthesis of 4-amino-4-deoxyl-arabinose and 
phosphoethanolamine (PEtN), respectively.TCS CrrAB (recenltly discovered) activates PmrAB and not the PhoPQ via H239_3062 (now referred 
to as CrrC) with subsequent upregulation of arnBCADTEF and pmrC. In addition, the recently identified, novel PEtN-encoding gene mcr-1, which 
modifies by adding phosphoethanolamine to the lipid A of LPS. Green colour - novel protein-encoding genes. Yellow and dashed lines - missing 
links (genes) or pathways not yet fully understood, respectively. Taken from (Baron et al., 2016) 
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1.6.3 Aminoglycosides 
Resistance to aminoglycosides due to target modification involves G1405 
methylation of 16S rRNA (Garneau-Tsodikova and Labby, 2016). The first report of 
16s rRNA methyltransferase gene was armA in multidrug-resistant Klebsiella 
pneumoniae isolated in France (Galimand et al., 2003). Seven other enzymes 
associated with 16S rRNA methylation were reported which includes rmtA 
(Yokoyama et al., 2003), rmtB (Doi et al., 2004), rmtC (Wachino et al., 2006), rmtD 
(now renamed as rmtD1) (Doi and Arakawa, 2007; Doi et al., 2007b), rmtD2 
(shares 96.4% amino acid identity with rmtD1) (Tijet et al., 2011), rmtE (Davis et 
al., 2010) and npmA (Wachino et al., 2007). 
 
Aminoglycoside-modifying enzymes (AME) are  the most common aminoglycoside 
resistance mechanism (Garneau-Tsodikova and Labby, 2016). AME catalyze the 
modification at −OH or −NH2 groups of the 2-deoxystreptamine nucleus or the 
sugar moieties leading to in vivo resistance phenotype (Ramirez and Tolmasky, 
2010). AME are divided into acetylation of an amino group [N-acetyltransferases 
(AAC)], adenylation [O-nucleotidyltransferases (ANT)] and phosphorylation [O-
phosphotransferases (APH)] of a hydroxyl group (Ramirez and Tolmasky, 2010). 
The AME enzymes and its encoding gene are summarized in Table 3. 
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Enzymes Genes  Resistance phenotype 
N-acetyltransferases (AAC) 
AAC(3)-I aac(3)-Ia 
aac(3)-Ib 
Gentamicin 
AAC(3)-II aac(3)-Iia 
aac(3)-Iib 
aac(3)-Iic 
Gentamicin, Tobramycin 
AAC(3)-III aac(3)-IIIa 
aac(3)-IIIb 
aac(3)-IIIc 
Gentamicin, Tobramycin, Kanamycin, 
Neomycin, Paromycin 
AAC(3)-IV aac(3)-Iva Gentamicin, Tobramycin 
AAC(3)-VI aac(3)-Via Gentamicin 
AAC(6’)-I aac(6’)-Ia 
aac(6’)-Ib 
aac(6’)-Ic 
aac(6’)-Id 
aac(6’)-Ie  
aac(6’)-If 
aac(6’)-Ig 
aac(6’)-Ih 
aac(6’)-Ii 
Tobramycin, Amikacin 
AAC(6’)-II aac(6’)-Iia 
aac(6’)-Iib 
Gentamicin, Tobramycin 
AAC(6’)-
APH(2”) 
aac(6’)-
aph(2”) 
Gentamicin, Tobramycin, Amikacin 
AAC(2’-I) 
 
aac(2’)-Ia Gentamicin, Tobramycin 
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O-nucleotidyltransferases (ANT) 
ANT(2”)-I ant(2”)-Ia 
ant(2”)-Ib 
ant(2”)-Ic 
Gentamicin, Tobramycin, Kanamycin 
ANT(3”)-I ant(3”)-Ia Streptomycin, Spectinomycin 
ANT(4’)-I ant(4’)-Ia 
 
Tobramycin, Amikacin 
ANT(4’)-II ant(4’)-Iia Tobramycin, Amikacin 
ANT(6)-I ant(6)-Ia Streptomycin 
O-phosphotransferases (APH) 
APH(2”)-I aph(2”)-Ia Gentamicin, Tobramycin, Amikacin 
APH(3”)-I aph(3’)-Ia 
aph(3’)-Ib 
aph(3’)-Ic 
Kanamycin, Neomycin, Paromycin 
APH(3’)-II aph(3’)-Iia Kanamycin, Neomycin, Paromycin, 
Gentamicin B 
APH(3’)-III aph(3’)-IIIa Kanamycin, Neomycin, Paromycin, Amikacin, 
Gentamicin B 
APH(3’)-IV aph(3’)-Iva Kanamycin, Neomycin, Paromycin 
APH(3’)-V aph(3’)-Va 
aph(3’)-Vb 
aph(3’)-Vc 
Neomycin, Paromycin 
APH(3’)-VI aph(3’)-Via 
aph(3’)-Vib 
Kanamycin, Neomycin, Paromycin, Amikacin, 
Gentamicin B 
APH(3’)-VII aph(3’)VIIa Kanamycin, Neomycin 
APH(3”)-I aph(3”)-Ia 
aph(3”)-Ib 
Streptomycin 
APH(6)-I aph(6)-Ia 
aph(6)-Ib 
Streptomycin 
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aph(6)-Ic 
aph(6)-Id 
Table 3. Summary of the classification of aminoglycoside modifying enzymes 
(AME), AME genes and its resistance phenotypes. Adapted from (Shaw et al., 
1993). 
 
Another member of an aminoglycoside antibiotic is streptomycin and resistance is 
mediated by the linked strA-strB gene pair, inactivating two phosphotransferase 
enzymes (aminoglycoside-3”-phosphotransferase and aminoglycoside-6”-
phosphotransferase) (Shaw et al., 1993). These gene pair are widely disseminated 
among diverse Gram-negative bacteria and they have been detected in bacteria 
colonizing plants, animals, humans and farmed fish (Sundin and Bender, 1996; 
Sunde et al., 1998; L'Abee-Lund and Sorum, 2000). 
 
1.6.4 Quinolones 
Quinolone resistance arises due to point mutations in targeting both the gyrase 
and topoisomerase IV or to active efflux (Drlica and Zhao, 1997). The subunits of 
DNA gyrase are GyrA, a 97-kDa protein encoded by the gyrA gene, and GyrB, a 90-
kDa protein encoded by the gyrB gene (Jacoby, 2005). The corresponding subunits 
of topoisomerase IV are ParC (75 kDa) and ParE (70 kDa) (Jacoby, 2005). DNA 
gyrase can introduce negative supercoils into DNA, can remove both positive and 
negative supercoils, and can catenate and decatenate closed circular molecules 
(Jacoby, 2005). DNA topoisomerase IV can also remove positive and negative 
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supercoils and is even better at decatenation than is gyrase (Jacoby, 2005). The 
two enzymes work together in the replication, transcription, recombination, and 
repair of DNA (Jacoby, 2005). 
 
Resistance involves amino acid substitutions in a region of the GyrA or ParC 
subunit termed the “quinolone-resistance–determining region” (QRDR) (Jacoby, 
2005). This region occurs on the DNA-binding surface of the enzyme, (Morais 
Cabral et al., 1997) and for E. coli, DNA gyrase includes amino acids between 
positions 51 and 106 (Friedman et al., 2001), with “hot spots” for mutation at 
amino acid positions 83 and 87 (Jacoby, 2005). The QRDR in DNA gyrase is near 
tyrosine 122, which is covalently bound to phosphate groups on DNA in the initial 
strand-breaking reaction (Jacoby, 2005). 
 
AcrAB-TolC efflux pump in E. coli plays a major role in quinolone efflux and has 
multiple controls (Jacoby, 2005). Mutations in acrR (a repressor of acrAB) causes 
an increase in pump activity (Morais Cabral et al., 1997). Conversely, inactivation 
in marR (a repressor of marA) due to mutation allow MarA to activate acrAB, tolC, 
and a gene that decreases translation of ompF, hence collectively decreasing influx 
and increased efflux of quinolones (Cohen et al., 1989; Alekshun and Levy, 1997). 
 
The plasmid-mediated quinolone resistance gene was named “qnr” (Jacoby, 
2005). Qnr proteins were shown to be members of the pentapeptide repeat 
protein (PRP) family, and to be related to MfpA, a protein cloned from 
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Mycobacterium smegmatis that also causes (low-level) resistance to 
fluoroquinolones (Jacoby, 2005). 
 
Six major Qnr families have been identified: QnrA, QnrB, QnrS, QnrC, QnrD and 
QnrVC (Rodriguez-Martinez et al., 2016). For example, QnrA can reverse the ability 
of fluoroquinolones to inhibit DNA gyrase, (Tran and Jacoby, 2002) since it can 
bind directly to DNA, reduce the binding of gyrase to DNA and protecting 
topoisomerase IV from the quinolone (Jacoby, 2005). QnrA can bind to the DNA 
gyrase holoenzyme and its respective subunits, GyrA and GyrB (Jacoby, 2005). This 
binding of Qnr to gyrase does not require the presence of an enzyme-DNA-
quinolone complex since it takes place in the absence of relaxed DNA, 
ciprofloxacin and ATP (Tran et al., 2005a; Tran et al., 2005b). 
 
Two other mechanisms unrelated to Qnr, but also encoded by plasmid genes, have 
been discovered; one of these corresponds to an acetyltransferase [AAC(6 )-Ib-cr] 
(Robicsek et al., 2006) which is a variant of an enzyme involved in aminoglycoside 
modification (and resistance), the other includes active efflux pumps such as QepA 
and OqxAB (Hansen et al., 2004; Perichon et al., 2007; Yamane et al., 2007). QepA 
is member of the major facilitator superfamily (MFS) transporters able to 
eliminate hydrophilic fluoroquinolones from the cell (ciprofloxacin and norfloxacin 
especially) by an active efflux mechanism, leading to a moderate (2- to 64-fold) 
increase in the MIC  (Perichon et al., 2007; Yamane et al., 2007; Cattoir et al., 
2008a; Cattoir et al., 2008b). OqxAB is an efflux system in the resistance-
nodulation-cell division (RND) family of transporters, commonly found in K. 
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pneumoniae (Jacoby, 2005). OqxAB was initially recognized on transmissible 
plasmids responsible for resistance to olaquindox, used for growth enhancement 
in pigs (Sorensen et al., 2003; Hansen et al., 2004). OqxAB has a wide substrate 
specificity, including not only quinolones such as ciprofloxacin, flumequine, 
norfloxacin and nalidixic acid but also chloramphenicol and trimethoprim (Hansen 
et al., 2007). 
 
1.6.5 Chlorampenicol and florfenicol 
Both chloramphenicol (Cm) and its fluorinated derivative florfenicol (Ff) are both 
highly potent inhibitors of bacterial protein synthesis (50S subunit) (Schwarz et al., 
2004). Florfenicol are mostly used in veterinary medicine and not approved for 
human use (White et al., 2000). 
 
The most common mechanism in chloramphenicol resistance is enzymatic 
inactivation by acetylation of the drug via different types of chloramphenicol 
acetyltransferases (CATs) (Murray and Shaw, 1997). Other resistance mechanisms 
that have been reported includes efflux systems, inactivation by 
phosphotransferases, mutations of the target site and permeability barriers 
(Shaw, 1983; Murray and Shaw, 1997). CATs are composed of two defined types 
which distinctly differ in their structure; type A and type B CATs (Schwarz et al., 
2004). 
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The Type A CATs have been detected in a wide variety of bacteria (Shaw, 1983) 
(Murray and Shaw, 1997) with at least 16 distinct groups, A-1–A-16, of catA genes 
(Schwarz et al., 2004). For example in group A-1, catI gene was originally identified 
as part of transposon Tn9 (Alton and Vapnek, 1979) in Escherichia coli and has 
been detected on a variety of resistance plasmids of Gram-negative bacteria, such 
as Acinetobacter spp. (Elisha and Steyn, 1991), Photobacterium damselae subsp. 
piscicida, formerly known as P. piscicida (Kim and Aoki, 1993), and Pseudomonas 
putida(Nomoto and Yamagishi, 1991). Recently, cat genes of this group have also 
been identified in S. Typhi, (Parkhill et al., 2001) Serratia marcescens (Gilmour et 
al., 2003) and S. flexneri (Luck et al., 2001). 
 
Other than chloramphenicol resistance, some of the type A CATs have specific 
properties, such as the capability to mediate resistance also to fusidic acid (Volker 
et al., 1982; Shaw, 1983) or sensitivity to inhibition by thiol-reactive reagents 
(Murray et al., 1990). 
 
For Type B CATs, occasionally referred to as xenobiotic acetyltransferases, they 
also inactivate chloramphenicol (Cm) by acetylation (Schwarz et al., 2004). Type B 
cat genes are composed of at least five different groups: B-1–B-5 (Schwarz et al., 
2004). The first type B cat gene (catB1) describe was cloned from the chromosome 
of A. tumefaciens (Tennigkeit and Matzura, 1991; Goodner et al., 2001). As with 
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the catB2 gene, it was initially found on the multiresistance transposon Tn2424 
from E. coli (Parent and Roy, 1992). 
Florfenicol resistance mechanism is unknown but, it is associated with the flo 
determinant, a highly conserved gene sequence detected in Salmonella enterica 
serovar Typhimurium DT104 (Bolton et al., 1999; Briggs and Fratamico, 1999) and 
in the fish pathogen Pasteurella piscicida (Photobacterium damsela) (Kim and 
Aoki, 1996). In addition, the flo gene confers resistance to both chloramphenicol 
and florfenicol (Kim et al., 1993; Bolton et al., 1999). 
 
1.6.6 Fosfomycin 
Mechanisms of fosfomycin resistance in Gram-negative bacteria can be conferred 
by defects in the transporters across the cytoplasmic membrane, amino acid 
substitution in the MurA active site which decreases fosfomycin binding affinity, 
and production of the fosfomycin-inactivating enzyme FosA (Falagas et al., 2016). 
FosA is an Mn2+- and K+-dependent dimeric glutathione S-transferase, it works by 
catalyzing the nucleophilic addition of glutathione to the epoxide ring of 
Fosfomycin (Bernat et al., 1997) and can be found encoded on a bacterial 
chromosome or a plasmid (Ito et al., 2017). The fosA gene was first described in 
Serratia marcescens, carried on transposon Tn2921 located on a conjugative 
plasmid (Mendoza et al., 1980; Garcia-Lobo and Ortiz, 1982), but it has a high 
identity with chromosomal fosA of Enterobacter cloacae, where it likely originated 
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(Ito et al., 2017). In addition, other plasmid-borne glutathione transferase (FosA 
type) enzymes are FosA3, FosA4, FosA5, and FosC2 (Silver, 2007). 
1.6.7 Macrolide 
Acquired macrolide resistance results from a variety of mechanisms of resistance, 
several of which have already been reported in Enterobacteriaceae (Leclercq, 
2002; Ojo et al., 2004). This includes target site modification by methylases 
encoded by erm genes, in particular erm(A), erm(B), and erm(C). (Phuc Nguyen et 
al., 2009) 
 
In addition, macrolides may be inactivated by modifying enzymes that was first 
reported in Enterobacteriaceae (Arthur et al., 1987; O'Hara et al., 1989) e.g., 
esterases encoded by ere(A) or ere(B) genes or phosphotransferases encoded 
by mph(A), mph(B), and mph(D) genes (Phuc Nguyen et al., 2009). All of these 
genes confer full cross-resistance between erythromycin and azithromycin 
(Leclercq, 2002). 
 
1.6.8 Sulfonamide 
Sulfonamide resistance is conferred by mutations either in the DHPS 
(dihydropteroate synthase) gene (folP) (Swedberg et al., 1993) or from the 
acquisition of an alternative DHPS gene (sul) (Radstrom and Swedberg, 1988; 
Sundstrom et al., 1988; Perreten and Boerlin, 2003). DHPS is a catalytic enzyme in 
the folic acid biosynthesis pathway, resulting in the inhibition of dihydrofolic acid 
formation (Skold, 2000). 
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There are three alternative DHPS genes; sul1 is usually located on the 3’ conserved 
region of a class 1 integron (Skold, 1976) and is frequently identified with this 
potentially mobile element in the slurry and soil environment (Sundstrom et al., 
1988; Rosser and Young, 1999; Guerra et al., 2003). The sul2 gene was first 
identified on RSF1010 plasmid in Escherichia coli and has also been found on small 
nonconjugative resistance plasmids (Radstrom and Swedberg, 1988). While, the 
sul3 gene were found during a study identified in sulfonamide resistance in 
pathogenic E. coli isolates from swine from Switzerland (Perreten and Boerlin, 
2003).  
 
1.6.9 Tetracycline 
The most common tetracycline resistance mechanism in Gram-negative bacteria 
(E. coli) is the extrusion of the drug from the cytoplasm via efflux (Chopra and 
Roberts, 2001). Tetracycline-specific efflux pumps are members of the major 
facilitator superfamily (MFS) of efflux pumps (Paulsen et al., 1996). The 
tetracycline-specific efflux pump operates by transporting tetracycline in an 
energy-dependent fashion, via proton exchange, thereby reducing the 
intracellular concentration of the drug (Chopra and Roberts, 2001). The Tet pumps 
are divided into six groups based on amino acid sequence; Tet(A), Tet(B), Tet(C), 
Tet(D), and Tet(E) placed in group 1 due to amino acid sequence similarity (Chopra 
and Roberts, 2001) (Roberts, 2005). In addition, there are other Tet pumps which 
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includes Tet(G), Tet(H), Tet(K) and Tet(L) (Roberts, 2005). These tetracycline-
specific efflux pumps not only confers resistance to tetracycline but with pump 
encoded by tet(B) gene both tetracycline and minocycline can be extruded (Guay 
and Rothstein, 1993; Petersen et al., 1999). 
 
1.6.10 Trimethroprim  
Mechanism to trimethroprim is caused by modifications in the target enzyme 
dihydrofolate reductase (dfr) encoded by dfr genes (Brolund et al., 2010). So far 
30 dfr genes have been described and they are usually associated with integrons 
(Skold, 2001). The dfr genes are consecutively numbered from dfr1 onwards since 
this was the first gene observed (Skold and Widh, 1974). In addition, the most 
prevalent trimethoprim resistance gene among Gram-negative bacteria seems to 
be dfr1, which occurs in a cassette in both class 1 and class 2 integrons (Skold, 
2001). In a study done by Brolund et al., molecular characterization of 
trimethroprim resistance in E. coli showed other dfr genes alongside dfrA1 were 
observed which includes dfrA5, dfrA7, dfrA14 or dfrA17 (Brolund et al., 2010). 
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Study objectives 
AMR is a global health threat that will contribute to 10 million death by 2050. In 
2017, the World Health Organisation (WHO) has released a priority list of 
pathogens of great importance. Top of the priority lists are those designated 
critical pathogens: carbapenem-resistant Pseudomonas aeruginosa, 
Acinetobacter baumannii, Enterobacteriaceae and 3rd generation cephalosporin 
resistant E. coli and Klebsiella spp. 
 
With these emerging pathogens compromising the ability to treat infections, a 
global action plan has been developed by the WHO to tackle AMR (WHO, 2015). 
These plans set 5 strategic objectives which includes (WHO, 2015):  
 
§ Improving awareness and understanding of antimicrobial resistance 
§ Strengthening knowledge through surveillance and research 
§ Reducing the incidence of infection 
§ Optimising the use of antimicrobial agents 
§ Developing an economic case for sustainable investment that takes 
account of the needs of all countries, and increases investment in new 
medicines, diagnostic tools, vaccines and other interventions. 
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A more simplistic bundled approach could focus on 4 key points: 
 
§ Surveillance – screening diagnostic tools, antimicrobial stewardship 
§ Effective detection – new rapid diagnostics 
§ Effective treatment – development of antimicrobial agents 
§ Effective control strategies – international collaboration 
 
Hence, the objectives in this study are defined in relation to this approach:  
 
Chapter 2 
- Molecular analysis (acquired resistance gene and other mobile genetic elements) 
of carbapenem-resistant Acinetobacter baumannii clinical isolates from Brunei 
Darussalam. 
 
- Evaluation of an acidimetric method for the detection of carbapenemase 
production in carbapenem-resistant Pseudomonas aeruginosa clinical isolates 
from Brunei Darussalam. 
 
Chapter 3 
- Investigation of the mechanisms of resistance amongst carbapenem-resistant K. 
pneumoniae (CRKP) clinical isolates from Brunei Darussalam. 
 
- Characterisation by multiple phenotypic (RAPID CARB Blue kit, Micronaut-S Beta 
Lactamase VII, OXA-48 K-SeT) and molecular methods of CRKP clinical isolates 
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from Brunei Darussalam. In addition, evaluation of an OXA-48 K-SeT lateral flow 
assay for the detection of OXA-48 carbapenemase in CRE clinical isolates. 
 
Chapter 4 
Part 1: 
- Development and evaluation of a novel media for the detection of colistin-
resistant Gram-negative pathogens. 
 
Part 2: 
- To perform antimicrobial surveillance and determine the prevalence of colistin-
resistant E. coli isolated from chicken cloacal and human clinical faecal samples in 
Brunei Darussalam. 
 
Part 3: 
- Molecular analysis of novel mcr-1 variants found during surveillance. 
 
Chapter 5 
- Investigating the impact of acquiring plasmid-mediated polymyxin resistance 
(PMPR) in E. coli isolated from chickens and humans on the survival, virulence and 
fitness in a G. mellonella infection model. 
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Chapter 2 
Carbapenem-resistant Gram-negative 
Non-fermenters in Brunei Darussalam 
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2.1 Introduction 
In this chapter, phenotypic and genotypic methods will be performed for detecting 
carbapenemases, resistance mechanisms and associated mobile genetic elements 
(MGE) in carbapenem resistant Gram-negative non-fermenters collected in Brunei 
Darussalam. The non-fermenters include Pseudomonas aeruginosa and 
Acinetobacter baumannii, an important World Health Organization (WHO) critical 
pathogen lists.  
 
With regards to detecting carbapenemases, Modified Hodge Test (MHT) is the 
only method used in Brunei’s Microbiology Laboratory. However, there are 
limitations to this method such as a lack of specificity and longer time to a result. 
In addition, molecular diagnostic techniques are not practiced, as Brunei’s 
Microbiology Laboratory is dependent on culture and antibiotic susceptibility 
testing (AST). In order to progress and combat AMR, phenotypic and genotypic 
tools should be performed to complement one another. Hence, introducing new 
phenotypic methods and molecular diagnostic tools will allow earlier detection, 
inform on resistance mechanisms, better treatment outcomes and improve 
infection control management.  
 
Recent attention has focused on non-lactose fermenting Gram-negative bacteria 
such as Acinetobacter baumannii and Pseudomonas aeruginosa that 
predominantly cause hospital-acquired infections such as urinary tract infection 
 
 
101 
(UTI), bloodstream infection (BSI), lower respiratory tract infection (LRTI) and 
meningitis (CDC, 2011). 
Carbapenem-resistant P. aeruginosa (CRPA) and A. baumannii (CRAB) are very 
well documented in Southeast Asia (SEA) (Suwantarat and Carroll, 2016). 
Mechanisms of CR in P. aeruginosa are multifactorial and involve non-enzymatic 
mechanism such as porin loss (OprD gene mutation), the combination of efflux 
pumps (MexAB-OprM) and overexpression of AmpC ß-lactamases (Suwantarat 
and Carroll, 2016). Additionaly, enzymatic mechanisms such as IMP-type metallo-
β-lactamase (blaIMP) and Verona integron-mediated MBL (blaVIM) carbapanemase 
genes have also been reported in isolates from surveillance studies in the 
Southeast Asia region (Koh, 2008; Khosravi et al., 2010; Khuntayaporn et al., 2012; 
Khuntayaporn et al., 2013; Kim et al., 2013; Tang et al., 2014; Teo et al., 2015)  
 
The successful global dissemination of multi-drug resistance (MDR) Acinetobacter 
spp is in association with the successful clonal lineage international clone I, II, III 
(Matsui et al., 2018) (previously named European clone, EU I, II, III or Global clone 
1, 2) (Higgins et al., 2010). With respect to CRAB in SEA region, the dominant type 
of OXA-carbapenemase gene is mediated by blaOXA-23 belonging to global clone 2 
(GC2), (Kim et al., 2013; Teo et al., 2015) although both GC1 and GC2 have been 
reported worldwide (Chaisathaphol and Chayakulkeeree, 2014). Apart from SEA 
region, Global clone 2 has been reported in Europe and now in South Korea, China 
and Australia (Kim et al., 2013). This shows the importance of clonal spread where 
Acinetobacter baumannii infections with acquired carbapenemase gene is a 
serious infection control problem (Higgins et al., 2010). Other OXA 
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carbapenemases reported in CRAB in this region includes the blaOXA-40 and blaOXA-
58 (Koh, 2008; Kim et al., 2013; Tang et al., 2014; Teo et al., 2015). With respect to 
the MLST and plasmid acquired by GC2 in OXA-23 A. baumannii isolates in the SEA 
region, it is unknown. 
 
With the global spread of CRAB, molecular tools such as PCRs targeting the genes 
encoding carbapenemases, clonal typing and other mobile genetic elements 
should be performed. For example, the use of multiplex PCR for detecting OXA 
carbapenemases (OXA-23-like, OXA-24-like, OXA-51-like, OXA-58-like) in 
Acinetobacter spp (Woodford et al., 2006). 
 
Carbapenemase detection in carbapenem-resistant Gram-negative non-
fermenters can be a problem in routine diagnostic microbiology laboratories due 
to limited diagnostic capacity, especially in developing countries (Zellweger et al., 
2017). Although, other methods such as combined disk synergy test (Carbapenem 
Inactivation Method, CIM; ROSCO Kit) and biochemical/acidimetric tests 
(CarbaAcinetoNP, RAPIDEC® CARBA NP, Blue-Carba) have been developed and 
evaluated, their availability and costs will be the limiting factor for its use in 
routine diagnostic laboratories in developing countries (Osei Sekyere et al., 2015). 
In addition, most of these methods works best in Enterobacteriaceae and less 
likely with non-fermenters (Osei Sekyere et al., 2015). 
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Carbapenem inactivation method (CIM) is a method for detecting metallo-b-
lactamase (MBL) specifically VIM carbapenemases and the OXA-type carbapenem-
hydrolyzing class D b-lactamase, CHDL subgroups (OXA-23, OXA-40, OXA-58 and 
OXA-143) in A. baumannii (van der Zwaluw et al., 2015). CIM works by using 10µg 
MEM, meropenem (susceptibility-testing disk) immersed and incubated for 2 
hours with the test bacterial isolate suspension and placed on Mueller-Hinton 
(MH) agar inoculated with the E. coli indicator control type strain (American Type 
Culture, Collection, ATCC 25922) as the background (van der Zwaluw et al., 2015). 
The only challenge with this method is detecting weak carbapenemase activities, 
especially with CHDL (van der Zwaluw et al., 2015). 
 
CarbAcineto NP test is the updated version of the Carba NP (for 
enterobacteriaceae) used specifically for carbapenemase detection in 
Acinetobacter spp, that is based on the colorimetric changes and pH-based 
detection of hydrolysis of the β-lactam ring of imipenem, performed on Trypticase 
soy (TS) agar (Dortet et al., 2014a; Dortet et al., 2014b). The updated version uses 
NaCl solution replacing the lysis buffer and increasing the bacterial inoculum to a 
full calibrated loop in order to increase the enzyme quantity (Dortet et al., 2014b). 
The use of NaCl solution provides two advantages; it does not buffer enough to 
interfere with slight pH changes and efficient lysis of the bacteria due to its 
hyperosmotic properties (Dortet et al., 2014b). The presence MBL-producers will 
result in a color change of phenol red solution (red to yellow/orange) in less than 
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15 mins (Dortet et al., 2014b). However, the limitation of this test is the use of 
higher inoculum to produce a positive result.  
 
RAPIDEC® CARBA NP test kit detects carbapenemase from bacterial colonies from 
a selective or non-selective agar plate (Garg et al., 2015). The time for detection is 
around 30 minutes to 2 hours with sensitivity and specificity of 97.8% (Garg et al., 
2015). The test was performed using a loop full of bacterial colony picked up from 
overnight Muller-Hinton agar plates and mixed with API suspension medium 
(provided with the kit) and incubated at 37°C (Garg et al., 2015). Positive results 
showed a colour change from red to yellow/orange and negative results remain 
red (Garg et al., 2015). 
 
In an evaluation study done by Poirel et al., they have documented RAPIDEC® 
CARBA NP with sensitivity and specificity of 96% when testing it against pre-
characterized strains (Poirel and Nordmann, 2015). They have also reported false 
negative results with Group D carbapenemases; which is in accordance with the 
fact that Group D carbapenemases are known to lack significant carbapenemase 
activity (Poirel and Nordmann, 2015). Carbapenemase activity was detected in A. 
baumannii isolates with OXA-23, but no activity with carbapenem-resistant A. 
baumannii due to the overexpression of chromosomally-encoded oxacillinase 
gene, blaOXA-66 (an OXA-51-like enzyme) (Poirel and Nordmann, 2015). 
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Blue-Carba test was a modification version of the Carba NP test, the aim being to 
contain costs and increase simplicity (Pires et al., 2013). Carbapenemase 
production detection with this method showed 100% sensitivity and specificity for 
all Gram-negative carbapenemase-producing bacteria (Pires et al., 2013). 
However, with OXA-48 producers higher inocula are required (Pires et al., 2013). 
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2.2 Objectives 
- Molecular analysis (acquired resistance gene and other mobile genetic elements) 
of carbapenem-resistant Acinetobacter baumannii clinical isolates from Brunei 
Darussalam. 
 
-To evaluate an acidimetric Blue-Carba method for the production of 
carbapenemases in carbapenem-resistant Pseudomonas aeruginosa clinical 
isolates from Brunei Darussalam. 
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2.3 Methods 
2.3.1 Bacterial isolates collection 
Carbapenem-resistant Acinetobacter baumannii (CRAB) (n=109) and 
Pseudomonas aeruginosa (CRPA) (n=22) clinical Isolates were collected from July 
2014 – February 2015 and stored in Pro-Lab Diagnostics™ Microbank™ Bacterial 
and Fungal Preservation System, cryobeads (Fisher Scientific, Leicestershire, UK) 
at -70⁰C in Microbiology Laboratory Services, Brunei Darussalam. Isolates were 
recovered as part of routine testing done in the Microbiology Laboratory Services, 
based on their carbapenem resistance profiles (resistance to either imipenem or 
meropenem or both). 
 
2.3.2 Transportation of clinical isolates to the United Kingdom (UK) 
Isolates from Pro-Lab Diagnostics™ Microbank™ Bacterial and Fungal Preservation 
System, cryobeads (Fisher Scientific, Leicestershire, UK) were seeded onto pre-
poured Mueller Hinton II Agar (ISOLAB, Selangor, Malaysia) incubated at 37⁰C for 
24 hours and transported using Trans® Amies (MWE, Wiltshire, UK) to Queen Mary 
University of London, Blizard Institute, Centre for Immunobiology, UK with an 
estimated delivery of 3 days using FEDEX courier. 
 
Isolates were inoculated back onto Mueller-Hinton 2 (MH2) agar (Sigma-Aldrich, 
Dorset, UK) in the UK for further testing. 
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2.3.3 Source of samples 
Clinical samples were obtained mostly from the Intensive Care Unit (ICU) and 
medical wards in RIPAS hospital and also from other district hospitals in Brunei 
Darussalam. Source of specimens were from respiratory, pus and faecal samples 
unless otherwise stated in the methodology. 
 
2.3.4 Media and broth preparation 
Media used: 
Mueller-Hinton 2 (MH2) agar (Sigma-Aldrich, Dorset, UK), Luria-Bertani (LB) agar 
(Sigma-Aldrich, Dorset, UK), MacConkey agar (Sigma-Aldrich, Dorset, UK). 
 
Broth used: 
Luria-Bertani (LB) broth (Sigma-Aldrich, Dorset, UK), Mueller-Hinton 2 (MH2) 
broth (Sigma-Aldrich, Dorset, UK), Trpyticase Soy Broth (TSB) (Oxoid, Basingstoke, 
UK) 
 
All media and broth were weighed out following the manufacturer’s instruction to 
a final volume of 500 ml in distilled water. Media and broth were then autoclaved 
at 15 lbs/sq inch at 121oC for 15min. 
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2.3.5 Antibiotic Susceptibility Testing (AST) and Mininum Inhibitory 
Concentration (MIC) 
AST and minimum inhibitory concentration (MIC) for both A. baumannii and P. 
aeruginosa clinical isolates were tested prior in Brunei using VITEK® 2XL machine, 
VITEK® 2 GN ID (Gram-Negative Identification) and AST card (GN-75) (bioMérieux, 
Marcy l’Etoile, France) according to CLSI guidelines (CLSI, 2014). AST results were 
interpreted as S, I or R (Sensitive, Intermediate or Resistance).  
 
The antibiotic panel tested includes amikacin, ampicillin, aztreonam, cefepime, 
cefoxitin, ceftazidime, ceftriaxone, ciprofloxacin, colistin, gentamicin, imipenem, 
meropenem, netilmicin, piperacillin, piperacillin/tazobactam, 
ampicillin/sulbactam, co-trimoxazole, levofloxacin and ticarcillin/clavulanic acid.  
 
2.3.6 Molecular Methodologies  
2.3.6.1 DNA extraction  
Analytical Grade Chelex® 100 (Bio-Rad, Hertfordshire, UK) were used for DNA 
extraction of isolates. Briefly, 5% of chelex were made by mixing 0.5 g of chelex 
powder with 10 ml of distilled water. 
 
A 5 µl loop full obtained from a bacterial overnight culture on MH2 media was 
added into 100 µl of 5% Chelex solution in a 1.5 ml sterile Eppendorf tube. The 
mixtures were then heated in a heat block at 100°C for 15 mins. The mixtures were 
centrifuged using Heraeus Biofuge Pico centrifuge (DJB Labcare, Buckinghamshire, 
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UK) at 13000 rpm for 1 min. The DNA lysate (supernatant) was pipetted out and 
saved down in a new sterile Eppendorf tube and stored at 2-8°C for further testing. 
 
2.3.6.2 DNA purification 
Wizard® SV Genomic DNA Purification kit (Promega, Southampton, UK) was used 
for isolating genomic DNA from Gram-negative bacteria following manufacturers 
instruction. 
 
1 ml of an overnight culture were pipetted into 1.5 ml sterile Eppendorf tubes. The 
tube was centrifuged using Heraeus Biofuge Pico centrifuge (DJB Labcare, 
Buckinghamshire, UK) at 13,000 rpm for 2 mins to pellet the cells. Supernatant 
was then removed. 600 µl of Nuclei Lysis Solution was added. The cells were then 
resuspended by gently pipetting.  The mixture was then incubated at 80°C for 5 
mins to lyse the cells and then cool down to room temperature.  3 µl of RNase 
solution was added to the cell lysate. Tubes were inverted 2–5 times to mix and 
then incubated at 37°C for 15–60 mins. The samples were cool down to room 
temperature.  
 
200 µl of Protein Precipitation Solution was added to the RNase-treated cell lysate. 
The cell lysate was vortexed at high speed for 20 seconds. The mixture was 
incubated on ice for 5 mins and then centrifuged at 13,000 rpm for 3 mins. The 
supernatant containing the DNA was transferred to a clean 1.5 ml Eppendorf tube 
containing 600 µl of room temperature isopropanol.  
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The mixture was mixed gently by inversion until the thread-like strands of DNA 
form a visible mass and then centrifuged at 13,000 rpm for 2 minutes using 
Heraeus Biofuge Pico centrifuge (DJB Labcare, Buckinghamshire, UK). The 
supernatant was removed, and the tube drained on clean absorbent paper. 600 µl 
of 70% ethanol (at room temperature) was then added and gently inverted several 
times to wash the DNA pellet. The mixture was centrifuged at 13,000 rpm for 2 
mins and ethanol carefully aspirated. The tube was then drained on clean 
absorbent paper and the pellet allowed to air-dry for 10–15 mins.  
 
100 µl of DNA Rehydration Solution was added to the tube and DNA rehydrated 
by incubating at 65°C for 1 hour. The solution was periodically mixed by gently 
tapping the tube.  
 
Alternatively, the DNA was rehydrated by incubating the solution overnight at 
room temperature or at 4°C.  The DNA was then stored at 2–8°C for further testing. 
 
2.3.7 PCR (Polymerase Chain Reaction) 
2.3.7.1 Master Mix 
ThermoPrime 2x ReddyMix PCR Master Mix, with 1.5 mM MgCl2 (Thermofisher 
Scientific, Dartford, UK) 
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Final 1X reaction of this master mix contains 0.625 u ThermoPrime Taq DNA 
Polymerase, 75 mM Tris-HCl (pH 8.8 at 25°C), 20 mM (NH4)2SO4, 1.5 mM MgCl2, 
0.01% (v/v) Tween® 20, 0.2 mM each of dATP, dCTP, dGTP and dTTP, precipitant 
and red dye for electrophoresis. 
 
2.3.7.2 PCR preparation 
ThermoPrime 2X ReddyMix PCR Master Mix, with 1.5 mM MgCl2 (Thermofisher 
Scientific, Dartford, UK) were used unless otherwise stated in the methodology. 
For 1X concentration, 500 µl of the ThermoPrime 2X ReddyMix PCR Master Mix 
was added to 500 µl of nuclease free water to final volume of 1 ml. 
 
25 µl of 1X ThermoPrime ReddyMiX PCR Master Mix were dispensed into 0.9 µl 
amplicon tubes. 1 µl of forward and reverse primers were added. 2 µl of DNA 
lysate (template) was then added to the mixture. 
 
2.3.7.2.1 Gel electrophoresis 
Bionic™ Buffer, 10X Concentrate 
Bionic™ Buffer, 10X Concentrate (Sigma-Aldrich, Dorset, UK) was used for the 
electrophoresis buffer. Briefly, the 1X concentration was prepared by taking 100 
ml of Bionic™ Buffer, 10X Concentrate diluted into 1 Litre of distilled water. 
 
TBE buffer (Tris/Borate/EDTA), 10X Molecular Biology Grade  
 
 
113 
TBE buffer consists of a mixture containing Tris base, boric acid and EDTA. TBE 
buffer (Tris/Borate/EDTA), 10X Molecular Biology Grade (Promega, Southampton, 
UK) were used for gel preparation. Similarly, 1X concentration was made by 
diluting 100 ml of TBE buffer into 1 litre of distilled water. 
 
2.3.7.2.1.1 Agarose gel preparation 
1.5% agarose gel were prepared unless otherwise stated in the methodology. The 
gel was prepared 15-20 mins prior to the end of the PCR run.  1.5% of Ultrapure™ 
Agarose (Thermofisher Scientific, Dartford, UK) was added with 100 ml of 1X TBE 
buffer in a conical flask. The mixture was heated in a microwave and then cooled 
down. 5 µl of ethidium bromide solution (10 mg/ml), molecular grade (Promega, 
Southampton, UK) were added to the molten mixture. The molten mixture was 
then poured onto gel electrophoresis plastic cast together with a well comb and 
allowed to fully solidified. 
 
2.3.7.2.1.2 Electrophoresis chamber  
DNA ladders (100 bp or/and 1Kb bp) (NEW ENGLAND BioLabs, Hitchin, UK) were 
firstly loaded onto the gel’s well immersed in 1X Bionic™ buffer in the chamber. 
DNA samples (controls and tests) were then loaded onto the remaining wells. 
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Positive and negative leads are connected to the chamber and a power supply. 
The voltage for running the gel electrophoresis in most of these studies was 120 V 
for approximately 45 mins. 
 
2.3.7.2.1.3 Band visualization from gel electrophoresis 
Bands were visualized using G:BOX (Syngene, Cambridge, UK) under UV 
transillumination and recorded. 
 
2.3.8 DNA amplicon purification 
The DNA amplicons of the positive bands were cleaned using MinElute® PCR 
purification Kit (Qiagen, Crawley, UK) following manufacturers instruction. 
 
PCR sample was diluted 5-fold with Buffer PB. The mixture was then transferred 
to QIAquick spin column in a provided 2 ml collection tube. The tube was 
centrifuged for 1 min at 13,000 rpm using Heraeus Biofuge Pico centrifuge (DJB 
Labcare, Buckinghamshire, UK).  The flow-through was discarded and placed back 
with the column. The DNA was then washed with 0.75 ml of Buffer PE and 
centrifuged for 1 min. The flow-through again discarded and placed into a 1.5 ml 
sterile Eppendorf tube. The DNA was eluted by adding 50 µl EB buffer (10 mM Tris-
chloride, pH 8.5) or water, by centrifuging again for 1 min. 
 
The concentration of the purified DNA (ng/µl) were measured using NanoDrop 
ND-1000 Spectrophotometer (Labtech International, Heathfield, UK).  Following 
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the manufacturer’s instruction, the DNA sample absorbance is measured at a 
wavelength of 260 nm. 2 sets of ratios are calculated. The first is 260/280, the ratio 
of absorbance at 260 nm and 280 nm is used to assess the purity of DNA. A ratio 
of approximately 1.8 is generally accepted as pure DNA. Lower than 1.8, may 
indicate the presence of protein, phenol or other contaminants that absorb 
strongly at or near 280 nm. 
 
The second is 260/230, the ratio absorbance at 260 nm and 230 nm, a secondary 
measure of nuclei acid purity. This ratio is often higher than the ratio of 260/280 
and are commonly in the range of 1.8-2.2. Ratio lower than this value may indicate 
the presence of co-purified contaminants. 
 
The final nuclei acid quantification is calculated using Beer-Lambert equation 
(modified to use an extinction coefficient with units ng-cm/ µl): 
Beer-Lambert equation, c = (A * e)/b 
 
c = the nucleic acid concentration in ng/microliter, 
A = the absorbance in AU, 
e = the wavelength-dependent extinction coefficient in ng-cm/microliter 
b = the path length in cm.  
 
2.3.9 Sanger sequencing 
Purified DNA templates were sent for Sanger sequencing (SourceBioScience, 
Cambridge, UK). All sequencing reactions were performed on an ABI 3730Xl 
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analyzer (Applied Biosystems, Warrington, UK) with 50cm array using BigDye® 
Terminator v3.1 Cycle Sequencing Kit protocol (SourceBioScience, Cambridge, 
UK). Chromatograms were analysed and consensus sequence assembled using 
GeneTool Lite v1.0. Nucleotide and amino acid sequences were compared using 
blastn, blastp (NCBI, Rockville, Maryland) and ExPASy translate tool (Swiss 
Institute of Bioinformatics).  
 
2.4 Molecular analysis of carbapenem-resistant A. baumannii clinical 
isolates 
2.4.1 Molecular typing 
2.4.1.1 RAPD typing and DiversiLab rep-PCR typing 
RAPD (random amplification of polymorphic DNA) typing is a technique where one 
or more primers of variable length are arbitrarily selected and allowed to anneal 
to the DNA template at low stringency (Power, 1996). RAPD PCR was performed 
on 50 ng DNA template, as previously described (Renders et al., 1996). DNA 
extraction was performed as mentioned in section 2.3.6.1 and carried out in 25 µl 
volume. After PCR, amplicons are run on 2% agarose gel. Band profiles differing by 
one or two bands are considered not to be epidemiologically relevant genetic 
differences (Kersulyte et al., 1995). 
 
Primers used are listed in Appendix A and PCR cycling conditions in Table 3. 
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For gel electrophoresis and band visualization see section 2.3.7.2 
 
Based on preliminary results from RAPD typing, 4 CRAB clinical isolates (AB98, 
AB114, AB133 and AB143) were sent for Diversilab rep-PCR typing. DiversiLab rep-
PCR typing (bioMérieux, Nürtingen, Germany) was done by our collaborators at 
the University of Cologne, Germany (Higgins et al., 2010). The results were 
analysed with the DiversiLab software using the modified Kullback–Leibler 
statistical method to determine distance matrices and the unweighted pair group 
method with arithmetic averages (UPGMA) to create dendrograms (Higgins et al., 
2010). Isolates that clustered >95% were considered related (Saeed et al., 2006). 
The controls included representative isolates belonging to pan-European A. 
baumannii clonal complexes I, II and III (Higgins et al., 2010). 
 
2.4.2 PCR for OXA carbapenemases, 16s rRNA methyltransferase and AmpC 
resistance genes  
Multiplex PCR were used for the identification of OXA carbapenemases (OXA-23-
like, OXA-24-like, OXA-51-like and OXA-58-like), 16s rRNA methyltransferase 
(rmtA, rmtB, rmtC, rmtD, armA and npmA), and single PCR were used to amplify 
AmpC as previously described (Corvec et al., 2003; Woodford et al., 2006; Fritsche 
et al., 2008). 
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DNA extraction was performed as mentioned in section 2.3.6.1 . 2 µl of the 
bacterial lysate was added to 25 µl of ThermoPrime 2x ReddyMix PCR Master Mix 
and 1 µl each of the forward and reverse primers in a 0.6 ml PCR tube. 
 
For PCR preparation, gel electrophoresis and band visualization see section 
2.3.7.2 
 
DNA amplicon of single PCR producing positive band was cleaned (see section 
2.3.8) and sent for Sanger sequencing (see section 2.3.9). 
 
2.4.3 PCR for Integron, mapping of Class 1 integron and insertion element 
Multiplex PCR was used for screening of integrons (int1, int2, and int3), PCR for 
mapping of class 1 integron in the 5’ and 3’ conserved segment and insertion 
element (ISAba1) as previously described (Lévesque et al., 1995; Dillon et al., 2005; 
Ruiz et al., 2007). 
 
 
DNA extraction was performed as mentioned in section 2.3.6.1 . 2 µl of the 
bacterial lysate was added to 25 µl of ThermoPrime 2x ReddyMix PCR Master Mix 
and 1 µl each of the forward and reverse primers in a 0.6 ml PCR tube. 
 
For PCR preparation, gel electrophoresis and band visualization see section 
2.3.7.2 
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DNA amplicon of single PCR producing positive bands was cleaned (see section 
2.3.8) and sent for Sanger sequencing (see section 2.3.9). 
 
PCR cycling conditions used in this study are listed in Table 4. 
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PCR reaction PCR cycling conditions References 
RAPD typing Initial denaturation 94⁰ C for 5min, 
following 4 cycles of 94⁰ C for 5 min, 
40⁰ C for 5 min and 72⁰ C for 5 min; 
then 30 cycles of 94⁰ C for 1 min, 
55⁰ C for 1 min and 72⁰ C for 2 min 
Final extension of 10 min at 72⁰ C.  
(Kersulyte et al., 1995) 
Multiplex OXA 
carbapenemases 
Initial denaturation 94⁰ C for 5 min, 
following 30 cycles of 94⁰ C for 25 s, 
52⁰ C for 40 s and 72⁰ C for 50 s. 
Final extension of 6 min at 72⁰ C.  
 
(Woodford et al., 
2006) 
Multiplex 16s rRNA 
methyltransferase  
Initial denaturation 96⁰ C for 1 min, 
following 25 cycles of 94°C for 15s, 
58° C (45° C for those isolates found 
to be PCR negative at 58° C) for 30 
s, 72° C for 60 s. Final extension of 5 
min at 72°C. 
 
(Fritsche et al., 2008) 
AmpC PCR Initial denaturation of 94°C for 90 s 
followed by 30 cycle of 30 s at 94° 
C, 30 s at 57°C and 1 min at 
(Corvec et al., 2003) 
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72°C.  Final extension at 72°C for 10 
min. 
 
Multiplex integron PCR Initial denaturation 94⁰C for 2 min, 
35 cycle of 94⁰C for 1 min, 59⁰C for 
1 min and 72⁰C for 1 min. Final 
extension at 72⁰C for 7 min. 
 
(Dillon et al., 2005) 
5’ and 3’ conserved 
segment (CS) PCR 
mapping of class 1 
integron 
Three-step profile: 35 cycles of 1 
min at 94⁰ C, 1 min at 55⁰ C, and 5 
min at 72⁰ C for a total of 35 cycles. 
5 s added to the extension time at 
each cycle. 
 
(Lévesque et al., 1995) 
ISAba1 PCR Initial denaturation of 94° C for 2 
min, 30 cycles of 92⁰ C for 1 min, 
annealing 52⁰ C for 1 min and 72⁰ C 
for 1 min. Final extension of 72⁰C 
for 10 min. 
 
(Ruiz et al., 2007) 
Table 4. PCR cycling conditions for each PCR reactions. 
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A. baumannii 12 (AB12) (EU clone 2/clinical isolate PFGE-UK defined UK lineage 
South East clone) (Betts et al., 2017), A. baumannii 14 (AB14) (EU clone 2/clinical 
isolate PFGE-UK defined UK lineage OXA-23 clone 1) (Coelho et al., 2006; Turton 
et al., 2009; Wareham et al., 2011), A. baumannii 16 (AB16) (EU clone 1/clinical 
isolate PFGE-UK defined UK lineage OXA-23 clone 2) (Coelho et al., 2006; Turton 
et al., 2009; Wareham et al., 2011) and type strain ATCC A. baumannii 19606 
(AB19606) were used as control unless otherwise stated. 
 
2.5 Blue-Carba test for carbapenemase detection in Carbapenem-
resistant P. aeruginosa (CRPA) clinical isolates. 
Blue-Carba test method was used for the detection of carbapenemase in CRPA 
clinical isolates as previously described (Pires et al., 2013). Blue-Carba test was 
performed by direct inoculation of bacterial colonies growing on Mueller-Hinton 
agar plates and by direct inoculation of bacterial colonies into Mueller-Hinton 
(MH2) broth. 
 
The bacterial isolates were then added to the test and control solution. 
 
2.5.1 Test solution 
Test solution is a mixture comprising of 10 ml of 0.04% bromothymol blue sodium 
salt (Thermo Fisher Scientific, Lanchashire, UK), 0.06 g of Imipenem powder 
(Sigma-Aldrich, Dorset, UK), 10 µl of Zinc sulfate, ZnSO4 solution (Sigma-Aldrich, 
Dorset, UK) and 2 drops of 0.5 M Hydrochloric acid, HCL (Sigma-Aldrich, Dorset, 
UK) adjusted to a final pH 7.0.  
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2.5.2 Control solution 
Negative control solution is a mixture comprising of 10 ml of 0.04% bromothymol 
blue sodium salt and drops of 0.5 M HCL adjusted to a final pH 7.0. 
 
2.5.3 Blue-Carba set up for direction inoculation from MH plates 
96 well sterile microtiter plates were used for the test and control solution. 
100 µl of test and control solution was added to the wells. A 5 µl loop of bacteria 
were then added to the wells. Plates were incubated at 37 °C on shaking incubator 
for a total of 2 hours.  
 
2.5.4 Blue-Carba setup for direct inoculation of bacterial colonies into Mueller-
Hinton (MH2) broth 
MH2 broth was prepared as mentioned in section 2.3.4  
 
Briefly, 3 ml of MH2 broth was pipetted out into a sterile 25 ml universal tube. A 
5 µl loop full of isolates were inoculated into the broth.  The universal tubes were 
then incubated at 37° C for 24 hours on innova 2100 platform shaker (New 
Brunswick Scientific; Eppendorf, Stevenage UK). 
 
750 µl of the bacterial inoculum from the turbid MH2 broth was pipetted out into 
1.5 ml sterile Eppendorf tube. The tubes were centrifuged at 13000 rpm for 1 min 
using Heraeus Biofuge Pico centrifuge (DJB Labcare, Buckinghamshire, UK).  
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100 µl of supernatant were dispensed into test and control solution. 
Two positive controls Klebsiella pneumoniae [KP19 (2015)] (NDM-1-like) and P. 
aeruginosa [PA25] (imipenem and meropenem resistance) and American Type 
Culture Collection (ATCC) P. aeruginosa (PA27853) as negative control were used 
in this study. 
 
2.5.5 Interpretation of Blue-Carba Assays  
Positive results 
Test group yellow and control remains blue or green or test group green and 
control remains blue (Figure 9) 
 
Negative results 
No colour change (remains blue) in the test and control group (Figure 9).
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Figure 9. Blue-Carba assay result interpretations. A- Positive results, B- Negative 
results, C- Test group and D- Control group 
 
B A 
C 
D 
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2.6 Results 
2.6.1 Carbapenem-resistant Acinetobacter baumannii (CRAB) 
2.6.1.1 Antibiotic Susceptibility Testing (AST) 
One hundred and nine carbapenem-resistant A. baumannii (CRAB) clinical isolates 
were tested using VITEK 2XL (bioMérieux, Marcy l’Etoile, France).  
 
Co-resistance were observed with penicillin (ampicillin, piperacillin) 
cephalosporins (ceftazidime, cefoxitin, cefepime, ceftriaxone), aminoglycosides 
(gentamicin, netilmicin), fluoroquinolones (ciprofloxacin, levofloxacin), 
piperacillin/tazobactam, ticarcillin/clavulanic acid, ampicillin/sulbactam, co-
trimoxazole and aztreonam. Colistin remained susceptible (Figure 10).  
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Figure 10. Co-resistance in carbapenem-resistant A. baumannii clinical isolates. 
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2.6.1.2 Molecular typing  
2.6.1.2.1 RAPD PCR  
RAPD analysis showed clonal diversity belonging to either EU clone 2/OXA-23 
clone 1 and EU clone 1/OXA-23 clone 2 (Figure 11) (Table 5). Four isolates (AB98, 
AB114, AB133, AB143) were chosen as a representative for all isolates and sent 
for further confirmation using DiversiLab rep-typing on the basis of 
indistinguishable profiles or those with different RAPD profiles. 
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Figure 11. RAPD analysis of carbapenem-resistant A. baumannii clinical isolates from Brunei against reference strains EU clones. Lane 1- AB 12 
(EU clone 2/ South East clone), Lane 2- AB 14 ( Eu clone 2/OXA-23 clone 1), Lane 3- AB 16 (EU clone 1/OXA-23 clone 2), Lane 4- AB143, Lane 5- 
AB 114, Lane 6- AB186, Lane 7- AB117, Lane 8- AB210, Lane 9- AB133, Lane 10- AB103, Lane 11- AB116, Lane 12- AB98, Lane13- Negative control 
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Isolates Characteristics Comments 
AB12 Reference strain EU clone 2/ South East clone 
AB14 Reference strain Eu clone 2/OXA-23 clone 1 
AB16 Reference strain EU clone 1/OXA-23 clone 2 
AB143 Test isolate Eu clone 2/OXA-23 clone 1 
AB114 Test isolate EU clone 1/OXA-23 clone 2 
AB186 Test isolate Eu clone 2/OXA-23 clone 1 
AB117 Test isolate Eu clone 2/OXA-23 clone 1 
AB210 Test isolate Eu clone 2/OXA-23 clone 1 
AB133 Test isolate EU clone 2/ South East clone 
AB103 Test isolate Eu clone 2/OXA-23 clone 1 
AB116 Test isolate Eu clone 2/OXA-23 clone 1 
AB98 Test isolate EU clone 1/OXA-23 clone 2 
Table 5. RAPD profiles comparison of carbapenem-resistant A. baumannii clinical 
isolates from Brunei against reference strains EU clones.
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2.6.1.2.2 DiversiLab rep-PCR typing 
Four of the CRAB clinical isolates (AB98, AB114, AB133 and AB143) DiversiLab 
analyses are shown in Figure 12 and Figure 13. Susceptibility testing of these 
isolates is shown in Table 6. All isolates had similar AST profiles, except for 
netilmicin and gentamicin. 
 
 
 
 
Figure 12. DiversiLab rep-PCR analysis. Dendogram of four CRAB isolates (labelled 
Brunei#98 (AB98), Brunei#114 (AB114), Brunei#133 (AB133), Brunei#143 (AB143)) 
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and generated image of rep-PCR banding patterns showing representative of 
Worldwide clones (WW) and European clone (EU). WW- an old nomenclature used 
in this DiversiLab system program, however now renamed as IC, International 
Clone. 
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Figure 13. Dendogram showing the % similarity of the four Brunei CRAB isolates.  Based on this, isolates 143 (AB143) and 133 (AB133) are 
identical, showing 99.5% similarity. Isolate 114 (AB114) is identical to isolate 98 (AB98) showing 99.7% similarity. And between the two clones, 
there is ~60% similarity, hence unrelated. 
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Isolates  Source of 
specimen  
AK CAZ FEP CIP CRO COL IMI MEM NET TZP CN 
AB98 Tracheal aspirate ≤ 16 
 
≥ 32 
 
≥ 32 ≥ 4 ≥ 64 ≤ 2 
 
≥ 8 ≥ 8 ≤ 8 ≥ 128/4 ≥ 16 
AB114 Sputtum  ≤ 16 ≥ 32 ≥ 32 ≥ 4 ≥ 64 ≤ 2 ≥ 8 ≥ 8 ≤ 8 ≥ 128/4 ≤ 4 
 
AB133 Endotracheal 
aspirate 
≤ 16 ≥ 32 ≥ 32 ≥ 4 ≥ 64 ≤ 2 ≥ 8 ≥ 8 ≥ 32 ≥ 128/4 8 
AB143 Tracheal aspirate ≤ 16 ≥ 32 ≥ 32 ≥ 4 ≥ 64 ≤ 2 ≥ 8 ≥ 8 ≥ 32 ≥ 128/4 ≥ 16 
Table 6. Characteristics of carbapenem-resistant A. baumannii isolates sent for DiversiLab rep-typing.  Susceptibility testing results are based on 
MIC breakpoints according to CLSI guidelines. AK- amikacin, CAZ- ceftazidime, FEP- cefepime, CIP- ciprofloxacin, CRO- ceftriaxone, COL- colistin, 
IMI- imipenem, MEM- meropenem, NET- netilmicin, TZP- piperacillin/tazobactam and CN- gentamicin. ≥ - resistance, ≤ - sensitive, no symbol - 
intermediate 
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2.6.1.2.3 OXA b-lactamase and mobile genetic elements (MGE) 
All CRAB clinical isolates carried blaOXA-51-like and blaOXA-23-like genes (Figure 14), 
armA, ampC were positive for Class 1 integron and insertion sequence (ISAba1). 
Mapping of the integron gene cassette, although not characterized showed two 
(AB92, AB101) belonged to integron family In634 according to the integron 
database (http://integrall.bio.ua.pt/). In634 comprises of aacA4 (aminoglycoside 
6'-N-acetyltransferase), catB8 (chloramphenicol acetyltransferase), aadA1a 
(aminoglycoside 3'-adenyltransferase), dfrA1b (dihydrofolate reductase type I), 
aacA3 (aminoglycoside 3 -N-acetyltransferase) and blaP2 (carbenicillin-
hydrolysing penicillinase) (Ito and Hirano, 1997) which was first reported in 
Salmonella enterica subsp. enterica serovar Typhi (Salmonella typhi) GenBank 
accession number AY123251 (Pai et al., 2003). Susceptibility profiles, resistance 
gene determinant and genetic environment of AB92 and AB101 are shown in 
Table 7.  
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Figure 14. Multiplex PCR of OXA beta-lactamases in CRAB clinical isolates. Lane 1- AB14 (positive control for both OXA-23-like and OXA-51-like), 
Lane 2- AB19606 (positive control for OXA-51-like), Lane 3- water (negative control), Lane 4- AB84, Lane 5- AB98, Lane 6- AB114, Lane 7- AB133, 
Lane 8- AB143. Lane 4-7 – all were positive for OXA-23-like (501 bp) and OXA-51-like (353 bp). 
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Isolate  Source of 
specimen  
AK  CAZ FEP CIP CRO COL IMI MEM NET SAM TZP CN Resistance 
determinant 
Mobile 
genetic 
element 
AB92 Endotracheal 
aspirate 
≤ 16 
 
≥ 32 
 
≥ 32 ≥ 4 ≥ 64 ≤ 2 
 
≥ 8 ≥ 8 ≤ 8 ≥ 32/16 ≥ 128/4 ≥ 16 blaOXA-23-like, 
blaOXA-51-like, 
armA, ampC 
ISAba1, 
In634  
AB101 Endotracheal 
aspirate 
≤ 16 ≥ 32 ≥ 32 ≥ 4 ≥ 64 ≤ 2 ≥ 8 ≥ 8 ≤ 8 ≥ 32/16 ≤ 16/4 ≤ 4 
 
blaOXA-23-like, 
blaOXA-51-like, 
armA, ampC 
ISAba1, 
In634  
Table 7. Susceptibility testing results (MICs), resistance determinant and genetic environment of CRAB clinical isolates. AK- amikacin, CAZ- 
ceftazidime, FEP- cefepime, CIP- ciprofloxacin, CRO- ceftriaxone, COL- colistin, IMI- imipenem, MEM- meropenem, NET- netilmicin, SAM- 
ampicillin/sulbactam, TZP- piperacillin/tazobactam and CN- gentamicin. 
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2.6.2 Carbapenem-resistant Pseudomonas aeruginosa (CRPA) 
2.6.2.1 Antibiotic susceptibility testing (AST) 
Twenty-two carbapenem resistance P. aeruginosa (CRPA) clinical isolates were tested using 
VITEK 2XL (bioMérieux, Marcy l’Etoile, France).  
 
Co-resistance were observed with ampicillin and co-trimoxazole. Amikacin, ciprofloxacin, 
netilmicin, levofloxacin and colistin were susceptible (Figure 15). 
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Figure 15. Co-resistance in carbapenem-resistant P. aeruginosa (CRPA) clinical isolates.  
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2.6.2.2 Carbapenemase production 
Twenty-two of the carbapenem-resistant P. aeruginosa clinical isolates were 
negative for carbapenemase production using direct bacterial colonies and MH2 
broth with the Blue-Carba method. 
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2.6 Summary 
Carbapenem-resistant A. baumannii clinical isolates 
§ 109 CRAB clinical isolates were collected from endotracheal aspirate, 
tracheal aspirate, ETT-tip, sputum and pus. 
§ AST and MICs were performed on these isolates with VITEK® 2XL system, 
prior in Brunei’s Microbiology Laboratory. 
§ All A. baumannii clinical isolates were resistance to carbapenems 
(imipenem, meropenem), penicillin (ampicillin, piperacillin) 
cephalosporins (ceftazidime, cefoxitin, cefepime, ceftriaxone), 
aminoglycosides (gentamicin, netilmicin), fluoroquinolones (ciprofloxacin, 
levofloxacin), piperacillin/tazobactam, ticarcillin/clavulanic acid, 
ampicillin/sulbactam, co-trimoxazole and aztreonam.  Colistin remained 
susceptible. 
§ Molecular typing (RAPD and DiversiLab rep-typing) showed isolates 
belonged to either International clone 1 or 2.  
§ All CRAB clinical isolates carried OXA-23-like and the intrinsic OXA-51-like 
carbapenemase genes.   
§ Other resistance genes include armA 16S rRNA methylase determinant, 
ampC, ISAba1 and a class 1 integron. 
§ MDRAB is prevalent in Brunei and similar to epidemic strains (acquiring 
OXA-23-like carbapenemases) reported globally. 
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Carbapenem-resistant P. aeruginosa clinical isolates 
§ 22 P. aeruginosa clinical isolates collected from endotracheal aspirate, 
tracheal aspirate and sputum were resistance to carbapenems (imipenem 
and meropenem) ampicillin and co-trimoxazole. Amikacin, ciprofloxacin, 
netilmicin, levofloxacin and colistin remained susceptible. 
§ All CRPA clinical isolates recovered in Brunei were tested for 
carbapenemase production. 
§ Blue-Carba test was negative for carbapenemase production. This could be 
due to the absence of acquired carbapenemase genes and the presence of 
other resistance mechanisms such as porin loss mediating the carbapenem 
resistance.  
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Chapter 3 
Carbapenem-Resistant Enterobacteriaceae 
(CRE) in Brunei Darussalam 
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3.1 Introduction 
In Chapter 2, phenotypic and genotypic methods were performed as an 
introductory diagnostic tool on carbapenem-resistant Gram-negative Non-
fermenters (P. aeruginosa and A. baumannii), an important WHO critical 
pathogen. In this chapter, using tools that have been performed previously and 
additional new diagnostic tools, carbapenem-resistant Enterobacteriaceae (CRE) 
(another important WHO critical pathogen) in particular Klebsiella pneumoniae 
causing an outbreak in Brunei’s Hospital will be investigated. 
 
The prevalence of MDR Klebsiella pneumoniae is a global public health threat with  
high mortality and morbidity, especially those harbouring Extended Spectrum 
βeta-lactamases (ESBLs) and more importantly carbapenemases (CRKP) 
(Tumbarello et al., 2006). These pathogens can be hospital-associated or 
community-acquired causing urinary tract infection (UTI), pneumonia, intra-
abdominal infection and bloodstream infections (Tumbarello et al., 2006). 
 
Carbapenems, drugs of last resort  used to treat multi-drug resistant Gram-
negative bacteria have  become ineffective due to the emergence of CRE (IovIeva 
and Doi, 2017). More worryingly are those CRE acquiring plasmid-encoded 
carbapenemases of class A (KPC, IMI, GES), B (IMP, VIM, NDM) and D (OXA-48-like 
producers) (IovIeva and Doi, 2017). In Southeast Asia, Class D carbapenemases 
(blaOXA-48-like gene and its variants) are now the commonest carbapenemase 
reported in Enterobacteriaceae (Evans and Amyes, 2014). The OXA-48 enzyme 
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was first identified in 2001 in K. pneumoniae isolates from Turkey, since then many 
variants have been described, this includes OXA- 162 in Turkey, OXA-163 in 
Argentina, OXA-181 in India, OXA-204 in Tunisia and OXA-232 from France and in 
Singapore (Castanheira et al., 2011; Nordmann et al., 2011a; Dimou et al., 2012; 
Poirel et al., 2012; Potron et al., 2013; Teo et al., 2013). 
 
More importantly, CRE infections are extremely difficult to control in hospitals and 
the community, hindered by limited therapeutic options, spread between 
bacterial species and dissemination of resistance through successful epidemic 
clones. Therefore, rapid and effective diagnostics are required in tackling the 
problem of CRE.  
 
Novel assays using both genotypic and phenotypic approaches have been 
developed which includes genetic detection of resistance gene profiles (PCR, 
LAMP, microarrays, genome sequencing) (Osei Sekyere et al., 2015), selective 
culture media (chromogenic/supplemented) (Hornsey et al., 2013b), combination 
disc testing (van Dijk et al., 2014) and direct or indirect detection of carbapenem 
hydrolyzing enzymes (MALDI-TOF, acidometric Carba NP and Blue-Carba) (Pires et 
al., 2013; Dortet et al., 2015; Mirande et al., 2015). However, each of these 
methods requires variable levels of technical skill, investment into equipment and 
quality assurance optimization. Strains producing OXA-48-like carbapenem 
hydrolyzing class D enzymes (CHDL) have proven particularly difficult to detect in 
clinical laboratories, due in part to relatively low MICs, conflicting interpretive 
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rules associated with automated systems (Woodford et al., 2010) and a lack of 
suitable inhibitor compounds to use in confirmatory tests.  
Recent development of OXA-48-like enzyme detection (OXA-48 K-SeT) using an 
antibody-mediated approach (Ote et al., 2015) was designed to detect current 
CHDL OXA-48-like variants (OXA-48, 181, 204, 232 and 244) (Potron et al., 2013). 
The principle of the test was immunological capture of two epitopes specific to 
the OXA-48 enzyme using colloidal gold nanoparticles bound to a nitrocellulose 
membrane within a lateral flow device (Ote et al., 2015). 
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3.2 Objectives 
- To investigate the mechanism of resistance amongst carbapenem-resistant K. 
pneumoniae clinical isolates from Brunei Darussalam. 
 
-To characterize CRKP by multiple phenotypic (RAPID CARB Blue kit, Micronaut-S 
Beta Lactamase VII, OXA-48 K-SeT) and molecular methods. Evaluation of the OXA-
48 K-SeT for the detection of OXA-48 carbapenemase family in CRKP clinical 
isolates (Brunei) and CRE islolates (UK collection). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
149 
3.3 Methods 
3.3.1 Bacterial collection and transportation 
Carbapenem-resistant K. pneumoniae [KP41 (2015), KP42 (2015), KP43 (2015), 
KP44 (2015), KP45 (2015)] were recovered from 5 patients admitted over a 3-
month period (May – July 2015) to general and intensive care units (ICU) at the 
main (RIPAS) and Tutong district hospital (PMMPMHAB) in Brunei. Isolates were 
recovered from blood culture (n = 1), endotracheal samples (n = 1), pus (n = 2) and 
sputum samples (n = 1). These isolates were found carbapenem-resistant in Brunei 
and stored as part of Microbiology routine laboratory for CRE collection. 
 
For wide evaluation of the OXA-48 K-SeT assay, 82 additional enterobacterial 
isolates were collected from The Royal London Hospital, UK. 78 clinical isolates 
resistant to one or more carbapenems were collected (K. pneumoniae, n= 60; 
Escherichia coli, n= 11; Enterobacter cloacae, n= 6; Enterobacter aerogenes, n=1) 
and 4 susceptible type strains as control for each species (K. pneumoniae NCTC 
9633, E. coli NCTC 12241, E. cloacae 13380, and E. aerogenes NCTC 9375).  
 
Further details on the collection and transportation, see Chapter 2 section 2.3.1 
and 2.3.2  
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3.3.2 AST and MIC Determination 
AST and MIC of CRKP clinical isolates were tested prior in Brunei as mentioned in 
Chapter 2, section 2.3.5 
 
Disc diffusion testing, MIC using Micronaut-S Beta Lactamase VII (BioConnections, 
Knypersley, UK) (cefotaxime, ceftazidime, cefepime and meropenem) and Etest 
strip (colistin, polymyxin B and ceftazidime/avibactam) were performed again in 
the UK. 
 
AST was performed using Kirby-Bauer disc diffusion method. Antibiotic discs were 
sourced from Oxoid, Basingstoke, United Kingdom. The MICs were determined by 
Etest strips (BioMérieux, Basingtoke, UK and Launch Diagnostic, Kent, UK), broth 
microtiter dilution (BMD) and agar dilution on Mueller-Hinton 2 (MH2) agar. 
 
AST and MICs follow guidelines from European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) (EUCAST, 2015) and/or Clinical & Laboratory 
Standards Institute (CLSI) (CLSI, 2015). 
 
The discs used on the CRKP clinical isolates includes colistin (CT, 25 µg), cefoxitin 
(FOX, 30 µg), minocycline (MH, 30 µg), imipenem (IPM, 10 µg), azithromycin (AZM, 
15 µg), doxycycline (DO, 30 µg), spectinomycin (SH, 100 µg), apramycin (APR, 15 
µg) and sulfonamide (S, 10 µg). 
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Antibiotic discs were sourced from Oxoid, Basingstoke, United Kingdom. Etest 
strips were sourced either from BioMérieux, Basingtoke, UK or Launch Diagnostic, 
Kent, UK. 
 
3.3.3 Micronaut-S Beta Lactamase VII testing on CRKP clinical isolates 
Micronaut-S Beta Lactamase VII (BioConnections, Knypersley, UK) (Figure 16) was 
used for the phenotypic identification of ESBL, AmpC, and carbapenemases using 
a range of antibiotics with and without inhibitors as well determination of MICs 
according to CLSI guidelines.  
 
Bacterial inoculum was prepared according to the manufacturer’s instruction. 
Briefly, 0.5 MacFarland standard was made up in 5 ml of 0.85% NaCl (Oxoid, 
Basingstoke, UK). 50 µl of the aliquot was then transferred into 11 ml MH 2 broth 
provided and vortexed. 100 µl of the suspension was dispensed into the wells. The 
plate was then sealed with an unperforated plate sealer and incubated at 37⁰ C 
for 18-24 h. The plate was read visually by looking at the turbidity of the wells. 
Phenotypic confirmatory test for ESBL, AmpC and carbapenemases follows the 
calculation and algorithm according to the manufacturer’s protocol. 
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 1 2 3 4 5 6 7 8 9 10 11 12 
A CEP 128  
CMC 32/4 
 
CAZ 128 
 
CZC 32/4 
 
CZB 32 
 
CTX 128 
 
C/C 32/4 
 
CTB 32 
 
MER 128 
 
MEE 32 
 
MEB 32 
 
 
B CEP 64  
CMC 16/4 
 
CAZ 64 
 
CZC 16/4 
 
CZB 16 
 
CTX 64 
 
C/C 16/4 
 
CTB 16 
 
MER 64 
 
MEE 16 
 
MEB 16 
 
 
C CEP 32  
CMC 
8/4 
 
CAZ 32 
 
CZC 
8/4 
 
CZB 8 
 
CTX 32 
 
C/C 8/4 
 
CTB 8 
 
MER 32 
 
MEE 8 
 
MEB 8 
 
 
D CEP 16  
CMC 
4/4 
 
CAZ 16 
 
CZC 
4/4 
 
CZB 4 
 
CTX 16 
 
C/C 4/4 
 
CTB 4 
 
MER 16 
 
MEE 4 
 
MEB 4 
 
 
E CEP 8  
CMC 
2/4 
 
CAZ 8 
 
CZC 
2/4 
 
CZB 2 
 
CTX 8 
 
C/C 2/4 
 
CTB 2 
 
MER 8 
 
MEE 2 
 
MEB 2 
 
 
F CEP 4  
CMC 
1/4 
 
CAZ 4 
 
CZC 
1/4 
 
CZB 1 
 
CTX 4 
 
C/C 1/4 
 
CTB 1 
 
MER 4 
 
MEE 1 
 
MEB 1 
 
GC/B 
 
 
G CEP 2  
CMC 0.5/4 
 
CAZ 2 
 
CZC 0.5/4 
 
CZB 0.5 
 
CTX 2 
 
C/C 0.5/4 
 
CTB 0.5 
 
MER 2 
 
MEE 0.5 
 
MEB 0.5 
 
GC/E 
 
 
H CEP 1  
CMC 0.25/4 
 
CAZ 1 
 
CZC 0.25/4 
 
CZB 0.25 
 
CTX 1 
 
C/C 0.25/4 
 
CTB 0.25 
 
MER 1 
 
MEE 0.25 
 
MEB 0.25 
 
GC 
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Figure 16. Micronaut-S Beta Lactamase VII plate layout adapted from manufacturer’s protocol. [CEP (Cefepime), CMC (Cefepime/ Clavulanic 
acid), CAZ (Ceftazidime), CZC (Ceftazidime/ Clavulanic acid), CZB (Ceftazidime/ 3-APB), CTX (Cefotaxime), C/C (Cefotaxime/ Clavulanic acid), CTB 
(Cefotaxime/ 3-APB, 3-aminophenylboronic acid), MER (Meropenem), MEE (Meropenem/ EDTA, Ethylenediaminetetraacetic acid), MEB 
(Meropenem/ 3-APB, 3-aminophenylboronic acid), GC (Growth Control), GC/B (Growth Control/ 3-APB, 3-aminophenylboronic acid), GC/E 
(Growth Control/ EDTA, Ethylenediaminetetraacetic acid)]. Black shaded area contains no antibiotic or growth control and not used in this 
experiment.
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3.3.4 Detection of carbapenemases using Rapid CARB Blue kit in CRKP clinical 
isolates 
Rapid CARB Blue kit (ROSCO, Tasstruo, Denmark) is a commercial version of Blue-
Carba test. This method is based on the identification of the hydrolysis of the beta-
lactam ring of a carbapenem in the presence of an indicator and does not require 
lysis buffer. 
 
Rapid CARB Blue kit was performed according to the manufacturer’s instruction. 
Briefly, 10 µl loop of bacterial isolate was added to 200 µl 0.9% NaCl solution 
adjusted to pH 8.5 (8.3 - 8.7) using 0.01 N NaOH in a sterile tube. The mixture was 
vortexed for 1 min and maintained at room temperature for 30 min. 1 Imipenem 
(2) + Bromothymol Blue tablets were added to the mixture. The mixture was again 
vortexed for 1-2 seconds to disintegrate the tablet. The tube was then incubated 
at 37⁰ C for 15 min, 30 min or 1 h, respectively. 
 
The control was performed in the same process using CARB Negative Control Blue 
Diatab. 
 
Interpretation of results: 
Positive for carbapenemase 
- Test suspension color change from blue to yellow. 
- Test suspension green to yellow and negative control is blue, or 
- Test suspension yellow and negative control is green 
Negative for carbapenemase 
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-No colour change in test suspension and negative control, remains blue for both. 
 
Uninterpretable 
If the negative control shows light-yellow color, no matter the result of Imipenem 
+ Bromothymol Blue, result reported as uninterpretable. 
 
3.3.5 OXA-48-like detection in CRKP clinical isolates from Brunei using lateral 
flow assay, CORIS OXA-48 K-SeT 
Rapid testing using CORIS OXA-48 K-SeT (CORIS BioConcept, Gembloux, Belgium) 
was used to confirm the presence of OXA-48-like variant in CRKP Brunei clinical 
isolates according to the manufacturer’s protocol. Single colony (using 5 µl loop) 
of the CRKP clinical isolates grown overnight on MH2 media was re-suspended in 
10 drops of LY-A buffer (TRIS-HCl, NaN3, pH7.5) in tubes provided. Three drops of 
the homogenized solution were then applied to the sample well on the cassette. 
Tests were read by eye within 15 minutes.  
 
3.3.6 Evaluation of OXA-48 K-SeT for the detection of carbapenemase OXA-48-
like variants using clinical isolates from The Royal London Hospital 
Eighty-two enterobacterial isolates were used in the evaluation. Seventy-eight 
were clinical isolates (Klebsiella pneumoniae n=60, Escherichia coli n=11, 
Enterobacter cloacae n=6, E. aerogenes n=1) with resistance to one or more 
carbapenems (ertapenem, imipenem, meropenem) along with a susceptible type 
strain as a representative control for each bacterial species (K. pneumoniae NCTC 
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9633, E. coli NCTC 12241, E. cloacae 13380, E. aerogenes NCTC 9375). Resistance 
or reduced susceptibility to carbapenems in the clinical isolates was identified by 
disc diffusion and/or Etest (bioMerieux, Macy L’Etoile, France) and confirmed by 
broth microtitre dilution (MIC of ertapenem ≥1 µg/ml) according to Clinical 
Laboratory Standards Institute (CLSI) methodology. 
 
The lower limit of detection (CFU/ml) of the OXA-48 K-SeT device was determined 
using K. pneumoniae NCTC 9633 and KP41 (blaOXA-48) grown in trypticase soy broth, 
TSB (Oxoid Basingtoke, UK).  Cells from 1 ml of overnight cultures were harvested 
by centrifugation. The supernatant was removed, and the pelleted cells were re-
suspended in phosphate buffered saline (PBS). Serial dilutions (10-1 - 10-9) were 
made by dispensing 100 µl into 900 µl of PBS in a 1.5 ml sterile Eppendorf tubes. 
The dilutions were then plated onto MH agar with viable counts (CFU/ml) 
recorded following 18 h incubation.  
 
OXA-48-like detection using CORIS OXA-48 K-SET (CORIS BioConcept, Gembloux, 
Belgium) was performed according to the manufacturer’s protocol as mentioned 
in section 3.3.6 
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3.3.6.1 Evaluation of OXA-48 K-SeT in blood culture simulation 
Similar clinical isolates from The Royal London Hospital were used for blood 
culture simulation. Heparinised horse blood (Oxoid, Basingstoke, United Kingdom) 
was pre-warmed to 37° C prior to use. 10ml of heparinised horse blood was 
supplemented into Aerobic FA Plus 30 ml blood culture bottle. 0.1 ml of test 
organism (102 CFU/ml) was inoculated aseptically into the same blood culture 
bottle. Blood culture bottle was then incubated at 37°C for 18 h.  0.1 ml aliquot of 
blood was withdrawn from the overnight blood culture bottle into sterile 1.5 ml 
Eppendorf tube without further dilution. The tube was centrifuged at 12000 RPM 
for 3 minutes. The supernatant was discarded. Ten drops of LY-A buffer were 
added to the pellet. Three drops of the mixture were dispensed onto OXA-48 K-
set cassettes. 
 
Adequate growth of each isolate under simulated blood culture conditions was 
confirmed by subculture on MH II agar. 
 
3.3.7 Molecular analysis of CRKP clinical isolates  
3.3.7.1 Clonal typing of CRKP clinical isolates 
RAPD PCR (see Chapter 2, section 2.4.1.1) using ERIC2 primer was performed on 
all 5 CRKP clinical isolates from Brunei.  
 
 
 
158 
3.3.7.2 Multilocus sequence typing (MLST) of CRKP clinical isolates 
Multilocus sequence typing (MLST) using Pasteur scheme of seven conserved K. 
pneumoniae housekeeping genes (gapA, infB, mdh, pgi, phoE, rpoB and tonB) was 
performed as previously described (Diancourt et al., 2005) (Brisse et al., 2009). 
 
DNA extraction was performed as mentioned in section 2.3.6.1 . 2 µl of the 
bacterial lysate was added to 25 µl of ThermoPrime 2x ReddyMix PCR Master Mix 
and 1 µl each of the forward and reverse primers in a 0.6 ml PCR tube. 
 
Primers for MLST are found in Appendix A. 
 
PCR cycling conditions: 
Initial denaturation at 94⁰ C for 2 min, followed by 35 cycles of 94⁰ C for 30 s, 50⁰ 
C for 1 min and 72⁰ C for 30 s. Final extension of 72⁰ C for 5 min. 
 
For gel electrophoresis and band visualization see section 2.3.7.2 
 
DNA amplicons producing positive bands were cleaned (see section 2.3.8) and sent 
for Sanger sequencing (see section 2.3.9). 
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3.3.7.3 PCR for virulence and capsular types 
PCR was used for the detection of K. pneumoniae virulence (kfu, fimH, uge, wabG, 
ureA) determinants and the K1 hypermucoviscous (cps) phenotype as previously 
described. (Compain et al., 2014) Primers used are found in Appendix A. 
 
DNA extraction was performed as mentioned in section 2.3.6.1 . 2 µl of the 
bacterial lysate was added to 25 µl of ThermoPrime 2x ReddyMix PCR Master Mix 
and 1 µl each of the forward and reverse primers in a 0.6 ml PCR tube.  
 
PCR conditions: 
Initial denaturation at 95° C for 15 min, followed by 30 cycles at 94° C for 30 s, 60° 
C for 90 s, and 72° C for 60 s, and a final extension at 72° C for 10 min. 
 
For gel electrophoresis and band visualization see section 2.3.7.2 
 
DNA amplicons producing positive bands were cleaned (see section 2.3.8) and sent 
for Sanger sequencing (see section 2.3.9). 
 
3.3.7.4 Molecular characterisation of resistance determinants in CRKP clinical 
isolates 
Characterisation of CRKP clinical isolates was initially performed using a 
commercial ARM-D™ for β-Lactamase ID kit and further confirmation using 
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multiplex PCR for β-lactamase detection and other resistant gene determinants 
that have been previously described. 
 
3.3.7.4.1 ARM-D™ for β-Lactamase ID 
The ARM-D™ for β-Lactamase ID kit (Alpha laboratories, Hampshire, UK) is a 
commercial kit providing two control reactions that detect genes encoding 
members of the β-lactamase families: IMP-1, NDM, OXA-48, CTX-M-14, CTX-M-15, 
CMY-2, DHA, VIM, and KPC. And an endogenous internal control is also included 
to reduce false negatives; it targets a conserved region common in Gram-negative 
bacteria. The kit also consists of single tube containing all primers in a 10X Primer 
Mix and a custom DNA polymerase supermix (ARM-D 2X Supermix). The ARM-D 
2X Supermix includes DNA polymerase, PCR reaction buffer, dNTPs, and agarose 
gel loading dye.  
 
PCR was carried out as per the manufacturer's instructions for the ARM-D for β-
Lactamase ID kit. DNA extraction was performed as mentioned in section 2.3.6.1 . 
1 µl of template DNA or control is added to the ARM-D 2X Supermix.  
 
PCR cycling conditions:  
Hot start of 98° C for 30 seconds, followed by 25 cycles of 98° C for 5 seconds, 60° 
C for 10 seconds, and 72° C for 20 seconds, and a final extension of 72° C for 30 
seconds.  
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PCR amplicons were stained with ethidium bromide and resolved on a 2.5% 
agarose gel. 
 
For gel electrophoresis and band visualization see section 2.3.7.2 
 
3.3.7.4.2 Multiplex PCR for detecting resistance determinants 
Mulitplex PCR were performed for the detection of beta-lactamase genes (bla1-6) 
(Dallenne et al., 2010), BIC/NDM beta-lactamase genes (Poirel et al., 2011b), 
quinolone resistance gene (Cattoir et al., 2007) and aminoglycoside modifying 
enzyme (Noppe-Leclercq et al., 1999) as previously described.  
 
DNA extraction was performed as mentioned in section 2.3.6.1 . 2 µl of the 
bacterial lysate was added to 25 µl of ThermoPrime 2x ReddyMix PCR Master Mix 
and 1 µl each of the forward and reverse primers in a 0.6 ml PCR tube.  
 
PCR set up mentioned in Chapter 2, section 2.3.7. Primers used are found in 
Appendix A. 
 
PCR cycling conditions: 
Aminoglycoside multiplex PCR  
Initial denaturation for 30 s at 94° C, followed by 45 cycles of an annealing step for 
40 s (at 58 °C for triplex assay 1, 49 °C for triplex assay 2, and 55 °C for duplex assay 
3) and an extension step for 90 s at 72 °C. 
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Beta-lactamases (bla1-6) 
Initial denaturation at 94° C for 10 min, followed by 30 cycles of 94° C for 40 s, 60° 
C for 40 s and 72° C for 1 min. Final extension at 72° C for 7 min. For the 
carbapenemase gene multiplex PCR assays, the annealing temperature was 
optimal at 55° C for amplification of blaVIM, blaIMP and blaKPC genes, and optimal at 
57° C for amplification of blaGES and blaOXA-48 genes. 
 
Carbapenemase (BIC/NDM)  
Initial denaturation 10 min at 94° C, followed by 36 cycles of amplification 
consisting of 30 s at 94° C, 40 s at 52° C, and 50 s at 72° C. Final extension of 5 min 
at 72° C.  
 
Quinolone multiplex PCR 
Initial denaturation of 10 min at 95° C, followed by 35 cycles of amplification 
consisting of 1 min at 95° C, 1 min at 54° C and 1 min at 72° C. Final extension of 
10 min at 72° C. 
 
For gel electrophoresis and band visualization see section 2.3.7.2 
 
3.3.7.4.3 Cloning of β-lactamase  
Full coding sequences of genes identified in KP41 (2015) isolates were cloned using 
Zero Blunt™ TOPO™ PCR Cloning Kit, with pCR™-Blunt II-TOPO™ Vector (Figure 
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17), One Shot™ TOP10 Chemically Competent E. coli, and PureLink™ Quick Plasmid 
Miniprep Kit (Thermo Fisher Scientific, Lancashire, UK) according to the 
manufacturer’s protocol. 
 
TOPO® cloning reaction was set up using the following reagents in order; fresh PCR 
product (0.5-4 µl), salt solution (1 µl), water (add to a volume of 5 µl) and pCR™II-
Blunt-TOPO® (1 µl) to a final volume of 6 µl in a 0.9 ml microcentrifuge. 
 
The mixture was incubated at room temperature for 5 mins (22⁰ C- 23⁰ C). The 
reaction mixture was then placed on ice. 
 
Transformation steps were then performed using Transform One Shot® 
competent cells. 2 µL of the TOPO® Cloning reaction was added into a vial of One 
Shot® chemically competent E. coli and was mixed gently in a sterile 1.5 ml 
Eppendorf tube. The tube was then incubated on ice for 5–30 minutes. The One 
Shot® chemically competent E. coli cell was heat-shocked for 30 seconds at 42°C 
without shaking. The tubes were immediately transferred to ice. 250 µL of room 
temperature S.O.C. medium was added and incubated horizontally on an innova 
2100 platform shaker (New Brunswick Scientific; Eppendorf, Stevenage UK) (200 
rpm) at 37°C for 1 hour.  
 
10–50 µL were seeded and spread on a prewarmed selective plate (LB plates 
containing 50 mg/L kanamycin) and incubated overnight at 37°C. Transformant 
colonies grown on the plate were selected for analysis.  
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Transformants were analysed by PCR using the M13 Forward (−20) and M13 
Reverse primers. Briefly, 48 µL of PCR SuperMix High Fidelity (22 U/ml DNA 
polymerase mixture in 66 mM Tris-SO4 (pH 9.1 at 25° C), 19.8 mM (NH4)2SO4, 2.2 
mM MgSO4, 220 μM dGTP, 220 μM dATP, 220 μM dTTP, 220 μM dCTP and 
stabilizers) were added with 1 µL each of the M13 forward and M13 reverse PCR 
primer into a 0.9 ml microcentrifuge tube. Individual colonies were then 
resuspended in the mixture. 
 
PCR cycling conditions were as follows: 
10 minutes at 94°C to lyse the cells and inactivate nucleases. Amplification for 
20−30 cycles and final extension, incubate at 72°C for 10 minutes. 
 
Since the PCR SuperMix High Fidelity is colourless, 5 µl of Gel Loading Dye, Purple 
6X (NEW ENGLAND BioLabs, Hitchin, UK) were added. 
 
For gel electrophoresis and band visualization see section 2.3.7.2 
 
Positive gel band was cleaned (as mentioned in Chapter 2, section 2.3.8) and sent 
for Sanger sequencing (as mentioned in Chapter 2, section 2.3.9) 
 
 
 
 
 
 
165 
 
 
 
 
 
 
 
 
 
 
 
lacZα 
ccdB  
Kanamycin 
pCR- Blunt II- TOPO  
3519 bp 
pUC ori  
Zeocin 
Plac  
Beta-lactamase gene product  
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Figure 17. Schematic diagram of a vector constructed for the expression of beta-lactamase gene. pCR-Blunt II- TOPO vector encodes the pUC 
origin of replication, lacZα, ccdB lethal gene, kanamycin resistance and zeocin resistance gene. The beta-lactamase gene insert is expressed 
under the lac promoter (Plac).  
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3.3.7.5 Plasmid analysis 
3.3.7.5.1 PCR-based replicon typing  
Plasmid replicon typing on CRKP clinical isolates was performed using a 
commercial PCR-based replicon typing kit (DIATHEVA, Cartoceto, Italy) with 
additional single PCRs for IncX4 and ColE-like plasmid replicons  (Potron et al., 
2011; Johnson et al., 2012; Potron et al., 2013). Briefly, 24 µl of the amplification 
mixes was aliquoted into each of the PCR vials. 1 µl DNA samples to be tested were 
then added into the corresponding PCR vial containing amplification mixes and 
vortexed. PBRT positive controls were thawed and vortexed for 30- 40 seconds. 
1µl of each positive control was added into the corresponding PCR vial containing 
amplification mix and vortexed briefly. 
 
PCR-based replicon typing kit PCR conditions: 
Initial denaturation at 95° C for 10 min, followed by 30 cycles at 95° C for 60 s, 60° 
C for 30 s, and 72° C for 60 s, and a final extension at 72° C for 5 min. 
 
5µl of DNA loading buffer was added directly to amplified samples and ethidium 
bromide on a 2.5% agarose gel was prepared. 
 
ColE-type PCR conditions: 
Initial denaturation at 95° C for 10 min, followed by 30 cycles at 95° C for 60 s, 60° 
C for 30 s, and 72° C for 60 s, and a final extension at 72° C for 5 min. 
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IncX4 replicon PCR conditions 
initial denaturing step at 95° C for 5 min, followed by 25 cycles of 95° C for 1 min, 
52° C for 30 sec, and 72° C for 1 min, and a final extension of 72° C for 5 min.  
 
The amplified products were electrophoresed in 1% agarose gels, stained with 
ethidium bromide. 
 
For gel electrophoresis and band visualization see section 2.3.7.2 
 
3.3.7.5.2 Plasmid sizing  
Plasmid location of each b-lactamase gene and sizing of KP41 (2015) was 
performed by pulsed-field gel electrophoresis (PFGE) of S1-digestion DNA and 
Southern hybridisation with specific intragenic DNA probes as previously 
described (Barton et al., 1995) done by our collaborators in Lieden University, 
Netherlands. 
 
3.3.7.5.3 Sequencing of the entire blaOXA-232-encoding plasmid (pKP41-OXA-232) 
The sequence of the entire blaOXA-232-encoding plasmid (pKP41-OXA-232) was 
determined using a primer walking approach (Figure 18). Inverse PCR, using long-
range Taq polymerase (Invitrogen™ Platinum™ SuperFi™ DNA Polymerase; 
Thermo Fisher Scientific, Lanchashire, UK), in combination with the primers 
OXA232invL and OXA-232invR was used to amplify the entire sequence. Additional 
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primers were used to sequence the extremities flanking blaOXA-232. All the primer 
sequences used are found in Appendix A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Inverse PCR primer walking approach for pKP41-OXA-232. Amplification 
starts from OXA-232 coding sequence and the amplification moves from the right 
and left to cover the whole plasmid. R- right side, L- Left side. 
 
PCR conditions of long-range Taq polymerase: 
Initial denaturation of 98° C for 30 s followed by 35 cycles of 10 s at 98° C, 10 s at 
51.2° C and 3 m at 72° C.  Final extension at 72° C for 5 min. 
 
 
pKP41-OXA-232 
OXA-232invR 
pKP41invR1 
OXA-232invL 
pKP41invL1 
pKP41invL3 
pKP41invR3 
pKP41invR2 
OXA primers 
pKP41invL2 
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PCR conditions for extremities flanking blaOXA-232: 
Initial denaturation of 94° C for 2 min followed by 35 cycles of 10 s at 94° C, 1 min 
at 55° C and 1 min at 72° C.  Final extension at 72° C for 7 min. 
 
3.3.8 Bacterial conjugation  
Transfer of plasmid-mediated resistance genes by conjugation was investigated 
using rifampicin-resistant CSH26 and sodium azide-resistant J53 strains of 
Escherichia coli as recipients. Conjugation experiments were set up by mixing 0.5 
mL of exponential-phase cultures in 4 mL of Luria–Bertani (LB) (Sigma-Aldrich, 
Dorset, UK) broth and then incubating overnight at 37⁰ C without shaking. 
Transconjugants were selected by growth on LB agar supplemented with 
rifampicin (128 mg/L) and either ampicillin (32 mg/L), cefotaxime (16 mg/L) or 
ertapenem (1 mg/L) for conjugation to E. coli CSH26 or with sodium azide (100 
mg/L) and cefotaxime (0.0625–2 mg/L) using E. coli J53. 
 
3.3.9 Whole Genome Sequencing (WGS) 
3.3.9.1 Sample preparation 
A single colony of the strain from overnight culture plate was mixed in 100 µl 
sterile saline. The mixture is inoculated onto MH 2 agar plate and incubated at 37 
⁰C for 24 h. 1/3 plate lawn of the strain were mixed into barcoded bead tube 
supplied by MicrobesNG (Birmingham) using 5 µl loop. The bead tubes were mixed 
by inverting 10 times. The tubes were sent at room temperature back to 
MicrobesNG (Brimingham).  
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3.3.9.2 Packaging and transportation of samples  
Samples are packaged and transported according to Category B infectious 
substance assigned to UN3373  
(http://www.who.int/csr/resources/publications/biosafety/WHO_CDS_EPR_2007
_2cc.pdf)(WHO, 2007). 
 
3.3.9.3 Sequencing of isolates 
The genomic DNA from KP41 (2015) was subjected to whole-genome sequencing 
using 2 x 250-bp paired-end reads on an Illumina MiSeq platform (Illumina, Inc., 
San Diego, CA) This generated a total of 338,242 reads with an average length of 
521 bp (Figure 22). Trimmomatic algorithm (version 0.36) (Bolger et al., 2014) 
were performed to trim the generated reads and their quality assessed by in-
house scripts combined with SAMtools (version 1.3.1) (Li et al., 2009), BedTools 
(version 2.25.0) (Quinlan and Hall, 2010), and BWA-mem (version 2) (Li and 
Durbin, 2009) algorithms. SPAdes algorithm (version 3.7.1) (Bankevich et al., 2012) 
were performed to subsequently assemble de novo high-quality filtered reads into 
98 scaffolds, with a minimum length of 211 bp and an N50 of 316,659 bp. 
Additionally, the sequence coverage of the de novo assemblies was approximately 
190 reads per assembled base.  
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3.3.9.4 In silico of resistance determinants of WGS  
Contigs and the draft genome assembly of KP41 (2015) isolate were anlaysed in 
silico using online tools (http://www.genomicepidemiology.org/) available at the 
Centre for Genomic Epidemiology (Lygby, Denmark). Genes encoding genotypic 
and phenotypic resistance (ResFinder 3.1), chromosomal (MLST 2.0) and plasmidic 
(PlasmidFinder 2.0) epidemiological markers were compared to reference 
sequences in Pubmed (NCBI). Sequences with < 100 % nucleotide identity were 
analysed by blastx (NCBI) to identify potential new alleles or non-synonymous 
mutations. 
 
3.3.9.5 Capsule and lipopolysaccharide serotype prediction (Kaptive Web) 
A user-friendly program Kaptive web (http://kaptive.holtlab.net/) was used to 
predict the capsule and lipopolysaccharide serotype in Klebsiella genomes. WGS 
data of KP41 (2015) were uploaded into this program in a single compressed data 
directory and analyzed against the Klebsiella primary K locus and the Klebsiella O 
locus databases. 
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3.4 Results 
3.4.1 Phenotypic analysis 
3.4.1.1 AST, MIC and carbapenemase detection 
Susceptibility testing identified resistance to azithromycin, cephalosporins, 
carbapenems, fosfomycin, minocycline and nitrofurantoin in all isolates. Isolates 
remained susceptible (Etest, bioMérieux, Marcy l’Etoile, France) to colistin (COL 
<1 mg/L), polymyxin B (POL <1 mg/L) and the combination of ceftazidime (CAZ) 
and avibactam (AVI) (1 mg/L) (Table 6). The MICs of cefotaxime (CTX >128mg/L), 
cefepime (FEP >128mg/L), ceftazidime (CAZ >128mg/L) and meropenem (MEM 
>32mg/L), determined using a Micronaut-S Beta Lactamase VII panel (Merlin 
Diagnostika, Bornheim-Hersel, Germany) confirmed resistance to all β-lactams 
(Table 8). In addition, phenotypic identification with this test showed AmpC and 
ESBL positive. 
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Antibiotic  Zone of inhibition 
(mm) 
Antibiotic profile (S, I, R or Unknown) MIC (mg/L) Antibiotic zone 
diameter and MIC 
breakpoint guidelines 
Apramycin (15 µg)  16 Unknown - - 
Azithromycin (15 µg) 6  R - - 
Colistin (25 µg) 13 Unknown - - 
*Colistin - S < 1 (EUCAST, 2015) 
#Cefepime  - R > 128 (EUCAST, 2015) 
#Cefotaxime - R > 128 (EUCAST, 2015) 
Cefoxitin (30 µg) 6  R - (EUCAST, 2015) 
#Ceftazidime  - R > 128 (EUCAST, 2015) 
*Ceftazidime/avibactam - S 1 (EUCAST, 2017) 
Doxycycline (30 µg) 11 I - (CLSI, 2015) 
Fosfomycin (200 µg) 18 R - (EUCAST, 2015) 
Imipenem (10 µg) 10 R - (EUCAST, 2015) 
#Meropenem - R > 32 (EUCAST, 2015) 
Minocycline (30 µg) 10 R - (CLSI, 2015) 
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Table 8. AST and MICs for CRKP clinical isolate, KP41 (2015). This result is identical to other CRKP clinical isolates tested [KP42 (2015), KP43 
(2015), KP44 (2015), KP45 (2015)]. S- sensitive, I- intermediate, R- resistance, Unknown – no available breakpoints.  *- MICs tested with Etest 
strips, #- MICs tested with Micronaut-S Beta Lactamase VII. 
 
 
 
 
Nitrofurantoin (200 µg) 6 R - (EUCAST, 2015) 
*Polymyxin B  - S < 1 - 
Spectinomycin (100 µg) 20 Unknown - - 
Sulfonamide (10 µg) 16 Unknown - - 
 
 
176 
All isolates were positive for carbapenemase production using RAPID CARB blue 
kit. (Figure 19) 
  
Figure 19. Rapid CARB Blue kit test against CRKP clinical isolates. Positive colour 
change from blue to yellow was observed. T- test, C- control 
 
 
 
 
 
 
 
 
 
 
 
T C 
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3.4.1.2 OXA-48 K-SeT lateral flow in CRKP clinical isolates, OXA-48 K-SeT 
evaluation and blood culture simulation 
 
All CRKP clinical isolates were positive for OXA-48-like on the lateral flow assay 
(identified by PCR as OXA-232) (Figure 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Detection of OXA-48-producing CRKP clinical isolates using OXA-48 K-
SeT cassettes. C- control and T – test organism. 2 x 106 CFU/ml of CRKP clinical 
isolates were inoculated (3 drops) into the well (W) and read after 5 mins. 
 
3.4.1.2.1 Evaluation of OXA-48 K-SeT assay 
Eighty-two additional enterobacterial isolates were tested from The Royal London 
Hospital, UK.  Molecular analysis of these isolates confirmed that 53 produced an 
OXA-48-like carbapenemase including 2 K. pneumoniae with the OXA-181 and 
W 
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OXA-232 variant (Table 7). Twenty-five isolates were carbapenem resistant due to 
the production of either KPC, VIM or NDM (n=13) β-lactamases or had hyper ampC 
and/or permeability lesions. The OXA-48 K-SeT assay gave a positive result for all 
53 OXA-48 producing strains and was negative with all of the other isolates tested, 
including 5 isolates positive for blaOXA-1. Correlation of viable colony counts with a 
positive result for OXA-48 using the NCTC 9633 and KP41 strains assessed the 
lower limit of detection of the assay as 2.41 x 106 CFU/ml. In this evaluation, the 
sensitivity, and specificity for the detection of OXA-48 using the OXA-48 K-SeT was 
therefore 100% (Table 9). Positive and negative results could be differentiated 
within 10 minutes. Results were identical whether the cassettes were inoculated 
with lysates prepared from MH II plates or BacT/ALERT blood culture bottles. 
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OXA-48 K-SeT Carbapenem-Resistant Enterobacteriaceae (78) 
OXA-48-like carbapenemase Other carbapenemase No carbapenemase* 
Positive (53)       
K. pneumoniae 46; OXA-48 (44), 0 0 
 
OXA-181 (1), OXA-232 (1) 
  
E. coli 5 0 0 
 
   
E. cloacae 2 0 0 
Negative (25)    
K. pneumoniae 0 8 6 
 
 
KPC (2), NDM (3), VIM (2), KPC+NDM (1) 
 
E. coli 0 2 4 
 
 
KPC (1), NDM (1) 
 
E. cloacae 0 3 1 
 
 
NDM (2), VIM (1) 
 
E. aerogenes 0 0 1 
Table 9. Evaluation for the detection of OXA-48 production in CRE using OXA-48 K-SeT cassette. 
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3.4.2 Genotypic analysis 
3.4.2.1 Clonal typing and virulence determinants 
Molecular typing using RAPD PCR revealed the isolates were clonally related 
(Figure 21). And MLST identified CRKP clinical isolates belonged to ST 231 
(http://bigsdb.pasteur.fr/klebsiella/klebsiella.html) (Table 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. RAPD typing of CRKP clinical isolates. All CRKP isolates showed 
indistinguishable profiles (clonally related). 
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Table 10. MLST Pasteur scheme allele results from PCR of seven housekeeping 
genes (gap A, infB, pgi, rpoB, phoE, mdh, tonB). + genes were present. All isolates 
belonged to sequence type, ST 231. 
 
Genes associated with virulence showed iron uptake (kfu), fimbrial mediated 
adhesion (fimH), lipopolysaccharide biosynthesis (uge and wabG) and urease 
production (ureA). And negative for K1 hypermucoviscous (cps) phenotype 
associated with heightened virulence (Compain et al., 2014). 
 
3.4.2.2 Detection of resistance gene determinants  
ARM-D™ for β-Lactamase ID kit revealed all isolates were positive for blaOXA-48–like. 
Further PCR confirmed all isolates were positive for blaTEM, blaSHV, blaCTX-M, blaOXA-
48–like and qnrS alleles. No other carbapenemase genes were detected. BLASTN 
analysis of the assembled sequence showed 100% nucleotide identity with the 
blaOXA-232 sequence (accession number JX423831.1) that encodes a 
carbapenemase hydrolyzing class D enzyme (CHDL) (Potron et al., 2013). The class 
A β-lactamases in each isolate were similarly identified as blaTEM-1b, blaSHV-11 and 
Isolates Housekeeping gene PCR Allele 
KP41-KP45 (2015) gapA + 2 
 infB + 6 
 pgi + 3 
 rpoB + 1 
 phoE + 26 
 mdh + 1 
 tonB + 77 
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blaCTX-M-15. 
 
3.4.2.3 Plasmid typing, sizing and sequencing  
PCR-based replicon typing documented the presence of A/C, FIA, FIIK and ColE-
like replicons. The plasmidic location of each β-lactamase gene by pulsed field gel 
electrophoresis (PFGE) of S1-digestion DNA and Southern hybridization with 
specific intragenic DNA probes showed blaOXA-232 gene was carried on a small ColE-
like plasmid of ~6Kb. The blaCTX-M-15 gene was localized to a ~161.7Kb IncF plasmid 
containing fused FIA-FIIk replicons and the blaTEM-1b to a non-typeable plasmid of 
~8.4Kb. 
 
The sequence of the entire blaOXA-232-encoding plasmid carried several 
mobilization genes (mobA-D), a replication gene (repA), truncated part of genes 
encoding a putative LysR-type transcriptional regulator (ΔlysR), an erythromycin 
esterase (ΔereA), and part of an ΔISEcp1 upstream of the blaOXA-232 gene (Figure 
22). 
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Figure 22. Genetic structure of pKP41-OXA-232 in comparison with other ColE-like plasmids encoding blaOXA-232 (GenBank accession 
no. JX423831) and blaOXA-181 (GenBank accession no. JN205800). The entire blaOXA-232-encoding plasmid with several mobilization genes (mobA-
D), a replication gene (repA), truncated part of genes encoding a putative LysR-type transcriptional regulator (ΔlysR), an erythromycin esterase 
(ΔereA), and part of an ΔISEcp1 upstream of the blaOXA-232 gene. The reading frames are shown as grey shaded arrows, with the arrowhead 
indicating the direction of transcription. The truncated reading frames are shown as grey shaded rectangles. The mobile genetic elements are 
shown as white shaded rectangles flanked by two (complete) or one (truncated) black triangles. The areas shaded in grey 
indicate nucleotide identity in plasmid sequences, with the percentage indicated. 
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3.4.2.4 Bacterial conjugation  
Transfer of plasmid-mediated resistance genes by conjugation was investigated 
using rifampicin (RIF) resistant CSH26 and sodium azide (AZ) resistant J53 strains 
of E. coli as recipients. Neither, the blaOXA-232 or blaCTX-M15 containing plasmids could 
be mobilized to either E. coli strain under the antibiotic selection methods used. 
 
3.4.2.5 WGS analysis 
The draft genome sequence of KP41 (2015) revealed a genome size of 5,692,661 
bp, with an average G+C content of 56.94%. Provisional annotation using the ab 
initio gene finder algorithm Prokka (version 1.11) (Seemann, 2014) revealed a total 
of 5,570 coding sequences (CDSs), including at least 82 tRNAs, 23 rRNAs (8 
complete and 15 partial), and 19 ncRNAs from the complete genome.  
 
Comparative analysis of the WGS data in-silico and the phenotypic susceptibility 
data was used to define and characterise the entire resistome of KP41. Multiple 
genes encoding resistance to aminoglycosides (aph(3’)-Ia, aac(6’)-Ib3, rmtf), β-
lactams (blaOXA-232 , blaTEM-1B, blaCTX-M-15, blaSHV-12, blaLEN-12), fluoroquinolones 
(qnrS1, oqxA, oqxB, aac(6’)-Ib-cr), fosfomycin (fosA), macrolide (erm(42)),  
phenicols (catA1, floR), rifamipicin (ARR-2) and sulphonamides (sul2) were 
identified using ResFinder and correlated entirely with the susceptibility profile of 
KP41 determined in-vitro. PlasmidFinder confirmed the presence of the A/C2, 
ColK(P3), FIB, and FII(K) replicon types, as we have shown earlier based on PCR-
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based replicon typing (Diatheva, Fano, Italy), while PHAST (Zhou et al., 2011) 
revealed the presence of four intact, one incomplete, and two putative prophages. 
K. pneumoniae KP41 (2015) contains genes for iron acquisition, such as kfuA and 
kfuC and several virulence genes including fyuA, irp1, irp2 ybtA, ybtE, ybtP, ybtQ, 
ybtS, ybtT, ybtU and ybtX (yersiniabactins), as well as mrkD and mrkH (type 3 
fimbriae formation). In silico analysis of OXA-232 CRKP also revealed the absence 
of rspj mutation (He et al., 2018) causing tigecycline resistance and aac(6’)-Ian 
amikacin resistance gene (Troyano-Hernaez et al., 2018). 
 
Additionally, from Kaptive Web K locus result, the assembly of KP41(2015) isolate 
matches with KL51 (K locus 51) and the O locus typing identified as O1v2. In terms 
of the diversity in both K and O locus in our KP41 (2015) compared to the core 
chromosomal phylogeny of the 309 global genomes targeting the globally 
distributed MDR clones showed our isolate belonged to ST 231 clone.  
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3.5 Summary  
§ Five CRKP clinical isolates were recovered from Brunei Hospital. Isolates 
were recovered from blood culture, endotracheal samples, pus and 
sputum samples. 
§ All isolates were resistant to, meropenem (MIC > 32 mg/L), cephalosporins, 
fosfomycin, minocycline, nitrofurantoin but remained susceptible to 
colistin (MIC < 1 mg/L), polymyxin B (MIC < 1 mg/L) and 
ceftazidime/avibactam (MIC = 1 mg/L).  
§ Rapid CARB Blue kit identified carbapenemase producers in all CRKP 
isolates. 
§ OXA-48 K-SeT lateral flow assay performed in all CRKP clinical isolates were 
positive for blaoxa-48 alleles  
§ Further evaluation of the OXA-48 K-SeT lateral flow assay with 82 
enterobacterial isolates showed sensitivity and specificity of detecting 
OXA-48 producing isolates to be 100% (95% CI, 91.9-100% and 84.2-100%, 
respectively). With the blood simulation, results were identical whether 
the cassettes were inoculated from lysates prepared on MH II plates or 
BacT/Alert blood culture bottles. 
§ Molecular typing showed all CRKP isolates were assigned to sequence type 
(ST) 231. ST231 is also an important clone in K. pneumoniae isolates 
acquiring important ß-lactamases including OXA-232 with diverse plasmid 
backbones. Other important ST include ST14 acquiring OXA-232 and NDM-
1 enzymes. 
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§ Virulence factor genes; Kfu (iron uptake), fimH (fimbrial-mediated 
adhesion), uge and wabG (lipopolysaccharide biosynthesis) and ureA 
(urease production) were found in all isolates except for cps (K1 
hypermucoviscous) phenotype associated with heightened virulence. 
§ Molecular detection of acquired genes encoding Class A, B, C and D beta-
lactamases were performed by a commercial ARM-D™ for β-Lactamase ID 
kit and multiplex PCR. 
§ All isolates were carbapenem-resistant harbouring OXA-232 
carbapenemases and carried class A beta-lactamases blaTEM-1b, blaSHV-11 
and blaCTX-M-15. 
§ Plasmid replicon typing showed all strains contained the plasmids A/C, FIA, 
FIIK and ColE-like replicons. 
§ The blaOXA-232 was carried on small ColE-like plasmid of ca. 6141 kb. While 
blaCTX-M-15 ESBL gene was localised to an IncF plasmid containing fused FIA-
FIIk replicons, and the blaTEM-1b to a non-typeable plasmid. 
§ Conjugation showed neither blaOXA-232- nor blaCTX-M-15 - containing plasmids 
could be mobilised to either of the E. coli recipient strains. 
§ WGS analysis of KP41 (2015) further identified genes encoding resistance 
to aminoglycosides (aph(3’)-Ia, aac(6’)-Ib3, rmtf), β-lactams (blaOXA-232 , 
blaTEM-1B, blaCTX-M-15, blaSHV-12, blaLEN-12), fluoroquinolones (qnrS1, oqxA, 
oqxB, aac(6’)-Ib-cr), fosfomycin (fosA), macrolide (erm(42)),  phenicols 
(catA1, floR), rifamipicin (ARR-2) and sulphonamides (sul2) using ResFinder 
that correlates to susceptibility testing in-vitro.
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Chapter 4 
Emergence of plasmid-mediated polymyxin 
resistance (PMPR), mcr genes in Brunei 
Darussalam 
 
Part 1: Development and evaluation of novel 
CHROMagar™ COL-APSE media 
 
Part 2: Surveillance of PMPR from poultry farms and 
human clinical faecal samples in Brunei Darussalam 
 
Part 3: A novel PMPR determinant recovered from 
poultry farm in Brunei Darussalam 
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4.1 Introduction 
In Chapter 3, CRE (carbapenem-resistant OXA-232 producing Klebsiella 
pneumoniae) in Brunei Darussalam which poses a global health threat was 
characterized. In this chapter, another important global public health issue arises 
with the emergence of plasmid-mediated colistin resistance mcr-1 gene reported 
in China in 2015 (Liu et al., 2016). Since it was first reported, plasmid-mediated 
colistin resistance (mcr genes) have been reported globally and has been identified 
in animals, humans and the environment (Zhi et al., 2016). 
 
Lack of new antibiotics to treat highly resistant Gram-negative clinical infections 
has resulted in the repurposing of an old drug such as colistin (Falagas and 
Kasiakou, 2005). However, the downside to colistin is the neurotoxicity and 
nephrotoxicity effects (Falagas and Kasiakou, 2005). 
 
Our understanding with colistin resistance was initially limited to a chromosomal-
mediated mechanism involving in the activation of the two-component systems 
(TCSs) PhoP/PhoQ and PmrA/PmrB by specific mutations or environmental stimuli 
leading to an overexpression of LPS-modifying genes as mentioned in Chapter 1, 
section 1.6.2.1.1. However, with plasmid-mediated colistin resistance, the mcr-1 
gene encodes phosphoethanolamine transferase (pEtN) enzyme through the 
addition of pEtN to the lipid A component of the lipopolysaccharides (LPS) 
conferring resistance to colistin (Liu et al., 2016). (Figure 23)
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Figure 23. Schematic diagram of plasmid-mediated colistin resistance mechanism. The mcr-1 gene encodes phosphoethanolamine transferase 
(pEtN) adding pEtN to Lipid A component of the Lipopolysaccharides (LPS), which in turn cause the negatively charge phosphate group (P) of the 
Lipid A subunits to become positively charge not allowing the cationic colistin to alter the LPS, leading to resistance.  
P 
P 
Plasmid-mediated 
MCR-1 P 
Colistin 
Lipid A 
Lipopolysaccharide 
Phosphate group 
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In 2012, WHO has reclassified colistin as critically important for human medicine 
(WHO, 2011 ). Unfortunately, the use of colistin is not only in clinical settings but 
also in veterinary medicine for prophylactic and treatment purposes (Rhouma et 
al., 2016). In addition, colistin is used as in-feeds antibiotic growth promoters and 
has been going on for decades, especially in swine and veal calves (Catry et al., 
2015; Kempf et al., 2016; Rhouma et al., 2016). This was further shown, in a 
retrospective study done by Jianzhong Shen and colleagues, (Shen et al., 2016) 
where MCR-1 was present in Escherichia coli from food-producing animals as far 
back as the mid-1980s, suggestive of the use of colistin in animal feeds.  
 
In 2006 the European Union (EU) banned antibiotics for growth promotion while 
the United States (US) implemented legislation based on a voluntary cessation of 
antibiotic use for growth-promotion as well as re-labelling of antibiotics (Founou 
et al., 2016). However, in China colistin is widely used in agriculture and the largest 
user worldwide, with an astounding 11,942 tonnes per year by the end of 2015 
(Liu et al., 2016). With increasing production of animal husbandry, by 2021 the 
amount of colistin use will continue to increase to 16,000 tonnes per year, a 4.75% 
average annual increase use in this country (Liu et al., 2016). Colistin use was 
eventually put to a halt in 2016, where an announcement was made by the formal 
Ministry of Agriculture in China to ban colistin as growth promoter (feed additive) 
in animals, a major big step for the country (Walsh and Wu, 2016). Resistance to 
colistin in humans was believed to be linked to colistin ingestion; however, there 
is evidence of independent emergence of colistin-resistant bacteria in humans 
without colistin usage, that likely suggests such bacteria may pre-exist in the 
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human gut and be selected upon colistin therapy (Rolain and Olaitan, 2016; 
Olaitan et al., 2016b). 
 
As of 2018, multiple mcr gene variants (mcr-1- 8) have been reported (Partridge 
et al., 2018; Wang et al., 2018b). Mostly, the reported variants are from human 
and veterinary specimens in different bacterial species (E. coli, K. pneumoniae, 
Salmonella sp, Moraxella sp, Aeromonas sp, R. ornithinolytica) (Schwarz and 
Johnson, 2016) (Wang et al., 2019) and on different plasmid types such as IncX4, 
IncI2, IncFIB and IncHI2 (Zurfluh et al., 2016; Wang et al., 2018a). Moreover, mcr-
1 plasmids have been reported in a variety of different MLST clades and only some 
of which fall into the B2 group of human pathogens (He et al., 2017; Wang et al., 
2017). Most worryingly, mcr-1 is now starting to emerge in ST131, a virulent strain 
associated with a variety of clinical infections (Ortiz de la Tabla et al., 2017; Wang 
et al., 2017). Now, a new highly virulent mcr-1-mediated colistin resistance 
Escherichia coli lineage, sequence type 95 (ST95), associated with meningitis and 
severe avian infection has emerged. In contrast to ST131, ST95 is a global 
pandemic clone of ExPEC (Extra-intestinal pathogenic Escherichia coli), and this 
lineage is the low frequency of MDR among clinical isolates(Forde et al., 2018). 
 
With the Increasing number of mcr cases, the need to implement screening 
strategies such as the use of selective media or rapid testing kit is crucial, an 
important step in AMR surveillance. Hence, it necessary to screen for mcr genes 
in animals, humans and environment to understand its dissemination throughout 
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the world. Now with the evolving CRE and the emergence of plasmid-mediated 
colistin resistance, the greatest concern is the development of pan-drug resistance 
leaving no treatment options. Although there has been unprecedented research 
in new drugs and using an unorthodox drug combination for combatting plasmid-
mediated colistin resistance Gram-negative infections, it is still far from reality. 
 
Therefore, prevention is key and tackling AMR through One Health approach 
would hopefully allow AMR containment and stop their dissemination. The One 
Health approach involves a network of animal health, human health and 
environment working together to produce policies, legislation and research to 
achieve better public health outcome following existing guidelines from the WHO, 
the Food and Agriculture Organization of the United Nations (FAO) and World 
Organization for Animal Health (OIE) (WHO, 2017b). With prompt recognition of 
MCR-1 producers in the animal, human and environment sectors, hopefully, it will 
prevent future epidemic spread.
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4.2 Objectives 
Part 1: 
- To develop and evaluate our CHROMagar™ COL-APSE media for the detection of 
PMPR and compare it with existing SuperPolymyxin medium. 
 
Part 2: 
-  To determine the prevalence by performing antibiotic resistance surveillance for 
colistin resistance E. coli mcr genes from chicken farms and human clinical faecal 
samples in Brunei Darussalam. 
 
Part 3: 
- Molecular analysis of novel mcr-1 variants found during surveillance.  
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Part 1:  Development and evaluation of novel CHROMagar™ COL-
APSE media 
4.3 Methods 
4.3.1 CHROMagar™ COL-APSE media preparation 
CHROMagar™ COL-APSE media is a selective media for the isolation and 
differentiation of colistin-resistant Gram-negative pathogens which is important 
in antimicrobial resistance surveillance. 
 
CHROMagar™ COL- APSE plates were prepared in-house using dehydrated 
CHROMagar™ base media (CHROMagar™, Paris, France) supplemented with the 
CHROMagar™ COL- APSE supplement (X192) and growth supplement S1. The X192 
contains antimicrobials (colistin sulfate, 4 mg/L and linezolid, 1 mg/L) at 
concentrations designed to enhance the growth of polymyxin resistant (PR) Gram-
negative species and suppress the growth of Gram-positive bacteria, while 
avoiding significant synergy between the active compound (Table 11). 
 
Compound Amount/L# 
CHROMagar™ base media 42.5 g 
Distilled water 1000 ml 
CHROMagar™ COL-APSE supplement (X192) 2 ml 
CHROMagar™ growth supplement S1 4 ml 
Table 11. CHROMagar™ COL-APSE preparation. #For 50 x 20 ml plates. 
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The medium was not autoclaved but instead sterilized by boiling at 100 °C for 10 
mins to preserve the chromogenic compounds included in the mixture, prior to 
the addition of all of the supplements.  
 
4.3.2 SuperPolymyxin™ media preparation 
SuperPolymyxin™ is the first selective culture medium for the screening of 
polymyxin-resistant Gram-negative bacteria, which was developed by Nordmann 
and colleagues (Nordmann et al., 2016b).  
 
SuperPolymyxin plates were prepared according to the protocol described by 
Nordmann and colleagues (Nordmann et al., 2016b). Briefly, 15 g of EMB agar 
powder manufactured by Sigma-Aldrich (Dorset, UK) were mixed in 400 ml 
distilled water at a final concentration 3.75% (w/v) and autoclaved at 15 lbs/sq 
inch at 121oC for 15min. After autoclaving, the EMB medium was cooled down for 
1 h at 56⁰C. Colistin (3.5 μg/ml), daptomycin (10 μg/ml) and amphotericin B (5 
μg/ml) were then added to the medium. The poured plates were then stored in a 
cold room protect from direct light exposure at 4⁰C for 1 week. 
 
All of the additional antibiotics used were sourced from Sigma-Aldrich (Dorset, UK) 
or Cambridge Bioscience (Cambridge, UK). Preparation of antibiotic stock solution 
preparation see section 4.3.3 below. 
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4.3.3 Antibiotic stock solution preparation  
Antibiotic stock solution was prepared using the formula previously described: 
(Andrews, 2001) 
1000/P x V x C = W 
P = potency given by the manufacturer (μg/mg) 
V = volume required (mL), 
C = final concentration of solution (multiples of 1000) (mg/L) 
W = weight of antibiotic in mg to be dissolved in volume V (mL) 
 
Preparation of further stock solutions, from the initial 10,000 mg/L solution, 
hence the following was prepared: 
1 mL of 10,000 mg/L solution + 9 mL diluent* = 1000 mg/L 
100 µl of 10,000 mg/L solution + 9.9 mL diluent* = 100 mg/L 
*diluent used in this study are all distilled water 
 
For colistin and polymyxin B, both are prepared in 25 ml sterile glass bottle instead 
of universal tubes to avoid its binding to polystyrene. 
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4.3.4 Evaluation of CHROMagar™ COL-APSE and SuperPolymyxin media  
Sixty-one MCR-1 veterinary clinical Isolates provided by Denmark and France, 12 
type strains (8 ATCC and 4 NCTC) and 11 human clinical isolates (6 from Clinical 
Microbiology Laboratory, the Royal London Hospital and 5 from Microbiology 
Laboratory Services, RIPAS Hospital, Brunei). 
 
4.3.5 Determination of Lower Limit of Detection (LLD) 
The lowest limit of detection was assessed using serial dilutions (10-1 – 10-9) of an 
overnight culture grown at 37 °C for 24 h in 3 ml of Luria-Bertani (LB) broth. Ten-
fold serial dilutions (100 μl in 900 μl) were made in phosphate-buffered saline 
(PBS) and 20 μl of each dilution plated onto unsupplemented MH 2 (control) and 
CHROMagar COL-APSE plates using the Miles and Misra procedure. 
 
Colony counts obtained on CHROMagar COL-APSE were subtracted from the 
number recovered on MH 2 agar to quantify the total number of COL resistant 
organisms (CFU) within the total population plated, required for viable growth on 
each selective media. 
 
4.3.6 Performance testing using bacterial organisms in mixed culture 
Two pools containing mixtures of COL resistant (R) and COL susceptible (S) 
organisms were used to assess the performance of the media with complex 
polymicrobial samples. 
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Pool 1 - A. baumannii AB205 (COL resistant), E. coli E7 (COL resistant), E. cloacae 
NCTC 10005 (COL resistant), E. faecalis ATCC 2912 (COL resistant), K. pneumoniae 
KP19 (COL resistant), M. morgannii MM2 (COL resistant), P. aeruginosa ATCC 
27853 (COL heteroresistant), S. marcescens NCTC 10211 (COL resistant), P. 
mirabilis NCTC 13376 (COL resistant). 
 
Pool 2 - A. baumannii ATCC 19606 (COL susceptible), E. coli ATCC 25922 (COL 
susceptible), E. faecalis ATCC 2912 (COL resistant), P. aeruginosa ATCC 27853 (COL 
heteroresistant), K. pneumoniae ATCC 9633 (COL susceptible) 
 
Internal and external quality control of the stability of the media was assessed 
using P. mirabilis NCTC 13376, E. coli ATCC 25922, K. pneumoniae ATCC 9633 and 
E. faecalis ATCC 2912. Media for use with pools containing P. mirabilis NCTC 13376 
was supplemented with PNPG.  
 
4.3.7 Agar dilution method for determining colistin and polymyxin B MICs using 
multi-point inoculator 
Isolates included in the CHROMagar™ COL-APSE study underwent agar dilution 
method for colistin and polymyxin B MICs. The multi-point inoculator delivers 
approximately 1µL spot of inoculum onto the agar surface. The final inoculum on 
the agar will approximately be 104 CFU per spot (Figure 24). 
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Figure 24. Multi-point inoculator. Individual inoculating pins (delivering 
approximately 1 µl spot of inoculum onto agar) are arranged into the existing 
holes. 
 
4.3.7.1 Inoculation preparation  
2-3 colonies were selected from MH 2 agar plates grown overnight. These colonies 
were then inoculated into 3ml of pre-poured 0.9% sterile saline (Oxoid, 
Basingstoke, UK) and mixed until 0.5 McFarland standard was reached.  The 0.5 
McFarland suspension is diluted 10-fold by transferring 100 μl to 900 μl saline in 
Eppendorf tubes. The tubes were mixed twice by inversion. 400 μl were then 
transferred into the multi-point inoculator wells (Figure 25). 
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Figure 25. 36-well multi-point inoculator. 400 µl of bacterial inoculum was 
dispensed individually into these wells. 
 
Antibiotic plates were then inoculated starting with the lowest concentration. The 
multi-point inoculators are then autoclaved after each use. 
 
As a purity control, the bacterial suspension was seeded onto a media and 
incubated at 37⁰ C for 24 h. 
 
4.3.7.2 Preparation of MH2 agar containing antibiotics  
MH 2 agar plates were prepared as mentioned in Chapter 2, section 2.3.4 
 
Colistin and Polymyxin B stock solutions were prepared as mentioned in section 
4.3.3 
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Colistin and Polymyxin B were added onto MH 2 agar separately from the lowest 
to the highest concentrations (0.15 – 32 mg/L) according to CLSI guidelines for 
agar dilution method. 
 
The purity of each inoculum suspension was first checked. If the suspension is not 
pure, results were not reported. The MIC of each isolate is read as the lowest 
concentration without visible growth.   
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4.4 Results 
4.4.1 CHROMagar COL-APSE media versus SuperPolymyxin agar 
The in vitro activity (MIC, mg/L) of both COL and POL B when determined by agar 
dilution was comparable (+/- 1 dilution) for all Enterobacteriaceae isolates tested 
(Table 12). However, the MICs of COL and POL B differed by at least three dilutions 
for S. maltophilia NCTC 10258 and A. baumannii AB205. The mcr-1 gene was 
present in 61 of the E. coli, 58 (95 %) of which were also phenotypically resistant 
to COL (MIC > 2 mg/L). Three isolates containing mcr-1 had colistin MICs below the 
pharmacodynamic breakpoint when the MIC was determined by agar dilution. 
Three COL-resistant A. baumannii and two K. pneumoniae (MIC 8 - >256 mg/L) 
clinical isolates were also identified and included in the evaluation of both media. 
The mechanism of resistance in these three strains is yet to be determined, 
despite sequencing for mutations in mgrB, pmrA/B and the phoP/Q regulatory 
genes known previously to be associated with mutational polymyxin resistance. 
(Jayol et al., 2015) When susceptibility to COL was determined by BMD, the MIC 
of COL was comparable to that determined by agar dilution (+/- 1 dilution vs all 
strains).  
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Isolates 
MIC (mg/L)/ Agar dilution 
Polymyxin Resistance 
Mechanism 
Lowest Limit of Detection (C.F.U) 
Colistin Polymxyin B 
CHROMAgar 
COL-APSE 
SuperPolymyxin 
Intrinsic Resistance to Polymyxins 
P. mirabilis NCTC 13376 >256 >256 Intrinsic 101 101 
S. marcescens NCTC 10211 >256 >256 Intrinsic 101 101 
M. morgannii MM2 >256 >256 Intrinsic 101 101 
E. faecalis ATCC 2912  >256 256 Intrinsic >109 >109 
E. gallinarum ATCC 49573 >256 >256 Intrinsic >108 >108 
C. albicans ATCC 10231 256 256 Intrinsic >107 >107 
E. cloacae NCTC 10005  128 256 Intrinsic 102 101 
S. maltophilia NCTC 10258 8 64 Intrinsic 101* 102‡ 
Susceptible to Polymyxins 
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P. aeruginosa ATCC 27853  2 2 NA 102* 105 
Salmonella Group D (non-Typhi) 
Sal3 2 2 N/A 10
4* 106 
E. coli E17 1 2 MCR-1 107 107 
Salmonella enterica Subspecies 
diarizonae Sal1 1 2 N/A 10
5* 106 
A. baumannii ATCC 19606 1 2 NA 106 106 
E. coli E44 1 1 MCR-1 >109 >109 
Salmonella enterica Subspecies 
diarizonae Sal4 1 1 N/A 10
5* 106 
K.  pneumoniae KP32 0.5 1 NA 106 106 
Salmonella enterica Subspecies 
diarizonae Sal2 0.5 1 N/A 10
5* 106 
Salmonella Group D (non-Typhi) 
Sal5 0.5 1 N/A 10
3* 105 
E. coli ATCC 25922 0.5 0.5 NA 106 106 
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E. coli 40875 (calf) 0.5 0.5 MCR-1 106 106 
K. pneumoniae ATCC 9633 0.5 0.5 NA >109* 105 
Acquired Resistance to Polymxins 
A. baumannii AB219 >256 >256 Unknown 101 101 
A. baumannii AB205 >256 32 Unknown 
101 101 
A. baumannii AB287 8 4 Unknown 101* 101 
K. pneumoniae KP6 128 256 Unknown 101 101 
K. pneumoniae KP19 64 64 Unknown 101 101 
#E. coli 35095 (calf) >256 >256 MCR-1 101 101 
#E. coli 35175 (calf) 64 32 MCR-1 101 101 
#E. coli 29881 (calf), 33907 
(calf), 34936 (calf), 35593 (calf) 32 32 MCR-1 10
1 101 
^E. coli E10 32 16 MCR-1  101* 104 
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^E. coli E9, E33, E3, E1, E35, 
E29, E32, E13, E24, E20, E25  
 
32 16 MCR-1 101 101 
^E. coli E27 16 32 MCR-1 101 101 
^E. coli E8, E11, E39, E40, E34, 
E2, E37, E41, E36, E31 and #E. 
coli 412049521 
 
 
16 16 MCR-1 101 101 
^E. coli E30 16 16 MCR-1 101* 103 
^E. coli E14, E12, E22, E19, E7, 
E47, E16, E18, E43, E46, E28, 
E26,14042624, 412016126 and 
#E. coli 27852 (calf), 37914 
(calf), 41323 (chicken), 41339 
(chicken), 41848 (calf)  
16 16 MCR-1 101 101 
^E. coli E49 16 16 MCR-1 101* 103 
^E. coli E5 8 16 MCR-1 101* 103 
 
 
208 
#E. coli 35062 (calf) 16 8 MCR-1 101* 103 
#E. coli 412044854 and 
413040864  
 
16 8 MCR-1 101 101 
#E. coli 34692 (calf) 16 8 MCR-1 101* 102 
^E. coli E45 8 16 MCR-1 101 101 
#E. coli 32218 (calf) 8 8 MCR-1 101 101 
Table 12. Lowest limit of detection (C.F.U) comparison between CHROMagar COL-APSE and SuperPolymyxin media. ^isolates were supplied by 
a group from Denmark and #isolates were supplied by a group from France. *CHROMagar COL-APSE sensitivity enhanced and ‡SuperPolymyxin 
sensitivity enhanced 
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Growth on CHROMagar COL-APSE on plates inoculated with 103 CFU was observed 
for all COL R Gram-negative isolates. All of the COL-susceptible 
Enterobacteriaceae, COL-resistant Gram-positive (Enterococci spp) and fungal 
(Candida spp) isolates failed to grow at these inocula (Figure 26). The growth of 
the P. aeruginosa ATCC 27853 type strain (COL MIC 2 mg/L), however, was 
supported on CHROMagar COL-APSE at 103 CFU. Although this isolate is deemed 
susceptible to COL according to current CLSI breakpoints and is recommended as 
a control strain for antimicrobial susceptibility testing, it should be noted that it 
has frequently been shown to exhibit heteroresistance to COL in vitro when 
population analysis profiling (PAP) is used as the gold standard. (Bergen et al., 
2011) The -70° C stock of ATCC 27853 held in our laboratory and used in this study 
consistently demonstrates heteroresistance to COL when assessed using the PAP 
method.  
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Figure 26. Growth of isolates on CHROMagar Unsupplemented, CHROMagar COL-APSE and SuperPolymyxin agar. Growth of isolates observed 
on CHROMagar COL-APSE were AB287, AB219, AB205, KP6, KP19, MM2 (intrinsic resistance to colistin), E. cloacae NCTC 10005 (intrinsic 
resistance to colistin), EC35095, E25, P. aeruginosa ATCC 25922 (heteroresistance), S. maltophilia NCTC 10258 (intrinsic resistance to colistin), S. 
marcescens NCTC 10211 (intrinsic resistance to colistin) and SAL3. With SuperPolymxin, growth of AB219, AB205, KP6, KP19, MM2 (intrinsic 
resistance to colistin), E. cloacae NCTC 10005 (intrinsic resistance to colistin), EC35095, E25 and S. marcescens NCTC 10211 (intrinsic resistance 
to colistin) were observed. 
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The growth on SuperPolymyxin media with an inoculum of 103 CFU was similar but 
visibly weaker for each of the COL-resistant non-fermenters. The growth of one 
strain of COL-resistant A. baumannii (MIC 8 mg/L) and S. maltophilia (MIC 32 mg/L) 
was not supported at all (Figure 26). It is possible that the antimicrobial synergy is 
known to exist between COL and daptomycin (Phee et al., 2013) against A. 
baumannii could account for the poor growth or inhibition of these species that 
we observed on SuperPolymyxin agar. In contrast to growth on SuperPolymyxin, 
the chromogenic properties of the CHROMagar COL-APSE media enabled the clear 
differentiation of COL-resistant Enterobacteriaceae from non-fermenters. 
Phenotypic identification as either dark pink to reddish (E. coli), metallic blue 
(Klebsiella, Enterobacter and Serratia spp) or colourless natural pigmentation 
(Morganella) was also possible, while on SuperPolymyxin only COL-resistant E. coli 
could be identified by their metallic green appearance. In the limit of detection 
studies, COL-resistant strains could be recovered on both media at 101 CFU, while 
the growth of strains deemed susceptible to COL was only possible when using an 
inoculum of >104 (Table 10).  
 
The stability of the media confirmed that there was no reduction in performance 
(103 CFU/ml) for up to 4 weeks. Swarming of P. mirabilis NCTC 13376 was observed 
when it was used to inoculate both CHROMagar COL-APSE and SuperPolymyxin 
plates. The addition of 50 mg/L p-nitro-phenyl glycerol (PNPG) to the CHROMagar 
COL-APSE plates reduced this significantly (Figure 27). 
 
 
213 
 
 
 
 
 
 
 
Figure 27.  Growth of simulated bacterial pools inoculated using L-spreader method. A) CHROMagar COL-APSE without PNPG containing A. 
baumannii AB205 (COL R), E. coli E7 (COL R). E. cloacae NCTC 10005 (COL R), E. faecalis ATCC 2912 (COL R), K. pneumoniae KP19 (COL R), M. 
morgannii MM2 (COL R), P. aeruginosa ATCC 27853 (COL heteroresistant), S. marcescens NCTC 10211 (COL R) and P. mirabilis NCTC 13376 (COL 
R)  B) CHROMagar COL-APSE + 50 mg/L PNPG containing A. baumannii AB205 (COL R), E. coli E7 (COL R). E. cloacae NCTC 10005 (COL R), E. faecalis 
ATCC 2912 (COL R), K. pneumoniae KP19 (COL R), M. morgannii MM2 (COL R), P. aeruginosa ATCC 27853 (COL heteroresistant), S. marcescens 
NCTC 10211 (COL R) and P. mirabilis NCTC 13376 (COL R) C) CHROMagar COL-APSE + 50 mg/L PNPG simulated pool containing A. baumannii 
A B C 
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ATCC 19606 (COL susceptible), E. coli ATCC 25922 (COL susceptible), E. faecalis ATCC 2912 (COL resistant), P. aeruginosa ATCC 27853 (COL 
heteroresistant), K. pneumoniae ATCC 9633 (COL susceptible) 
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Part 2. Prevalence and surveillance of PMPR from poultry farms and 
clinical human faecal samples in Brunei Darussalam 
 
4.5 Methods 
4.5.1 Chicken cloacal samples 
Three hundred cloacal swabs obtained from three different farms (A, B and C) 
from different geographic location were selected in this study in Brunei in July 
2016. Consent was given by these farms for sample collection. The selected farms 
are the major poultry producers and food distributor for supermarkets in Brunei. 
Three hundred cloacal swabs from healthy chickens were collected before 
undergoing slaughter using a transport swab (Transwab® Amies, Corsham, UK). 
 
4.5.2 Human faecal samples  
Two hundred and twenty-four human faecal samples were collected during a 
period in July 2017 and January 2018 as part of Brunei’s Microbiology Laboratory 
routine testing. Faecal samples obtained were from different hospitals and clinics 
around Brunei. Similarly, faecal samples were collected using a transport swab 
(Transwab® Amies, Corsham, UK). 
 
Swabs were then transported to the UK (mentioned in Chapter 2, section 2.3.2 ). 
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4.5.3 Sample processing and bacterial identification 
On arrival, chicken cloacal swabs were inoculated directly onto CHROMagar™ COL-
APSE media. However, with the human faecal samples, it was first enriched with 
colistin 50 µg disc in 10 ml of TSB broth (Oxoid, Basingtoke, UK) (TSB) at a final 
concentration of 5 mg/L in 25 ml sterile universal tube. The enriched human faecal 
samples were incubated at 37⁰ C for 24 h without shaking. Turbid universal tubes 
were then seeded onto CHROMagar COL-APSE media.  
 
CHROMagar™ COL-APSE media from both chicken and humans were incubated at 
37⁰ C for 24 h. Red colonies (colonial morphology) isolated from the media were 
identified as E. coli using MALDI-Tof MS (Bruker, Coventry, UK) according to the 
manufacturer’s instructions. Briefly, individual colonies were lightly smeared on 
to the target plate and overlaid with matrix (α-cyano-4-hydroxycinnamic acid in 
50 % acetonitrile/2.5 % trifluoroacetic acid). Once dried, the plates are loaded into 
the mass spectrometer, where each sample is vaporised (desorption) by the laser 
and ionised. The mass analyser detects these ions, creating a spectral image 
unique to bacterial and fungal genera and most species (Clark et al., 2013). 
 
The Isolates were saved at -70˚C in Pro-Lab Diagnostics™ Microbank™ Bacterial 
and Fungal Preservation System, cryobeads (Fisher Scientific, Leicestershire, UK) 
until further testing. 
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4.5.4 Isolates used in prevalence studies 
One hundred and seventy-four positive colistin-resistant E. coli isolates recovered 
from CHROMagar COL-APSE media from chicken cloacal swabs and 106 from 
human faecal swabs were chosen for the period prevalence studies. 
 
4.5.5 Isolates used in surveillance analysis  
RAPD PCR with ERIC2 primers (as mentioned in Chapter 2, Section 2.4.1.1) were 
performed on 60 E. coli mcr-1-like positive isolates from chickens and 102 from 
humans. Fifty-two distinguishable profiles of colistin-resistant E. coli isolates were 
then selected for surveillance from both chicken (n= 26) and human samples (n= 
26) (Figure 29 and Figure 31). 
 
4.5.6 Susceptibility testing and MICs 
Susceptibility to β-lactams; ampicillin (2 µg), augmentin (30 µg), aztreonam (30 
µg), cefpirome (30 µg), cefotaxime (30 µg), ceftriaxone (30 µg), cefoxitin (10 / 30 
µg), cefpodoxime (10 µg), cephalothin (30 µg), cefepime (30 µg), cefuroxime (30 
µg), ceftazidime / avibactam (50 µg), ceftolozane / tazobactam (30 / 10 µg), 
piperacillin / tazobactam (75 / 10 µg), ertapenem (10 µg), imipenem (10 µg), 
meropenem (10 µg); amikacin (30 µg), gentamicin (10 µg), kanamycin (30 µg), 
neomycin (30 µg), netilmicin (30 µg), tobramycin (10 µg), spectinomycin (100 µg), 
colistin (25 µg), chloramphenicol (30 µg), tetracycline (10 µg), tetracycline (30 µg), 
levofloxacin (5 µg), minocycline (30 µg), norfloxacin (10 µg ), ciprofloxacin (1 / 5 
µg), moxifloxacin (5 µg), trimethroprim (5 µg), tigecycline (5 µg), doxycycline (30 
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µg) and streptomycin (10 µg) was assessed in disc diffusion assays on Mueller-
Hinton II (MH II) agar (Oxoid, Basingstoke, UK). The activities of apramycin (15 µg), 
florfenicol (30 µg), pefloxacin (5 µg), enrofloxacin (5 µg) and ceftiofur (30µg), 
antimicrobials often used in veterinary practice, were also investigated.  
 
Minimum Inhibitory Concentrations (MICs) of colistin were determined by agar 
dilution (as mentioned in section 4.3.7) and/or the E-test method (bioMérieux, 
Marcy l’Etoile, France). Clinical Laboratory Standards Institute (CLSI), CLSI VET08 
and European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
breakpoints were used to define resistance where available (EUCAST, 2018; CLSI, 
2018; CLSIVET08, 2018)  
 
4.5.7 PCR amplification of mcr genes 
DreamTaq Green PCR Master Mix (2X) (Thermofisher Scientific, Dartford, UK) was 
used for the PCR reaction. Master mix contains DreamTaq DNA polymerase, 2X 
DreamTaq Green buffer, dATP, dCTP, dGTP and dTTP, 0.4 mM each, and 4 mM 
MgCl2. And it also contains a density reagent and two dyes for monitoring 
electrophoresis progress: the blue dye migrates with 3- 5 kb DNA fragments in a 1 
% agarose gel and the yellow dye migrates faster than 10 bp DNA fragments in 1 
% agarose gel with absorption peaks at 424 nm and 615 nm, respectively. 
 
PCR amplification was performed using primers targeting mcr genes (1-2) as 
described previously (Cavaco et al., 2016).  
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DNA extraction was performed as mentioned in section 2.3.6.1 . 2 µl of the 
bacterial lysate was added to 25 µl of DreamTaq Green PCR Master Mix (2X) and 
2 µl of primers (multiplex mcr-1 and mcr-2) in a 0.6 ml PCR tube. 
 
For gel electrophoresis and band visualization see section 2.3.7.2 
 
See Appendix A for list of primers used. 
 
4.5.7.1 Cycling condition 
PCR cycling conditions used were as follows: 
Initial denaturation 15 min at 94⁰ C, followed by 25 cycles of 30 s at 94⁰ C, 90s at 
58⁰ C and 60s at 72⁰ C. Final extension of 72⁰ C at 10 min. 
 
4.5.8 WGS analysis  
Contigs and draft genome assembly of all 52 colistin-resistant E. coli isolates were 
determined in silico using online tools from Centre for Genomic Epidemiology 
(CGE) as mentioned in Chapter 3, section 3.3.9.4 with additional tools 
SerotypeFinder 2.0, VirulenceFinder 2.0 and pMLST 2.0.  
 
With regards to MLST, those isolates not assigned a sequence type (ST) from the 
CGE database are then directed to the EnteroBase database for ST assignment 
(available at http://enterobase.warwick.ac.uk/species/index/ecoli) (Zhou et al., 
2018). 
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4.5.9 Phylotyping 
Phylotypes A, B1, B2 or D of 46 E. coli mcr-1-like isolates from chicken samples 
were determined by triplex PCR phylogroup targeting chuA, yjaA and TspE4.C2 
(putative lipase esterase) genes (Clermont et al., 2000). Phylotyping are 
performed to identify the virulent extra-intestinal E. coli strains belonging to 
mainly group B2 and, to a lesser extent, to group D (Clermont et al., 2000). While 
the commensals belonged to either group A or B1 (Clermont et al., 2000). 
 
DNA extraction was performed as mentioned in section 2.3.6.1 . 2 µl of the 
bacterial lysate was added to 25 µl of DreamTaq Green PCR Master Mix (2X) and 
2 µl of primers in a 0.6 ml PCR tube. 
 
For gel electrophoresis and band visualization see section 2.3.7.2 
 
Primers are listed in Appendix A.  
 
Phylotypes of 52 colistin-resistant E. coli isolates for surveillance analysis were 
performed by in silico ClermonTyping (Beghain et al., 2018). The ClermonTyping 
tool allows a given strain sequence to be assigned to E. albertii, E. fergusonii, 
Escherichia clades I–V, E. coli sensu stricto as well as to the seven main E. coli 
phylogroups (A, B1, B2, C, D, E and F) (Beghain et al., 2018). The phylogroup E is 
formerly a small set of unassigned strains of which O157:H7 is the best-known 
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member and is now well recognised (Tenaillon et al., 2010). While phylogroup F 
consists of strains that form a sister group to phylogroup B2 (Jaureguy et al., 2008; 
Clermont et al., 2011). Phylogroup C has been proposed for strains that is closely 
related to, but distinct from, phylogroup B1 (Moissenet et al., 2010; Clermont et 
al., 2011). 
  
Contigs and the draft genome assembly of all isolates were analysed using this 
online tool available at  http://clermontyping.iame-research.center/ 
 
4.5.10 Serotyping 
Serotyping of O antigens was performed on 46 colistin-resistant E. coli isolates 
from chicken samples using antisera pools obtained from Statens Serum Institut 
(SSI Diagnostica, Denmark), specific for human enterotoxigenic E. coli (ETEC) (O11, 
O20, O21, O27, O32, O48, O78, O80) and invasive O serotypes common to poultry, 
pigs and sheep (O10, O18ab, O35, O83, O87, O95, O116, O120). Antisera (80 µl) 
was added to equal volumes of boiled bacterial culture in microtitre plates and 
incubated at 50-52 °C for 18-24hr. A positive reaction for any serotype was 
recorded as a precipitate covering the entire bottom of each well. Negative O 
serotypes were reported when the bacterial suspension produced only small 
white spots confined to the center of wells. 
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Serotypes of 52 colistin-resistant E. coli isolates for surveillance analysis were 
determined in silico using online tools from Centre for Genomic Epidemiology 
(CGE) as mentioned in section 4.5.8
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4.6 Results  
4.6.1 Prevalence mcr genes 
4.6.1.1 In chicken cloacal samples 
Three hundred cloacal swabs collected from three different chicken farms showed 
58% (174/300) recovery of colistin-resistant E. coli on CHROMagar COL-APSE 
media.  The mcr-1 gene was detected in every strain by PCR. Co-resistance was 
highest with aminoglycosides (apramycin, 100% and kanamycin, 72%) quinolones 
(pefloxacin, 92%), phenicols (chloramphenicol, 98% and florfenicol, 100%), β-
lactams (amoxicillin/clavulanic, 86% and cefpodoxime, 52%) antibiotics (Figure 
28). No reference (EUCAST/CLSI) zone diameter breakpoints are available for 
apramycin or florfenicol. Isolates with no zone of inhibition are considered 
resistant.  
 
RAPD analysis revealed considerable diversity (Figure 29). There were 6 different 
profiles identified out of 60 colistin-resistance E. coli isolates tested. However, 
only 12 colistin-resistance E. coli isolates was shown in Figure 29.  
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Figure 28. Percentage of co-resistance in E. coli mcr-1-like isolates in chickens. 
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Figure 29. Representative RAPD profiles of colistin-resistant E. coli (12/60) isolated from chickens. Considerable diversity is seen with different 
RAPD profiles (P). 
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4.6.1.2 In humans faecal samples 
41.7 % (106/254) of the faecal samples grew colistin-resistant E. coli on 
CHROMagar COL-APSE media. And all of the 106 colistin-resistant E. coli isolates 
were positive for mcr-1 gene by PCR. The MICs for Polymyxins were in the range 
of 3-32 mg/L.  
 
Co-resistance was highest with aminoglycoside (apramycin, 100%), quinolones 
(pefloxacin, 83%), phenicols (chloramphenicol, 83% and florfenicol, 100%), β-
lactams (amoxicillin/clavulanic, 84%) antibiotics (Figure 30).  
 
RAPD analysis (Figure 31) revealed considerable diversity, with 26 distinguishable 
profiles.   
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Figure 30. Percentage of co-resistance in E. coli mcr-1-like isolates in humans. 
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Figure 31. Representative RAPD profiles of colistin-resistant E. coli (11/102) isolated from humans. Considerable diversity is seen with different 
profiles (P).   
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4.6.2 Surveillance of colistin-resistant E. coli isolates  
Contigs of 52 colistin-resistant E. coli isolates were anlaysed in silico using online 
tools (http://www.genomicepidemiology.org/). The characteristics of each 
colistin-resistant E. coli isolates from chickens and humans are shown in Table 13. 
Susceptibility testing results for all isolates are found in Appendix B. There were 
common E. coli ST clones observed between chicken farms and human faecal 
samples (Table 15) and variation in the number of virulence factors observed in all 
isolates (Table 13). There was no carriage of carbapenemase genes in all of the 
isolates. However, ESBL genes (CTX-M-3 and CTX-M-65) were identified in 2 of the 
isolates.  
 
There were differences in the sequence type, ST using alleles to type each of the 
plasmids by pMLST 2.0 except for B1 and B42 shown in Table 14. Most of the 
colistin-resistant E. coli isolated from chickens and humans are non-typable. There 
were missing alleles with respect to the plasmid scheme (IncI1, InHI1 and IncN), 
indicative of novel or undescribed plasmids. Hence, there is no statistical 
association between the plasmid types and the mcr-1 carriage. 
 
The most prevalent phylotype performed by PCR in colistin-resistant E. coli 
isolated from chickens were group D (50% n=23/46), followed by B1 (26%, 
n=12/46), A (15%, n= 7/46) and B2 (9% n=4/46). While results from in silico 
ClermonTyping showed the most prevalent phylotype in chickens were 
phylogroup B1 (35%, n=9/26), followed by D (23%, n=6/26), A (19%, n=5/26), E 
(8%, n=2/26), F (8%, n=2/26), B2 (3.5%, n=1/26) and unknown/novel (3.5%, 
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n=1/26). In humans, the most prevalent phylotype was phylogroup A (38%, 
n=10/26), D (31%, n=8/26), B1 (15%, n=4/26), unknown/novel (7%, n=2/26), B2 
(4.5%, n=1/26) and F (4.5%, n=1/26). However, there are phylogroup B2 (extra-
intestinal infection) observed in the chickens using the triplex PCR phylogroup 
assignment (n=4). While by ClermonTyping method; chickens (n=1) and humans 
(n=1) (Table 15). Interestingly, discrepancies were reported in 50% (10/20) of 
colistin-resistant E. coli isolates tested with triplex PCR phylotype and in silico 
Clermontyping (Table 16). 
 
Serotypes associated with animal (avian, porcine, ovine) infections were found in 
42 % (19/45), but no avian (APEC) or human enterotoxigenic (ETEC) serogroups 
were found.  
 
 
 
 
231 
Lab ID Species Colistin MIC (mg/L) 
mcr 
genes ST 
Resistance 
determinant Virulence factor genes Serotype 
Incompatibility 
group 
Farm A         
A8 E. coli 4 mcr-1.1 ST115 
strA, strB, aadA1, 
aph(3')-Ia, blaCMY-2, 
blaTEM-1B, qnrS1, 
fosA4, cmIA1, floR, 
sul3, tet(A), dfrA1 
iss, celb, astA, iroN, iha, 
lpfA, gadA, eilA, invasin O21:H15 
IncFI, ColpVC, 
Col8282, 
IncHI1A, 
IncFIA(HI1) 
*A12 E. coli >16 mcr-1.1 ST2705 
aadA1, aph(3')-1a, 
blaTEM-1B, qnrS1, 
floR, sul3 
gadB :H10 p0111, IncI2, IncX1 
*A13 E. coli 2 mcr-1.1 ST2473 
aadA2, aadA1, 
aph(3')-Ia, blaTEM-1B, 
qnrS1, fosA4, 
cmIA1, floR, sul3, 
tet(A), tet(M), 
dfrA15 
iss, lpfA, gad O168:H28 
IncFIA(HI1), 
IncHI1A, 
IncHI1B(R27) 
*A25 E. coli 2 mcr-1.1 ST2705 
blaTEM-1B, qnrS1, 
floR, sul3, gad :H10 
p0111, IncX1, 
IncI2 
A28 E. coli >32 mcr-1.1 ST226 
aph(6)-Id, aadA2, 
blaTEM-1B, 
fosA4,cmIA1, floR, 
sul2, sul3, tet(A), 
dfrA5 
gad, ireA O18:H10 IncI1 
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*A31 E. coli 2 mcr-1.1 ST8262 
aph(6)-Id, fosA4, 
sul2, sul3 air, eilA O166:H23 
IncFIB(pLF82), 
IncHIA, 
IncFIA(HI1) 
A33 E. coli 1 mcr-1.1 ST2732 
aph(4)-Ia, strA, 
aph(3')-Ia, aadA1, 
strB, blaTEM-1B, 
blaCTX-M-3, oqxA, 
oqxB, fosA4, floR, 
catA2, catA1, 
cmIA1, dfrA12, 
dfrA14, mph(A) 
astA, cma, eilA, gad, iha, 
lpfA, iatB, mchF O33:H28 IncHI2, IncFII 
A41 E. coli 2 mcr-1.1 ST117 
aph(3')-Ia, aadA1, 
aadA2, blaTEM-1B, 
qnrB4, fosA4, floR, 
cmIA1, sul1, sul3, 
tet(A), dfrA5, 
dfrA12, dfrA17, 
mph(A) 
iss, iroN, cma, astA, pic, 
eilA, gad, iha, lpfA, gadB, 
ireA, invasin 
O8:H19 
col(BS512), 
IncHI1B(R27), 
IncI1, IncHI1A, 
IncFIA(HI1) 
A53 E. coli 2 mcr-1.1 ST2223 
aph(4)-Ia, aadA2, 
strA, strB, blaTEM-1B, 
qnrS1, qnrB4, 
fosA4, floR, cmIA1, 
catA2, cat, sul1, 
sul2, sul3, tet(A), 
dfrA12 
iroN, astA, gad, cma O75:H42 
IncI2, IncN, 
IncX4, IncX1, 
p0111, IncI, 
IncHI2A, IncHI2, 
IncFII(pSE11), 
InFII, 
IncFIB(AP00191
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8), IncB/O/K/Z, 
ColpVC, Col156 
Farm B         
*B1 E. coli 4 mcr-1.1 ST711 
aph(4)-Ia, aac(3)-
Iva, strA, blaDHA-1, 
qnrS1, qnrB4, 
fosA4, florR, cmIA1, 
sul1, sul3, tet(A), 
tet(M), dfrA14, 
mph(A) 
iroN, lpfA, cma O8:H10 
IncI1, IncX4, 
IncHI1B(R27), 
IncN, IncHI1A, 
IncFII, 
IncFIA(HI1) 
*B5 E. coli 2 mcr-1.1 ST117 
aph(4)-Ia, aph(3')-
Ia, aadA2, blaTEM-1B, 
fosA4, cmIA1, floR, 
sul2, sul3, tet(A), 
cma, iss O71:H52 IncN, IncI1 
B7 E. coli 2 mcr-1.1 ST1011 
aph(4)-Ia, blaTEM-176, 
fosA3, florR, cmIA1, 
catA1, sul1, sul3, 
dfrA12,  mph(A) 
iss, iatB :H25 IncN, IncHI2, IncI2 
*B11 E. coli 4 mcr-1.1 ST4684 
aph(4)-Ia, blaTEM-1B, 
qnrS1, fosA4, floR, 
sul2, sul3, 
lpfA O9:H7 
IncHI1B(R27), 
IncHI1A, IncX4, 
IncFIA(HI1) 
*B12 E. coli 2 mcr-1.1 ST1011 
aph(4)-Ia, aadA1, 
blaTEM-1B, fosA3, 
catA1, cmIA1, sul3, 
iss :H25 IncN, IncI2, IncHI2 
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sul1, dfrA12 , 
mph(A) 
*B23 E. coli 2 mcr-1.1 ST117 
aph(4)-Ia, blaTEM-1B, 
fosA4, floR, tet(B), 
dfrA12, 
astA, iss, pic, iroN O45:H4 
IncI2, IncFII, 
IncFIC(FII), 
IncFIB(AP00191
8) 
B25 E. coli 2 mcr-1.1 ST162 
aph(4)-Ia, blaTEM-1C, 
sul3, tet(B), dfrA5, 
mph(A) 
gad, lpfA, iss O134:H19 IncX4, IncFII(29) 
*B28 E. coli >32 mcr-1.1 ST1727 
blaTEM-1B, qnrS1, 
fosA4, floR, sul2, 
sul3, tet(A) 
iss, lpfA, cma, gad, iroN :H7 
IncI2, 
IncFIB(AP00191
8), IncFII(pCoo), 
p0111 
*B42 E. coli 2 mcr-1.1 ST48 
strA,aph(3')-Ia, 
aph(6)-Id, aadA2, 
blaTEM-1B, blaDHA-1, 
qnrS1, qnrB4, 
fosA4, cmIA1, floR, 
sul1, sul3,   dfrA1, 
dfrA15, dfrA17, 
mph(A) 
gad :H11 IncX4, IncN 
B47 E. coli 1 mcr-1.1 ST1140 
aph(4)-Ia, blaTEM-1C, 
fosA4, floR, sul3, 
dfrA1, mph(A) 
gad, gadB O38:H39 IncI1 
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*B52 E. coli 4 mcr-1.1 ST359 
aph(4)-Ia, aadA2, 
blaTEM-1B, blaDHA-1, 
qnrB4, cmIA1, floR, 
sul1, sul3, dfrA17,  
mph(A) 
cba, iroN, gad, astA, cma, 
iss, lpfA, cvaB, tsh NT 
IncFII, 
IncFIC(FII), 
IncI2, IncI1, 
IncX1, 
IncFIB(AP00191
8) 
Farm C         
*C1 E. coli 1 mcr-1.1 ST7687 
aph(4)-Ia, aph(3')-
Ia, aac(3)-Iid, 
blaTEM-1B, floR, sul3 
eila, air, gad, gadB O17/77:H31 IncX4, IncHI2 
*C19 E. coli 2 mcr-1.1 ST10 
aph(3")-Ib, aadA2, 
aph(6)-Id, aph(3')-
Ia, blaTEM-1B, qnrS1, 
fosA4 , floR,  catA2, 
sul1, sul2, sul3, 
dfrA5, dfrA12, 
mph(A) 
gad, astA, gadB :H32 
IncQ1, IncHI2, 
IncFII(29), IncI2, 
IncI1 
C22 E. coli 2 mcr-1.8 ST101 
aph(4)-Ia, aadA1, 
aac(3)-Iva, aph(3')-
Ic, blaTEM-1B, blaCTX-
M-65, qnrS1, fosA4, 
floR, cmlA1, sul3, 
tet(A), tet(M), 
dfrA15, dfrA14 
astA, cma, lpfA, iss, eilA, 
gad, iha, lpfA, mchF O88:H31 
IncHI1A, 
IncHIB(R27), 
IncFIA(HI1), 
IncFII, IncY, 
IncI2, 
IncFIC(FII), 
IncFIB(AP00191
8) IncI1, IncX1 
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C28 E. coli 1 mcr-1.1 ST2372 
strA, aph(3')-Ia, 
aph(4)-Ia, strB, 
blaTEM-1B, oqxA, 
oqxB, fosA4, floR, 
cmIA1, catA2, 
catA1, sul3, tet(A), 
tet(M), mph(A) 
astA, cma, gad, iroN O37:H25 
ColpVC, IncI2, 
IncFII, 
IncFIB(AP00191
8), Col156, 
IncB/O/K/Z, 
ColpVC, IncFII 
C45 E. coli 2 mcr-1.1 ST1642 
aph(4)-Ia, blaTEM-1C, 
qnrS1, fosA4, floR, 
sul3, tet(A), 
lpfA, astA O8:H7 
IncFII, IncY, 
IncFIB(AP00191
8), 
IncFIB(plF82), 
IncI2, IncX1, 
IncFII(29) 
C55 E. coli 2 mcr-1.1 ST155 
strA, aph(4)-Ia, 
aph(3')-Ia, strB, 
blaTEM-1B, fosA4, 
floR, sul3, dfrA1, 
dfrA5 
mchF, gad, iroN, tsh, lpfA, 
iss O38:H21 
IncI2, IncX4, 
IncFII(29) 
Humans         
1 E. coli 4 mcr-1.1 ST224 
aadA2, aadA1, 
cmlA1, floR, sul3, 
tet(A), mph(A) 
cma, iss, iroN, gad, lpfA O102:H23 
IncX4, 
IncFIB(AP00191
8), IncFII 
8 E. coli 4 mcr-1.1 ST206 
aadA1, aadA2, 
aph(3'')-Ib, aph(4)-
Ia, aph(6)-Id, blaTEM-
1B, fosA4, cmIA1, 
astA O96:H5 
IncHI1A, 
IncFII(29), 
IncX4, 
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floR, sul2, sul3, 
dfrA12, dfrA17 
IncHI1B(R27), 
IncFIA(HI1) 
25 E. coli 2 mcr-1.1 ST58 
aadA1, blaTEM-1B 
QnrS1, cmIA1, sul3, 
tet(A), dfrA15 
astA, cma, iss, gad, lpfA O8:H25 
IncFIC(FII), 
IncFIB(AP00191
8), IncI2 
*46 E. coli 4 mcr-1.1 ST8379 
aadA1, aadA2, 
blaTEM-1A, cmIA1, 
floR, sul3, tet(A), 
dfrA12, mef(B) 
gad O45:H26 
IncN, Col440I, 
IncFIA(HI1), 
IncFIB(K) 
49 E. coli 2 mcr-1.1 ST746 
aph(3')-Ia, aadA1, 
blaDHA-1, qnrS1, 
qnrB4, floR, sul1, 
sul2, sul3, tet(A), 
dfrA17, mph(A) 
gad O8:H37 IncX4, IncX2 
50 E. coli 4 mcr-1.1 ST69 
aadA1, qnrS1, floR, 
sul3, tet(B) eilA, gad, lpfA, air O25:H18 
IncFIA(HI1), 
IncHI1A, 
IncHI1B(R27) 
53 E. coli 4 mcr-1.1 ST93 
aph(3'')-Ib, aph(6)-
Id, aph(3')-Ia, 
aadA1, blaTEM-1B, 
fosA4, sul3, sul2, 
tet(A) 
astA, cba, cma, iha, iss O51:H52 
IncHI1A, 
IncHI1B(R27), 
IncFIA(HI1), 
p0111, IncI2 
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54 E. coli 2 mcr-1.1 ST1642 
aph(3')-Ia, blaTEM-
176, QnrS1, floR, 
tet(A), dfrA14 
iss, astA, lpfA, gad O48:H7 
IncFIA, 
IncFIB(AP00191
8), IncI2, 
IncFIB(pLF82), 
IncX1 
59 E. coli 2 mcr-1.1 ST38 
aph(4)-Ia, aadA1, 
aadA2, blaTEM-1B, 
cmIA1, floR, sul3, 
tet(B), dfrA17 
iss, senB, eilA, iha, iatB, 
gadB, AfaB O86:H45 
IncFIA(HI1), 
IncHI1A, 
IncHI1B(R27), 
IncN 
60 E. coli 2 mcr-1.1 ST1638 
aadA1, blaTEM-176, 
qnrS1, floR, tet(A), 
dfrA1 
iss, iroN, gadB O124:H12 
IncX4, IncX1, 
InFII, IncI2, 
IncFIB 
(AP001918), Col 
(MG828) 
61 E. coli 2 mcr-1.1 ST1011 
aph(4)-Ia, aadA2, 
blaTEM-1B, floR, 
catA1, sul1, sul3, 
dfrA5, dfrA12, 
mph(A) 
iss, eilA, iatB O157:H16 
IncFIB(AP00191
8), IncFII, IncI2, 
Col156 
63 E. coli >32 mcr-1.1 ST1011 
aph(4)-Ia, aadA2, 
aac(3)-Iva, aac(3)-
Iid, aadA1, blaTEM-
1B,  fosA4, floR, 
catA1, sul1, sul3, 
iss, astA :H16 IncX4, IncFIB(K), IncX1 
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tet(A), dfrA12, 
mph(A) 
*64 E. coli 4 mcr-1.1 ST 8380 
aadA1, QnrS1, floR, 
sul3, dfrA14, 
mph(A), 
gad, eilA, lpfA, iatB :H31 
IncHI1A, 
IncHI1B(R27), 
IncFIA(HI1) 
67 E. coli 4 mcr-1.1 ST372 
aph(6)-Id, blaTEM-1B, 
catA1, sul2, tet(B), 
mph(A) 
iss, vat :H31 IncFII(pRSB107), IncX4 
70 E. coli 4 mcr-1.1 ST46 
aadA1, blaTEM-1B, 
qnrS1, fosA4, floR, 
sul3, tet(A) 
gad O9:H4 
IncHI1B(R27), 
IncFIA(HI1), 
IncHI1A 
*84 E. coli 2 mcr-1.1 ST8168 vanC1XY, mdf(A) astA :H29 IncX4 
86 E. coli 4 mcr-1.1 ST1121 
aph(6)-Id, aph(3'')-
Ib, blaTEM-1B, QnrS1, 
floR, sul3, tet(A), 
dfrA14, 
gad, lpfA, lambda bor :H38 IncX4, p0111 
92 E. coli 2 mcr-1.1 ST1201 tet(A) lambda bor, etpD O124:H38 
IncI2, 
IncFIB(AP00191
8), IncFII(pCoo) 
96 E. coli 4 mcr-1.1 ST48 
aadA1, blaTEM-176, 
qnrS1, floR, sul3, 
tet(A), dfrA5 
gad, iss, etpD O8:H11 IncX4, IncX1, p0111 
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106 E. coli >32 mcr-1.1 ST359 
aph(4)-Ia, aph(3'')-
Ib, aph(3')-Ia, 
aph(6)-Id, aadA2, 
blaDHA-1, blaTEM-1B, 
qnrB4, cmIA1, floR, 
catA2, sul1, sul2, 
sul3, tet(A), tet(D), 
dfrA17, mph(A) 
iroN, cba, astA, cma, iss, 
lpfA, mchF O35: 
IncFII, 
IncFIC(FII), 
IncI1, 
IncFIB(AP00191
8), IncI2, IncFII 
109 E. coli >32 mcr-1.8 ST93 
aph(4)-Ia, aph(3'')-
Ib, aph(6)-Id, blaTEM-
1B, qnrS1, qnrD, 
fosA4, floR, catA2, 
sul3, 
iss, iha, astA O51:H52 
IncHI1B(R27), 
IncFIA(HI1),IncH
I1A 
111 E. coli 4 mcr-1.1 ST115 
aph(3')-Ia, aph(3'')-
Ib, aph(6)-Id, 
aadA1, blaTEM-1B, 
qnrS1, fosA4, 
cmIA1, floR,  sul2, 
sul3, tet(B), mph(A) 
iss, astA, celB O21:H16 
Col8282, 
Col156, IncY, 
IncI2, 
IncFIB(AP00191
8), IncFII, IncX1, 
IncB/O/K/Z 
112 E. coli 4 mcr-1.8 ST117 blaTEM-1B, tet(A) iss, lpfA, ireA, hlyE O2:H4 
IncFII(pHN7A8), 
IncFII(pSE11), 
IncFII, IncI2, 
Col156, 
IncFIB(AP00191
8) 
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113 E. coli 2 mcr-1.1 ST1011 
aph(3')-Ia, aadA1, 
blaTEM-176, qnrS1, 
cmIA1, floR, sul3, 
tet(A), dfrA14 
astA, cma, eilA, iss, lpfA, 
iatB O86:H4 
IncI2, IncFII, 
ColpVC, 
IncFIC(FII), 
IncFIB(pLF82), 
IncFIB(AP00191
8), IncX1, IncY 
*121 E. coli 2 mcr-1.1 ST8376 
aph(3')-Ia, aadA17, 
blaTEM-1B, qnrS1, 
fosA4, floR, tet(A),  
dfrA12, lnu(F), 
mph(A) 
gad O8: IncX4, IncFII, IncX1 
124 E. coli 2 mcr-1.8 ST1011 
aph(4)-Ia, aadA1, 
aadA2,  aac(3)-Iva, 
blaTEM-1B, qnrS1, 
fosA4,  cmIA1, floR, 
catA1, sul2, sul3, 
tet(A), mph(A) 
eilA, iatB O157:H9 
IncI2, IncU, 
p0111, 
Col(MG828) 
Table 13. Characteristics of 52 colistin-resistant E. coli strains isolated from chicken cloacal and human faecal clinical samples. *- ST were 
determined by EnteroBase database. The letters (A, B and C) represents individual farms where the chicken cloacal samples were collected. NT- 
Non typeable by SerotypeFinder 2.0, Centre for Genomic Epidemiology (CGE). 
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E. coli 
Isolates 
IncI MLST IncI Allele 
ardA, pilL, 
repI1, sogS, 
trbA 
IncHI1 MLST IncHI1 Allele 
HCM1_043, HCM1_064, 
HCM1_099, HCM1_116, 
HCM1_178ac, HCM1_259 
IncN MLST IncN Allele 
korA, repN, traJ 
Chicken 
A8 NT NT Unknown, 
nearest 
ST 3,1,10 
 
1,1,1,1,-,2 NT NT 
A12 Unknown -,-,-,-,- NT NT NT NT 
A13 NT NT Unknown, 
nearest 
ST10,3,1 
 
1,1,1,1,-,2 NT NT 
A25 Unknown -,-,-,-,- NT NT NT NT 
A28 ST26 (CC-2) 4,1,1,2,13 NT NT NT NT 
A31 NT NT NT NT NT NT 
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A33 NT NT Unknown -,-,-,-,-,- NT NT 
A41 NT NT Unknown, 
nearest 
ST1,3,10 
 
1,1,1,1,1,2 NT NT 
A53 Unknown, 
nearest 
ST 8,208,67,1
14,174 
 
2,3,5,10,6 Unknown -,-,-,-,-,- Unknown, 
nearest 
ST12,2,3,1,17 
 
-,1,- 
B1 Unknown, 
nearest ST1 
9,1,1,1,1 Unknown, 
nearest 
ST 1,3,10 
 
1,1,1,1,1,2 ST1 
 
1,1,1 
B5 ST13 1,1,1,1,5 NT NT Unknown, 
nearest 
ST1,3,17,12,2 
 
-,1,- 
B7 Unknown -,-,-,-,- Unknown -,-,-,-,-,- Unknown, 
nearest 
ST12,2,17,3,1 
 
-,1,- 
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B11 NT NT Unknown, 
nearest 
ST 1,10,3 
 
1,1,1,1,-,2 NT NT 
B12 Unknown -,-,-,-,- Unknown -,-,-,-,-,- Unknown, 
nearest 
ST12,1,2,17,3 
-,1,- 
B23 Unknown -,-,-,-,- NT NT NT NT 
B25 NT  NT NT NT NT 
B28 Unknown -,-,-,-,- NT NT NT NT 
B42 NT NT NT NT ST1 1,1,1 
B47 Unknown, 
nearest ST1 
9,1,1,1,1, NT NT NT NT 
B52 Unknown, 
nearest 
ST121 
4,6,1,2,22 NT NT NT NT 
C1 NT  Unknown -,-,-,-,-,- NT NT 
C19 ST80 (CC-31) 4,2,1,4,5 Unknown -,-,-,-,-,- NT NT 
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C22 Unknown, 
nearest 
ST295 
48,-,-,-,- NT NT NT NT 
C28 ST71 (CC-7) 11,10,4,14,8 NT NT NT NT 
C45 Unknown -,-,-,-,- NT NT NT NT 
C55 Unknown, 
nearest 
ST3,220,101 
 
1,2,2,-,4 NT NT NT NT 
Human 
1 NT NT NT NT NT NT 
8 NT NT Unknown, 
nearest 
ST1,10,3 
1,1,1,1,1,2 NT NT 
25 Unknown -,-,-,-,- NT NT NT NT 
46 NT NT NT NT Unknown, 
nearest 
ST17,12,2,3,1 
-,1,- 
49 NT NT NT NT NT NT 
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50 NT NT Unknown, 
nearest 
ST10,1,3 
1,1,1,1,-,2 NT NT 
53 Unknown, 
nearest 
ST 214, 276 
37,-,-,-,- Unknown, 
nearest 
ST3,1,10 
1,1,1,1,-,2 NT NT 
54 Unknown -,-,-,-,- NT NT NT NT 
59 Unknown -,-,-,-,- Unknown, 
nearest 
ST1,10,3 
1,1,1,1,1,2 NT NT 
60 Unknown -,-,-,-,- NT NT NT NT 
61 Unknown -,-,-,-,- NT NT NT NT 
63 NT NT NT NT NT NT 
64  NT NT Unknown, 
nearest 
ST10,3,1 
1,1,1,1,-,2 NT NT 
67 NT NT NT NT NT NT 
70 NT NT Unknown, 
nearest 
ST1,3,10 
1,1,1,1,-,2 NT NT 
 
 
247 
84 NT NT NT NT NT NT 
86 NT NT NT NT NT NT 
92 Unknown  -,-,-,-,- NT NT NT NT 
96 NT NT NT NT NT NT 
106 Unknown, 
nearest 
ST284,18,100
,121,164,47,
26 
4,6,1,2,35 NT NT NT NT 
109 NT NT Unknown, 
nearest ST10, 
3, 1 
1,1,1,-,2 NT NT 
111 Unknown, 
nearest 
ST221 
 
39,-,-,-,- NT NT NT NT 
112 Unknown  -,-,-,-,- NT NT NT NT 
113 Unknown -,-,-,-,- NT NT NT NT 
121 NT NT NT NT NT NT 
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124 
 
ST71 (CC-7) 
 
11, 10, 4, 14, 8 NT NT NT NT 
Table 14. pMLST of colistin-resistant E. coli isolated from chicken. Numbering of alleles with the respective plasmid scheme are in order. *CC- 
clonal complex, NT- Non typeable, - missing alleles 
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Sequence Type, 
ST 
Chicken 
Farm A 
Chicken 
Farm B 
Chicken 
Farm C 
Human Clinical 
Samples 
ST48 - E. coli B42 - E. coli 96 
ST115 E. coli A8 - - E. coli 111 
ST117 E. coli A41 E. coli B5, E. coli B23 - E. coli 112 
ST359 -  E. coli B52 - E. coli 106 
ST1011 -  E. coli B7, E. coli B12 - E. coli 61, E. coli 
63, E. coli 113 
ST1642 - - E. coli C45 E. coli 54 
Table 15. Colistin-resistant E. coli clones identified from 3 chicken farms versus 
human clinical samples. The six common STs found in chicken and human faecal 
samples.
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Colistin-
resistant E. 
coli Isolates 
Clermontyping Triplex PCR  
Chickens   
A8 D D 
A12 A D* 
A13 B1 B2* 
A25 A D* 
A28 A D* 
A31 D D 
A33 D D 
A41 E NT 
A53 Unknown/novel NT 
B1 B1 B1 
B5 F D* 
B7 D D 
B11 B1 A* 
B12 D A* 
B23 F B1* 
B25 B1 B1 
B28 B1 B2* 
B42 A B2* 
B47 E NT 
B52 B1 NT 
C1 B2 B2 
C19 A A 
C22 D D 
C28 B1 D* 
C45 B1 NT 
C55 B1 NT 
Humans   
1 B1 NT 
8 A NT 
25 B1 NT 
46 A NT 
49 A NT 
50 D NT 
53 A NT 
54 B1 NT 
59 D NT 
60 A NT 
61 D NT 
63 D NT 
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Table 16. In 
silico ClermoTyping and triplex PCR phylogroup of 52 colistin-resistant E. coli 
strains. *Discrepancies observed, NT- Not Tested 
 
64 D NT 
67 B2 NT 
70 A NT 
84 B1 NT 
86 A NT 
92 A NT 
96 A NT 
106 Unknown/novel NT 
109 Unknown/novel NT 
111 D NT 
112 F NT 
113 D NT 
121 A NT 
124 D NT 
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Part 3:  A novel PMPR determinant recovered from poultry farms in 
Brunei Darussalam 
 
4.7 Methods 
4.7.1 Bacterial isolate 
E. coli C22 from the chicken cloacal sample were investigated. 
 
4.7.2 Antibiotic Susceptibility Testing (AST) and Minimum Inhibitory 
Concentration (MIC)  
AST and MICs were performed as mentioned in 4.5.6 
 
Apart from colistin, additional MICs were tested against E. coli C22 that includes 
polymyxin B, cephalothin, cefotaxime, ceftazidime, ceftaroline, ciprofloxacin, 
florfenicol and fosfomycin were determined by agar dilution (mentioned in section 
4.4.3.5) and/or the E-test method (bioMérieux, Marcy l’Etoile, France) according 
to CLSI and EUCAST (CLSI, 2018; EUCAST, 2018). 
 
Overproduction of chromosomal AmpC β-lactamase by C22 was assessed in a 
modified Hodge test using a cefoxitin (30 µg) disc and E. coli ATCC 25922 as the 
reporter strain on MH II agar supplemented with and without cloxacillin (200 
mg/L) (Mammeri et al., 2008). Effects of AmpC inhibitors were assessed using a 
Total ESBL + AmpC Confirm kit (Rosco Diagnostics, Denmark). 
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4.7.3 Amplification of mcr genes by PCR 
The mcr genes were determined by PCR and cycling conditions as mentioned in 
section 4.5.7 and 4.5.7.1 respectively. 
 
The region flanking the mcr sequence was investigated by PCR mapping using 
primers targeting the insertion element ISApI1 and the nikB gene using 
combinations of ISApI1-F (5’-ATCCAACCATTTGAACGACCGTCC-3’),  
ISApI1-R (5’-ACCCAGTGCTTCTGTTACCAAACG-3’),  
Nik B-F (5’-ATGAAATTGAGAAAGCACAGGGACGGGATT-3’) and  
NikB-R (5’-GTGAATTGTCACGCTGTTGCTG-3’) specific primers.  
 
PCR amplicons were cleaned using MinElute® PCR purification Kit (Qiagen, 
Crawley, UK) as mentioned in Chapter 2, section 2.3.8 
 
4.7.4 Replicon Typing 
Plasmid replicon typing was performed on E. coli C22 using commercial PCR-based 
replicon typing kit (DIATHEVA, Cartoceto, Italy) as mentioned in Chapter 3, section 
3.3.7.5.1 
 
4.7.5 DNA cloning  
Positive amplicons were purified using Qiaquick PCR purification kits (Qiagen, 
Crawley, UK) and ligated to the pCR-Blunt II TOPO vector (Invitrogen, Paisley, UK). 
See Chapter 3, section 3.3.7.4.3 for detailed PCR cloning description. 
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4.7.6 Conjugation  
Transfer of plasmid mediated resistance genes by conjugation was investigated 
using sodium azide (AZ) resistant E. coli J53 as the recipient. E. coli C22 and J53 
grown to mid-log phase in Luria-Bertani (LB) broth were mixed 1:1 in 4.5 ml fresh 
LB and incubated at 37°C for a further 4 h without shaking. Transconjugants 
(ECJ53/C22) were selected by plating 200 µl of the conjugation onto MH II agar 
supplemented with colistin (4 mg/L) and sodium azide (150 mg/L). The efficiency 
of conjugation was calculated as the number of transconjugants per donor cell 
(t/d). Donor and transconjugant cultures were serially diluted (10-1 – 10-7) in 
phosphate buffered saline (PBS) and 20 µl of each dilution plated onto MH II agar 
supplemented with colistin (donor) and colistin/sodium azide (transconjugant) 
using the Miles and Misra Method (Miles et al., 1938). Successful transfer of mcr 
to transconjugants was confirmed by PCR.  
 
Antimicrobial susceptibility of transformants and transconjugants was performed 
by Etest and by broth microtitre dilution MIC determination for colistin and 
polymyxin B.  
 
The presence of IncI2-like in E. coli C22 was further confirmed with IncI2-like 
plasmid to transconjugants (ECJ53/C22) by PCR using primers IncI2_F (5’-
CTGTCGGCATGTCTGTCTC-3’) and IncI2_R (5’-CTGGCTACCAGTTGCTCTAA-3’) with 
the resulting amplicons sequenced using the Sanger method as mentioned in 
Chapter 2, section 2.3.9 
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4.7.7 Whole Genome Sequencing (WGS) 
4.7.7.1 Sample preparation and packaging and transportation of samples 
See Chapter 3, section 3.3.9.1and  
3.3.9.2  
 
4.7.7.2 Sequencing of isolates and in silico analysis of WGS data 
The entire genome of E. coli C22 isolate and accessory plasmids were sequenced 
using Illumina HiSeq technology. Genomic DNA was extracted and purified by Solid 
Phase Reverse Immobilisation (Agencourt, SPRI, Beckman Coulter) and quantified 
using the Quantit dsDNA HS assay (Thermo-Fisher, East Grinstead, UK) and an 
Eppendorf AF2200 plate reader (Eppendorf UK Limited, Stevenage). Genomic DNA 
libraries were prepared using a Nextera XT Library Prep Kit (Illumina, San Diego, 
USA) with the following modifications: Two nanograms of DNA were used as the 
input, and PCR elongation time was increased to 1 min from 30 seconds. DNA 
quantification and library preparation were then carried out on a Hamilton 
Microlab STAR automated liquid handling system (Hamilto, Nevada, USA). The 
library was quantified using the Kapa Biosystems Library Quantification Kit for 
Illumina on a Roche light cycler 96 qPCR machine (Roche Diagnostics Ltd, Burgess 
Hill, UK). Libraries were sequenced on the Illumina HiSeq using a 250 bp paired 
end protocol. 
 
Raw reads were adapter trimmed using Trimmomatic 0.30 with a sliding window 
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quality cutoff of Q15 (Bolger et al., 2014). De novo assembly was performed on 
samples using SPAdes version 3.7, (Bankevich et al., 2012) and contigs annotated 
using Prokka 1.11 (Seemann, 2014). 
 
Contigs and the draft genome assembly of C22 were anlaysed in silico using online 
tools (http://www.genomicepidemiology.org/) available at the Centre for 
Genomic Epidemiology (Lygby, Denmark). Genes encoding genotypic and 
phenotypic resistance (ResFinder 3.1, KmerResistance 2.2), virulence 
determinants (Virulence Finder 2.0), serotype (SerotypeFinder 2.0) chromosomal 
(MLST 2.0) and plasmidic (PlasmidFinder 2.0, pMLST 2.0) epidemiological markers 
were compared to reference sequences in Pubmed (NCBI). Sequences with < 100 
% nucleotide identity were analysed by blastx (NCBI) to identify potential new 
alleles or non-synonymous mutations. Mutations in the lpxCAD, pmrA/B, phoP/Q 
operons and insertions within mgrB previously found to be associated with 
polymyxin resistance were sought by pairwise alignment with sequences from E. 
coli str. K-12 substrain MG1655 (Accession number: NC_000913.3). 
 
Further characterization of the plasmid pEC-MCR1.8 and images was performed 
by our collaborators in Leiden University, Netherlands. 
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4.7.7.3 Comparative analysis of mcr alleles 
The amino acid sequences of MCR alleles deposited in GenBank (last accessed 
17/04/2018) known to confer reduced susceptibility to polymyxins were aligned 
using ClustalW algorithm.  
 
4.7.8 NG-Test MCR-1 lateral flow assay 
During the characterization of our novel variant, NG-Test MCR-1 lateral flow assay 
was developed and provided to us by NG Biotech, France for evaluation. This was 
tested against our colistin-resistant E. coli isolates including E. coli C22. However, 
there was only limited number of kits available for testing. 
 
NG-Test MCR-1 (NG Biotech, France) is a rapid qualitative immunoassay for the 
detection of the MCR-1 enzyme using a cultured bacterial colony. The sample 
loaded onto lateral flow cassette well will migrate by capillarity through 
nitrocellulose membrane towards the conjugate pad, and if MCR-1 positive, the 
enzyme will react with labelled anti-MCR-1 mouse monoclonal antibodies 
immobilized on the test zone (T) producing a positive red line as well as the control 
zone (C). A negative result will only produce red line with the control zone (C). 
Notably, due to varying intensity of the red line test (T) depending on the MCR-1 
enzyme level in the sample, a weak line is considered as a positive result. 
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The control line (C) is made of labelled streptavidin and labelled monoclonal 
antibodies reacting with biotin BSA and goat anti-mouse polyclonal antibodies 
immobilized on the membrane. 
 
4.7.8.1 Bacterial Isolates  
Thirty-six positive MCR-1 producing Escherichia coli obtained from chicken cloacal 
and humans faecal swabs were collected from Brunei were tested. Eight clinical 
isolates from the Royal London Hospital (Aeromonas sp. AH10(2018), n=1; 
Escherchia coli EC5(2018) and EC60, n=2; Klebsiella pneumoniae KP25(2018), 
KP27(2018) and KP28(2018) n=3; Salmonella sp. SAL1 and SAL2 n=2) and 9 types 
strains (Proteus mirabilis NCTCC13376, Serratia marcescens NCTCC10211, 
Enterococcus faecalis ATCC29212, Enterococcus gallinarum ATCC49573, Candida 
albicans ATCC10231, Enterobacter cloacae NCTC10005, Stenotrophomonas 
maltophilia NCTC10258, Pseudomonas aeruginosa ATCC27853, Escherichia coli 
ATCC25922) were also used for evaluation in this study. Bacterial identification 
was performed by MALDI-ToF (matrix-assisted laser desorption ionisation-time of 
fight). Mutliplex mcr PCR and/or Illumina MiSeq were used for mcr gene detection.  
 
Additionally, human faecal swabs that were found to be positive for having 
Enterobacteriaceae with MCR-1 (n=14) and swabs that were negative (n=2) were 
used to further assess the potential of the MCR-1 immunoassay to detect MCR-1 
from direct swabs. 
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4.7.8.2 Sample preparation  
Thirty-six E. coli MCR-1, 8 clinical isolates from Royal London Hospital and 9 control 
strain type, overnight bacterial culture was grown on MH 2 agar. Five drops (150 
µl) of extraction buffer were dispensed in an Eppendorf tube provided. A colony 
was taken from MH 2 agar using 5 µl sterile loop and suspended in the tube with 
the extraction buffer. The tube lid was then closed and vortex to homogenise the 
mixture before use. 
 
100 µl of the mixture were pipetted and dispensed on the lateral flow device. 
Results were read after 15 minutes. 
 
As with the swabs, all the 16 swabs were inoculated in 3ml TSB (Trypticase soy 
broth) with colistin (final concentration 1 mg/L) and incubated at 37oC shaking for 
2hr. Positive swabs that became turbid (n= 14) were centrifuged and their 
supernatant was used for the lateral flow test.  Similarly, the same process with 
the negative swabs that grew turbid (n= 1). 
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4. 8 Results 
4.8.1 Susceptibility testing, typing and virulence-associated genes in E. coli C22 
Isolate E. coli C22 was recovered in pure culture on CHROMagar COL-APSE media, 
confirmed as E. coli by colonial morphology and by MALDI-TOF MS analysis. 
Susceptibility testing confirmed resistance to colistin (MIC 8 mg/L) and polymyxin 
B (12 mg/L) and also an MDR phenotype. E. coli C22 was resistant to all penicillins, 
cephalosporins (except ceftazidime), aztreonam, quinolones, aminoglycosides 
(except amikacin), fosfomycin, chloramphenicol and tetracyclines (Table 17). The 
isolate was susceptible to carbapenems (imipenem, meropenem) the combination 
of ceftazidime / avibactam (MIC = 0.032 mg/L) and to tigecycline (MIC = 0.38 
mg/L). No AmpC-like activity was detected in either the modified Hodge or using 
the ROSCO combined disc test. Amongst the veterinary antimicrobials tested, 
resistance to apramycin, florfenicol, pefloxacin, enrofloxacin and ceftiofur was 
inferred, as there was complete growth of C22 up to the margins of the discs 
(Table 17). 
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Antimicrobial agent Disc susceptibility MIC 
(µg/ml) 
Interpretati
on 
Concentration 
(µg) 
Zone 
diameter 
(mm) 
 
Aminoglycosides  
 Amikacin 30 19 ≤ 8 S 
Apramycin• 15 6 NA R 
Gentamicin 10 11 > 4 R 
Kanamycin 30 16 NA R 
Neomycin 30 9 NA R 
Netilmicin 30 13 3 R 
Spectinomycin 100 22 NA R 
Streptomycin 10 6 NA R 
Tobramycin 10 6 > 4 R 
β-lactams: Carbapenems  
Ertapenem 10 22 > 1 I 
Imipenem 10 25 ≤ 2 S 
Meropenem 10 25 ≤ 2 S 
β-lactams: Cephalosporins  
Cephalothin 30 6 NA R 
Cefoxitin 10 / 30 20 / 25 NA R 
Cefuroxime 30 6 > 8 R 
Cefpodoxime 10 6 NA R 
Cefotaxime 30 12 > 2 R 
Ceftriaxone 30 12 > 2 R 
Ceftiofur• 30 6 NA R 
Cefepime 30 17 > 4 R 
Cefpirome 30 6 NA R 
β-lactams: Monobactams & Penicillins  
Aztreonam 30 22 3 R 
Ampicillin 2 6 > 8 R 
β-lactam / β-lactamase inhibitor combinations  
Amoxicillin/Clavulanate 30 6 > 8 R 
Ceftazidime/Avibactam 50 27 ≤ 8 S 
Ceftolozane/Tazobacta
m 
40 
22 > 1 
R 
Piperacillin/Tazobacta
m 
85 
25 ≤ 8 
S 
Folate pathway inhibitors  
Sulfamethoxazole 100 6 NA R 
Trimethoprim 5 6 > 4 R 
Fluoroquinolones / Quinolones  
Ciprofloxacin 1 / 5 6 / 11 > 0.5 R 
Enrofloxacin• 5 8 NA R 
Levofloxacin 5 12 > 1 R 
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Moxifloxacin 5 10 NA R 
Norfloxacin 10 10 > 1 R 
Pefloxacin• 5 6 NA R 
Phenicols  
Chloramphenicol 30 6 > 8 R 
Florfenicol• 30 6 NA R 
Lipopeptides  
Colistin 25 12 > 2 R 
Tetracyclines  
Doxycycline 30 10 NA R 
Minocycline 30 11 NA R 
Tetracycline 10 / 30 6 / 6 NA R 
Tigecycline 5 21 ≤ 1 S 
Table 17. Antimicrobial susceptibility of E. coli C22. • Antimicrobial used in 
veterinary medicine; NA – no zone diameter breakpoint available, S- susceptible, 
R – resistant, I - intermediate  
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There was no reaction with any of the O specific antisera contained in the Statens 
Serum pools used and a serotype could therefore not be assigned phenotypically.  
 
Analysis of the adk, fumC, gyrB, icd, mdh, purA and recA gene sequences used in 
the E. coli multi-locus sequence typing scheme (MLST) (Zhou et al., 2018), 
identified alleles 43, 41, 15, 18, 11, 7 and 6, consistent with sequence type (ST) 
101, a globally disseminated clone, belonging to phylogenetic lineage B 
(Fernandes et al., 2016). PCR-based replicon typing identified multiple plasmid 
replicons in C22 belonging to FIA, FIB, FIC, FII, HI1A, HI1B, I1, I2, X1 and Y types. 
The presence of lpfA (fimbrial adhesin), iroN (enterobactin siderophore receptor 
protein), iss (serum resistance), gad (acid resistance) and cma (inhibition of lysis) 
virulence associated genes were also documented with iroN, iss and cma co-
localised to an IncFIB plasmid, whereas lpfA, gad and an additional copy of iss were 
mapped to the chromosome. 
 
4.8.2 Polymyxin Resistance Determinants 
Multiplex PCR confirmed the presence of a mcr-1-like gene and Sanger 
sequencing, revealed a variant with a single non-synonymous nucleotide 
difference (A8G) from mcr-1.1 (Table 18) designated mcr-1.8 by NCBI (Accession 
number KY683842) and resulting in a glutamine to arginine substitution (Q3R) in 
the transmembrane portion of the protein, physically distant from the 
extracellular catalytic domain. The previously identified MCR-1.2 and MCR-1.12 
also contain respectively the amino acid substitutions Q3L and Q3H with no 
attributable loss of catalytic function (Di Pilato et al., 2016). PCR mapping 
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confirmed the nikB ABC transporter 220 bp upstream of the mcr coding region but 
absence of the ISApI1 sequence.  
 
The entire mcr gene along with the upstream element and promoter was inserted 
into pCR-Blunt II TOPO and transformed in E. coli TOP10. Colistin and polymyxin B 
MICs were increased by 4- to 16- fold (Table 19).  
 
Polymyxin resistance was transferable from E. coli C22 to J53. All transconjugants 
recovered displayed colistin and polymyxin B MICs of 4 mg/L (Table 19) and were 
also positive for the mcr-1.8 gene. Conjugation was estimated to occur at a 
frequency of 2.6 x 10-4 t/d. 
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PEtN 
 
Species 
 
1 
 
2/1 3 
 
6/7 
 
12 24 39 
 
62 
 
156 216 235 
 
279 355 
 
413 441 444 453 537 
MCR-1.1 E. coli M M Q V R A I M M A M T A V D A H R 
MCR-1.2 K. pneumoniae . . L . . . . . . . . . . . . . . . 
MCR-1.3 E. coli . . . . . . V . . . . . . . . . . . 
MCR-1.4 E. coli . . . . . . . . . . . . . . N . . . 
MCR-1.5 E. coli . . . . . . . . . . . . . . . . Y . 
MCR-1.6 Salmonella enterica  . . . . . . . . . . . . . . . . . H 
MCR-1.7 E. coli . . . . . . . . . T . . . . . . . . 
MCR-1.8 E. coli . . R . . . . . . . . . . . . . . . 
MCR-1.9 E. coli . . . . . . . . . . . . . A . . . . 
MCR-1.10 Moraxella sp . V . . C S . . V . T . T . . T . . 
MCR-1.11 E. coli . . . V* . . . . . . . . . . . . . . 
MCR-1.12 E. coli  . . H . . . . . . . . . . . . . . . 
MCR-1.13 E. coli . . . . . . . . I . . . . . . . . . 
MCR-1.14 E. coli . . . . . . . L . . . . . . . . . . 
MCR-1.15 K. pneumoniae _ . . . . . . . . . . K . . . . . . 
 
Table 18. Amino acid substitutions in MCR1.2 – 1.15 relative to the MCR-1 peptide sequence. GeneBank MCR protein accession numbers: 1.1 
(WP_049589868.1), 1.2 (WP_065274078.1), 1.3 (WP_077064885.1), 1.4 (WP_076611062.1), 1.5 (WP_076611061.1), 1.6 (WP_077248208.1), 1.7 
(WP_085562392.1), 1.8 (WP_085562407.1), 1.9 (WP_099982800.1), 1.10 (WP_096807442.1), 1.11 (WP_099982815.1), 1.12 (WP_104009850.1), 
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1.13 (WP_109545056.1), 1.14 (SPQ84451.1), 1.15 (WP_116786830.1). Amino acid numbering based on MCR 1.1 peptide sequence. Identical 
amino acids represented as . Deletion in MCR-1.15 represented as _ Insertion in MCR-1.11 represented as V* 
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Strain CEF                    CTX CAZ CPT CST PMB *FOF TET CIP CHL KAN AZM TGC CZA  
E. coli C22 >256 32 0.5 >32 8 12 >1024 256 12 >256 6 24 0.38 0.032 
E. coli J53 AZR 8 0.047 0.094 0.06 0.38 0.75 0.38 2 0.016 6 2 3 NT NT 
E. coli J53 AZR:pEC-MCR1.8 6                                  0.047 0.125 0.06 4 4 0.19 2 0.012 6 3 3 NT NT 
E. coli TOP10 NT                                       NT NT NT 0.125 0.5 NT NT NT NT NT NT NT NT 
E. coli TOP10:mcr-1.8 NT NT NT NT 2 2 NT NT NT NT NT NT NT NT 
Table 19. MICs (mg/L) by Etest for antibiotics against wild-type strain, recipient and transconjugant strains of E. coli. CEF, cephalothin; CTX, 
cefotaxime; CAZ, ceftazidime, CPT, ceftaroline; CST, colistin; PMB, polymyxin B; *FOF, fosfomycin (MH II media supplemented with Glucose 6-
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phospate); TET, tetracycline; CIP, ciprofloxacin; CHL, chloramphenicol; KAN, kanamycin; AZM, Azithromycin; TGC, Tigecycline; CZA, 
ceftazidime/avibactam, NT; Not tested. 
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4.8.2.1 Characterisation of plasmid, pEC-MCR1.8 
Whole-genome sequencing of E. coli C22 with the Illumina HiSeq platform 
(Illumina, Inc., San Diego, CA) followed by de novo assembly and annotation 
identified the mcr-1.8 gene as the only antimicrobial resistance gene, located 
between the topB (encoding a DNA topoisomerase III) and nikB (relaxase) genes, 
on a 63,056 bp IncI2 plasmid (pEC-MCR1.8) (performed with the assistance of our 
collaborator from Leiden University, Netherlands). Nucleotide sequence analysis 
of pEC-MCR1.8 (KY792081) confirmed a similar position of mcr-1.8 and absence of 
the ISApl1 locus as in other IncI2 plasmids encoding mcr-1-like genes (Figure 32). 
The graphical sequence comparison was generated using Easyfig software (Figure 
32). The presence of shufflon segments present in raw reads were assembled 
using the pMRY16-002_4 as an IncI2 reference plasmid and the assembled 
shufflon region was confirmed by Sanger sequencing (performed with the 
assistance from our collaborators from Federation University, Australia and Leiden 
University, Netherlands) (Brouwer et al., 2015; Sekizuka et al., 2017). 
 
Apart from mcr-1.8 gene, pEC-MCR1.8 predicted to encode 85 open reading 
frames in total, including genes for replication, maintenance, partitioning and 
stability, as well as conjugal transfer/ formation of type IV pilus. Immediately 
downstream of mcr-1.8 was the pap2 gene predicted to encode a membrane-
associated phosphatase enzyme (Fan et al., 2014).  
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Figure 32. Comparison of pEC-MCR1.8 with selected IncI2 plasmids carrying mcr-1.1. Open reading frames are represented with arrows and the 
direction of transcription by arrowheads. Open reading frames encoding proteins involved in replication, partitioning, stability, transfer/ type IV 
pilus formation, antibiotic resistance and other known or unknown functions are colour-coded. The shufflon region is indicated with black 
rectangles. Areas shaded in blue indicate nucleotide identity. Figure was generated by our collaborators in Lieden University, Netherlands. 
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4.8.2.2 Resistome of E. coli C22 
Comparative analysis of the WGS data in silico and the phenotypic susceptibility 
data was used to define and characterise the entire resistome of E. coli C22 
confirms the presence of multiple resistance genes to aminoglycosides (aph(4)-Ia, 
aadA1, aac(3)-IVa, aph(3’)-Ic), β-lactams (blaTEM-1B, blaCTX-M-65), fluoroquinolones 
(qnrS1), fosfomycin (fosA4), phenicols (cmI1, floR), trimethoprim (dfrA15, dfrA14), 
sulphonamides (sul3) and tetracyclines (tetA, tetM).  
 
No mutations in the lpxCAD or mgrB genes were identified in C22 but 
polymorphisms were present in phoP/Q and pmrA/B predicted to encode the 
amino acid changes I44L (phoP), I165F (phoQ), S29G (pmrA), D282G and Y358N 
(pmrB) relative to the K12 sequence (Sun et al., 2009). 
 
Of note β-lactam- (blaCTX-M-65), tetracycline- (tetA), phenicol- (floR) and 
aminoglycoside-resistance (aph(4)-Ia, aac(3)-IVa,) were associated with an I1 
plasmid whereas fosfomycin- (fosA4) and sulfonamide-resistance (sul3) were 
localised to a HI mulitreplicon (HIA, HIB and FIA) plasmid.  
 
In silico WGS analysis with SerotypeFinder 2.0 predicted an O88:H31 serotype, 
which is also not detectable using the available antisera pools. 
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4.8.3 NG-Test MCR-1 rapid testing 
All 36 E. coli mcr-1 isolates tested positive (Figure 33A) and 9 type strain and 8 non 
mcr-1 clinical isolates with different resistance mechanism were negative (Figure 
33B) (Table 20).  
 
 
Figure 33. NG-Test MCR-1 (NG Biotech, France) cassette. A) Positive results 
showing red lines on both the Control (C) and Test (T) panels. B) Negative results 
showing red lines only with the Control (C). 
 
Samples NG-Test MCR-1 Lateral flow 
Positive Negative 
E. coli MCR-1 isolates from chickens and 
humans (n= 36) 
36 0 
Clinical isolates from the Royal London 
Hospital (n= 8) 
0 8 
Control type strains (n= 9) 0 9 
Positive human swabs (n= 15) 14 1 
Negative human swabs (n= 2) 0 2 
Table 20. NG-Test MCR-1 lateral flow evaluated against 70 samples. 
C T 
C T 
A 
B 
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4.9 Summary 
§ CHROMagar COL-APSE was developed and evaluated for the isolation and 
differentiation of colistin-resistant Gram-negative pathogens 
§ Both CHROMagar COL-APSE and SuperPolymxin media were able to 
support the growth of COL resistant Gram-negative bacteria while 
suppressing COL resistant Gram-positive pathogens.  
§ CHROMagar COL-APSE supported the growth of all COL resistant strains 
down to an inoculum as low as 101 CFU in clinical isolates.  
§ Similarly, 101 CFU inocula were also supported by SuperPolymyxin, but 
only for 50/58 (86%) of the E. coli isolates with COL resistance 
accompanied by mcr-1, suggesting it may have slightly lower sensitivity in 
the detection of these strains. 
§ CHROMagar COL-APSE was slightly more sensitive in the detection of 
Enterobacteriaceae producing MCR-1, it also provides the benefit of 
presumptive chromogenic identification.  
§ Period prevalence studies were undertaken with 300 chicken cloacal swabs 
from three different farms and 254 human faecal samples from 
Microbiology Laboratory, RIPAS Hospital, Brunei Darussalam. 
§ All swabs were screened using CHROMagar COL-APSE media. Growth of E. 
coli on media were further screened for mcr-related genes. 
§ High prevalence rates of E. coli mcr gene were observed in chicken (58%) 
and human samples (41.7%).  
§ Co-resistance was highest with aminoglycosides, quinolones, phenicols, β-
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lactams antibiotics in both chicken and human colistin-resistant E. coli 
isolates. 
§ RAPD PCR showed clonal diversity and no avian (APEC) or human 
enterotoxigenic (ETEC) serogroups were found.  
§ Tripex PCR phylogroup and in silico ClermonTyping showed the most 
prevalent phylotypes were mostly commensals. However, there were 
discrpancies observed in 50% of the colistin-resistant E. coli isolates in 
chickens while performing both methods. 
§ 52 colistin-resistant E. coli isolates were selected for WGS analysis based 
on their distinguishable RAPD profiles. 
§ Colistin MICs ranges from 1->32 mg/L 
§ Diverse sequence type (STs) were found from both chicken and humans. 
However, there were overlapping clones observed (ST48, ST115, ST117, 
ST359, ST1011 and ST1642). 
§ Four novel mcr-1.8 variants were observed from chicken and human faecal 
samples. 
§ In silico serotyping by WGS analysis showed no APEC or ETEC serogroups. 
§ The fosA4 gene was observed more in colistin-resistant E. coli isolates 
isolated in chickens than from humans.  
§ A novel mcr-1.8 variant was first found from chicken cloacal samples during 
surveillance and this isolate was E. coli C22. 
§ E. coli C22 MICs to colistin and polymyxin B were MIC 8 mg/L and 12 mg/L, 
respectively and was resistant to all penicillins, cephalopsorins (except 
ceftazidime), aztreonam, quinolones, aminoglycosides (except amikacin), 
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fosfomycin, chloramphenicol and tetracyclines. 
 
§ PCR mapping confirmed the nikB ABC transporter but absence of the 
ISApI1 sequence. 
§ PCR-based replicon typing identified multiple plasmid replicons in C22 
belonging to FIA, FIB, FIC, FII, HI1A, HI1B, I1, I2, X1 and Y types. 
§ Virulence associated genes were observed which included lpfA (fimbrial 
adhesin), iroN (enterobactin siderophore receptor protein), iss (serum 
resistance), gad (acid resistance) and cma (inhibition of lysis). And with 
iroN, iss and cma co-localised to an IncFIB plasmid, whereas lpfA, gad and 
an additional copy of iss were mapped to the chromosome. 
§ The mcr-1-like gene in E. coli C22 carried a non-synonymous mutation at 
position 8 (A→G) resulting in a glutamine to arginine (Q→ R). 
§ E. coli C22 belonged to sequence type (ST) 101, a globally disseminated 
clone and SerotypeFinder 2.0 predicted an O88:H31 serotype. 
§ The mcr-1.8 gene was the only resistance gene located on IncI2 plasmid 
(pEC-MCR1.8) by PCR mapping, replicon typing and analysis of the entire 
WGS data.  
§ Multiple resistance genes are also observed in silico in E. coli C22 to 
aminoglycosides (aph(4)-Ia, aadA1, aac(3)-IVa, aph(3’)-Ic), β-lactams 
(blaTEM-1B, blaCTX-M-65), fluoroquinolones (qnrS1), fosfomycin (fosA4), 
phenicols (cmI1, floR), trimethoprim (dfrA15, dfrA14), sulphonamides 
(sul3) and tetracyclines (tetA, tetM).  
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§ The NG-Test MCR-1 (NG Biotech, France) lateral flow assay showed high 
sensitivity and specificity. A robust diagnostic tool for the determination of 
mcr-1 genes.  
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Chapter 5 
Comparative virulence of polymyxin resistant 
E. coli of human and avian origin   
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5.1 Introduction 
In Chapter 4, the prevalence and surveillance of plasmid-mediated polymyxin 
resistance in poultry farms and human faecal samples in Brunei Darussalam was 
reported. In this chapter, the pathogenicity and fitness costs of acquiring plasmid-
mediated polymyxin resistance in Galleria mellonella infection model are 
investigated. 
 
G. mellonella is an insect from the order Lepidoptera which comes from the family 
Pyralidae (snout moths) (Tsai et al., 2016). G. mellonella larvae (greater wax moth 
or honeycomb moth) have been extensively studied for virulence as well as for 
drug testing (Tsai et al., 2016). More importantly, the impact of acquiring 
antibiotic resistance gene on bacterial fitness (Zhang et al., 2017). The range of 
microorganism that has been studied in G. mellonella model includes 
Acinetobacter baumannii, (Peleg et al., 2009; Gaddy et al., 2012) Pseudomonas 
aeruginosa, (Jander et al., 2000; Miyata et al., 2003) Staphylococcus aureus, 
(Desbois and Coote, 2011) and Candida albicans (Fuchs et al., 2010). G. mellonella 
larvae are inexpensive, easily obtained in large numbers, no ethical approval 
required, does not require special lab equipment and their short life cycle makes 
them ideal for large-scale studies (Ramarao et al., 2012; Tsai et al., 2016). Although 
lacking in adaptive immune response, their innate immune response shows a 
similar immune response in vertebrates (Tsai et al., 2016). The innate immune 
response consists of the cellular and humoral immune response (Tsai et al., 2016). 
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Cellular response involves phagocytic cells known as hemocytes, found within the 
hemolymph which functions analogously to mammalian blood (Tsai et al., 2016). 
Other than phagocytosis, these hemocytes also functions in encapsulation and 
clotting (Tsai et al., 2016). While, the humoral response involves soluble effector 
molecules that immobilize and kill the pathogen and includes complement-like 
proteins, melanin and antimicrobial peptides (Tsai et al., 2016). 
 
Pathogenicity in E. coli are not only dependent on their phylotypes or serotypes 
but also from acquiring virulence factors. Genetic virulence factors include flagella, 
curli, fimbriae, adhesion, biofilm (Bekal et al., 2003; Gomes et al., 2011; Kao et al., 
2014; Faraji et al., 2016) or biochemical factors such as host cell surface modifying 
enzymes, toxins and antibiotics which contributes to the physical attributes of 
bacteria and provide a competitive advantage (Cossart et al., 1989; Burnside et al., 
2010; Kim et al., 2015; Schroeder et al., 2017).  
 
MCR-1 dissemination has now been seen in over 40 countries since its first 
discovery in late 2015, in China (Skov and Monnet, 2016). The main bacterial host 
of mcr-1 has been identified mainly in Escherichia coli and has been reported on 
both broad-host-range and narrow-host-range of plasmid replicon types, including 
IncI2, IncX4, IncP, IncHI1 and IncHI2 (Liu et al., 2016; Sonnevend et al., 2016; Webb 
et al., 2016; Zhang et al., 2016). The successful dissemination of resistance 
plasmids largely depends on the fitness cost imposed on hosts (Andersson and 
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Hughes, 2010). Therefore, there is a need to understand the biological cost of 
resistance which is critical for controlling the dissemination of multidrug-resistant 
strains.  
 
Studies on the biological effects of colistin resistance have been reported mainly 
in Acinetobacter baumannii with extremely limited data on Enterobacteriaceae 
(Hraiech et al., 2013; Beceiro et al., 2014; Wand et al., 2015). Additionally, there 
are limited studies on the effect of mcr-1 on fitness and virulence in 
Enterobacteriaceae. However, there have been studies in G. mellonella model 
looking at virulence of extraintestinal pathogenic E. coli isolates which causes a 
range of serious infection such as bacteremia, meningitis pneumonia and more 
commonly associated with uncomplicated urinary tract infection (Alghoribi et al., 
2014; Williamson et al., 2014; Ciesielczuk et al., 2015). 
 
The presence of plasmid-mediated polymyxin resistance, mcr genes in animals and 
humans has raised the question whether the expression of mcr-1 genes would 
modulate pathogenicity. Hence, the impact of mcr- 1 gene on in vivo fitness and 
virulence is further warranted.  
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5.2 Objectives 
- To investigate the impact of acquiring plasmid-mediated polymyxin resistance 
(PMPR) in E. coli isolated from chickens and humans on the survival, virulence and 
fitness in G. mellonella infection model.
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5.3 Methods 
5.3.1 Galleria mellonella assay 
Forty colistin-resistant E. coli strains (humans, n= 20 and chickens, n= 20) (Table 
21) were tested for virulence in G. mellonella larvae. Characteristics of all colistin-
resistant E. coli strains used in this study are mentioned in Chapter 4, section 4.6.2, 
Table 12A 5 µl loop full E. coli mcr-1 colony picked up from overnight MH 2 agar 
was inoculated into 3 ml of LB broth in 25 ml sterile universal tube. Serial dilution 
was performed (100 μl pellet suspension in 900 μl PBS) at a final dilution of 1 x 107 
CFU/ml (1 x 105 CFU/larvae) which is the optimal bacterial inoculum (105 
CFU/larvae) prepared using a published method (Betts et al., 2014; Ciesielczuk et 
al., 2015). 
 
Colistin-resistant E. coli strains 
Chicken Human 
A8 H1 
A12 H8 
A13 H25 
A28 H49 
A33 H53 
A41 H54 
A53 H59 
B1 H60 
B7 H61 
B11 H64 
B25 H67 
B28 H84 
B47 H86 
B52 H92 
C1 H96 
C19 H106 
C22 H109 
C28 H112 
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C45 H113 
C55 H124 
Table 21. Colistin-resistant E. coli strains from chickens and humans. Human 
colistin-resistant E. coli strains are given a letter ‘H’ (Human) in front of the number 
due to the statistical program used.  
 
Ten G. mellonella larvae (TruLarv™, BioSystems Technology, Devon, UK) per test 
isolate were infected with 10 µl aliquot of the serially diluted bacterial suspension 
(107 CFU/ml) in the first left proleg (Figure 34, Figure 35 and Figure 36) using a 22-
gauge gastight syringe (Hamilton, Bonaduz, Switzerland). Another 10 sets of G. 
mellonella larvae were injected with PBS as a stress control. Larvae were 
incubated aerobically at 37° C on Grade 1 WhatmanTM filter paper (Whatman plc, 
Maidstone, UK) in a 90 mm petri dish sterile polystyrene clear (Fisher Scientific, 
Loughborough, UK) for 72 hours. 
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Figure 34 (Not to scale). External morphology of G. mellonella larva in supine 
position. A. Mesothoracic legs B. Prothoracic/Pro-legs. (Adapted from Smith et al.) 
(Smith, 1965b) 
 
 
 
 
A B 
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Figure 35. Ten larvae per plate were used for the virulence studies. 
 
 
Figure 36. Injection of 107 CFU/ml (105 CFU/larva) of the test isolates in the first 
proleg. 
 
Larvae were considered dead if they did not respond to touch. The virulence assay 
was performed in triplicates on three separate occasions with three different 
batches of larvae. 
 
Petri dishes were incubated at 37° C and monitored daily for 3 days (24 h, 48 h and 
72 h) post-injection to record morbidity and mortality. G. mellonella larvae were 
considered infected if they expressed dark pigmentation (melanisation) after 
inoculation. Larvae were scored as dead if they did not respond to touch stimuli 
by blunt sterile forceps.  
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5.3.2 Galleria mellonella assay - transconjugants 
Bacterial conjugation was performed as mentioned in Chapter 4, Part 3, section 
4.7.6. Transconjugants were selected by growth on LB agar supplemented with 
colistin (4 mg/L) using E. coli J53 (EC J53) as the recipient. 
 
Two colistin-resistant E. coli transconjugants (E. coli A53/ECJ53 and E. coli 
B28/ECJ53) were provided with assistance from our MSc student (Sadia Miah). E. 
coli C22 conjugation was performed successfully as mentioned in Chapter 4, 
section 4.8.2. Overall, there were only three successful transconjugants observed 
(E. coli B28/EC J53, E. coli A53/EC J53 and E. coli C22/EC J53).  
 
All the transconjugants and EC J53 (control) were infected with differing bacterium 
inoculums in order to elicit appropriate live and dead larvae populations. An 
inoculum of 109 CFU/ml (107 CFU/larvae) was then selected for the infection. The 
virulence and fitness cost of acquiring the plasmid MCR-1 were then assessed. The 
susceptibility testing was performed for all three transconjugants and the 
recipient ECJ53. These transconjugants were characterized by WGS (WGS analysis 
methods mentioned in Chapter 3, section 3.3.9). 
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5.3.3 Survival analysis 
Survival analysis was performed using Kaplan-Meier survival curves. Kaplan-Meier 
is used to measure the fraction of subjects living for certain amount of time after 
treatment, (Goel et al., 2010) however in this study; it is the measure of mortality 
(number of G. mellonella larvae death) after being infected. This analysis was 
already performed in a previously published study (Ciesielczuk et al., 2015). Cox 
proportional hazards model was used to make a pairwise comparison between 
isolate (Ciesielczuk et al., 2015). In addition, this model was also use to investigate 
the impact of individual E. coli sequence types (ST) and previously published 
virulence determinants (Ciesielczuk et al., 2015) on G. mellonella larval survival. 
Survival curve analysis was then performed with assistance from our collaborator 
Dr Lynette M Phee. 
 
5.3.4 Statistical analysis  
Statistical analysis performed using StataCorp. 2013. Stata Statistical Software: 
Release 13. College Station, TX: StataCorp LP.  
 
Statistical analysis was performed with assistance from our collaborator Dr 
Lynette M Phee. 
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5.3.5 Growth curve assay 
Fitness cost was performed by investigating the growth kinetics of three successful 
E. coli mcr-1-like transconjugants and the recipient (E. coli B28/EC J53, E. coli 
A53/EC J53 and E. coli C22/EC J53 and ECJ53)  
 
A 5 µl of overnight culture were inoculated in 3 ml LB broth and incubated on an 
innova 2100 platform shaker (New Brunswick Scientific; Eppendorf, Stevenage UK) 
at 37° C for 24 h. After 24 hours, the bacterial suspension was further diluted, 3 µl 
into 3 ml of LB broth. 100 µl of the diluted suspension was dispensed into 96-well 
round bottom microtiter plate in triplicates incubated and analysed for 19 hours 
using CLARIOstar (BMGLABTECH, Aylesbury, UK) microplate reader, grew at 37◦C 
with vigorous aeration (200 rpm). The culture cell density was determined every 
30 minutes by measuring the OD540.  
 
The curves were generated by CLARIOstar Data analysis. The curves with error bar 
were produced using GraphPad Prism version 8.0 and statistical analysis were 
calculated using Mann-Whitney U test. 
 
5.3.6 Endotoxin detection 
ToxinSensor™ Chromogenic LAL Endotoxin Assay kit (antibodies-online GmbH, 
Aachen, Germany) was used in this study. This test utilizes a modified Limulus 
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Amebocyte Lysate and a synthetic color producing substrate to detect endotoxin 
chromogenically in a broad range of 0.005 - 1 EU/ml.  
 
Twelve E. coli mcr-1-like isolates were investigated for endotoxin activity. Six 
isolated from chickens (E. coli C22, E. coli C28, E. coli B52, E. coli B28, E. coli C55, 
E. coli B47) and 6 from humans (E. coli 1, E. coli 8, E. coli 49, E. coli 59, E. coli 60, E. 
coli 61). All these isolates were selected based on the differences in their STs. 
Characteristics of these isolates are mentioned in Chapter 4, section 4.6.2, Table 
12Table 12 
 
A 5 µl loop of test isolate was inoculated in 3 ml LB broth in a sterile universal tube 
incubated at 37° C for 24 hours on innova 2100 platform shaker (New Brunswick 
Scientific; Eppendorf, Stevenage UK). 1 ml of the bacterial mixture from overnight 
were pipetted out into sterile 1.5 ml sterile Eppendorf tube and centrifudged on 
Heraeus Biofuge Pico centrifuge (DJB Labcare, Buckinghamshire, UK) at 13,000 
rpm for 1 minute to pellet the cells. The supernatant of the test isolates was 
removed and placed into a new sterile Eppendorf tube. 
 
100 μl of standards, samples (supernatant) and LAL reagent water were dispensed 
into different endotoxin-free vials. 100 μl of reconstituted LAL was added to each 
vial. The capped vial was then vortexed for 3 seconds. All vials were then incubated 
at 37°C on a heat block for 45 minutes. Final endotoxin concentration was serially 
diluted to produce a concentration of 1, 0.5, 0.25 and 0.125 EU/ml. Briefly, 0.2 ml 
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of 5 EU/ml endotoxin stock solution was added with 0.8 ml of LAL Reagent Water 
to make the 1 EU/ml solution. Serial dilution with concentration was then made 
0.5, 0.25, 0.125 EU/ml (500 µl of 1 EU/ml solution was transferred into a vial 
containing 500 µl LAL Reagent water). The endotoxin concentration was then 
incubated for 10 minutes at 37°C.  
 
After incubation, 100 μl of reconstituted chromogenic substrate solution was 
added to each vial. The mixtures were mixed gently by swirling and incubated for 
6 minutes at 37°C. 500 μl of reconstituted stop solution (color-stabilizer #1), color-
stabilizer #2, color-stabilizer #3 were added to each vial and mixed gently by 
swirling. 100 µl of the solution was then dispensed into flat bottom well plate 
(nunc™ 96, SLS, Nottingham, UK) in triplicates.  
 
The absorbance of each reaction was read at 545 nm with distilled water as blank 
to adjust the photometer to zero absorbance. CLARIOstar (BMGLABTECH, 
Aylesbury, UK) microplate reader was used to read the absorbance. Standards 
(linear regression) and the test results were plotted on a graph generated by the 
CLARIOstar Data analysis programme.
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5.4 Results 
5.4.1. G. mellonella analysis in E. coli mcr-1-like wildtype strains 
G. mellonella killing showed differences in larval survival rates for all the fourty E. 
coli mcr-1-like strains (wild-type) as shown in Figure 37, Figure 38, Figure 39 and 
Figure 40. 
 
Pairwise comparison of hazard ratio was performed for all these strains (human 
versus avian origin) and ranked from the most virulent to the least virulent shown 
in Table 22.  
 
Virulence factors (VF) were ranked based on their Hazard Ratio and Kaplan-Meier 
curve analysis shown in Table 23 and Figure 41. A strain with cvaB (colivin V 
secretion/processing ATP-binding protein) showed the most heightened virulence 
according to the calculated Hazard Ratio. Similarly, other VF such as vat, hylE, 
AfaB, senB, tsh, eptD, cba, pic, iatB, iss and cma were observed to be virulent 
(Table 23 and Figure 41 A to L). Interestingly, carriage of lpfA, gadB, gad, invasin, 
air, celB and gad are associated with lower virulence scores and low mortality 
rates (Table 23 and Figure 41 M to S).  
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Figure 37. Kaplan-Meier survival curves for all 20 colistin-resistant E. coli strains isolated from chickens versus the PBS control over 72h.
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Figure 38. A to D represent Kaplen-Meier survival estimates (Percent survival versus Time elapsed (h)) of individual strains from chicken. 
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Figure 39. Kaplan-Meier survival curves for all 20 colistin-resistant E. coli strains isolated from humans versus PBS control over 72h. 
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Figure 40. A to D represent Kaplen-Meier survival estimates (Percent survival versus Time elapsed (h)) of individual strains from humans.
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Strains  Origin 
 
Sequence type (ST) 
 
Plasmid replicon 
 
Virulence factor 
 
Serotype 
 
Rank 
B52 Avian ST359 IncFII, IncFIC(FII), IncI2, IncI1, IncX1, IncFIB(AP001918) 
cba, iroN, gad, 
astA, cma, iss, 
lpfA, cvaB, tsh 
NT 1 
H67 Human ST372 IncFII(pRSB107), IncX4 iss, vat :H31 2 
H113 Human ST1011 
IncI2, IncFII, ColpVC, IncFIC(FII), 
IncFIB(pLF82), 
IncFIB(AP001918), IncX1, IncY 
astA, cma, eilA, 
iss, lpfA, iatB O86:H4 3 
A53 Avian ST2223 
IncI2, IncN, IncX4, IncX1, p0111, 
IncI, IncHI2A, IncHI2, 
IncFII(pSE11), InFII, 
IncFIB(AP001918), IncB/O/K/Z, 
ColpVC, Col156 
iroN, gad, astA, 
cma O75:H42 4 
H124 Human ST1011 IncI2, IncU, p0111, Col(MG828) eilA, iatB O157:H9 5 
H112 Human ST117 
IncFII(pHN7A8), IncFII(pSE11), 
IncFII, IncI2, Col156, 
IncFIB(AP001918) 
iss, lpfA, ireA, 
hlyE O2:H4 6 
H59 Human ST38 IncFIA(HI1), IncHI1A, IncHI1B(R27), IncN 
iss, senB, eilA, 
iha, iatB, gadB, 
AfaB 
O86:H45 7 
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H106 Human ST359 IncFII, IncFIC(FII), IncI1, IncFIB(AP001918), IncI2, IncFII 
iroN, cba, astA, 
cma, iss, lpfA, 
mchF 
O35: 8 
H109 Human ST93 IncHI1B(R27), IncFIA(HI1),IncHI1A iss, iha, astA O51:H52 9 
H96 Human ST48 IncX4, IncX1, p0111 gad, iss, etpD O8:H11 10 
H92 Human ST1201 IncI2, IncFIB(AP001918), IncFII(pCoo) lambda bor, etpD O124:H38 11 
B11 Avian ST4684 IncHI1B(R27), IncHI1A, IncX4, IncFIA(HI1) lpfA O9:H7 12 
H61 Human ST1011 IncFIB(AP001918), IncFII, IncI2, Col156 iss, eilA, iatB O157:H16 13 
A41 Avian ST117 col(BS512), IncHI1B(R27), IncI1, IncHI1A, IncFIA(HI1) 
iss, iroN, cma, 
astA, pic, eilA, 
gad, iha, lpfA, 
gadB, ireA, 
invasin 
O8:H19 14 
C55 Avian ST155 IncI2, IncX4, IncFII(29 mchF, gad, iroN, tsh, lpfA, iss O38:H21 15 
H84 Human ST8168 IncX4 astA :H29 16 
H53 Human ST93 IncHI1A, IncHI1B(R27), IncFIA(HI1), p0111, IncI2 
astA, cba, cma, 
iha, iss O51:H52 17 
B7 Avian ST1011 IncN, IncHI2, IncI2 iss, iatB :H25 18 
B47 Avian ST1140 IncI1 gad, gadB O38:H39 19 
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B28 Avian ST1727 IncI2, IncFIB(AP001918), IncFII(pCoo), p0111 
iss, lpfA, cma, 
gad, iroN :H7 20 
C28 Avian ST2372 
ColpVC, IncI2, IncFII, 
IncFIB(AP001918), Col156, 
IncB/O/K/Z, ColpVC, IncFII 
astA, cma, gad, 
iroN O37:H25 21 
A13 Avian ST2473 IncFIA(HI1), IncHI1A, IncHI1B(R27) iss, lpfA, gad O168:H28 22 
C45 Avian ST1642 
IncFII, IncY, IncFIB(AP001918), 
IncFIB(plF82), IncI2, IncX1, 
IncFII(29) 
lpfA, astA O8:H7 23 
B1 Avian ST711 IncI1, IncX4, IncHI1B(R27), IncN, IncHI1A, IncFII, IncFIA(HI1) iroN, lpfA, cma O8:H10 24 
C19 Avian ST10 IncQ1, IncHI2, IncFII(29), IncI2, IncI1 gad, astA, gadB :H32 25 
C22 Avian ST101 
IncHI1A, IncHIB(R27), 
IncFIA(HI1), IncFII, IncY, IncI2, 
IncFIC(FII), IncFIB(AP001918) 
IncI1, IncX1 
astA, cma, lpfA, 
iss, eilA, gad, iha, 
lpfA, mchF 
O88:H31 26 
H64 Human ST8380 IncHI1A, IncHI1B(R27), IncFIA(HI1) 
gad, eilA, lpfA, 
iatB :H31 27 
A33 Avian ST2732 IncHI2, IncFII 
astA, cma, eilA, 
gad, iha, lpfA, 
iatB, mchF 
O33:H28 28 
H8 Human ST206 IncHI1A, IncFII(29), IncX4, IncHI1B(R27), IncFIA(HI1) astA O96:H5 29 
 
 
306 
H60 Human ST1638 IncX4, IncX1, InFII, IncI2, IncFIB (AP001918), Col (MG828) iss, iroN, gadB O124:H12 30 
C1 Avian ST7687 IncX4, IncHI2 eila, air, gad, gadB O17/77:H31 31 
H86 Human ST1121 IncX4, p0111 gad, lpfA, lambda bor :H38 32 
H25 Human ST58 IncFIC(FII), IncFIB(AP001918), IncI2 
astA, cma, iss, 
gad, lpfA O8:H25 33 
H54 Human ST1642 IncFIA, IncFIB(AP001918), IncI2, IncFIB(pLF82), IncX1 
iss, astA, lpfA, 
gad O48:H7 34 
H49 Human ST746 IncX4, IncX2 gad O8:H37 35 
A8 Avian ST115 IncFI, ColpVC, Col8282, IncHI1A, IncFIA(HI1) 
iss, celb, astA, 
iroN, iha, lpfA, 
gadA, eilA, 
invasin 
O21:H15 36 
A28 Avian ST226 IncI1 gad, ireA O18:H10 37 
B25 Avian ST162 IncX4, IncFII(29) gad, lpfA, iss O134:H19 38 
A12 Avian ST2705 p0111, IncI2, IncX1 gadB :H10 39 
H1 Human ST224 IncX4, IncFIB(AP001918), IncFII cma, iss, iroN, gad, lpfA O102:H23 40 
Table 22. Virulence ranking of colistin-resistant E. coli strains ranking from most virulent (1) to least virulent (40) based on their Hazard Ratio. 
NT- Non Typeable.
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Virulence factors p-value Hazard Ratio (HR) 95% Confidence Interval, CI 
cvaB <0.001 2.546 1.761, 3.681 
vat <0.001 2.515 1.740, 3.636 
hlyE <0.001 2.095 1.434, 3.061 
AfaB <0.001 1.989 1.353, 2.924 
senB <0.001 1.989 1.353, 2.924 
tsh <0.001 1.973 1.494, 2.607 
eptD <0.001 1.953 1.486, 2.567 
cba <0.001 1.932 1.530, 2.440 
pic 0.046 1.526 1.007, 2.312 
iatB <0.001 1.472 1.234, 1.757 
iss <0.001 1.353 1.167, 1.569 
cma 0.004 1.254 1.077, 1.459 
mchF 0.346 1.120 0.885, 1.419 
astA 0.131 1.120 0.967, 1.298 
iroN 0.166 1.119 0.954, 1.313 
lambdabor 0.669 1.074 0.775, 1.489 
eilA 0.854 1.016 0.861, 1.198 
Iha 0.935 1.008 0.833,1.220 
ireA 0.777 0.961 0.730, 1.265 
lpfA 0.006 0.815 0.704, 0.943 
gadB 0.019 0.787 0.644, 0.961 
gad <0.001 0.653 0.564, 0.756 
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invasin 0.019 0.636 0.436, 0.928 
air 0.01 0.542 0.339, 0.865 
celB <0.001 0.174 0.072, 0.419 
gadA <0.001 0.174 0.072, 0.419 
Table 23. Virulence factors present in colistin-resistant E. coli strains isolated from chicken and humans ranked according to their Hazard Ratio 
(HR). cvaB- colicin V secretion/processing ATP-binding protein, vat- vacuolating autotransporter toxin, hlyE- avian E. coli haemolysin, AfaB- 
chaperone AfaB, senB- plasmid-encoded enterotoxin, tsh- temperature sensitive hemagglutinin, eptD- type II secretion protein, cba- colicin B, 
pic- serine protease autotransporters of Enterobacteriaceae (SPATE), iatB- inverse autotransporter beta-barrel domain-containing protein, iss- 
Increased serum survival, cma- colicin M, mchF- ABC transporter MchF, astA- EAST1 heat-stable toxin, iroN- enterobactin siderophore receptor 
protein, lambdabor- serum resistance lipoprotein bor, eilA- salmonella HilA homolog, iha- adherence protein, ireA- siderophore receptor, lpfA- 
long polar fimbriae, gadB- glutamate decarboxylase beta, gad- glutamate decarboxylase, invasin- invasin region at inverse autotransporter, beta-
domain, iatB, air- enteroaggregative immunoglobulin repeat protein, celB- endonuclease colicin E2 and gadA- glutamate decarboxylase alpha.  
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Figure 41. Kaplan Meier survival curves of individual virulence factor genes.  A to L represents individual virulence factor genes with high Hazard 
Ratio scores showing high mortality rates. M to S shows lower ranked VF scores with low mortality rates. 
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All E. coli mcr-1 isolates showed an endotoxin activity of greater than >1 EU/ml 
(Figure 42 and Table 24). 
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Figure 42.  Endotoxin activity of colistin-resistant E. coli strains isolated from chickens and humans. Green dots – represents the standards (0.125, 
0.25, 0.5 and 1 EU/ml). Purple dots – test isolates with endotoxin activity that clusters between 1.716 – 1.951 EU/ml.
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Table 24. Endotoxin activity (EU/ml) of colistin-resistant E. coli strains from chickens and humans. 
Isolates Endotoxin activity (EU/ml) Sequence type, ST Origin 
E. coli 61 1.951 ST1011 Human 
E. coli B28 1.914 ST1727 Avian 
E. coli B52 1.909 ST359 Avian 
E. coli 1 1.902 ST224 Human 
E. coli B47 1.878 ST1140 Avian 
E. coli 60 1.871 ST1638 Human 
E. coli C22 1.862 ST101 Avian 
E. coli 59 1.835 ST38 Human 
E. coli 49 1.824 ST746 Human 
E. coli C55 1.812 ST155 Avian 
E. coli C28 1.809 ST2372 Avian 
E. coli 8 1.716 ST206 Human 
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5.4.2 G. mellonella analysis in E. coli mcr-1-like transconjugants 
E. coli C22/EC J53 transconjugant showed enhanced virulence when compared to 
the background EC J53 with HR of 21.653 followed by E. coli B28/EC J53 and E. coli 
A53/EC J53 (Table 25, Figure 43 and Figure 44). 
 
WGS analysis of all the transconjugants showed E. coli B28/EC J53 co-harboured 
other plasmids while E. coli A53/EC J53 and E. coli C22/EC J53 harboured only one 
plasmid replicon type, IncI2 (Table 26). In addition, E. coli B28/EC J53 
transconjugant acquires more virulence factors. However, the most virulent genes 
were not observed according to the calculated Hazard Ratio. In addition, E. coli 
B28/EC J53 showed less G. mellonella killing compared to E. coli C22/EC J53 
transconjugant. As with E. coli A53/EC J53 transconjugant is shown to be less 
virulent than E. coli C22/EC J53, although both transconjugant carried similar 
replicon type and virulence factor genes. 
 
Susceptibility testing showed E. coli C22/EC J53 transconjugant was resistant to 3rd 
generation cephalosporin hence acquiring an ESBL phenotype (Table 27). Growth 
kinetics of the transconjugant and ECJ53 recipient strain did not show obvious 
difference after 20h assessment. Mann-Whitney U test showed all the three 
curves were not significant with p-value of 0.5887 (Figure 45), 0.3095 (Figure 46) 
and 0.5887 (Figure 47). Therefore, acquiring mcr-1-like genes does not affect the 
growth of the host. 
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Transconjugants (7log/larvae) Hazard Ratio (HR) p-value 95% Confidence Interval, CI 
E. coli C22/ECJ53 21.653 <0.001 8.434, 55.592 
E. coli B28/ECJ53 18.198 <0.001 7.447, 44.473 
E. coli A53/ECJ53 4.253 0.007 1.476, 12.260 
Table 25. Virulence ranking of colistin-resistant E. coli transconjugants according to their Hazard Ratio. 
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Figure 43. E. coli mcr-1-like transconjugants at 7 log cfu/larva isolated from chicken versus PBS/J53 control.  
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Figure 44. A &B Survival curves of transconjugants at 7 log cfu/larva, PBS and J53. 
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Characteristics 
Donor Recipient Transconjugant 
E. coli A53 E. coli B28 E. coli C22 E. coli J53 E. coli A53/EC J53 E. coli B28/EC J53 E. coli C22/EC J53 
Main 
resistance 
gene 
mcr-1.1 mcr-1.1 mcr-1.8 - mcr-1.1 mcr-1.1 mcr-1.8 
Plasmid 
replicon type 
IncI2, IncN, IncX4, 
IncX1, p0111, IncI, 
IncHI2A, IncHI2, 
IncFII(pSE11), 
InFII, 
IncFIB(AP001918), 
IncB/O/K/Z, 
ColpVC, Col156 
IncI2, 
IncFIB(AP001918), 
IncFII(pCoo), 
p0111 
IncHI1A, 
IncHIB(R27), 
IncFIA(HI1), 
IncFII, IncY, IncI2, 
IncFIC(FII), 
IncFIB(AP001918) 
IncI1, IncX1 
- IncI2 IncI2, 
IncFIB(AP001918), 
IncFII(pCoo) 
IncI2 
MLST ST 2223 ST 1727 ST 101 ST 10 ST 10 ST 10 ST10 
Virulence 
associated 
gene 
iroN, gad, astA, 
cma 
iss, lpfA, cma, 
gad, iroN 
astA, cma, lpfA, 
iss, eilA, gad, iha, 
lpfA, mchF 
iss, gad iss, gad iss, gad, iroN, cma iss, gad 
Table 26. Summary of the characteristics of the E. coli mcr-1-like wild-type donor strains, recipient and its transconjugants.
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 Isolate 
 MIC 
(mg/L) 
Etest 
Zone Diameter (mm) 
CT AMC (30) 
KF 
(30) 
FOX 
(30) 
CPD 
(10) 
EFT 
(30) 
FEP 
(30) 
ETP 
(10) 
IMP 
(10) 
MEM 
(10) 
ENR 
(5) 
CIP 
(5) 
PEF 
(30) 
MH 
(30) 
C 
(30) 
FFC 
(30) 
AK 
(30) 
K 
(30) 
APR 
(15) 
E. coli A53 >256 6 6 6 6 21 30 23 27 28 6 11 6 8 6 6 20 6 6 
E. coli A53/EC J53 6 19 17 27 25 25 33 28 28 30 27 28 26 22 24 22 19 19 16 
E. coli J53 2 21 18 26 25 22 35 31 29 32 29 30 32 22 24 24 19 20 16 
E. coli B28 >256 6 6 6 6 22 35 18 29 19 6 6 6 11 6 6 24 6 6 
E. coli B28/EC J53 4 16 16 28 26 26 34 32 30 32 20 24 18 20 6 6 19 19 16 
E. coli J53 2 21 18 26 25 22 35 31 29 32 29 30 32 22 24 24 19 20 16 
E. coli C22 8 6 6 25 6 6 17 22 25 25 8 11 6 11 6 6 19 6 6 
E. coli C22/EC J53 4 13 6 28 6 6 18 29 28 30 27 27 26 22 23 24 19 18 16 
E. coli J53 0.38 21 18 26 25 22 35 31 29 32 29 30 32 22 24 24 19 20 16 
Table 27. Susceptibility testing of transconjugants and their respective donor and recipient (EC J53) according to EUCAST, CLSI and/or CLSI VET 
guidelines. (CLSI, 2018) (CLSIVET08, 2018) (EUCAST, 2018) CT= colistin, AMC= augmentin, KF= cephalothin, FOX= cefoxitin, CPD= cefpodixme, 
EFT= ceftiofur, FEP= cefepime, ETP= ertapenem, IMP= imipenem, MEM= meropenem, ENR= enrofloxacin, CIP= ciprofloxacin, FFC= florfenicol, 
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AK= amikacin, K= kanamycin, APR= apramycin. MIC breakpoint for colistin - susceptible ≤2 and resistant 2. Red colour- Resistance, Green colour 
– Sensitive, Yellow colour – Intermediate and Unshaded box- no reference breakpoint guidelines available.
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Figure 45. Growth kinetics between E. coli A53/ECJ53 transconjugant and EC J53 recipient. 
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Figure 46. Growth kinetics between E. coli B28/ECJ53 transconjugant and EC J53 recipient ECJ53. 
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Figure 47. Growth kinetics between E. coli C22/ECJ53 transconjugant and EC J53 recipient. 
 
 
333 
5.5 Summary 
§ Forty E. coli colistin resistance strains isolated from chickens and humans 
were investigated for virulence in G. mellonella infection model. 
§ Differences in G. mellonella killing were observed in all strains isolated 
from chickens and humans. These data were analysed by using Kaplan-
Meier survival curves and cox proportional hazards ratio. 
§ cvaB (colivin V secretion/processing ATP-binding protein) promoted 2.546 
greater G. mellonella killing but was present in only one strain. Other VF 
were vat, hylE, AfaB, senB, tsh, eptD, cba, pic, iatB, iss and cma also 
showed virulence: Likewise, carriage of lpfA, gadB, gad, invasin, air, celB 
and gad were associated with reduced virulence. 
§ No difference in endotoxin activity in colistin-resistant E. coli strains was 
observed in LAL assay. 
§ Plasmids from three donor strains (E coli A53, E. coli B28 and E. coli C22) 
enhanced the virulence of EC J53 transconjugants. 
§ However, plasmids from E. coli C22 and E. coli A53 showed differences in 
G. mellonella killing, despite the transfer of similar virulence factors and 
plasmid replicon type. The only difference being the plasmid from E. coli 
C22 encoded MCR-1.8. 
§ The E. coli B28/EC J53 transconjugant carried additional plasmid replicon 
types and additional virulence factors. 
§ Growth assays did not demonstrate an obvious fitness cost on acquisition 
of mcr-1-like encoding plasmids. 
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Chapter 6 
Discussion 
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6.1 Introduction 
Antimicrobial resistance is a critical global problem, posing threats and challenges 
in human medicine and public health (WHO, 2018). The rise of AMR and drying-
up of the antimicrobial development pipeline has impacted on the ability of 
antibiotics to save countless lives, limbs, surgical procedures and cancer (Spellberg 
et al., 2004). Economically AMR is costly whereby within the next 30 years, 
treating AMR could cost up to US$3.5 billion per year (Hofer, 2019). Aggravating 
this problem further is the emergence and spread of critical Gram-negative 
pathogens (carbapenem-resistant Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacteriaceae) (WHO, 2017a) which further limits 
therapeutic options, especially when carbapenems have become last-line 
antibiotics for treatment (Papp-Wallace et al., 2011). Plasmid-mediated 
carbapenem resistance (IMP-like, VIM-like, KPC-like, NDM-like, OXA-48-like) 
acquired by these pathogens has disseminated globally (Nordmann et al., 2011a). 
Colistin, an old antibiotic has therefore been repurposed to treat multidrug-
resistance clinical infections acquiring these carbapenemase genes. 
Unfortunately, with the recent emergence of plasmid-mediated colistin 
resistance, mcr-1 reported China in 2015, the AMR crisis has escalated further (Liu 
et al., 2016). The mcr-1 gene has been found in animals and humans which further 
threatens public health (Liu et al., 2016). 
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The complex public health issue has led to the ‘One Health’ approach to tackle the 
problem. This need to involve multiple government sectors (human health, animal 
health, agriculture, environment, policy makers) able to communicate and work 
together to achieve public health outcomes and strengthen AMR surveillance 
(WHO, 2017b). Furthermore, AMR surveillance is still underdeveloped in most 
developing countries especially in Southeast Asia (SEA) which includes Brunei 
Darussalam (Hsu et al., 2017). AMR surveillance is important in this region as it 
has been seen as a hotspot for wider global resistance dissemination (Hsu et al., 
2017).  
 
The WHO suggest other approaches apart from surveillance to tackle AMR which 
focus on improving awareness and the understanding of AMR, reducing the 
incidence of infection, optimizing the use of antimicrobial agents, and an increase 
in investment into new medicines, vaccines and diagnostic tools (WHO, 2015). 
Such guidelines would help resource-poor countries tackle and contain AMR and 
prevent dissemination locally and internationally.  
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6.2 Phenotypic and genotypic analysis of carbapenem-resistant 
Gram-negative Non-fermenters from Brunei Darussalam 
 
6.2.1 Molecular analysis of carbapenem-resistant A. baumannii (CRAB) clinical 
isolates in Brunei and Southeast Asia 
Carbapenem-resistant Acinetobacter baumannii (CRAB) is an important 
opportunistic pathogen, usually associated with hospital-acquired infections. In A. 
baumannii, blaOXA-23 is the most prevalent carbapenemase-encoding gene 
worldwide (Mugnier et al., 2010; Hammami et al., 2011; Bakour et al., 2014).  
 
Additionally, one of the most successful clonal lineages of A. baumannii is 
international clone II (IC II), which clusters in clonal complex 92 (CC92) according 
to the multilocus sequence typing (MLST) Oxford scheme developed by Bartual et 
al. (Bartual et al., 2005) and sequence type 2 (ST2) using the alternative Pasteur 
MLST scheme (Matsui et al., 2014). A. baumannii IC 2 has been associated with 
nosocomial outbreaks and multidrug resistance (Diancourt et al., 2010) and has 
spread globally (Karah et al., 2012). In Japan, A. baumannii IC 2 is also reported to 
be strongly associated with multidrug or carbapenem resistance (Endo et al., 
2012; Kouyama et al., 2012; Matsui et al., 2014) and has caused nosocomial 
outbreaks (Asai et al., 2014; Alshahni et al., 2015; Ushizawa et al., 2016). 
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In this study, all the CRAB isolates carried an OXA-23-like gene and produced the 
intrinsic OXA-51-like carbapenemase enzymes. Most of the isolates from Brunei 
belonged to either Global Clone I/GC1/IC1 and II/GC2/IC2, which are again the 
typical clones circulating in SEA. Co-resistance to other antibiotics was also 
identified including ampicillin, ceftazidime, cefepime, ciprofloxacin, netilmicin, 
piperacillin, piperacillin/tazobactam, ampicillin/sulbactam, gentamicin, co-
trimoxazole and ticarcillin/clavulanic acid hence, exhibiting an MDR phenotype. 
 
There are a wide range of mobile genetic elements related to carbapenem 
resistance in A. baumannii which includes ISAba1, ISAba2, ISAba3, ISAba4 and 
IS18 (Pagano et al., 2016). It is also well known that the presence of the ISAba1 
insertion element upstream of blaOXA-23 gene acts as a promoter increasing the 
level of expression of blaOXA-23 required to cause carbapenem resistance (Poirel et 
al., 2011a; Turton et al., 2006). In study done Villalón et al., ISAba1 was the 
common insertion sequences with the highest prevalence (93.2%) in epidemic 
clones of multidrug-resistant A. baumannii investigated from Spain (Villalon et al., 
2013).  
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Other mobile genetic elements include three transposons related to blaOXA-23: 
Tn2006, Tn2007 and Tn2008 (Pagano et al., 2016). Tn2006 in relations to blaOXA-23 
gene is flanked by two copies of the insertion sequence ISAba1, which is located 
in opposite directions (Pagano et al., 2016). As with Tn2008, it is similar to Tn2006 
but lacks the second copy of ISAba1 (Pagano et al., 2016). In Tn2007, the blaOXA-23 
gene is associated with one copy of ISAba4 located upstream to this gene 
(Mugnier et al., 2010). 
 
Three important classes of integron 1, 2 and 3 that have an important role in the 
dissemination of antimicrobial resistance genes (Mazel, 2006; Gillings, 2014). The 
highest prevalence was identified with class 1 integron in A. baumannii isolates in 
Europe, Asia and United States (Lee et al., 2009).  
 
Additionally, most acquired MBL genes in A. baumannii have been found within 
class 1 integrons, often containing an array of resistance gene cassettes (Peleg et 
al., 2008; Potron et al., 2015). While class 2 integrons are included in the Tn7 
family of transposons, containing a transposition module formed by five 
transposition genes, tnsA, tnsB, tnsC, tnsD, and tnsE, rather than the one or two 
seen in many other transposable elements and consist of an integrase gene 
followed by gene cassettes (Mazel, 2006; Pagano et al., 2016). However, with class 
3 integrons, it is less prevalent than class 2 but there are also located in 
transposons (Cambray et al., 2010).  
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CRAB clinical isolates from Brunei also harboured armA and a class 1 integron, 2 
of which contained gene cassettes similar to the ones reported by Pai et al. (Pai et 
al., 2003) aacA4'-8, catB8, aadA1a, dfrA1b, aacA3 and blaP2 (also named as 
blaCARB-1/2 subgroup) (carbenicillin-hydrolysing penicillinase) (Ito and Hirano, 1997) 
cassette which further support resistance to most of the aminoglycoside 
antibiotics tested in this study. Of note, it is known that when multiple genes are 
present in a cassette, the position of the cassette in the array influences the level 
of antibiotic resistance expressed and is highest when the AMR gene is first in the 
cassette (Collis and Hall, 1995). 
 
Although, not much is known with the MGE in clinical CRAB isolates in Brunei, 
hence, this will impact on the ability to define the blaOXA-23 epidemiology in this 
study.  
 
The earliest A. baumannii isolates shown to carry the armA gene were recovered 
in 2003 in Korea (Lee et al., 2006). Since then, this gene has been reported in 
strains from North America (Doi et al., 2007a), Japan (Tada et al., 2014), China 
(Huang et al., 2012), Malaysia (Lean et al., 2015), Nepal (Shrestha et al., 2015), 
India (Saranathan et al., 2014) and Italy (Milan et al., 2016). It was also found in 
isolates from Norway recovered from patients that had previously been 
hospitalized in Asia (Karah et al., 2012). 
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In this study, the armA 16S methyltransferase that mediates pan-aminoglycoside 
resistance was also identified and correlated to the phenotypic resistance tested 
against the aminoglycoside antibiotics (gentamicin and netilmicin).  
 
Fluoroquinolone resistance (ciprofloxacin) was also seen in our CRAB clinical 
isolates. However, in a study done by Peleg et al., plasmid-mediated quinolone 
resistance genes (PMQR) (qnrA, qnrB and qnrS) have yet to be demonstrated in A. 
baumannii (Peleg et al., 2008). It is likely that fluoroquinolone resistance in our 
isolates was due to a chromosomal mutation in the quinolone resistance-
determining regions (QRDRs) (gyrA, gyrB, ParC and ParE). However, in a study 
done by Chopra et al. (Chopra and Galande, 2011) mutants generated from A. 
baumannii (ATCC 17978) with high-level fluoroquinolone resistance (ciprofloxacin 
gatifloxacin, moxifloxacin and norfloxacin MIC of > 16 mg/L) did not exhibit any 
mutations in gyrA, gyrB, parC and parE when compared with the parental strain. 
The first report of fluoroquinolone resistance in A. baumannii that is independent 
of mutations in QRDRs and the absence of PMQR (Chopra and Galande, 2011). 
 
In relation to Southeast Asia, there are growing reports of OXA-23-like producing 
A. baumannii (Hsu et al., 2017). For example, in Singapore, the prevalence of CRAB 
in Singaporean public sector hospitals increased from 48% (2006-2008) to 62% in 
2010 (Hsu et al., 2010). OXA carbapenemases were the dominant type and again 
belonged to global clones I/1 and II/2 (Koh et al., 2007; Koh et al., 2012; Kim et al., 
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2013). Similarly in Malaysia, OXA-23 is also the major carbapenemase gene 
acquired by CRAB (Biglari et al., 2015 46), with a small collection of CRAB from a 
regional study identifying them also as members of global clone II/2 (Kim et al., 
2013). Interestingly in Vietnam, a small fraction of OXA-23-like producing CRAB 
isolates have been shown to co-produce the NDM-1 carbapenemase gene (Tada 
et al., 2015a). There are no publicly available data on CRAB in Myanmar, Laos and 
East Timor, although it is likely that the organism is present in these countries and 
not reported (Hsu et al., 2017). 
 
In summary, OXA-23 producing CRAB is the dominant carbapenemase circulating 
in Brunei’s hospital similar to those reported in other SEA. Co-resistance to other 
antibiotics was also observed alongside acquired aminoglycoside resistance, 
hence limiting therapeutic options. In this study, GC 1/IC 1 and GC 2/IC 2 clones 
were reported in CRAB clinical isolates. Infection control remains the critical 
intervention for containment of this pathogen to prevent further dissemination.  
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6.2.2 Carbapenemase detection in carbapenem-resistant Pseudomonas 
aeruginosa (CRPA) 
Multiple methods are available for the detection of carbapenemase production. 
These include phenotypic tests such as the Modified Hodge Test (MHT), disc-
inhibitors synergy tests, chromogenic and nonchromogenic screening media, 
biochemical tests, spectrophotometry and matrix-assisted laser desorption 
ionization-time of flight mass spectrometry (MALDI-TOF MS) (Osei Sekyere et al., 
2015). Molecular detection of carbapenemase genes can be performed by PCR 
(conventional, multiplex, real-time, GeneXpert system, Check-Direct CPE), 
microarray, loop-mediated isothermal amplification and next generation 
sequencing (NGS) (Osei Sekyere et al., 2015). Most of the phenotypic methods 
perform well for the detection of carbapenemases in Enterobacteriaceae; 
however, their performance in Gram-negative non-fermenters (CRNF) warrants 
further investigation (Osei Sekyere et al., 2015). 
 
To assess whether carbapenemases were likely to be produced by P. aeruginosa 
isolates (n= 22) collected in Brunei, we performed Blue-Carba test. Blue-Carba test 
has been reported to demonstrate 100% sensitivity and specificity, and this could 
not be confirmed here. All CRPA isolates were negative for carbapenemase 
production (n=22). 
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In Portugal, the Blue-Carba method was evaluated against 101 
Enterobacteriaceae (n= 44), Acinetobacter (n= 43) and Pseudomonas (n= 19) 
strains acquiring Ambler Class A, B, and D carbapenemases (KPC, NDM, IMP, SPM 
and OXA) and 49 noncarbapenemase producers (susceptible or resistance to 
carbapenems) (Pires et al., 2013). Interestingly, with the Pseudomonas species., 
12 P. aeruginosa and 1 P. pseudoalcaligenes harboring VIM-2 (Imipenem and 
meropenem MIC 1- >32 mg/L) were reported positive for carbapenemase 
production and 5 were negative (4 P. aeruginosa isolates with imipenem and 
meropenem MIC > 32 m/L and 1 P. aeruginosa with imipenem and meropenem 
MIC= 0.25 mg/L) (Pires et al., 2013). 
 
 P. aeruginosa clinical isolates from Brunei, although resistant to carbapenems 
(MIC ≥ 8 mg/L), no carbapenemases were detectable with the Blue-Carba assay. 
Hence, resistance is likely due to other non-enzymatic mechanisms such as porin 
loss due to mutations in the OprD gene leading to imipenem resistance or 
overexpression of efflux pumps in MexAB-OprM (Multidrug efflux system AB- 
Outer membrane protein M) (Meletis et al., 2012). 
 
In Southeast Asia, a country such as Thailand, the prevalence of Multidrug-
resistant (MDR) P. aeruginosa clinical isolates ranges from 20% and 30% as 
reported from 28 hospitals participating in The National Antimicrobial Resistance 
Thailand (NARST) program from 2000-2005 (Dejsirilert et al., 2009; Suwantarat 
and Carroll, 2016). Khuntayaporn et al. (Khuntayaporn et al., 2012) reported out 
of 261 MDR P. aeruginosa clinical isolates (collected during 2007-2009 from eight 
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tertiary hospitals across Thailand), the most common mechanism of imipenem 
resistance was the loss of OprD porin protein (98%). In Singapore, the prevalence 
of carbapenem-resistant Pseudomonas aeruginosa, CRPA (resistant to 
meropenem) reported by Tan et al. (Tan et al., 2008) was 11.2% of 188 isolates 
collected during 2006-2007. The carbapenem resistance mechanism reported in 
P. aeruginosa isolates was mostly multifactorial (Suwantarat and Carroll, 2016). 
While the acquired MBL genes (blaIMP-1, blaIMP-7 and blaVIM-6) represented only 
1.7% of all P. aeruginosa isolates collected in 2001 at Singapore General Hospital 
(Suwantarat and Carroll, 2016). These MBL genes were previously reported in 
Japan, Canada and Malaysia (Koh, 2008). While in Vietnam, there is limited data 
on CRPA prevalence, although a novel blaIMP-51 has been reported (Tada et al., 
2015b). In Malaysia, CRPA prevalence was 21% (Lim et al., 2009) while 32 out of 
90 isolates of imipenem-resistant P. aeruginosa clinical isolates collected during 
2005-2008 from the University of Malaysia Medical Center were positive for MBL 
genes identified by multiplex PCR; blaIMP-7 (n= 12), blaIMP-4 (n= 2), blaVIM-2 (n= 17) 
and blaVIM-11 (n= 1) (Khosravi et al., 2010). 
 
Further evaluation for carbapenemase production was done by Simner et al. 
(Simner et al., 2017) in sixty-seven CRPA using a battery of assays; Rapid CarbaNP, 
Neo-Rapid Carb screen, Manual CarbaNP CLSI, Manual Blue Carba, Modified Carba 
NP, Boronic acid synergy test, Metallo-ß-lactamase Etest, Modified Hodge Test 
(MHT), Carbapenem inactivation method (CIM), Modified carbapenem 
inactivation method. From this evaluation, 14 CRPA isolates producing KPC, VIM, 
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IMP and SPM and 53 were non-carbapenemase producers could be differentiated 
(Simner et al., 2017). In addition, Rapidec Carba NP, Neo-Rapid Carb screen, Rapid 
Carba Blue Screen, Manual Blue Carba, Modified Carba NP and Modified 
carbapenem inactivation method assays showed 100% sensitivity with the 14 
carbapenemase producing CRPA (Simner et al., 2017). However, only 100% 
specificity with Carbapenem inactivation method and Manual Carba NP CLSI in 53 
non-carbapenemase producing CRPA (Simner et al., 2017).  
 
In a large study done by Pasteran et al. (Pasteran et al., 2015) 300 clinical isolates 
(188 carrying known carbapenemase-encoding gene and 112 without 
carbapenemase production) were evaluated for the performance of the Blue-
Carba test. Clinical isolates belonged to the National and Regional Reference Lab 
and submission from diverse locations in Latin America (Schmunis and Salvatierra-
Gonzalez, 2006). Among the clinical isolates evaluated 22 P. aeruginosa harbors 
Class A (GES-5) and Class B (IMP-13, IMP-16, IMP-18, VIM-2, VIM-11, SPM-1) 
carbapenemase gene while 44 P. aeruginosa harboured ESBLs gene, AmpCs and 
other non-enzymatic resistance mechanisms (efflux overproduction, porin loss or 
both) (Pasteran et al., 2015). Positive carbapenemase production was observed 
with those P. aeruginosa isolates harboring Class A and B gene and negative with 
the 44 carbapenemases non-producers (Pasteran et al., 2015). 
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In another study done Sun et al. (Sun et al., 2017a) 256 Gram-negative isolates 
(139 carbapenemase producers and 117 carbapenemase non-producers) and 
among them were 8 P. aeruginosa isolates were evaluated using six phenotypic 
methods for carbapenemase detection (modified Hodge test (MHT), Triton Hodge 
test (THT), Carba NP test (CNPt), simplified Carba NP test (CNPt-direct), Blue-Carba 
NP test (BCT) and carbapenem inactivation method (CIM). All P. aeruginosa 
isolates did not harbor beta-lactamase gene and their MICs of imipenem and 
meropenem 4-16 mg/L and 2-8 mg/L, respectively. All showed no carbapenemase 
production with six phenotypic methods tested including the Blue-Carba test (Sun 
et al., 2017a). 
 
From all these evaluation studies, the performance of the Blue-Carba test is best 
when Gram-negative non-fermenters harbour carbapenemase genes. With the 
low prevalence of CRPA acquiring MBL genes in Southeast Asia, it raises the 
question of whether Blue-Carba testing would be ideal in Brunei’s Laboratory 
setting. In our study, the number of CRPA clinical isolates tested is low; hence, this 
warrant a more robust evaluation with a large number of samples. 
 
On the contrary, a carbapenemase detection test is not required or encouraged 
to be performed in clinical microbiology laboratories for clinical management 
(Jimenez et al., 2017). The test is recommended for epidemiological reasons such 
as infection control purposes to avoid horizontal transmission and cohorting 
patients (Jimenez et al., 2017). It is also important to note that not all these 
phenotypic methods are readily available in developing countries, this is partly 
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due to the costs of these test and the laboratory capacity for testing these 
pathogens. 
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6.3 Characterisation of carbapenem-resistant Klebsiella pneumoniae 
(CRKP) from Brunei Darussalam 
In an AMR surveillance studies, the rates of Extended Spectrum Beta-lactamase 
(ESBL) and carbapenem-resistant Enterobacteriaceae (CRE) in the Asia-Pacific 
region is much higher than in Europe and North America (Suwantarat and Carroll, 
2016). Brunei Darussalam is in the Asia-Pacific region, more associated with the 
Southeast Asia region and in close proximity to countries such as Malaysia, the 
Philippines, Singapore and Thailand. In addition, the Study for Monitoring 
Antimicrobial Resistance Trends (SMART) programme has identified CTX-M-14/15 
and NDM-like as the most prevalent ESBL and carbapenemase enzymes circulating 
here (Jean et al., 2017). 
 
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an important hospital-
acquired pathogen (Bocanegra-Ibarias et al., 2017). CRKP have been found to 
carry diverse carbapenemases such as KPC-like, OXA-48-like, NDM-like and VIM-
like (Bocanegra-Ibarias et al., 2017). In this study, we identified an outbreak of 
OXA-232 producing MDR K. pneumoniae of ST 231 that co-produced the class A β-
lactamases blaTEM-1b, blaSHV-11 and blaCTX-M-15 in Brunei’s hospitals. The 
identification of OXA-232 producing MDR K. pneumoniae in our study was 
performed phenotypically by the OXA-48 K-SeT lateral flow assay which showed 
100% sensitivity and specificity and also by molecular methods. 
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The OXA-232 carbapenemase is a class D β-lactamase with carbapenem 
hydrolyzing activity (CHDL) related to the OXA-48 enzyme from which it differs by 
five amino acids (Potron et al., 2013). It has been reported that OXA-232 
producing K. pneumoniae isolates typically display carbapenem MICs of ≥ 32 mg/L 
(Potron et al., 2013; Al-Marzooq et al., 2015; Bousquet et al., 2014). Despite the 
raised MIC for carbapenems, kinetic studies show that OXA-232 actually 
hydrolyses carbapenems less efficiently compared to other OXA-48-like variants 
(Oueslati et al., 2015). The presence of a truncated ΔISEcp1 insertion element 
upstream of the blaOXA-232 gene that provides a strong -35 and -10 promoter 
sequence on a high copy number plasmid (Poirel et al., 2003) and is required to 
mediate phenotypic resistance as seen in our isolates. 
 
OXA-48 producing CRE are most prevalent in Europe, the Mediterranean and 
North Africa (van Duin and Doi, 2017). Multiple reports of nosocomial outbreaks 
have seen OXA-48 K. pneumoniae of various sequence types reported in European 
hospitals, a problem that is often exceptionally difficult to control (Semin-Pelletier 
et al., 2015). In terms of pathogenicity, the carriage of a number of virulence 
factors has been associated with more invasive and severe infections (Rodrigues 
et al., 2016). In a study done by Holt et al., ST 231 MDR K. pneumoniae clone 
acquiring yersiniabactin (ybt) and aerobactin (iutA) genes was associated with 
lethal cases of community-acquired pneumonia (Rodrigues et al., 2016). 
Additionally, in our preliminary studies using isolate OXA-232 producing K. 
pneumoniae, KP41 (2015) ST 231 clone in the G. mellonella infection model 
showed marked virulence when compared to PBS control (data unpublished). 
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In Southeast Asia, OXA-48 case has been reported only in Vietnam (Al-Marzooq et 
al., 2015). However, cases of OXA-232 have been found in Singapore (ST 231) (Teo 
et al., 2013), Malaysia (ST 14) (Al-Marzooq et al., 2015) and South Korea (Jeong et 
al., 2015; Kwon et al., 2016). A number of these strains also carried the New Delhi 
Metallo-β-lactamase (NDM-1) often from patients with a history of travel and 
medical treatment in India (Al-Marzooq et al., 2015). A retrospective study in 
Thailand between March 2012 and September 2016 identified CRKP isolates that 
harbour OXA-232 and a few co-harbouring OXA-232 and NDM-1 (Laolerd et al., 
2018). However, as with the OXA-232 K. pneumoniae case recovered in Brunei, 
patients were hospitalized locally, and no history of recent travel could be 
obtained.  
 
There are several reports of OXA-232 case outside of Southeast Asia; K. 
pneumoniae isolates producing both OXA-232 and NDM-1 have been recovered 
in the USA (Doi et al., 2014) and France (Potron et al., 2013; Bousquet et al., 2014). 
Most belonged to ST 14, a sequence type common amongst NDM-1 producing K. 
pneumoniae recovered in Europe (Teo et al., 2013). In Germany, an OXA-232 and 
NDM-1 was reported in an E. coli strain (Rodrigues et al., 2016) with the same 
patient subsequently developing an infection with OXA-232 producing K. 
pneumoniae months later, suggesting in-vivo plasmid transfer between species 
(Rodrigues et al., 2016). In Mexico City, Enterobacteriaceae producing OXA-232 in 
combination with CTX-M-15 ESBLs were reported during surveillance studies in 
tertiary care hospitals (Torres-Gonzalez et al., 2015). However, the molecular 
 
 
352 
analysis did not identify evidence of clonal spread in this setting, again suggesting 
inter and intra-species transmission of plasmid-mediated resistance (Torres-
Gonzalez et al., 2015). In Mexico City, seven consecutive cases non-clonal 
Enterobacteriaceae isolates causing different clinical infections in a third-level 
paediatric hospital over four months period during April–July 2016 were reported 
(Aquino-Andrade et al., 2018). The OXA-232 was recovered from E. coli co-
harbouring CTX-M-15 (ESBL) (Aquino-Andrade et al., 2018). 
 
In Tunisia, Lahloui et al. recovered 11 CRKP clinical isolates in 2015, 8 were 
harbouring OXA-48, and 3 produced OXA-232 (Lahlaoui et al., 2017). All three 
OXA-232 isolates co-harbour other resistance determinants including CTX-M-15 
(ESBL), SHV-11 (penicillinase), aadA2 (aminoglycoside), qnrB1 (quinolone), fosA-
like (Fosfomycin), sul1 (sulphonamide) and dfrA12 (trimethroprim) and belonged 
to sequence type, ST147 (Lahlaoui et al., 2017). K. pneumoniae ST147 has been 
identified previously from Tunisia associated with NDM-1 and OXA-204 
carbapenemase genes (Izdebski et al., 2015; Grami et al., 2016). Additionally, 
ST147 has also been identified in Egypt associated carrying the NDM-1, USA 
(NDM-5) and South Korea (NDM-7) (Lee et al., 2014; Shin et al., 2016). 
 
An isolate similar to the clone found in our study, was reported in Switzerland by 
Mancini et al. (Mancini et al., 2018) where 6 CRKP clinical isolates were recovered 
from February to April 2017 from five different patients. Four CRKP clinical isolates 
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produced OXA-232 with blaCTX-M-15 and blaTEM-1b resistance gene and only two had 
blaCTX-M-15 and blaTEM-1b resistance genes (Mancini et al., 2018). However, all six 
CRKP clinical isolates belonged to sequence type, ST231 (Mancini et al., 2018). 
Sequencing of 16S rRNA aminoglycoside resistance genes revealed that all isolates 
possessed rmtF 16S rRNA methyltransferase gene (Mancini et al., 2018) but 
remained susceptible to ceftazidime/avibactam (Mancini et al., 2018). This is the 
first occurrence of the MDR ST231 clone in Europe (Mancini et al., 2018). A Similar 
ST231 clone has since been observed in a Polish hospital, from a patient previously 
hospitalized in Oman (Izdebski et al., 2018). 
 
With regards to the mobility of the blaOXA-232 gene in carbapenemase-producing 
Klebsiella pneumoniae in ST15 isolates from China (Yin et al., 2017a) and the Czech 
Republic (Skalova et al., 2017), it was localised to a ColE-type conjugative plasmid 
of 6,141 bp (Yin et al., 2017a). Others have found this gene to be readily 
mobilizable including studies in China and the Czech Republic (Potron et al., 2013; 
Jeong et al., 2015; Kwon et al., 2016; Rodrigues et al., 2016;  Skalova et al., 2017; 
Yin et al., 2017a). In our study, the blaOXA-232 gene was also localised to a ColE-
like plasmid, similar plasmid to the novel OXA-232 that was only very recently 
isolated in France from Enterobacteriaceae of patients who had travelled to India 
(Potron et al., 2013) and from patients in Singapore (Teo et al., 2013). 
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However, in our study, we were unable to demonstrate the transfer of blaOXA-232 
associated with ColE plasmids by conjugation with multiple recipients. Again, 
highlighting the issue of the spread of OXA-232 mediated resistance via the 
success of the ST231 clone rather than promiscuity of ColE plasmids. 
 
In summary, the ST 231 clone of K. pneumoniae is increasingly shown to support 
the carriage of a number of important β-lactamases and diverse plasmid 
backbones which include KPC-3, GES-5, SHV-12 Portugal, (Rodrigues et al., 2016) 
NDM-1-like reported in the UK and India (Teo et al., 2013) and CTX-M-15, TEM-1, 
TEM-1b, SHV-like reported in Switzerland  and Poland. (Mancini et al., 2018) 
(Izdebski et al., 2018) Currently, OXA-48-like carbapenem-hydrolyzing class D β-
lactamases is circulating in Southeast Asia.  
 
Therefore K. pneumoniae ST 231 may represent an emerging high-risk multi-drug 
resistant clone currently disseminating throughout Southeast Asia. Hence, it is 
important for enhanced surveillance for the international spread of this clone due 
to its capacity for the carriage of diverse and multiple ESBL and carbapenemase 
resistance genotypes. The introduction of OXA-48 K-SeT lateral flow assay would 
be an ideal screening tool for surveillance in carbapenem-resistant K. pneumoniae 
not only in Brunei Darussalam but also in other countries with this problem. 
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6.4 Surveillance and prevalence of plasmid-mediated polymyxin 
resistance in E. coli isolates from Brunei Darussalam 
6.4.1. CHROMagar COL-APSE for the isolation and detection of colistin resistance 
Gram-negative pathogens 
Selective culture media have been developed for the detection of colistin-
resistant Enterobacteriaceae due to the current emergence of mcr-like genes. A 
sensitive and selective culture media is an important tool in antimicrobial 
resistance surveillance.  
 
In this study, CHROMagar COL-APSE media was developed for the isolation and 
identification of colistin-resistant Gram-negative bacteria. CHROMagar COL-APSE 
was further evaluated and compared against SuperPolymyxin media (Nordmann 
et al., 2016b). An alternative media developed for screening and isolation of 
polymyxin-resistant Gram-negative bacteria. 
 
Both media were able to support the growth of COL (colistin) resistant Gram-
negative bacteria while suppressing COL resistant Gram-positive pathogens. The 
inoculum (clinical isolates) required to support the growth of all COL resistant 
strains was as low as 101 CFU. However, the growth of only 86% (50/58) of E. coli 
mcr-1 isolates was supported on SuperPolymyxin at 101 CFU, suggesting it may 
have lower sensitivity in the detection of these strains. Interestingly, 
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SuperPolymyxin was able to suppress the growth of all COL-susceptible 
Salmonella spp. (colistin MIC ranges from 0.5 – 2 mg/L). While CHROMagar COL-
APSE was not able to suppress the growth of 1 Salmonella spp. isolate (colistin 
MIC of 2 mg/L). Agerso et al. (Agerso et al., 2012) reported reduced susceptibility 
to polymyxins in Salmonella Enteritidis and other serogroup 9 strains within the 
epidemiological cut-off (> 2 mg/L) according to EUCAST, henceforth the definition 
of resistance in this species has been challenged. Although the mechanisms of 
polymyxin resistance in Salmonella spp remain unknown; a more sensitive 
medium may help in the recovery of COL resistant strains and aid in the 
elucidation of novel resistance mechanisms. 
 
We developed and evaluated the CHROMagar COL-APSE media for the isolation 
and identification of COL resistant Gram-negative bacterial pathogens. It was 
observed that CHROMagar COL-APSE was similar to SuperPolymyxin media for 
selective growth of COL resistant organisms. However, CHROMagar COL-APSE was 
found to be slightly more sensitive in the detection of Enterobacteriaceae 
producing MCR-1 and provides the benefit of presumptive chromogenic 
identification. Furthermore, the LLD of 101 CFU for both medium, suggests either 
could be used to confirm polymyxin resistance in organisms recovered from other 
growth media or if employed as a primary isolation medium.  
 
In this study we observed differences in the growth of P. aeruginosa ATCC 27853 
on both media, where CHROMagar COL-APSE showed a lower limit of detection 
(LLD) of 102 CFU when compared to SuperPolymyxin which required 105 CFU. This 
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is most likely due to the heteroresistant properties of this strain and a high 
frequency of COL resistance by spontaneous mutation (Li et al., 2006b). In A. 
baumannii strains, there was also the differential ability of CHROMagar COL-APSE 
and SuperPolymyxin to identify heteroresistant strains, and this may be due to a 
synergy between the selective antimicrobials in the media (Phee et al., 2013). The 
clinical relevance of heteroresistant to polymyxins is still unclear, although the 
ability to identify such strains maybe useful in optimizing or selecting COL based 
therapies on an individual basis.    
 
Of note, the addition of PNPG in our media was beneficial in suppressing the 
swarming of colistin-resistant Proteus spp without affecting the performance of 
the media. Hence, this media may provide a more robust means of selecting out 
COL resistant isolates within mixed specimens. 
 
More recently, another selective culture medium, LBJMR (Lucie Bardet-Jean-Marc 
Rolain), has been described, for the detection of colistin-resistant Gram-negative 
bacteria, including Enterobacteriaceae strains harboring the mcr-1 gene and also 
isolation of vancomycin-resistant Gram-positive bacteria (Bardet et al., 2017). 
Bardet et al. (Bardet et al., 2017) have included detection of vancomycin-resistant 
enterococci isolates in their media due to the increasing prevalence of this 
pathogen in Europe (Mendes et al., 2016), especially Enterococcus faecium, and 
causing nosocomial infection in the USA (Reyes et al., 2016) with high mortality 
rate due to their dissemination (Chiang et al., 2017). 
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LBJMR medium was then evaluated against SuperPolymyxin media, similar 
sensitivity with LBJMR was observed for Enterobacteriaceae for all colistin 
resistant strains with a detection limit of 101 CFU, including the 30 mcr-1 strains 
tested, and the inhibition of all susceptible strains (Bardet et al., 2017). 
Additionally, 68 stools samples (56 humans and 10 chickens from different 
countries; 2 VRE clinical isolate from La Timone Hospital) that were previously 
screened for mcr-1 by RT-PCR (56 positive and 10 negative) were evaluated 
(Bardet et al., 2017). The results for growth of colistin-resistant isolate with mcr-
1 were similar for both media (Bardet et al., 2017). As with the detection of 
colistin-resistant non-fermentative Gram-negative strain, higher sensitivity was 
observed on LBJMR than SuperPolymyxin medium (Bardet et al., 2017).  
Furthermore, all VRE strains were detected on LBJMR and not on SuperPolymyxin 
medium because of the presence of daptomycin (Bardet et al., 2017). However, 
LBJMR and CHROMagar COL-APSE medium performances have yet to be assessed. 
 
In this study, the differentiation of colistin-resistant Enterobacteriaceae based on 
colour compared to SuperPolymyxyin and LBJMR medium, CHROMagar COL-APSE 
showed better differentiation. Additionally, Proteus sp. swarming was inhibited 
by all three media. CHROMagar COL-APSE uses PNPG for inhibition while LBJMR 
inhibited Proteus sp. swarming due to the composition of the media which is 
deprived of electrolytes. In contrast to SuperPolymyxin medium, the inhibition 
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compound for Proteus sp. swarming was not clearly stated. The lower limit of 
detection was similar for all media 101 CFU. Heteroresistant strains were able to 
be identified with CHROMagar COL-APSE, however, warrants further testing for 
all medium. 
In summary, the CHROMagar COL-APSE, SuperPolymyxin and LBJMR media will be 
ideal for under-resourced laboratories due to their lower cost as initial screening 
tools (Osei Sekyere, 2018). Although molecular methods that can identify mcr-like 
genes in samples are available, they are more expensive, require advanced skill 
and in most cases, cannot detect resistant strains with novel resistance 
mechanisms or chromosomal mutations-mediated resistance (Osei Sekyere, 
2018). Furthermore, the presence of mcr-like genes does not always translate 
phenotypically into colistin resistance (Nordmann et al., 2016a; Nordmann et al., 
2016b; Bardet et al., 2017). More importantly, these culture media will act as tools 
for the surveillance and quick recovery of isolating COL resistant bacteria from 
complex human, veterinary and environmental samples. 
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6.4.2 Surveillance of MCR-1 in poultry farms and human clinical faecal samples  
A very high prevalence of E. coli mcr-1 isolate was identified from poultry farms 
58% recovered from 300 ceacal samples (174/300) and 41.7% in human clinical 
faecal samples (106/254).  
 
Around Southeast Asia, Malaysia has reported E. coli mcr-1 isolates in 16% (5/31) 
animal, 1% (1/95) in humans and 40% (2/5) in the environment (Yu et al., 2016). 
These results were obtained retrospectively from in silico screening of more than 
900 bacterial isolates from human, animal and environmental sources collected 
from different states in Malaysia, some of which have been archived since 2009 
(Yu et al., 2016). The MICs of colistin for the E. coli mcr-1 positive isolates range 
from 8- 12 mg/L determined by agar dilution method (Yu et al., 2016). Clonal 
diversity was observed in all isolates analysed by pulsed-field gel electrophoresis 
(PFGE); ST744 in the human clinical sample and ST3489, ST3014, ST410, ST117 
from animal and environmental sample (Yu et al., 2016). Additionally, S1 
nuclease–PFGE analysis further revealed the presence of multiple plasmids in all 
isolates (Yu et al., 2016). This correlates with the detection of different types of 
plasmid replicons in the draft genomes (Yu et al., 2016). Co-resistance were 
observed with aminoglycosides, fluoroquinolones, florfenicol, sulphonamides, 
tetracyclines and trimethoprim (Yu et al., 2016). More importantly, the presence 
of the florfenicol resistance gene floR was reported in all of the isolates, including 
the human isolate (Yu et al., 2016). Hence, the importance to regulate antibiotic 
 
 
361 
use in animal husbandry to prevent an animal-to-human transfer of resistance (Yu 
et al., 2016). 
 
In Singapore, two E. coli mcr-1 isolates (EC249 and EC362) were isolated from 
human clinical samples (surveillance rectal swab and intraoperative sacral sore 
tissue) from patients admitted into different wards in a public tertiary care 
hospital with a range of comorbidities (Teo et al., 2016). Patients had no travel 
history, previous hospital admission with only exposure to broad spectrum 
antibiotics and none had prior receipt of polymyxin B (Teo et al., 2016). 
 
One patient was associated with E. coli (EC362) infection (Teo et al., 2016). 
Interestingly, these patients were infected or colonized with other 
Enterobacteriaceae before/after the isolation of the index mcr-1 positive isolates 
(Teo et al., 2016). Additionally, these E. coli mcr-1 isolates also co-harboured 
blaKPC-2 (Teo et al., 2016). Analysis of mcr-1 neighbouring region revealed the mcr-
1-pap2 element was present in all isolates (Teo et al., 2016) similar to our studies. 
However, the ISApI1 mobile element was observed only in EC362 (Teo et al., 2016) 
which has been suggested by several studies that the ISApI1 may not always be 
associated with mcr-1 (Liu et al., 2016; Ye et al., 2016). The nikB gene was only 
present in EC249 (Teo et al., 2016). 
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In Thailand, 317 non-duplicate colistin-resistant Enterobacteriaceae clinical 
isolates (37 E. coli and 280 K. pneumoniae) were screened by PCR for the mcr-1 
gene (Eiamphungporn et al., 2018). 29.7% (11/37) were positive for mcr-1 in E. 
coli isolates with colistin MIC of 4-32 mg/L whilst only 1.4% (4/280) mcr-1 positive 
in K. pneumoniae (Eiamphungporn et al., 2018). 
 
In Laos, Olaitan et al. have reported the presence of E. coli mcr-1 gene in 6 human 
clinical samples (colistin MICs 6 to 12 mg/L) and 3 in pigs (colistin MICs 4 to 6 mg/L) 
(Olaitan et al., 2016a). In another study, Malhotra-Kumar et al. screened 24 
Extended-Spectrum β-lactamase (ESBL, blaCTX-M) harbouring E coli recovered 
from 22 rectal swabs taken from chickens on two farms in the Van Lam district of 
the Hung Yen province, and from a pig farm and a pig slaughterhouse located in 
the Hoai Duc region of the Hanoi province, Vietnam (Malhotra-Kumar et al., 2016). 
37.5% (9/24) of ESBL E. coli ESBL strains were positive for mcr-1, six were isolated 
from the rectal swabs of pigs on the farm, one from a rectal swab from a pig about 
to be slaughtered, and two strains from swabs collected from the lairage area of 
the slaughterhouse (Malhotra-Kumar et al., 2016). However, the media for 
screening of the rectal swabs was not stated. The MICs for colistin in all 9 strains 
by macrobroth dilution were 4 or 8 mg/L (Malhotra-Kumar et al., 2016). MCR-1 
sequence showed 100% similarity to the gene reported in China (Liu et al., 2016). 
In our study, the prevalence of ESBLs reported phenotypically (cefpodoxime 10 
µg, as marker) versus WGS analysis data in chickens are 52% and 23% while in 
humans 11% and 8% a higher rate of ESBLs in colistin-resistant E. coli strains 
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isolated from chicken than in humans. However, two-sample independent t-test 
(performed on Microsoft Excel for Mac, Version 16.20) of ESBL genes carried in 
colistin-resistant E. coli strains isolated from chickens and humans (WGS analysis 
results) showed the difference was not associated with a statistically significant 
effect, t (50) = 1.54, p = 0.06. 
 
Outside of Southeast Asia, China where mcr-1 was first reported by Liu et al., 
clinical isolates (902 E coli and 420 K pneumoniae) recovered from two tertiary 
hospitals in Guangdong and Zhejiang provinces were screened retrospectively, 
while samples were collected from pigs at slaughter and recovered 804 isolates 
and 523 isolates from raw meat (Liu et al., 2016). All isolates were screened for 
the presence of mcr-1 gene, to understand the spread of mcr-1 in food animals 
and food (Liu et al., 2016). The prevalence of mcr-1 in animals was shown to be 
much higher than in human clinical isolates and mostly reported in E. coli isolates 
(Liu et al., 2016). The number of E. coli mcr-1 positive isolates were as follows; pigs 
at slaughter 20.6% (166/804), retail meat 14.9% (78/523) and humans inpatient 
1.4% (13/902) while 0.7% (3/420) from inpatient in K. pneumonia isolates (Liu et 
al., 2016). Since then, further reports of mcr-1 from China has been observed from 
human clinical isolates (Li et al., 2018a; Li et al., 2018b), animals (Liu et al., 2019) 
and the environment (Shen et al., 2018). 
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In the United Kingdom, Doumith et al. identified 15 isolates with the mcr-1 gene 
(13 isolates from 12 humans and 2 isolates from poultry meat) from genome 
sequences screening of >24000 Salmonella, E. coli, Klebsiella spp., Enterobacter 
spp., Campylobacter spp. and Shigella spp. from human and food isolates from 
the Public Health England (PHE) sequence archive (Doumith et al., 2016). These 
15 isolates include 10 unrelated Salmonella from human gastrointestinal 
infections submitted between 2012 and 2015 (8 Salmonella Typhimurium isolates, 
1 isolate of Salmonella Paratyphi B var Java and 1 isolate of Salmonella Virchow); 
2 isolates of Salmonella Paratyphi B var Java phage type Colindale from poultry 
meat imported from the EU and 3 isolates of E. coli from 2 patients (Doumith et 
al., 2016). The colistin MICs of 14 mcr-1 positive isolates range from 4-8 mg/L 
(Doumith et al., 2016). Unfortunately, one negative E. coli mcr-1 isolate by PCR 
after recovery from storage was now colistin susceptible (MIC 1 mg/L), hence 
suggestive of plasmid loss (Doumith et al., 2016). 
 
Other resistance determinants were reported in three of the E. coli isolates which 
include CTX-M-27 or CTX-M-14 and one of the Salmonella spp. isolates produce 
blaCMY-2 (Doumith et al., 2016). Chromosomal colistin resistance caused by 
mutations in the pmrAB, phoPQ and mgrB genes were not observed in all the 15 
mcr-1 positive isolates (Doumith et al., 2016). 
 
In France, the prevalence of E. coli mcr-1 in livestock (turkey, broiler and pigs) from 
2007-2014 were 1.6% (23/1045) (Perrin-Guyomard et al., 2016). As with Germany, 
the prevalence of mcr-1 in German broilers from 2010 to 2014 were 6.7% (total 
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number of isolates investigated n=2,555 and total number of mcr-1 positive 
isolates, n=173) (Irrgang et al., 2016). Additionally, in the Netherlands, mcr-1 was 
detected at low prevalence in E. coli isolates from livestock (<1%) (Veldman et al., 
2016). 
 
Looking at all these reports from various countries, our study has reported the 
highest rate of E. coli mcr-1-like genes isolated from animals and human clinical 
samples. Furthermore, out of 162 colistin-resistant E. coli isolates (60 from 
chickens and 102 from humans) that were RAPD typing, 52 distinguishable profile 
were observed showing considerable diversity. Interestingly, there were clones 
(ST48, ST115, ST117, ST359, ST1011 and ST1642) found in chicken that was also 
present in humans. Hence, there might be a possible movement of resistance 
between livestock and human populations, although such studies have not been 
established (Woolhouse et al., 2015). However, one study showed by WGS 
analysis, methicillin-resistant Staphylococcus aureus (MRSA) lineage with clonal 
complex, CC97 has entered the human population from a livestock source on 
more than one occasion over the past 100 years (Spoor et al., 2013). In another 
study, there is evidence of S. aureus CC398 from livestock-to-human jumps have 
occurred more frequently human-to-livestock jumps over the evolutionary history 
of that lineage (Ward et al., 2014). In our study, there is a possible movement of 
clones through the food-borne route, although this warrants further investigation.  
 
The ST48 clone (part of a clonal complex, CC10, that differs from ST10 by only a 
single nucleotide) in E. coli mcr-positive has been reported from hospital sewage 
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and human clinical samples in China and Switzerland, respectively (Zhao et al., 
2017; Zurfluh et al., 2017). E. coli MCR-1 belonging to ST115 has been reported in 
animals from Germany, Denmark, Slovakia and United States and only one human 
case from Denmark (Drali et al., 2018). With regards to the environment, ST115 
was reported in E. coli mcr-1 reported in sea water of Algiers coast and ST359 from 
river water in Switzerland (Zurfuh et al., 2016; Drali et al., 2018). The ST117 and 
ST1011 clones were reported in clinical E. coli mcr-1 isolates from New York and 
Egypt, respectively (Elnahriry et al., 2016; Macesic et al., 2017). Interestingly, 
ST117 was observed in diseased chickens from China (Ding et al., 2018). From 
another study, ST1011 was reported in E. coli strains co-harbouring mcr-1 and 
blaNDM from chickens in China (Liu et al., 2017). Again, in China, ST1642 was seen 
in ESBL-producing E. coli (CTX-M-65) in well water which a primary source of 
irrigation water and drinking water for humans and farm animals (Sun et al., 
2017b). Therefore, ST48, ST115, ST117, ST359, ST1011 and ST1642 are important 
clones as it exists in all three compartments (humans, animals and environment), 
that warrants further investigation. 
 
In our study, we also identified different plasmid backbones for mcr-1-like (IncI2, 
IncHI2 and IncX4), in all colistin-resistant E. coli isolates although the localization 
of mcr-1-like genes was not performed for all but only one in E. coli (EC C22) 
isolated from chickens that were located on IncI2 plasmid, similar to the plasmid 
replicon type reported in China (Liu et al., 2016). 
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Additionally, the predicted serotypes from WGS in our studies did not show the 
classical Enterohemorrhagic E. coli with serotype O157:H7 which is major 
foodborne pathogen causing severe disease in humans worldwide (Lim et al., 
2010). Serotype O157:H7 is usually associated with Shiga toxins genes (stx1 or stx2) 
(Lim et al., 2010). However, in our study, there are two E. coli mcr-1-like isolates 
from humans that express somatic (O) antigen 157 but different flagella (H) 
antigen, H16 (E. coli 61, ST1011) and H9 (E. coli 124, ST1011). Interestingly, these 
two E. coli isolates did not acquire the Shiga toxin genes. Virulence factor genes 
were diverse for all the colistin-resistant E. coli isolates. In silico ClermoTyping 
have shown some phylotypes belonged to Extra-intestinal pathogenic E. coli 
(ExPEC), which clusters mostly in groups B2 and D, showing a link between 
phylogeny and virulence (Escobar-Paramo et al., 2004). In chickens, 4% B2 (1/26) 
and 23% D (6/26) while in humans, 4% B2 (1/26) and 31% D (8/26) phylotypes 
which shows most of our isolates were commensals. Despite these findings, there 
were discrepancies in the results for colistin-resistant E. coli isolated from chickens 
obtained by PCR. Although the PCR used was only for detecting phylogenetic 
groups A, B1, B2 and D (Clermont et al., 2000). Phylotype groups B2 and D were 
observed in our study, the pathogenicity also depends on other factors such as 
virulence factors, resistance determinants and plasmid types and this could not 
be disregarded. Additionally, these chickens were healthy when sampling was 
carried out. In contrast, the sampling of human faecal samples was done without 
the patient’s data and diagnosis. 
 
 
 
368 
Serotyping of O antigens was performed on 46 colistin-resistant E. coli isolates 
from chickens using antisera pools specific for human enterotoxigenic E. coli 
(ETEC) (O11, O20, O21, O27, O32, O48, O78, O80) and invasive O serotypes 
common to poultry, pigs and sheep (O10, O18ab, O35, O83, O87, O95, O116, 
O120). Out of 19 negative colistin-resistant E. coli isolates tested with human ETEC 
O serotype, a discrepancy was seen in one isolate (E. coli A8) where the predicted 
serotype was O21. Hence false negative result was observed with the 
conventional serotyping. Similarly, with the invasive O serotype, another false 
negative result was seen with one of the negative colistin-resistant E. coli isolates 
(E. coli A28), where the predicted serotype showed O18. In contrast, six positive 
colistin-resistant E. coli isolates were tested for invasive O serotype, discrepancies 
were seen with WGS predicted O antigen serotypes (O168, O33, O45, O134, 
O17/77, and O37) that are not present in the invasive O serotype pool. Joenson 
and colleagues (Joensen et al., 2015), have shown in silico serotyping (on the basis 
of WGS data by SerotypeFinder) of E. coli isolates was more superior to 
conventional serotyping in terms of reproducibility, discriminatory and definitive 
power. However, discrepancies were seen and caused by several factors such as 
cross-reactions of O groups phenotypically, suspected transcription errors or 
typing mistakes, isolates had to be conventionally retested, poor sequence data 
and assemblies (Joensen et al., 2015). Therefore, in our study, the negative 
isolates performed conventionally and predicted to be positive by WGS, requires 
further conventional serotyping of specific individual O-antisera. The 
discrepancies with the positive isolates performed by conventional methods 
against the predicted serotype would rule out cross-reaction of the O groups. 
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The phylotypes of colistin-resistant E. coli isolates in our study were mostly 
commensals and few belonged to Phylogroup B2. However, discrepancies were 
observed using triplex PCR phylogroup and in silico ClermonTyping methods. The 
differences in the result could be due to not performing the updated PCR 
Phylogroup version which include additional Phylogroups C, E and F (Clermont et 
al., 2013). In contrast, given the high accuracy with in silico ClermonTyping, 
discrepancies have been reported resulting from SNPs in the primers, horizontal 
gene transfer, strain contamination and insertion elements (IS1) (Beghain et al., 
2018). 
 
There is one E. coli mcr-1 isolated from humans (EC 84) in our study predicted by 
WGS to carry the vanC1XY resistance gene cluster, which is an intrinsic gene found 
on the chromosome of Enterococcus gallinarum (Reynolds et al., 1999). Although 
there have not been any studies that show such genes can be acquired by an E. 
coli isolate, hence this could be contamination (mixed culture) when sending this 
isolate for WGS. 
 
Additionally, the fosA-like gene was found more abundant in colistin-resistant E. 
coli isolated from chickens than in humans. This is shown with independent 
samples t-test (performed on Microsoft Excel for Mac, Version 16.20) associated 
with a statistically significant effect, t (50) = 4.12, p = 0.00007. Thus, the acquired 
fosA-like genes in E. coli mcr-1-like isolates were associated with a statistically 
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significant larger mean value in chickens (mean, M= 0.81, standard deviation, SD= 
0.40) than in humans (M= 0.31, SD= 0.47).  
 
Hence, from all these findings, they may be a possible movement of resistance 
from animals to human which represents a public health concern. Given the high 
rate of MCR-1 in poultry, it could serve as a reservoir for the spread of plasmids 
harboring resistance and virulence genes through the food chain which warrants 
further investigation. 
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6.4.3. Novel MCR-1.8 variant recovered in E. coli isolate from chicken caecal 
samples 
Polymyxins are among the earliest antimicrobial agents described, yet they are 
increasingly being relied upon as therapies of last resort in the treatment of Gram-
negative infections (Olaitan et al., 2014). Polymyxin resistance is well known to be 
intrinsic to some bacterial species, however, recently polymyxin resistance has 
been shown to spread via plasmid-mediated mechanisms and has subsequently 
spread across the globe (Di Pilato et al., 2016; Liu et al., 2016; Xavier et al., 2016; 
Borowiak et al., 2017; Carattoli et al., 2017; Hernandez et al., 2017; Ling et al., 
2017; Litrup et al., 2017; Roer et al., 2017; Yin et al., 2017b; Fukuda et al., 2018; 
Wang et al., 2018a). The most widespread plasmid-mediated resistance 
determinants are PEtN enzymes (MCR-like) that modify native LPS and reduce the 
binding affinity of polymyxins and other antimicrobial peptides (Olaitan et al., 
2014). We identified a novel gene variant mcr-1.8 in a plasmid carried by an avian 
E. coli strain. This variant was located on a unique IncI2 like plasmid in a MDR E. 
coli sequence type (ST) 101 isolate.  
 
E. coli C22 isolate was obtained as part of a surveillance study (2017), pre-
slaughter from healthy birds. Screening of this isolate by PCR revealed a variant 
with a single non-synonymous nucleotide difference (A8G) identified as mcr-1.8. 
Colistin and polymyxin B MICs were 8 mg/L and 12 mg/L, respectively. When mcr-
1.8 was cloned and expressed in E. coli TOP10 under the native promoter, colistin 
and polymyxin B MICs were increased by 4- to 16- fold, clearly implicating the 
functionality of this enzyme in E. coli.   
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MCR 1.8 was encoded by pEC-MCR1.8, a 63,056 bp with an IncI2 replicon. Apart 
from IncI2, mcr-1 has been observed in IncHI2 and IncX4 (Matamoros et al., 2017). 
Plasmid pEC-MCR1.8 also encodes a typical conjugative (tra) and pilus (pil) 
apparatus for its mobilisation and transfer, as well as both hicA/B and stbD/E toxin 
/antitoxin modules involved in maintenance and plasmid stability. Both pEC-
MCR1.8 and polymyxin resistance was readily transferable to susceptible strains 
of E. coli J53 with a high frequency for in vitro transfer (10-4 t/d). Similarly, reports 
of the mcr-1.2 gene carried by IncX4 plasmids are highly transferable by 
conjugation to E. coli J53 with a frequency of 5 x105 (t/r) (Di Pilato et al., 2016). 
This suggests pEC-MCR1.8 could readily be transferred to susceptible strains in 
nature and has the potential to spread into key human pathogens.  
 
Levels of polymyxin resistance mediated by PEtN are moderate (MIC 2 – 4 mg/L) 
when compared with those seen in isolates with chromosomal (phoP/Q, pmrA/B) 
mechanisms of resistance (Liu et al., 2016; Olaitan and Li, 2016; Jeannot et al., 
2017). A recent study by Yang et al. highlighted amino acid substitutions in PmrA 
(R81S) (Quesada et al., 2015) and PmrB (V161M) (Sun et al., 2009) were 
responsible for reducing susceptibility to colistin in E. coli (Yang et al., 2017). In 
C22, we found mutations in phoP/Q and pmrA/B that are predicted to encode the 
amino acid changes I44L (phoP), I165F (phoQ), S29G (pmrA), D282G and Y358N 
(pmrB). These substitutions have not previously been linked with reduced 
susceptibility to polymyxins in E. coli, but D282G and Y358N are predicted to occur 
in the ATP binding domain of pmrB in Salmonella spp (Sun et al., 2009) and could 
contribute to polymyxin resistance.  
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Immediately downstream of mcr-1.8 was the pap2 gene predicted to encode a 
membrane-associated phosphatase enzyme, an enzyme that catalyses the 
removal of terminal phosphate groups from lipid carriers essential in the transport 
of hydrophilic small molecules across the outer membrane (Fan et al., 2014). The 
role of PAP2-like phosphatases in polymyxin resistance is unclear, although a 
study by Zurfluh and colleagues suggests that plasmid encoded PAP2 does not 
influence susceptibility to polymyxins (Zurfluh et al., 2016). 
 
In silico analysis of the resistome of C22 revealed co-carriage of many other 
plasmid-mediated resistance genes. Additionally, fosfomycin- (fosA4) and 
sulfonamide-resistance (sul3) that were localised to a HI mulitreplicon (HIA, HIB 
and FIA) plasmid could not be transferred to E. coli J53 by conjugation (data not 
shown) and we were unable to transfer co-resistance to any other antimicrobial 
following selection on sodium azide/colistin supplemented media. Highlighting 
that the mcr-1.8 gene was localized solely to pEC-MCR 1.8. 
 
E. coli C22 was assigned to ST101. This sequence type, associated with polymyxin 
resistance has been reported across Korea (Yoo et al., 2013), China (Yang et al., 
2017) but also in Brazil (Fernandes et al., 2016). In one report originating from 
Brazil (Fernandes et al., 2016), E. coli ST101 carrying mcr-1 on a highly 
transmissible IncX4 plasmid was isolated from a patient with a 2-month history of 
a right calcaneal ulcer. Polymyxin resistant E. coli ST101 isolates with mcr-1 were 
also recovered from retail meats on sale in a traditional market in Taiwan (Kuo et 
al., 2016). Of more concern, are reports that highlight the potential for E. coli 
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ST101 to act as a strain able to carry additional resistances including to 
carbapenems (NDM-1)  (Yoo et al., 2013). This suggests that ST101 could represent 
a hi-risk clone able to promote global dissemination of polymyxin and multi-drug 
resistance in E. coli.  
 
It is unclear whether modification of PEtN will attenuate or enhance virulence as 
well as generating resistance. John et al. found phosphoethanolamine and sialic 
acid substitutions to be more common amongst invasive strains of Neisseria 
meningitidis suggesting that PEtN lipid A modification may promote virulence 
(John et al., 2016). Colistin resistance due to an mgrB mutation was also shown to 
enhance the virulence of Klebsiella pneumoniae by decreasing the affinity for 
colistin and attenuating the host immune response (Kidd et al., 2017). In contrast, 
a study done by Yang et al. in which mcr-1 producing plasmids were transferred 
into susceptible strains of E. coli of different STs, virulence in animal models was 
markedly depleted (Yang et al., 2017). MCR-1 was shown to provide a significant 
fitness cost on E. coli both by impairing cell growth and alteration of the cellular 
architecture despite conferring resistance to polymyxins (Yang et al., 2017). 
 
Plasmid-encoded PEtn enzymes, able to mediate clinically relevant levels of 
polymyxin resistance in Enterobacteriaceae are an alarming development in the 
evolution of the problem of antimicrobial resistance (AMR). Although only 
recently identified as a novel mechanism of antimicrobial resistance (Liu et al., 
2016), 15 functional variants of the MCR-1 enzyme have now been described, 
including the mcr-1.8 allele encoded by the pEC-MCR1.8 plasmid that was 
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characterised here. This highlights the need for continual and enhanced 
surveillance for both the plasmids, host strains and bacterial species able to 
support the success and dissemination of this resistance determinant. Given 
existing knowledge of the global epidemiology of MCR-producing strains this may 
be particularly important for countries in Southeast Asia.  
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6.5 Comparative virulence of avian and human origin in Galleria 
mellonella model 
The G. mellonella infection model has been used to study virulence and treatment 
combinations over a range of a clinically relevant bacterial and fungal pathogen 
(Junqueira, 2012; Hornsey et al., 2013a; Wei et al., 2017; Betts et al., 2017).  
 
Heterogeneity in all forty colistin-resistant E. coli strains (resistance gene 
determinant, sequence type (ST), serotype, phylotype, virulence factor and 
plasmid replicon types) isolated from chickens and humans have shown 
differences in G. mellonella killing. Of note, acquiring antibiotic resistance genes 
by mutation or horizontal gene transfer may impact on the fitness cost (Andersson 
and Levin, 1999; Andersson and Hughes, 2010; Vogwill and MacLean, 2015). 
Additionally, Yang and colleagues have shown mcr-1 can impose a fitness cost on 
its E. coli hosts whereby increased expression of mcr-1 not only impaired cellular 
growth but diminished bacterial fitness and results in the critical changes in 
cellular architecture lethal to the bacterium (Yang et al., 2017). 
 
In our findings, differences in G. mellonella killing was observed with colistin-
resistant E. coli isolated from chickens and humans. Important to note exotoxins, 
endotoxins, adherence factors, secretion systems, iron acquisition and fimbria are 
commonly considered to be important virulence features in Gram-negative 
bacteria (Cosentino et al., 2013). In this study, cvaB (colicin V secretion/processing 
ATP-binding protein) was associated with the most virulent strain and the least 
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virulent were gadA (glutamate decarboxylase alpha) according to the calculated 
Hazard Ratio. CvaB, is part of an ABC transporter system, which transport colicin 
V (ColV) an antibacterial peptide toxin active against many E. coli strains and other 
members of the Enterobacteriaceae family (Hwang et al., 1997). While gadA is 
part of glutamate decarboxylase structural genes, which function as an important 
mechanism of acid resistance (Smith et al., 1992; Feehily and Karatzas, 2013).  
 
Other VF that demonstrates virulence and high mortality includes vat, hylE, AfaB, 
senB, tsh, eptD, cba, pic, iatB, iss and cma. However, carriage of lpfA, gadB, gad, 
invasin, air, celB and gad (associated with low virulence and low mortality) also 
shown to be protective according to calculated Hazard Ratio.  
 
In G. mellonella infection study done by Alghoribi et al. demonstrated clones of 
ST69 and ST127 of uropathogenic E. coli (UPEC) showed greater killing than the 
more recognised clones including ST73, ST95 and ST131 (Alghoribi et al., 2014). 
However, when we investigated our E. coli strains (transconjugant versus ECJ53 
recipient) the varied survival was not clonal in nature. G. mellonella killing with E. 
coli C22/EC J53 transconjugant showed enhanced virulence compared to E. coli 
B28/EC J53, E. coli A53/EC J53 and the ECJ53 background. All transconjugants had 
similar sequence type, ST10 to the background ECJ53 recipient. 
 
Wu and colleagues have looked at the fitness advantage of bearing IncI2 plasmid 
in vitro and reported that acquiring IncI2-type plasmid was more beneficial for 
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host E. coli DH5α than either IncHI2 or IncX4 plasmid (Wu et al., 2018). In contrast, 
the presence of IncHI2, IncFII and IncY plasmids showed a fitness cost (Wu et al., 
2018). In our findings, the E. coli B28/EC J53 transconjugant, have acquired 
additional plasmids, IncFIB(AP001918) and IncFII(pCoo) during the conjugation 
process which may lead to the fitness cost and less G. mellonella killing compared 
to E. coli C22/EC J53. However, the growth kinetics in our study between 
transconjugants and EC J53 recipients did not show any obvious differences; 
hence, acquisition of a mcr-1-like bearing plasmid may not affect a fitness cost. 
 
The E. coli A53/EC J53 transconjugant did show less G. mellonella killing compared 
to E. coli C22/EC J53 despite the number of virulence genes acquired, and plasmid 
replicon type was similar for both. Hence, the only difference observed was in the 
mcr gene determinant, mcr-1.1 in E. coli A53/EC J53 and mcr-1.8 in E. coli C22/EC 
J53. Furthermore, three other E. coli mcr-1.8 wildtypes (E. coli H124, E. coli H112 
and E. coli H109) were identified from humans that ranked higher in the Galleria 
virulence lists seen in Table 20. Therefore, one hypothesis for the enhanced 
virulence could be due to the acquisition of the mcr-1.8 gene. This could be worthy 
of further investigation. 
 
Interestingly, on analysis of the predicted serotypes, we noted frequent absence 
of the O antigen which may affect the architecture of the outer cell membrane. 
Strains with the higher colistin MICs were also noted to be lower down the 
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virulence rank according to the calculated Hazard Ratios (Table 28). Another 
hypothesis for the lower rank in virulence with high the colistin MICs is associated 
with the loss of O antigen resulting in reduced virulence. However, further 
investigation is still warranted. 
 
Colistin-
resistant E. coli 
strains 
Origin Ranking 
(Hazard 
Ratio) 
Serotyping Colistin MIC 
(mg/L) 
B52 Avian 1 Novel 4 
67 Human 2 :H31 4 
106 Human 8 O35: >32 
84 Human 16 :H29 2 
B7 Avian 18 :H25 2 
B28 Avian 20 :H7 >32 
C19 Avian 25 :H32 2 
64 Human 27 :H31 4 
86 Human 32 :H38 4 
A12 Avian 39 :H10 >16 
63 Human - :H16 >32 
A25 Avian - :H10 2 
B42 Avian - :H11 2 
B12 Avian - :H25 2 
121 Human - O8: 2 
Table 28. Colistin-resistant E. coli strains in relations to their serotypes, colistin 
MICs and virulence ranking. 
 
In conclusion, we have demonstrated varied G. mellonella killing by colistin-
resistant E. coli was not attributable to any specific clone. Acquisition of polymyxin 
resistance gene did not uniformly affect fitness or virulence with the possible 
exception of the transfer of plasmids encoding MCR-1.8. Strains studied were 
obtained from healthy poultry and from routine microbiology sampling of human 
clinical faecal samples. Although, the diagnosis of the patient was not obtained. 
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Further studies should focus on diseased animals or humans with severe E. coli 
infections. 
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6.6 Conclusion  
The work in the thesis demonstrates the high rate of resistance to carbapenems 
and polymyxins in critical Gram-negative bacteria in Brunei Darussalam. 
Carbapenem-resistant A. baummanni, OXA-232-producing K. pneumoniae 
belonging ST231 clone causes a hospital outbreak in Brunei’s hospital. Plasmid-
mediated polymyxin resistance in E. coli was found to be endemic in poultry (58%) 
and highly prevalent (41.7%) in the human samples studied. 
 
Unlike carbapenem resistance, polymyxin resistance was not associated with any 
predominant clone and did not readily correlate with virulence properties of the 
strain.  The enhanced virulence seen in one of the transconjugant isolates may be 
due to the acquisition of the mcr-1.8 gene. Further, extensive research in this area 
are needed to elucidate the underlying mechanism. However, given the high 
background rates, enhanced surveillance for MCR-1 within more virulent 
Enterobacterial backgrounds is warranted, particularly in Southeast Asian 
countries. 
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6.7 Future developments 
§ To introduce AMR surveillance in Brunei Darussalam using existing 
diagnostic tools developed in the study such as CHROMagar COL-APSE 
culture media, lateral flow assay and molecular techniques (PCR and 
WGS).  
§ To develop Brunei’s National Action Plan (NAP) on AMR surveillance 
focusing on pathogens listed in the WHO Global Antimicrobial Surveillance 
System (GLASS) (A. baumannii, E. coli, K. pneumoniae and Salmonella spp 
among the Gram-negatives) and WHO critical pathogen lists. The NAP 
must include stakeholders from the Ministry of Health, Ministry of Primary 
Resources and Tourism (Department of Agriculture and Agrifood) and 
Ministry of Development (Department of Environment, Parks and 
Recreation) working together to eventually come up with a policy that can 
be implemented in other districts in Brunei. 
§ To carry out AMR surveillance in patients with sepsis from blood cultures 
for the presence of plasmid-mediated polymyxin resistance. And also, to 
include AMR surveillance of CRE (OXA-232) and plasmid-mediated 
polymyxin resistance from other infected sites in patients admitted to the 
Intensive Care Unit (ICU) in Brunei’s hospital.
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Primer  Primer sequence (5’-3’) Expected 
size (bp) Reference 
Chapter 2 
RAPD typing     
ERIC2 N/A AAGTAAGTGGACTGGGGTGAGCG 
Variable 
(Renders 
et al., 
1996) 
OXA carbapenemases   
OXA-51-like F TAATGCTTTGATCGGCCTTG  353 
(Woodfor
d et al., 
2006) 
R TGGATTGCACTTCATCTTGG  
OXA-23-like F GATCGGATTGGAGAACCAGA 501 R ATTTCTGACCGCATTTCCAT 
OXA-24-like F GGTTAGTTGGCCCCCTTAAA 246 R AGTTGAGCGAAAAGGGGATT 
OXA-58-like F AAGTATTGGGGCTTGTGCTG 599 R CCC CTC TGCGCTCTACATAC 
Aminoglycoside 
methyltransferases 
   
(Fritsche 
et al., 
2008) 
rmtA F CTAGCGTCCATCCTTTCCTC 633 
 R TTTGCTTCCATGCCCTTGCC  
rmtB F TCAACGATGCCCTCACCTC 459 
 R GCAGGGCAAAGGTAAAATCC  
rmtC F GCCAAAGTACTCACAAGTGG 752 
 R CTCAGATCTGACCCAACAAG  
rmtD F CTGTTTGAAGCCAGCGGAACGC 376 
  GCGCCTCCATCCATTCGGAATAG  
armA F TATGGGGGTCTTACTATTCTGCCTAT 514 
 R TCTTCCATTCCCTTCTCCTTT  
npmA F CTCAAAGGAACAAAGACGG 641 
 R GAAACATGGCCAGAAACTC  
     
AmpC 
ACI5 F ACTTACTTCAACTCGCGACG  653 (Corvec et al., 2003) 
ACI6 R TAAACACCACATATGTTCCG    
Integrons 
Int1 
 
F 
 
CAGTGGACATAAGCCTGTTC 
 
160 
(Dillon et 
al., 2005) 
 R CCCGAGGCATAGACTGTA  
Int2 F GTAGCAAACGAGTGACGAAATG 788 
 R CACGGATATGCGACAAAAAGGT  
Int3 F GCCTCCGGCAGCGACTTTCAG 979 
 R ACGGATCTGCCAAACCTGACT   
Class 1 integron 
gene cassette 
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5’ CS F GGCATCCAAGCAGCAAG Variable (Lévesque 
et al., 
1995) 
3’ CS R AAGCAGACTTGACCTGA  
Insertion element, ISAba1 
ISAba1 F CATTGGCATTAAACTGAGGAGAAA 451 (Ruiz et al., 2007) 
ISAba2 R TTGGAAATGGGGAAAACGAA   
Chapter 3 
Virulence factor      
ybtS_for F GACGGAAACAGCACGGTAAA 242 
(Compain 
et al., 
2014) 
ybtS_rev R GAGCATAATAAGGCGAAAGA    
mrkD_for F AAGCTATCGCTGTACTTCCGGCA 340  
mrkD_rev R GGCGTTGGCGCTCAGATAGG    
entB_for F GTCAACTGGGCCTTTGAGCCGTC  400  
entB_rev R TATGGGCGTAAACGCCGGTGAT    
rmpA_for F CATAAGAGTATTGGTTGACAG 461  
rmpA_rev R CTTGCATGAGCCATCTTTCA    
kfu_for F GGCCTTTGTCCAGAGCTACG  638  
kfu_rev R GGGTCTGGCGCAGAGTATGC    
allS_for F CATTACGCACCTTTGTCAGC  764  
allS_rev R GAATGTGTCGGCGATCAGCTT   
iutA_for F GGGAAAGGCTTCTCTGCCAT  920  
iutA_rev R TTATTCGCCACCACGCTCTT    
magA_for F GGTGCTCTTTACATCATTGC  1283  
magA_rev R GCAATGGCCATTTGCGTTAG    
K2_for F CAACCATGGTGGTCGATTAG  531  
K2_rev R TGGTAGCCATATCCCTTTGG    
Beta- lactamases 
Bla1 
    
TEM-like F CATTTCCGTGTCGCCCTTATTC 800 
(Dallenne 
et al., 
2010) 
 R CGTTCATCCATAGTTGCCTGAC  
SHV-like F AGCCGCTTGAGCAAATTAAAC 713 
 R ATCCCGCAGATAAATCACCAC  
OXA-1/4/30 F GGCACCAGATTCAACTTTCAAG 564 
 R GACCCCAAGTTTCCTGTAAGTG  
Bla2     
CTX-M-1 Gp F TTAGGAARTGTGCCGCTGYA 688 
 R CGATATCGTTGGTGGTRCCAT  
CTX-M-2 Gp F CGTTAACGGCACGATGAC 404 
 R CGATATCGTTGGTGGTRCCAT  
CTX-M-9 Gp F TCAAGCCTGCCGATCTGGT 561 
 R TGATTCTCGCCGCTGAAG  
Bla3    
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ACC F CACCTCCAGCGACTTGTTAC 346 
 R GTTAGCCAGCATCACGATCC  
FOX F CTACAGTGCGGGTGGTTT 162 
 R CTATTTGCGGCCAGGTGA  
MOX/CMY F GCAACAACGACAATCCATCCT 895 
 R GGGATAGGCGTAACTCTCCCAA  
DHA F TGATGGCACAGCAGGATATTC 997 
 R GCTTTGACTCTTTCGGTATTCG  
CIT F CGAAGAGGCAATGACCAGAC 538 
 R ACGGACAGGGTTAGGATAGY  
ACT/MIR F CGGTAAAGCCGATGTTGCG 683 
 R AGCCTAACCCCTGATACA  
Bla4    
GES-like F AGTCGGCTAGACCGGAAAG 399 
 R TTTGTCCGTGCTCAGGAT  
PER-like F GCTCCGATAATGAAAGCGT 520 
 R TTCGGCTTGACTCGGCTGA  
VEB-like F CATTTCCCGATGCAAAGCGT 648 
 R CGAAGTTTCTTTGGACTCTG  
Bla5    
GES-like F AGTCGGCTAGACCGGAAAG 399 
 R TTTGTCCGTGCTCAGGAT  
OXA-48-like F GCTTGATCGCCCTCGATT 281 
 R GATTTGCTCCGTGGCCGAAA  
Bla6    
IMP-like F TTGACACTCCATTTACDG 139 
 R GATYGAGAATTAAGCCACYCT  
VIM-like F GAT GGT GTT TGG TCG CAT A 390 
 R CGA ATG CGC AGC ACC AG  
KPC-like F CATTCAAGGGCTTTCTTGCTGC 538 
 R ACGACGGCATAGTCATTTGC   
Carbapenemases     
BIC-like F TATGCAGCTCCTTTAAGGGC 537 
(Poirel et 
al., 2011b) 
 R TCATTGGCGGTGCCGTACAC  
NDM-like F GGTTTGGCGATCTGGTTTTC 621 
 R CGGAATGGCTCATCACGATC  
Quinolone      
qnrA F AGAGGATTTCTCACGCCAGG 580 
(Cattoir et 
al., 2007) 
 R TGCCAGGCACAGATCTTGAC  
qnrB F GGMATHGAAATTCGCCACTG 264 
 R TTTGCYGYYCGCCAGTCGAA  
qnrS F GCAAGTTCATTGAACAGGGT 428 
 R TCTAAACCGTCGAGTTCGGCG   
Aminoglycoside (Noppe-
Leclercq Duplex     aph(3ʹ)-VI F CGGAAACAGCGTTTTAGA 716 
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 R TTCCTTTTGTCAGGTC  et al., 
1999) ant(2’’)-Ia F T  
 R CGAGCCTGTAGGACT 404 
Duplex    
aac(6ʹ)-Ib F TATGAGTGGCTAAATCGAT 395 
 R CCCGCTTTCTCGTAGCA  
aph(3ʹ)-Ia F CGAGCATCAAATGAAACTGC 623 
 R GCGTTGCCAATGATGTTACAG  
Triplex    
aac(6ʹ)-Ih F TGCCGATATCTGAATC 407 
 R ACACCACACGTTCAG  
aac(3)-Ia F GACATAAGCCTGTTCGGTT 372 
 R CTCCGAACTCACGACCGA  
aac(3)-IIa F ATGCATACGCGGAAGGC 822 
 R TGCTGGCACGATCGGAG  
Plasmid replicon 
IncX4     
IncX4_F F AGCAAACAGGGAAAGGAGAAGACT 569 (Johnson 
et al., 
2012) 
 R TACCCCAAATCGTAACCTG  
ColE-like     
RepCol181-For F TACGGATTGCGGATGTTGCC 600 (Potron et 
al., 2013) RepCol181-Rev R GTGCTGGTGCGTCCATTTGG  
OXA-232 primer walking 
OXA-232invL  CCGATAATCGATGCCACCAA Variable 
This study 
pKP41invL1  GGAGTTAGCATGTCTGATTC  Variable 
pKP41invL2  GATCCACGTTTTGAGCAACA Variable 
pKP41invL3  CCAACAAGTAGCCAACAGG Variable 
OXA-232invR  GCCATCACAAAAGAAGTGCTC Variable 
pKP41invR1  AGGGTGAAAGGTTACATGCA Variable 
pKP41invR2  AACTGTACCCTGTTCGAGAA Variable 
pKP41invR3  CTTCTTGGCTCTGGAGAATG Variable 
Chapter 4 
Plasmid-mediated Polymyxin 
mcr-1-like F AGTCCGTTTGTTCTTGTGGC 320 
(Cavaco et 
al., 2016) 
 R AGATCCTTGGTCTCGGCTTG   
mcr-2-like F CAAGTGTGTTGGTCGCAGTT  715 
 R TCTAGCCCGACAAGCATACC   
Phyloytyping 
ChuA.1 F GACGAACCAACGGTCAGGAT 279 
(Clermont 
et al., 
2000) 
ChuA.2 R TGCCGCCAGTACCAAAGACA  
YjaA.1 F TGAAGTGTCAGGAGACGCTG 211 
YjaA.2 R ATGGAGAATGCGTTCCTCAAC  
TspE4C2.1 F GAGTAATGTCGGGGCATTCA 152 
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TspE4C2.2 R CGCGCCAACAAAGTATTACG  
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Appendix B (Antibiotic Susceptibility Testing 
table of colistin-resistant E. coli isolated from 
chickens and humans) 
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E. coli mcr-1-like 
isolates 
Amikacin 
(30 µg) 
Augmentin 
(30 µg) 
Colistin 
(25 µg) 
Cefpodoxime 
(10 µg) 
Cephalothin 
(30 µg) 
Ciprofloxacin 
(5 µg) 
Cefepime 
(30 µg) 
Minocycline 
(30 µg) 
A8 23 6 13 6 6 12 51 25 
A12 16 6 11 6 6 9 23 16 
A13 23 6 12 11 6 14 34 11 
A25 17 6 11 21 6 11 26 13 
A28 19 6 10 6 6 12 20 6 
A31 17 6 11 6 6 6 13 6 
A33 19 16 6 24 6 9 31 6 
A41 18 6 11 6 6 12 32 14 
A53 20 6 6 6 6 11 30 8 
B1 23 6 11 6 6 6 51 24 
B5 22 6 13 13 14 26 37 13 
B7 23 6 13 6 6 6 37 14 
B11 16 11 10 6 6 12 25 13 
B12 15 6 11 22 6 18 25 12 
B23 16 6 11 12 6 6 28 10 
B25 14 6 11 18 6 20 23 6 
B28 24 6 11 6 6 6 35 11 
B42 23 6 12 6 6 39 55 22 
B47 23 9 12 6 6 6 28 15 
B52 17 8 11 6 6 15 29 10 
C1 24 6 12 36 6 27 35 18 
C19 17 6 11 22 6 19 25 8 
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C22 19 6 12 6 6 11 17 11 
C28 18 6 11 13 6 6 29 6 
C45 24 19 12 6 6 35 22 11 
C55 20 14 11 24 6 20 30 13 
Antibiotic susceptibility testing of colistin-resistant E. coli isolated from chickens. Green colour- sensitive, Yellow colour- intermediate, Red 
colour- resistance. Bacteria that grows towards disc are resistance and measured as the size of the disc (6 mm). Columns that are not shaded - 
zone diameter (mm) breakpoints are not available.  
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E. coli mcr-1-like 
isolates 
Kanamycin 
(30 µg) 
Ertapenem 
(10 µg) 
Imipenem 
(10 µg) 
Meropenem 
(10 µg) 
Chloremphenicol 
(30 µg) 
Apramycin 
(15 µg) 
Florfenicol 
(30 µg) 
Pefloxacin 
(5 µg) 
A8 6 25 24 45 6 14 6 6 
A12 6 19 23 28 6 6 6 6 
A13 6 20 34 20 6 19 8 6 
A25 6 24 25 27 11 14 18 6 
A28 6 23 23 28 6 6 6 6 
A31 6 20 22 26 6 11 6 6 
A33 6 27 28 33 6 14 6 6 
A41 6 23 25 29 6 14 6 6 
A53 6 23 27 28 6 6 6 6 
B1 6 30 26 42 6 6 6 6 
B5 6 6 34 18 6 6 12 6 
B7 6 19 33 19 6 6 10 6 
B11 6 23 22 27 6 6 6 14 
B12 15 24 24 28 6 14 6 15 
B23 6 21 25 28 6 6 6 6 
B25 18 25 21 22 6 6 6 21 
B28 6 18 29 19 6 6 6 6 
B42 14 33 25 46 6 6 6 37 
B47 6 21 25 29 6 6 6 6 
B52 6 23 25 29 6 6 6 10 
C1 6 20 34 20 6 6 6 6 
C19 6 25 25 28 6 13 6 14 
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C22 6 22 25 25 6 6 6 6 
C28 6 28 25 29 6 6 6 6 
C45 20 24 33 35 6 6 6 19 
C55 6 29 29 32 6 6 6 13 
Antibiotic susceptibility testing of colistin-resistant E. coli isolated from chickens. Green colour- sensitive, Yellow colour- intermediate, Red 
colour- resistance. Bacteria that grows towards disc are resistance and measured as the size of the disc (6 mm). Columns that are not shaded - 
zone diameter (mm) breakpoints are not available.  
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E. coli mcr-1-like 
isolates 
Enroflaxacin 
(5 µg) Ceftazidime 30 µg/AVI 20 µg Ceftolozane 30 µg/Tazobactam 10 µg 
Cefoxitin 
(30 µg) 
Ceftiofur 
(30 µg) 
A8 6 31 27 9 18 
A12 6 25 18 6 14 
A13 6 29 26 23 25 
A25 6 24 28 21 22 
A28 6 22 16 6 14 
A31 6 25 22 7 15 
A33 10 29 28 23 27 
A41 8 28 22 6 20 
A53 6 30 23 6 21 
B1 6 29 25 6 22 
B5 6 32 30 25 27 
B7 6 30 26 6 22 
B11 16 25 21 11 20 
B12 17 26 22 20 22 
B23 6 26 23 6 22 
B25 22 25 21 21 18 
B28 6 29 24 6 22 
B42 34 28 25 6 21 
B47 6 27 21 10 15 
B52 11 27 24 6 22 
C1 6 30 26 22 26 
C19 16 27 24 19 22 
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C22 8 27 22 25 6 
C28 6 30 25 18 22 
C45 22 37 28 32 6 
C55 16 28 27 21 24 
Antibiotic susceptibility testing of colistin-resistant E. coli isolated from chickens. Green colour- sensitive, Yellow colour- intermediate, Red 
colour- resistance. Bacteria that grows towards disc are resistance and measured as the size of the disc (6 mm). Columns that are not shaded - 
zone diameter (mm) breakpoints are not available.  
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E. coli mcr-1-like 
isolates 
Amikacin 
(30 µg) 
Augmentin 
(30 µg) 
Colistin 
(25 µg) 
Cefpodoxime 
(10 µg) 
Cephalothin 
(30 µg) 
Ciprofloxacin 
(5 µg) 
Cefepime 
(30 µg) 
Minocycline 
(30 µg) 
1 21 15 12 25 14 6 28 15 
8 19 6 12 25 13 28 28 12 
25 20 6 13 25 9 12 28 16 
46 18 6 12 25 13 6 26 13 
49 19 6 13 15 6 6 26 11 
50 20 18 12 27 15 23 28 12 
53 20 6 12 26 14 13 28 17 
54 19 6 11 24 12 21 18 29 
59 20 6 12 25 12 30 27 9 
60 19 6 12 25 13 23 26 16 
61 22 6 13 24 12 10 27 15 
63 6 6 6 26 6 13 30 6 
64 20 6 12 24 11 11 27 11 
67 20 6 12 26 9 28 32 11 
70 20 6 12 24 17 12 28 12 
84 20 19 12 27 18 30 33 19 
86 20 6 12 25 14 23 27 13 
92 18 6 12 25 13 10 16 12 
96 20 6 12 26 16 24 28 17 
106 19 6 6 11 6 19 23 9 
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109 24 6 6 25 6 14 31 11 
111 23 6 13 25 12 13 28 11 
112 22 8 13 26 17 27 30 16 
113 20 6 12 25 14 14 28 16 
121 20 6 12 23 11 20 27 13 
124 18 6 6 25 6 13 24 11 
Antibiotic susceptibility testing of colistin-resistant E. coli isolated from humans. Green colour- sensitive, Yellow colour- intermediate, Red colour- 
resistance. Bacteria that grows towards disc are resistance and measured as the size of the disc (6 mm). Columns that are not shaded - zone 
diameter (mm) breakpoints are not available.  
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E. coli mcr-1-like 
isolates 
Kanamycin 
(30 µg) 
Ertapenem 
(10 µg) 
Imipenem 
(10 µg) 
Meropenem 
(10 µg) 
Chloremphenicol 
(30 µg) 
Apramycin 
(15 µg) 
Florfenicol 
(30 µg) 
Pefloxacin 
(5 µg) 
1 20 21 30 23 6 15 6 6 
8 6 20 27 21 6 6 6 16 
25 19 20 31 23 6 6 6 6 
46 6 26 27 21 6 14 6 6 
49 6 23 25 20 6 15 6 6 
50 22 22 31 23 15 15 6 17 
53 6 25 28 21 6 14 6 6 
54 6 21 28 29 6 13 6 19 
59 18 19 30 22 9 6 6 29 
60 6 24 27 22 6 14 6 14 
61 6 26 30 24 6 6 6 6 
63 6 24 26 19 6 6 6 6 
64 19 26 26 22 6 6 6 6 
67 18 24 29 21 24 15 22 26 
70 19 21 30 25 6 14 6 6 
84 20 24 31 32 25 15 24 27 
86 19 24 26 22 6 13 6 17 
92 6 26 29 20 6 13 6 6 
96 20 22 29 23 10 16 6 16 
106 6 20 16 17 9 6 10 11 
 
 
488 
109 6 19 26 20 6 6 6 6 
111 6 27 30 23 6 6 6 6 
112 21 21 30 25 25 15 22 17 
113 6 27 29 22 6 14 6 6 
121 6 27 28 23 6 15 6 11 
124 6 21 22 16 6 6 6 6 
Antibiotic susceptibility testing of colistin-resistant E. coli isolated from humans. Green colour- sensitive, Yellow colour- intermediate, Red colour- 
resistance. Bacteria that grows towards disc are resistance and measured as the size of the disc (6 mm). Columns that are not shaded - zone 
diameter (mm) breakpoints are not available.  
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E. coli mcr-1-like 
isolates 
Enroflaxacin 
(5 µg) Ceftazidime 30 µg/AVI 20 µg Ceftolozane 30 µg/Tazobactam 10 µg 
Cefoxitin 
(30 µg) 
Ceftiofur 
(30 µg) 
1 6 28 25 21 23 
8 19 28 24 20 22 
25 6 29 27 21 24 
46 6 30 25 19 22 
49 6 29 24 6 20 
50 17 30 27 21 25 
53 13 29 24 22 23 
54 22 29 26 20 27 
59 32 27 26 22 24 
60 18 28 25 21 22 
61 6 31 25 18 23 
63 8 30 23 15 24 
64 6 30 26 20 22 
67 27 29 25 21 24 
70 6 27 25 20 23 
84 29 30 27 22 25 
86 22 28 25 21 23 
92 6 29 25 21 24 
96 19 28 25 22 23 
106 11 26 22 6 15 
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109 9 32 28 10 26 
111 6 29 26 21 25 
112 20 27 25 21 23 
113 9 28 25 22 24 
121 15 29 25 20 22 
124 6 24 24 18 22 
Antibiotic susceptibility testing of colistin-resistant E. coli isolated from humans. Green colour- sensitive, Yellow colour- intermediate, Red colour- 
resistance. Bacteria that grows towards disc are resistance and measured as the size of the disc (6 mm). Columns that are not shaded - zone 
diameter (mm) breakpoints are not available.  
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Zone diameter breakpoints (mm) of antibiotics tested for 52 colistin-resistant E. coli isolates. N/A – Not Available.
Antimicrobial Discs Potency (µg) Zone diameter breakpoint (mm) Reference 
S³ R< 
Amikacin 30 18 15 (EUCAST, 2018) 
Augmentin (Amoxycillin-Clavulanic Acid) 30 19 19 (EUCAST, 2018) 
Colistin 25 N/A N/A N/A 
Cefpodoxime 10 21 21 (EUCAST, 2018) 
Cephalothin 30 18 15 (CLSI, 2015) 
Ciprofloxacin 5 26 24 (EUCAST, 2018) 
Cefepime 30 27 24 (EUCAST, 2018) 
Minocycline 30 16 13 (CLSI, 2018) 
Kanamycin 30 18 14 (CLSI, 2018) 
Ertapenem 10 25 22 (EUCAST, 2018) 
Imipenem 10 22 16 (EUCAST, 2018) 
Meropenem 10 22 16 (EUCAST, 2018) 
Chloramphenicol 30 17 17 (EUCAST, 2018) 
Apramycin 15 N/A N/A N/A 
Florfenicol 30 N/A N/A N/A 
Pefloxacin 5 24 24 (CLSI, 2018) 
Enrofloxacin 5 23 17 (CLSIVET08, 2018) 
Ceftiofur 30 21 18 (CLSIVET08, 2018) 
Cefoxitin 30 18 15 (CLSI, 2018) 
Ceftazidime 30 Avibactam 20 30/20 21 21 (CLSI, 2018) 
Ceftolozane 30 Tazobactam 10 30/10 21 18 (CLSI, 2018) 
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Evaluation of an Immunochromatographic Lateral Flow Assay (OXA-
48 K-SeT) for Rapid Detection of OXA-48-Like Carbapenemases in
Enterobacteriaceae
David W. Wareham,a,b Rishita Shah,a Jonathan W. Betts,a Lynette M. Phee,a,b Muhd Haziq F. Abdul Momina
Antimicrobial Research Group, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdoma;
Division of Infection, Barts Health NHS Trust, London, United Kingdomb
We evaluated an immunochromatographic lateral flow assay to detect OXA-48-like carbapenemases (OXA-48 K-SeT) in Entero-
bacteriaceae (n! 82). One hundred percent sensitivity and specificity were observed using bacteria recovered from both solid
medium and spiked blood culture bottles, and the results were obtained in<10 min.
The identification, treatment, and control of multidrug-resis-tant (MDR) bacterial infections are global health priorities.
Enterobacteriaceae with plasmids carrying genes encoding class A
(Klebsiella pneumoniae carbapenemases [KPC]), B (IMP, VIM,
and NDM), and D (OXA) carbapenemases (carbapenemase-pro-
ducing Enterobacteriaceae [CPE]) are one of the most important
groups of pathogens due to the burden of disease, lack of any new
treatments, and potential for dissemination (1). Rapid and effec-
tive diagnostics therefore underpin any strategy aimed at tackling
the problemofCPE.Considerable effort has beenmade to develop
novel assays using both genotypic and phenotypic approaches.
These approaches include the genetic detection of resistance gene
profiles (PCR, loop-mediated isothermal amplification [LAMP],
microarrays, and genome sequencing) (2), selective culture me-
dium (chromogenic or supplemented) (3), combination disk test-
ing (4), and direct or indirect detection of carbapenem-hydrolyz-
ing enzymes (matrix-assisted laser desorption ionization–time of
flight mass spectrometry [MALDI-TOF MS], acidometric Carba
NP, and Blue-Carba) (5–7). These methods require varied levels
of technical skill, investment into equipment, and quality assur-
ance optimization. Strains producing OXA-48-like carbapenem-
hydrolyzing class D enzymes (CHDL) have proven to be particu-
larly difficult to detect in clinical laboratories. This is due in part to
relatively low MICs, conflicting interpretive rules associated with
automated systems (8), and a lack of suitable inhibitor com-
pounds for use in confirmatory tests. A novel means of detecting
OXA-48-like enzymes using an antibody-mediated approach was
recently developed (9). The OXA-48 K-SeT assay relies on the
immunological capture of two epitopes specific to the OXA-48
enzyme using colloidal gold nanoparticles bound to a nitrocellu-
losemembranewithin a lateral flow device. Capture and detection
antibodies were designed to bind all current CHDL OXA-48-like
variants (OXA-48, -181, -204, -232, and -244).
In this study, we assessed the performance of theCorisOXA-48
K-SeT assay for detecting OXA-48-like-mediated carbapenem re-
sistance in a large collection of carbapenem-resistant Enterobacte-
riaceae and also determined whether it could provide robust re-
sults when working directly with organisms recovered from blood
culture bottles.
Eighty-two enterobacterial isolateswere used in the evaluation.
Seventy-eight were clinical isolates (K. pneumoniae, n! 60; Esch-
erichia coli, n! 11; Enterobacter cloacae, n! 6; Enterobacter aero-
genes, n! 1) with resistance to one or more carbapenems (ertap-
enem, imipenem, and/or meropenem) along with a susceptible
type strain as a representative control for each bacterial species (K.
pneumoniae NCTC 9633, E. coli NCTC 12241, E. cloacae 13380,
andE. aerogenesNCTC9375). Resistance or reduced susceptibility
to carbapenems in clinical isolates was identified by disk diffusion
and/or Etest (bioMérieux, Marcy L’Etoile, France) and confirmed
by broth microtiter dilution (ertapenem MIC, !1 "g/ml), ac-
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FIG 1 Detection of OXA-48-producing K. pneumoniae using OXA-48 K-SeT
assay cassettes. The device was inoculated with 2 # 106 CFU/ml of OXA-48-
producing KP41 and read after 5 min.
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cording to Clinical and Laboratory Standards Institute (CLSI)
methodology. Multiplex PCRs were used to detect the presence of
genes encoding class A, B, C, and D !-lactamases (10). PCR de-
tection and Sanger sequencing of entire blaOXA-48 alleles were un-
dertaken and used as the standard for all isolates designatedOXA-
48-like-positive strains (3, 11). OXA-48 K-SeT assay kits (Coris
BioConcept, Gembloux, Belgium) were obtained commercially
through BioConnections (Knypersley, United Kingdom) at the
catalogue price in August 2015 (£5/$7.6 per cassette).
Isolates were grown andmaintained onMueller-Hinton II cat-
ion-adjusted agar plates (Sigma-Aldrich, Gillingham, United
Kingdom). The detection of CHDL-producing isolates from solid
medium was undertaken, according to the manufacturer’s in-
structions. Briefly, a single colony was resuspended in 10 drops of
LY-A buffer (Tris-HCl, NaN3 [pH 7.5]), and 3 drops of the ho-
mogenized solution was then applied to the sample well. The tests
were read by eye within 15 min (Fig. 1). The lower limit of detec-
tion (in CFU per milliliter) of the OXA-48 K-SeT device was de-
termined using K. pneumoniaeNCTC 9633 and KP41 (blaOXA-48)
grown in Trypticase soy broth (TSB) (Sigma). Cells from 1 ml of
overnight cultures were harvested by centrifugation, resuspended
in phosphate-buffered saline (PBS), plated in serial dilutions
(10" 1 to 10" 9) onto MH agar, and viable counts (in CFU per
milliliter) were recorded after 18 h of incubation. Ten drops of
LY-A buffer were added to the cells pelleted from each dilution
and used to inoculate OXA-48 K-SeT assay cassettes, as described
above.
The ability of the OXA-48 K-SeT system to directly detect
OXA-48-producing isolates recovered using commercial micro-
bial blood culture medium was performed using the BacT/Alert
system (bioMérieux, Durham, NC). Aerobic FA Plus 30-ml bot-
tles were supplemented with 10 ml of heparinized horse blood
(Oxoid, Basingstoke, United Kingdom) before inoculation with
102 CFU of each of the test organisms. The bottles were incubated
at 37°C for up to 18 h before 0.1-ml aliquots were harvested, lysed,
and analyzed directly without further dilution. Adequate growth
of each isolate under simulated blood culture conditions was con-
firmed by subculture on MH II agar.
Molecular analysis of the isolates used in the analysis con-
firmed that 53 isolates produced an OXA-48-like carbapenemase,
including 2 K. pneumoniae isolates with the OXA-181 and OXA-
232 variants. Twenty-five isolates were carbapenem resistant due
to the production of either KPC, VIM, or NDM (n # 13) !-lacta-
mases or had hyper-ampC and/or permeability lesions. The
OXA-48 K-SeT assay gave a positive result for all 53 OXA-48-
producing strains and was negative for all of the other isolates
tested, including 5 isolates that produced OXA-1. A correlation of
the viable colony counts with the OXA-48 K-SeT assay results
obtained with K. pneumoniae NCTC 9633 and KP41 assessed the
lower limit of detection of the assay to be 2.41 $ 106 CFU/ml. The
results were identical whether the cassettes were inoculated with
lysates prepared fromMH II plates or from BacT/Alert blood cul-
ture bottles. In this evaluation, complete agreement between the
molecular and OXA-48 K-SeT assay results was demonstrated
(Table 1), and the sensitivity and specificity of the assay for detect-
ing OXA-48-producing isolates were both calculated to be 100%
(95% confidence interval, 91.9 to 100% and 84.2 to 100%, respec-
tively). Positive and negative results were clearly differentiated
within 10 min. Furthermore, the reads were not obscured by the
presence of red cells when using lysates from blood culture sets.
The OXA-48 K-SeT assay required minimal hands-on analyt-
ical time and no investment in any special equipment outside that
available in a routine microbiology laboratory. The assay was
highly sensitive and specific and was able to either rule in or rule
out the presence of an OXA-48-producing strain within minutes.
With a limit of detection of 106 CFU/ml, it might also be useful for
the direct detection of OXA-48-producing strains in urinary sam-
ples or other biological fluids. Although we did not undertake a
formal cost/benefit analysis, this assay has clear potential for de-
velopment as a simple rapid local point-of-care test able to iden-
tify and guide the treatment and control of carbapenem-resistant
infections due to OXA-48-producing Enterobacteriaceae.
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A B S T R A C T
Objectives: Carbapenem-resistant Enterobacteriaceae (CRE) are identiﬁed as a major global health
concern. The success of CRE is facilitated by the emergence, acquisition and spread of successful clones
carrying plasmid-encoded resistance genes. In this study, an outbreak of carbapenem-resistant Klebsiella
pneumoniae (CRKP) infections in patients hospitalised in Brunei Darussalam was investigated.
Methods: Over a 3-month period (May–July 2015), ﬁve multidrug-resistant K. pneumoniae were recovered
from individual patients admitted to intensive care units at two hospitals (RIPAS and PMMPMHAB) in
Brunei. Antimicrobial susceptibility was determined by broth microtitre dilution using a Micronaut-S
b-lactamase VII kit or by Etest. Carbapenemase production was conﬁrmed using the RAPID CARB Blue
screen, and classes A–D b-lactamases were detected by multiplex PCR. Molecular typing was performed
by random ampliﬁed polymorphic DNA (RAPD) PCR and multilocus sequence typing (MLST), with
associated virulence and capsular types identiﬁed by PCR and sequencing. Plasmids were extracted, sized
and characterised by PCR-based replicon typing.
Results: All isolates were resistant to cephalosporins, carbapenems, aminoglycosides, quinolones and
sulfonamides but remained susceptible to polymyxins. Isolates were indistinguishable by RAPD-PCR and
all belonged to sequence type (ST231). Resistance was due to the production of OXA-232 and CTX-M-15
b-lactamases, with the blaOXA-232 carbapenemase gene located on a ColE-like plasmid.
Conclusions: This is the ﬁrst report of plasmid-encoded OXA-232-producing CRKP in Brunei hospitals. All
isolates were members of ST231, which may be representatives of a high-risk CRKP clone disseminating
across Southeast Asia.
© 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All
rights reserved.
1. Introduction
Carbapenem-resistant Enterobacteriaceae (CRE) are identiﬁed
as a major global health concern [1]. The most worrying are those
with plasmid-encoded carbapenemases of the KPC, IMP, VIM, NDM
and OXA-48-like families. CRE infections are extremely difﬁcult to
control in hospitals and in the community, hindered by the lack of
effective treatments, spread between bacterial species and the
dissemination of resistance through successful epidemic clones.
Carbapenemases are usually classiﬁed as belonging to either
the serine (class A), metallo (class B) or oxacillinase (class D) family
of enzymes. Amongst the carbapenem-hydrolysing class D
b-lactamases (CHDLs), the OXA-48 variant is most prevalent
and is found in numerous enterobacterial species that are also
often multidrug-resistant (MDR) [2]. A number of variants of OXA-
48, with different peptide sequence and carbapenem-hydrolysing
properties, have been reported in recent years. These include OXA-
162 in Turkey, OXA-163 in Argentina, OXA-181 in India and OXA-
204 in Tunisia [2]. Recently, another variant (OXA-232) was found
$ This work was presented in part at the 26th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID), 9–12 April 2016, Amsterdam, The
Netherland.
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in France [2] and in a number of Southeast Asian countries [3,4].
The OXA-232 carbapenemase differs from OXA-48 by ﬁve amino
acids substitutions [2]. Of note, OXA-232 has relatively weak
carbapenem-hydrolysing activity evidenced by the lower mini-
mum inhibitory concentrations (MICs) of imipenem and merope-
nem required to inhibit clinical isolates. This makes strains
producing an OXA-232 carbapenemase difﬁcult to detect in the
microbiology laboratory [2].
Here we report on a MDR strain of Klebsiella pneumoniae
responsible for a cluster of infections in patients hospitalised in
Brunei Darussalam.
2. Materials and methods
2.1. Bacterial isolates and antimicrobial susceptibility testing
Over a 3-month period (May–July 2015), ﬁve MDR K. pneumo-
niae isolates were recovered from an equal number of individual
patients admitted to intensive care units at two hospitals (RIPAS
and PMMPMHAB) in Brunei. These isolates were obtained from
blood culture (n = 1), endotracheal samples (n = 1), pus (n = 2) and
sputum samples (n = 1). All CRE from clinical samples are
prospectively stored by the laboratory in Brunei and these were
the only ﬁve K. pneumoniae recovered during that period.
Antimicrobial susceptibility testing was performed using a
VITEK12XL system (bioMérieux, Marcy-l’Étoile, France). The MICs
of cefotaxime, cefepime, ceftazidime and meropenem were
determined using a Micronaut-S b-lactamase VII panel (Merlin
Diagnostika GmbH, Bornheim-Hersel, Germany), and those for
colistin, polymyxin B and the combination ceftazidime/avibactam
by Etest (bioMérieux). Resistance was deﬁned according to Clinical
and Laboratory Standards Institute (CLSI) breakpoints [5]. A
modiﬁed Hodge test and RAPID CARB Blue test (Rosco Diagnostica
A/S, Taastrup, Denmark) were performed for carbapenemase
detection. Production of an OXA-48-like class D enzyme was then
directly identiﬁed using an immunochromatographic lateral ﬂow
assay (Coris BioConcept, Gembloux, Belgium) [6].
2.2. Molecular characterisation
The genetic relatedness of each isolate was assessed using
random ampliﬁed polymorphic DNA (RAPD) PCR as previously
described [7]. Molecular typing was performed by multilocus
sequence typing (MLST) of seven conserved K. pneumoniae
housekeeping genes (gapA, infB, mdh, pgi, phoE, rpoB and tonB) [8].
2.3. Detection of virulence and antibiotic resistance genes
PCR was used for the detection of K. pneumoniae virulence (kfu,
ﬁmH, uge, wabG and ureA) determinants and the K1 hyper-
mucoviscous (cps) phenotype [8]. Genes encoding classes A–D
b-lactamases were identiﬁed with a series of multiplex PCRs [6,9].
The full coding sequence of all blaOXA-48-like genes was ampliﬁed
using external primers [10] and was sequenced using the Sanger
method. BLASTN analysis was performed on the assembled
sequence.
2.4. Plasmid analysis
Plasmid replicon typing was performed using a commercial
PCR-based replicon typing kit (Diatheva S.R.L., Cartoceto, Italy)
with additional single PCRs for IncX4 and ColE-like plasmid
replicons [2,11]. The plasmid location of each b-lactamase gene
and the plasmid sizes were determined by pulsed-ﬁeld gel
electrophoresis (PFGE) of S1-digested DNA and Southern hybrid-
isation with speciﬁc intragenic DNA probes.
2.5. Conjugation assays
Transfer of plasmid-mediated resistance genes by conjugation
was investigated using rifampicin-resistant CSH26 and sodium
azide-resistant J53 strains of Escherichia coli as recipients.
Conjugation experiments were set up by mixing 0.5 mL of
exponential-phase cultures in 4 mL of Luria–Bertani (LB) (Sigma-
Aldrich, Gillingham, Dorset, UK) broth and then incubating
overnight at 37 !C without shaking. Transconjugants were selected
by growth on LB agar supplemented with rifampicin (128 mg/L)
and either ampicillin (32 mg/L), cefotaxime (16 mg/L) or ertape-
nem (1 mg/L) for conjugation to E. coli CSH26 or with sodium azide
(100 mg/L) and cefotaxime (0.0625–2 mg/L) using E. coli J53.
2.6. Sequencing of the blaOXA-232-encoding plasmid
The sequence of the entire blaOXA-232-encoding plasmid
(pKP41-OXA-232) was determined using a primer walking
approach. Inverse PCR, using long-range Taq polymerase (Invi-
trogenTM PlatinumTM SuperFiTM DNA Polymerase; Thermo Fisher
Scientiﬁc, Paisley, UK), in combination with the primers OXA-
232invL (50-CCGATAATCGATGCCACCAA-30) and OXA-232invR (50-
GCCATCACAAAAGAAGTGCTC-30) was used to amplify the entire
sequence. Additional primers (Supplementary Table S1 in the
online version at DOI: 10.1016/j.jgar.2017.02.008) were used to
sequence the extremities ﬂanking blaOXA-232.
3. Results
Susceptibility testing conﬁrmed resistance to cephalosporins,
carbapenems, aminoglycosides, quinolones and sulfonamides in
all isolates. The MICs of cefotaxime, cefepime and ceftazidime
( >128 mg/L) and meropenem ( >32 mg/L) conﬁrmed resistance to
all b-lactams. All isolates remained susceptible to colistin (MIC
< 1 mg/L), polymyxin B (MIC < 1 mg/L) and the combination
ceftazidime/avibactam (MIC = 1 mg/L). All isolates were positive
for carbapenemase production, with an OXA-48-like class D
enzyme detected in the lateral ﬂow assay. Molecular typing
revealed that the isolates were clonally related and were assigned
to sequence type (ST) 231 (http://bigsdb.pasteur.fr/klebsiella/
klebsiella.html) following analysis of the MLST data.
Virulence determinants associated with iron uptake (kfu),
ﬁmbrial-mediated adhesion (ﬁmH), lipopolysaccharide biosynthe-
sis (uge and wabG) and urease production (ureA) were found in all
isolates, but not the K1 hypermucoviscous (cps) phenotype [8]
previously associated with heightened virulence.
Each isolate was positive for blaTEM, blaSHV, blaCTX-M and blaOXA-
48-like alleles. No other carbapenemase or extended-spectrum
b-lactamase (ESBL) genes sought (blaNDM, blaIMP, blaVIM, blaKPC,
blaGES and blaVEB) were found. BLASTN analysis of the assembled
OXA-48-like sequence showed 100% nucleotide identity with the
blaOXA-232 allele (GenBank accession no. JX423831.1) that encodes a
CHDL enzyme [2]. The class A b-lactamases in each isolate were
similarly identiﬁed as blaTEM-1b, blaSHV-11 and blaCTX-M-15.
Plasmid replicon typing revealed that the strains contained
plasmids with A/C, FIA, FIIK and ColE-like replicons. The blaOXA-232
gene was carried on a small ColE-like plasmid of ca. 6 kb (pKP41-
OXA-232). The blaCTX-M-15 ESBL gene was localised to an IncF
plasmid of ca. 161.7 kb containing fused FIA-FIIk replicons, and the
blaTEM-1b to a non-typeable plasmid of ca. 8.4 kb. Neither the
blaOXA-232- nor blaCTX-M15-containing plasmids could be mobilised
to either of the E. coli recipient strains under the antibiotic
selection methods used.
Sequencing of the extremities ﬂanking blaOXA-232 conﬁrmed
that it was located on a 6141-bp plasmid identical to one previously
characterised by Potron et al. [2]. The plasmid also carried several
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mobilisation genes (mobA–D), a replication gene (repA), truncated
parts of genes encoding a putative LysR-type transcriptional
regulator (DlysR) and an erythromycin esterase (DereA), and part of
an DISEcp1 upstream of the blaOXA-232 gene (Fig. 1).
4. Discussion
Local, regional and global spread of antimicrobial resistance can
often be linked to speciﬁc genes in association with speciﬁc
bacterial clones. Brunei Darussalam lies in Southeast Asia, in close
proximity to Malaysia, Singapore, Indonesia and The Philippines.
Antimicrobial resistance surveillance studies conducted across the
Asia-Paciﬁc region have frequently reported higher rates of ESBL-
producing and carbapenem-resistant bacteria than those seen in
Europe and North America [12]. Recent data from the Study for
Monitoring Antimicrobial Resistance Trends (SMART) programme
identiﬁed CTX-M-14/15 and NDM as the most prevalent enzymes
in this region [13]. Here we identiﬁed the spread of MDR K.
pneumoniae in Brunei involving a strain of ST231 producing the
OXA-232 carbapenemase.
OXA-232-producing K. pneumoniae isolates typically display
carbapenem MICs of !32 mg/L [2,3,14]. Phenotypic resistance is
further mediated by the presence of a truncated DISEcp1 insertion
element upstream of the blaOXA-232 gene, which provides a strong
"35 and "10 promoter sequence on a high-copy-number plasmid
[15] as in the isolates in the current study (Fig. 1).
CRE producing OXA-48 are most prevalent in Europe, the
Mediterranean and North Africa [1]. There are multiple reports of
nosocomial outbreaks with OXA-48-producing K. pneumoniae of
various sequence types in European hospitals, a problem that is
extremely difﬁcult to control [16]. In terms of pathogenicity,
carriage of a number of virulence factors has been associated with
more invasive and severe infections. Holt et al. identiﬁed a MDR
ST231 K. pneumoniae clone carrying yersiniabactin (ybt) and
aerobactin (iutA), which was associated with lethal cases of
community-acquired pneumonia [17] but was not present in any of
the isolates in the present study.
In Southeast Asia, OXA-48 has been reported only in Vietnam.
Cases of OXA-232 have been found in Singapore (ST231) [4],
Malaysia (ST14) [3] and South Korea [18,19]. A number of these
strains [3,18] also carried the New Delhi metallo-b-lactamase
(NDM-1), often from patients with a history of travel and medical
treatment in India. This was not the case with the OXA-232-
producing K. pneumoniae recovered in Brunei, as all patients were
hospitalised locally and no history of recent travel could be
obtained.
Outside of Southeast Asia, K. pneumoniae isolates producing
both OXA-232 and NDM-1 have been recovered in the USA [20]
and France [2,14]. Most belonged to ST14, a sequence type
common amongst NDM-1-producing K. pneumoniae recovered in
Europe [4]. In Germany, an OXA-232- and NDM-1-producing
strain of E. coli has also been reported [21], with the same
patient subsequently developing an infection with OXA-232-
producing K. pneumoniae months later, suggesting in vivo
plasmid transfer between species [21]. Enterobacteriaceae
producing OXA-232 in combination with CTX-M-15 ESBLs were
also found during surveillance studies in tertiary care hospitals
in Mexico City [22]. Molecular analysis did not identify
evidence of clonal spread in this setting, again suggesting
interspecies and intraspecies transmission of plasmid-mediated
resistance [22].
The ST231 clone of K. pneumoniae is increasingly shown to
support the carriage of a number of important b-lactamases and
diverse plasmid backbones. These include KPC-3-, GES-5- and
SHV-12- producing K. pneumoniae community-acquired infections
in Portugal [21], NDM-1 in the UK and India [4] and now OXA-48-
like CHDLs in Southeast Asia. We identiﬁed a nosocomial outbreak
involving a MDR ST231 OXA-232-producing strain of K. pneumo-
niae in Brunei. Although we were unable to demonstrate transfer of
pKP41-OXA-232 plasmid by conjugation, others have found the
blaOXA-232 gene to be readily mobilisable [19].
In conclusion, K. pneumoniae ST231 may represent an
emerging high-risk MDR clone currently disseminating through-
out Southeast Asia. Owing to its capacity for carriage of diverse
and multiple ESBL and carbapenemase resistance genotypes,
enhanced surveillance for international spread of this clone may
be warranted.
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Fig. 1. Genetic structure of pKP41-OXA-232 in comparison with other ColE-like plasmids encoding blaOXA-232 (GenBank accession no. JX423831) and blaOXA-181 (GenBank
accession no. JN205800). The reading frames are shown as grey shaded arrows, with the arrowhead indicating the direction of transcription. The truncated reading frames are
shown as grey shaded rectangles. The mobile genetic elements are shown as white shaded rectangles ﬂanked by two (complete) or one (truncated) black triangles. The areas
shaded in grey indicate nucleotide identity in plasmid sequences, with the percentage indicated.
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CHROMagar COL-APSE: a selective bacterial culture medium for
the isolation and differentiation of colistin-resistant Gram-
negative pathogens
Muhd Haziq F. Abdul Momin,1 David C. Bean,2 Rene S. Hendriksen,3 Marisa Haenni,4 Lynette M. Phee1,5 and
David W. Wareham1,5,*
Abstract
Purpose. A selective chromogenic culture medium for the laboratory isolation and differentiation of colistin resistant
Acinetobacter, Pseudomonas, Stenotrophomonas and Enterobacteriaceae spp. (CHROMagar COL-APSE) was developed,
evaluated and compared to an existing selective bacterial culture medium (SuperPolymyxin).
Methodology. The medium was challenged with 84 isolates, including polymyxin B (POL B)-susceptible and -resistant type
strains and colistin (COL)-resistant organisms recovered from human and animal samples. Susceptibility to COL and POL B
was determined by agar dilution and broth microtitre dilution. The lower limit for the detection of COL-resistant organisms
was also calculated for both CHROMagar COL-APSE and SuperPolymyxin media. The ability to isolate and correctly
differentiate COL-resistant organisms within mixed cultures was also assessed and compared using both media.
Results. Using CHROMagar COL-APSE, Gram-negative pathogens (n=71) with intrinsic (n=8) or acquired COL (n=63)
resistance were recovered with 100% specificity down to the lower limit of detection of 101 colony-forming units (c.f.u.). The
growth on SuperPolymyxin was similar, but notably weaker for COL-resistant non-fermentative bacteria (Acinetobacter,
Pseudomonas and Stenotrophomonas). CHROMagar COL-APSE was also more sensitive in supporting the growth of
Enterobacteriaceae with COL resistance associated with the carriage of mcr-1.
Conclusion. CHROMagar COL-APSE is a sensitive and specific medium for the growth of COL-resistant bacterial pathogens.
Due to the low limit of detection (101 c.f.u.), it may be useful as a primary isolation medium in the surveillance and recovery
of COL-resistant bacteria from complex human, veterinary and environmental samples, especially those with plasmid-
mediated MCR-1 or novel mechanisms of polymyxin resistance.
INTRODUCTION
Polymyxin B and E (colistin) are increasingly used in the
treatment of multi-drug-resistant bacterial infections. Both
are cationic polypeptides that bind the lipopolysaccharides
(LPS) of Gram-negative bacteria and disrupt the outer
membrane. Polymyxin resistance (PR), although intrinsic
amongst Gram-positive and some Gram-negative species
(Proteus, Morganella and Serratia spp.), is an emerging
problem in a number of other pathogens (Acinetobacter
baumannii, Pseudomonas aeruginosa, Escherichiacoli,
Salmonella enterica and Klebsiella pneumoniae). Resistance
can occur due to mutations/insertions in genes involved in
LPS biosynthesis (lpx, pmrA/B, mgrB and phoP/Q) and/or
can be acquired by the horizontal transmission of genes
encoding phosphoethanolamine transferase (pEtN)
enzymes. Plasmid-mediated colistin (COL) resistance due
to the mcr-1 pEtN gene was recently identified in China [1].
Since it was first described, bacteria producing MCR-1 have
been found in a wide range of food-producing animal,
human and environmental sources. Moreover, MCR-1-
producing isolates are often pan- (PDR) or extensively
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(XDR) drug resistant, which significantly limits the thera-
peutic options for these organisms.
A sensitive and specific means for the isolation of PR organ-
isms is critical for any strategy aimed at monitoring the
spread of these isolates and identifying new resistance deter-
minants. Furthermore, polymyxin resistance may often be
low level or unstable (heteroresistance), and there are well-
established difficulties (e.g. cation concentrations in broth,
adsorption of colistin to plastics, poor diffusion in agar) in
the accurate determination of COL MICs [2]. Molecular
detection is limited to the small number of mutations (mcr-
1–1.8) and MCR-like alleles (mcr-2, mcr-3 and mcr-4) dis-
covered to date [1, 3].
Selective bacterial culture media offer a means to rapidly
detect and identify organisms with resistance to polymyxins.
One such medium, SuperPolymyxin, uses an eosin
methylene blue (EMB) agar base, with selection for PR
Gram-negative bacteria achieved by the addition of a low
concentration of COL (3.5 µgml!1), along with daptomycin
(10 µgml!1) and amphotericin B (5 µgml!1) to suppress
Gram-positive and fungal growth. This medium has been
evaluated and proven to be sensitive and specific in the
selective growth of PR-resistant Enterobacteriaceae, either
from pure cultures or using spiked stool samples [4]. Here
we describe an alternative medium, CHROMagar COL-
APSE, designed to be selective in the isolation and differen-
tiation of all strains of Acinetobacter (A), Pseudomonas (P),
Stenotrophomonas (S) and Enterobacteriaceae (E) with
either intrinsic, acquired or uncharacterized mechanisms of
resistance. A potential advantage compared with SuperPoly-
myxin would be the ability to recover and differentiate PR
non-fermentative Gram-negative organisms as well as
Enterobacteriaceae.
METHODS
Media preparation
CHROMagar COL-APSE plates were prepared in-house
using dehydrated CHROMagar base media (CHROMagar,
Paris, France) supplemented as in Table 1 with the CHRO-
Magar COL-APSE supplement (X192). This contains
antimicrobials (colistin sulfate/oxazolidonones) at concen-
trations designed to enhance the growth of PR Gram-
negative species and suppress the growth of Gram-positive
bacteria, whilst avoiding significant synergy between the
active compounds. This +medium was not autoclaved, but
instead sterilized by boiling at 100 "C in order to preserve
the chromogenic compounds included in the mixture, prior
to the addition of all of the supplements. All of the
additional antibiotics used (colistin sulfate, polymyxin B,
daptomycin and amphotericin B) were sourced from Sigma-
Aldrich (Gillingham, UK) or Cambridge Bioscience (Cam-
bridge, UK) and prepared as stock solutions (10 000–100 µg
ml!1) in distilled water. Those containing COL or poly-
myxin B (POL B) were only handled in glass tubes and used
within 24 h. SuperPolymyxin plates were prepared exactly as
described by Nordmann et al. [4] using EMB manufactured
by Thermo Fisher Oxoid (Basingstoke, UK). CHROMagar
COL-APSE media for use with samples containing Proteus
spp. were prepared with the addition of 50mg l!1 p-nitro-
phenyl glycerol (PNPG).
Bacterial isolates and determination of polymyxin
minimum inhibitory concentrations (MICs)
Eighty-four isolates were used in the evaluation of CHRO-
Magar COL-APSE media (Table 2). These included 8 iso-
lates with intrinsic COL resistance (1 clinical human and 7
type strains), 13 COL susceptible isolates (6 human clinical,
3 veterinary clinical and 4 type strains) and 63 isolates with
acquired COL resistance (5 human clinical and 58 veteri-
nary clinical) contained within our collections.
The MICs of COL and POL B (0.006–256 µgml!1) were
determined for each isolate by agar dilution on Mueller–
Hinton II (MH 2) agar [5]. The plates were seeded with 104
c.f.u. using a multi-point inoculator and examined for
growth after incubation at 37 "C for 24 h. Susceptibility
(#2–4 µgml!1) and resistance (>2–8 µgml!1) to either
COL or POL B were interpreted according to current CLSI
and/or EUCAST species-specific breakpoints, where avail-
able [6, 7]. Susceptibility to COL was also determined by
broth microtitre dilution (BMD) to enable the MICs to be
compared to those obtained on solid media.
All clinical isolates were additionally screened for the pres-
ence of mcr-related genes by PCR using the CLR5-F (5¢-
CGGTCAGTCCGTTTGTTC-3¢), CLR5-R (5¢-CTTGG
TCGGTCTGTAGGG-3¢), MCR2-F (5¢-TGGTACAGCCCC
TTTATT-3¢) and MCR2-R (5¢-GCTTGAGATTGGGTTA
TGA-3¢) primers for the detection of mcr-1–1.8 and mcr-2,
respectively [1, 3].
Comparative growth on selective media
The ability of CHROMagar COL-APSE and SuperPoly-
myxin to support or suppress growth was first assessed
using a fixed inoculum of 103 c.f.u. of each strain. Overnight
cultures were used to prepare a 0.5 McFarland standard
(1.5$108 c.f.u.) further diluted in 0.85% saline (OXOID,
United Kingdom) and used to inoculate supplemented and
unsupplemented CHROMagar and SuperPolymyxin (EMB)
base plates.
Table 1. Preparation of CHROMagar COL-APSE plates
Compound Amount/L*
CHROMagar base medium 42.5 g
Distilled water 1000ml
Sterilize by heating to 100 "C
CHROMagar growth supplement S1 2ml
CHROMagar COL-APSE supplement (X192) 4ml
*For the production of 50$20ml CHROMagar COL-APSE plates.
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Table 2. Characteristics of bacterial isolates
Isolate MIC (mg l–1)/Agar dilution Polymyxin resistance mechanism Lowest limit of detection (c.f.u.)
Colistin Polymyxin B CHROMagar
COL-APSE
SuperPolymyxin
Intrinsic resistance to polymyxins
P. mirabilis NCTC 13376 >256 >256 Intrinsic 101 101
S. marcescens NCTC 10211 >256 >256 Intrinsic 101 101
M. morgannii MM2 >256 >256 Intrinsic 101 101
E. faecalis ATCC 2912 >256 256 Intrinsic >109 >109
E. gallinarum ATCC 49573 >256 >256 Intrinsic >108 >108
C. albicans ATCC 10231 256 256 Intrinsic >107 >107
E. cloacae NCTC 10005 128 256 Intrinsic 102 101†
S. maltophilia NCTC 10258 8 64 Intrinsic 101* 102
Susceptible to polymyxins
P. aeruginosa ATCC 27853 2 2 NA 102* 105
Salmonella enterica group D (non-Typhi) Sal3 2 2 N/A 104* 106
E. coli E17 1 2 MCR-1 107 107
Salmonella enterica subsp. diarizonae Sal1 1 2 N/A 105* 106
A. baumannii ATCC 19606 1 2 NA 106 106
E. coli E44 1 1 MCR-1 >109 >109
Salmonella enterica subsp. diarizonae Sal4 1 1 N/A 105* 106
K. pneumoniae KP32 0.5 1 NA 106 106
Salmonella enterica subsp. diarizonae Sal2 0.5 1 N/A 105* 106
Salmonella enterica group D (non-Typhi) Sal5 0.5 1 N/A 103* 105
E. coli ATCC 25922 0.5 0.5 NA 106 106
E. coli 408756 0.5 0.5 MCR-1 106 106
K. pneumoniae ATCC 9633 0.5 0.5 NA >109* 105
Acquired resistance to polymxins
A. baumannii AB219 >256 >256 Unknown 101 101
A. baumannii AB205 >256 32 Unknown 101 101
A. baumannii AB287 8 4 Unknown 101* 102
K. pneumoniae KP6 128 256 Unknown 101 101
K. pneumoniae KP19 64 64 Unknown 101 101
E. coli 35 095 >256 >256 MCR-1 101 101
E. coli 35 175 64 32 MCR-1 101 101
E. coli 29 881 32 32 MCR-1 101 101
E. coli 33 907 32 32 MCR-1 101 101
E. coli 34 936 32 32 MCR-1 101 101
E. coli 35 593 32 32 MCR-1 101 101
E. coli E10 32 16 MCR-1 101* 104
E. coli E9 32 16 MCR-1 101 101
E. coli E33 32 16 MCR-1 101 101
E. coli E3 32 16 MCR-1 101 101
E. coli E1 32 16 MCR-1 101 101
E. coli E35 32 16 MCR-1 101 101
E. coli E29 32 16 MCR-1 101 101
E. coli E32 32 16 MCR-1 101 101
E. coli E13 32 16 MCR-1 101 101
E. coli E24 32 16 MCR-1 101 101
E. coli E20 32 16 MCR-1 101 101
E. coli E25 32 16 MCR-1 101 101
E. coli E27 16 32 MCR-1 101 101
E. coli E8 16 16 MCR-1 101 101
E. coli E11 16 16 MCR-1 101* 102
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Lower limit of detection (LLD)
The sensitivity was compared by determining the lowest num-
ber (c.f.u.) of COL-resistant bacteria in the inocula required
for growth on each media. The lowest limit of detection (LLD)
was assessed using serial dilutions (10!1–10!9) of overnight
cultures grown at 37 "C for 24 h in 3ml of Luria–Bertani (LB)
broth. Tenfold serial dilutions were made in 0.85% saline (vol-
ume/volume) and 20 µl of each dilution was plated onto
unsupplemented MH 2 (control), CHROMagar COL-APSE
and SuperPolymyxin agar plates using the Miles and Misra
procedure [8]. Following incubation for 24 h at 37 "C, the col-
onies were counted and the number of bacteria recovered
were expressed as colony-forming units per ml (c.f.u. ml!1).
The colony counts after incubation on CHROMagar COL-
APSE and SuperPolymyxin agar were subtracted from the
number recovered on MH 2 agar to quantify the total number
of COL-resistant organisms (c.f.u.) within the plated popula-
tion required for viable growth on each selective media (LLD).
Table 2. cont.
Isolate MIC (mg l–1)/Agar dilution Polymyxin resistance mechanism Lowest limit of detection (c.f.u.)
Colistin Polymyxin B CHROMagar
COL-APSE
SuperPolymyxin
E. coli E39 16 16 MCR-1 101 101
E. coli E40 16 16 MCR-1 101 101
E. coli E34 16 16 MCR-1 101 101
E. coli E2 16 16 MCR-1 101 101
E. coli 412049521 16 16 MCR-1 101 101
E. coli E37 16 16 MCR-1 101 101
E. coli E41 16 16 MCR-1 101 101
E. coli E36 16 16 MCR-1 101 101
E. coli E31 16 16 MCR-1 101 101
E. coli E30 16 16 MCR-1 101* 103
E. coli E14 16 16 MCR-1 101 101
E. coli E12 16 16 MCR-1 101 101
E. coli 14042624 16 16 MCR-1 101 101
E. coli 412016126 16 16 MCR-1 101 101
E. coli E22 16 16 MCR-1 101 101
E. coli E19 16 16 MCR-1 101 101
E. coli E7 16 16 MCR-1 101 101
E. coli E47 16 16 MCR-1 101 101
E. coli E49 16 16 MCR-1 101* 103
E. coli E5 16 16 MCR-1 101* 103
E. coli E16 16 16 MCR-1 101 101
E. coli E18 16 16 MCR-1 101 101
E. coli E43 16 16 MCR-1 101* 103
E. coli E46 16 16 MCR-1 101 101
E. coli E28 16 16 MCR-1 101 101
E. coli E26 16 16 MCR-1 101 101
E. coli 27 852 16 16 MCR-1 101 101
E. coli 35 062 16 16 MCR-1 101* 103
E. coli 37 914 16 16 MCR-1 101 101
E. coli 41 323 16 16 MCR-1 101 101
E. coli 41 339 16 16 MCR-1 101 101
E. coli 41 848 16 16 MCR-1 101 101
E. coli 412044854 16 8 MCR-1 101 101
E. coli 413040864 16 8 MCR-1 101 101
E. coli 34 692 16 8 MCR-1 101* 102
E. coli E45 8 16 MCR-1 101 101
E. coli 32 218 8 8 MCR-1 101 101
*Enhanced sensitivity of CHROMagar COL-APSE.
†Enhanced sensitivity of SuperPolymyxin.
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Isolation and differentiation of organisms in mixed
culture
Two pools containing mixtures of COL-resistant (R) and
COL-susceptible (S) organisms were used to assess the per-
formance of the media with complex polymicrobial samples.
Pool one consisted of Proteus mirabilis NCTC 13376,
A. baumannii AB205 (COL R), E. coli E7 (COL R), E. cloa-
cae NCTC 10005 (COL R), E. faecalis ATCC 2912 (COL R),
K. pneumoniae KP19 (COL R), M. morgannii MM2 (COL
R), S. marcescens NCTC 10211 (COL R) and P. aeruginosa
ATCC 27853 (COL heteroresistant). Pool two consisted of
A. baumannii ATCC 19606 (COL S), E. coli ATCC 25922
(COL S), E. faecalis ATCC 2912 (COL R), P. aeruginosa
ATCC 27853 (COL heteroresistant) and K. pneumoniae
ATCC 9633 (COL S). The pools were made by mixing single
colonies of each isolate in 3ml 0.85% saline adjusted to a
0.5 McFarland standard (1.5!108 c.f.u. ml"1), and were
confirmed by viable colony counts. Further dilutions were
made to achieve a concentration of 105 c.f.u. ml"1 and
CHROM-agar COL-APSE plates were then inoculated with
10 µl (103 c.f.u.), either spread across the entire plate using a
L-shaped spreader, or streaked across the plate using a 10 µl
loop (Fig. 2).
The stability of CHROMagar COL-APSE following batch
production and storage at 4 #C was assessed using media
prepared centrally by E and O laboratories (Glasgow, UK)
and tested using P. mirabilis (NCTC 13376), E. coli (ATCC
25922), K. pneumoniae (ATCC 9633) and E. faecalis (ATCC
2912) as internal and external quality control and the con-
trol pools (103 c.f.u.) defined above. The media for use
with pools containing P. mirabilis were supplemented
with PNPG.
RESULTS
The in vitro activity (MIC mg l"1) of both COL and POL B
when determined by agar dilution was comparable (+/"1
dilution) for all of the Enterobacteriaceae isolates tested
(Table 2). However, the MICs of COL and POL B differed
by at least three dilutions for S. maltophilia NCTC 10258
and A. baumannii AB205. The mcr-1 gene was present in 61
of the E. coli, 58 (95%) of which were also phenotypically
resistant to COL (MIC >2 µgml"1). Three isolates contain-
ing mcr-1 had colistin MICs below the pharmacodynamic
breakpoint when the MIC was determined by agar dilution.
Three COL-resistant A. baumannii and two K. pneumoniae
(MIC 8 ->256 µgml"1) clinical isolates were also identified
and included in the evaluation of both media. The mecha-
nism of resistance in these three strains is yet to be deter-
mined, despite sequencing for mutations in mgrB, pmrA/B
and the phoP/Q regulatory genes known previously to be
associated with mutational polymyxin resistance [9]. When
susceptibility to COL was determined by BMD, the MIC of
COL was comparable to that determined by agar dilution
(+/"1 dilution vs all strains).
Growth on CHROMagar COL-APSE on plates inoculated
with 103 c.f.u. was observed for all COL R Gram-negative
isolates. All of the COL-susceptible Enterobacteriaceae,
COL-resistant Gram-positive (Enterococci spp) and fungal
(Candida spp) isolates failed to grow at these inocula
(Fig. 1). Growth of the P. aeruginosa ATCC 27853 type
strain (COL MIC 2 µgml"1), however, was supported on
CHROMagar COL-APSE at 103 c.f.u. Although this isolate
is deemed susceptible to COL according to current CLSI
breakpoints, and is recommended as a control strain for
antimicrobial susceptibility testing, it should be noted that it
has frequently been shown to exhibit heteroresistance to
COL in vitro when population analysis profiling (PAP) is
used as the gold standard [10]. The "70 #C stock of ATCC
27853 held in our laboratory and used in this study consis-
tently demonstrates heteroresistance to COL when assessed
using the PAP method.
The growth on SuperPolymyxin media with an inoculum of
103 c.f.u. was similar, but visibly weaker for each of the
COL-resistant non-fermenters. The growth of one strain of
COL-resistant A. baumannii (MIC 8 µgml"1) and S. malto-
philia (MIC 32 µgml"1) was not supported at all (Fig. 1). It
is possible that the antimicrobial synergy known to exist
between COL and daptomycin against A. baumannii [11]
could account for the poor growth or inhibition of these
species that we observed on SuperPolymyxin agar. In con-
trast to growth on SuperPolymyxin, the chromogenic prop-
erties of the CHROMagar COL-APSE media enabled the
clear differentiation of COL-resistant Enterobacteriaceae
from non-fermenters. Phenotypic identification as either
dark pink to reddish (E. coli), metallic blue (Klebsiella,
Enterobacter and Serratia spp) or colourless natural pig-
mentation (Morganella) was also possible, whilst on Super-
Polymyxin only COL-resistant E. coli could be identified by
their metallic green appearance. In the limit of detection
studies, COL-resistant strains could be recovered on both
media at 101 c.f.u., whilst the growth of strains deemed sus-
ceptible to COL was only possible when using an inoculum
of >104 (Table 1).
The stability of the media confirmed that there was no
reduction in performance (103 c.f.u. ml"1) for up to 4weeks.
Swarming of P. mirabilis NCTC 13376 was observed when
it was used to inoculate both CHROMagar COL-APSE and
SuperPolymyxin plates. The addition of 50mg l"1 p-nitro-
phenyl glycerol (PNPG) to the CHROMagar COL-APSE
plates reduced this significantly (Fig. 2).
DISCUSSION
We found that both CHROMagar COL-APSE and the
SuperPolymxin media were able to support the growth of
COL-resistant Gram-negative bacteria whilst suppressing
COL-resistant Gram-positive pathogens. Using clinical iso-
lates, CHROMagar COL-APSE supported the growth of all
of the COL-resistant strains down to an inoculum of as low
as 101 c.f.u. Growth with an inoculum of 101 c.f.u. was also
supported on SuperPolymyxin, but only for 50/58 (86%) of
the E. coli isolates with COL resistance accompanied by
mcr-1, suggesting that it may have slightly lower sensitivity
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in the detection of these strains (Table 2). SuperPolymyxin,
however, was found to be better (!1 dilution) at suppress-
ing the growth of COL-susceptible Salmonella spp. Reduced
susceptibility to polymyxins in Salmonella enteritidis and
other serogroup 9 strains has been reported, and the epide-
miological cut-off (>2mg l"1) for resistance has been chal-
lenged [12]. As the mechanisms for the reduced
susceptibility reported in Salmonella spp. remain unknown,
a more sensitive medium may help in the recovery of COL-
resistant strains and aid in the elucidation of alternative
resistance mechanisms.
The only other difference we observed between the two
media (Table 2) was differential growth of P. aeruginosa
ATCC 27853 on CHROMagar COL-APSE (LLD=102 c.f.u.)
when compared to SuperPolymyxin (LLD 105=c.f.u.).
Again, this may represent the heteroresistant properties of
this strain and a high frequency of COL resistance by spon-
taneous mutation. As with A. baumannii, synergy between
the selective antimicrobials in the media may be responsible
for the differential ability of CHROMagar COL-APSE and
SuperPolymyxin to identify heteroresistant strains. The clin-
ical relevance of heteroresistance to polymyxins is unclear,
although the ability to identify such strains easily may be
useful in optimizing or selecting COL-based therapies on an
individual basis.
Notably, the addition of PNPG was beneficial in suppressing
swarming of colistin-resistant Proteus spp. without affecting
the performance of the media. This provides a more robust
method to select out COL-resistant isolates within mixed
specimens.
In summary, we developed and evaluated a new chromo-
genic culture medium for the isolation and identification of
COL-resistant Gram-negative bacterial pathogens. CHRO-
Magar COL-APSE was similar to SuperPolymyxin as a
medium for the selective growth of COL-resistant organ-
isms, although we found CHROMagar COL-APSE to be
slightly more sensitive in the detection of Enterobacteriaceae
producing MCR-1, and it also provides the benefit of pre-
sumptive chromogenic identification. The low limit of
detection (101 c.f.u.) of both media suggest either could be
used to confirm polymyxin resistance in organisms recov-
ered from other growth media, or if they were employed as
a primary isolation medium. Evaluation of the media as
tools for the surveillance and recovery of COL-resistant
Fig. 1. Comparative growth of COL-susceptible and -resistant isolates on CHROMagar base media, CHROMagar COL-APSE and Super-
Polymyxin. Strains were streaked on the same segments of corresponding plates.
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Fig. 2. Growth of simulated pools of COL-susceptible and COL-resistant strains on CHROMagar base media and CHROMagar COL-
APSE. (a) CHROMagar COL-APSE simulated pool containing A. baumannii AB205 (COL R), E. coli E7 (COL R). E. cloacae NCTC 10005 (COL
R), E. faecalis ATCC 2912 (COL R), K. pneumoniae KP19 (COL R), M. morgannii MM2 (COL R), P. aeruginosa ATCC 27853 (COL heteroresist-
ant), S. marcescens NCTC 10211 (COL R) and P. mirabilis NCTC 13376 (COL R). The plate was inoculated with an L-shaped spreader.
(b) CHROMagar COL-APSE + 50 mg l!1 p-nitrophenyl glycerol (PNPG) simulated pool containing A.baumannii AB205 (COL R), E. coli E7
(COL R). E. cloacae NCTC 10005 (COL R), E. faecalis ATCC 2912 (COL R), K. pneumoniae KP19 (COL R), M. morgannii MM2 (COL R), P. aeru-
ginosa ATCC 27853 (COL heteroresistant), S. marcescens NCTC 10211 (COL R) and P. mirabilis NCTC 13376 (COL R). The plate was inoc-
ulated with an L-shaped spreader. (c) CHROMagar COL-APSE simulated pool containing A. baumannii AB205 (COL R), E. coli E7 (COL R).
E. cloacae NCTC 10005 (COL R), E. faecalis ATCC 2912 (COL R), K. pneumoniae KP19 (COL R), M. morgannii MM2 (COL R), P. aeruginosa
ATCC 27853 (COL heteroresistant), S. marcescens NCTC 10211 (COL R) and P. mirabilis NCTC 13376 (COL R). The plate was inoculated
using the streaking method. (d) CHROMagar COL-APSE + 50 mg l!1 p-nitrophenyl glycerol (PNPG) simulated pool containing
A. baumannii AB205 (COL R), E. coli E7 (COL R). E. cloacae NCTC 10005 (COL R), E. faecalis ATCC 2912 (COL R), K. pneumoniae KP19 (COL
R), M. morgannii MM2 (COL R), P. aeruginosa ATCC 27853 (COL heteroresistant), S. marcescens NCTC 10211 (COL R) and P. mirabilis
NCTC 13376 (COL R). The plate was inoculated using the streaking method. (e) CHROMagar COL-APSE simulated pool containing
A. baumannii ATCC 19606 (COL S), E. coli ATCC 25922 (COL S). E. faecalis ATCC 2912 (COL R), P. aeruginosa ATCC 27853 (COL heterore-
sistant) and K. pneumoniae ATCC 9633 (COL S). The plate was inoculated with an L-shaped spreader. (f) CHROMagar COL-APSE + 50
mg l!1 p-nitrophenyl glycerol (PNPG) simulated pool containing A. baumannii ATCC 19606 (COL S), E. coli ATCC 25922 (COL S). E. faeca-
lis ATCC 2912 (COL R), P. aeruginosa ATCC 27853 (COL heteroresistant) and K. pneumoniae ATCC 9633 (COL S). The plate was inoculated
with an L-shaped spreader.
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bacteria from complex human, veterinary and environmen-
tal samples is therefore underway, focusing on the identifi-
cation of those with MCR-mediated polymyxin resistance.
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The identification, treatment, and control of carbapenem-resistant Enterobacteria-ceae (CRE) infections are a major challenge for health care institutions and diag-
nostic laboratories worldwide. Those producing plasmid-mediated OXA-48, KPC, NDM,
or VIM-like carbapenemases (CPE) are most concerning, being frequently involved in
nosocomial outbreaks that are difficult and very costly to manage (1). A simple and
rapid test able to provide sensitive and specific identification of CRE and also the
carbapenemase present is critical in any strategy aimed at addressing this problem.
Numerous phenotypic (MIC determination, disc diffusion, selective culture media,
acidimetric) and genotypic (PCR amplification, microarrays, DNA sequencing) methods
have been used in the laboratory isolation, diagnosis, and confirmation of CRE (2).
Recently, two novel immunochromatographic lateral flow assays (Coris BioConcept,
Gembloux, Belgium) were developed for the specific detection of OXA-48 (OXA-48
K-SeT) and KPC-like (KPC K-SeT) carbapenemase producers. These assays have been
evaluated in multiple laboratories, using diverse sets of organisms (Escherichia coli,
Klebsiella, Enterobacter, Serratia, Providencia, Pseudomonas spp.) carrying multiple
!-lactamase, OXA-48 (OXA-48, -162, -181, -204, -232, -242), and KPC (KPC-2/3/4) allelic
variants (3, 4, 5, 6). Both have a reported sensitivity and specificity of 100% compared
to the results of molecular detection of carbapenemase genes as the gold standard (3,
4, 5, 6). They have also been shown to be compatible with organisms recovered from
most unsupplemented, selective, solid, and liquid culture media currently in use in
diagnostic laboratories and with bacteria taken directly from positive blood culture
bottles (BacT/Alert; bioMérieux, Macy L’Etoile, France) or culture-positive urinary sam-
ples (3, 4). A modification of this system, Resist-3 O.K.N. (Coris BioConcept) designed for
the simultaneous detection of OXA-48, KPC, and NDM-like enzymes using a single
disposable cartridge, has now been manufactured. Here we assessed the ability of the
Resist-3 O.K.N. assay to detect OXA-48, KPC, and NDM coproduction in a collection of
112 nonreplicate well-defined CRE isolates received in our laboratories.
All isolates were carbapenem-resistant Enterobacteriaceae (ertapenem MIC, !1 "g/
ml) recovered from routine clinical samples submitted to Barts Health NHS Trust or the
Antimicrobial Research Laboratory at Queen Mary University of London between
January 2011 and December 2016. Identification was performed using the Bruker
matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrom-
etry system (Bruker UK Ltd., Coventry, UK), with carbapenem MICs determined using
MicroScan WalkAway Negative Combo 36 panels (Siemens Healthcare Diagnostics,
Deerfield, IL) and confirmed with Etest gradient strips (bioMérieux). Multiplex PCRs
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were used to confirm the presence of class A (KPC, BKC, SME, VEB, PER, GES), B (IMP, VIM,
NDM, SIM, SPM, DIM, GIM, KHM, FIM, AIM, DIM, TMB, FRI), and D (OXA-like) carbapenemase
genes, and all allelic variants identified were confirmed by Sanger sequencing of the entire
coding regions (7, 8). The collection consisted of carbapenemase-producing Klebsiella
pneumoniae (n! 57), E. coli (n! 17), Enterobacter spp. (n! 14), and Providencia stuartii
(n ! 3) and single isolates of Citrobacter koseri, Morganella morganii, and Proteus
mirabilis (Table 1). Carbapenemases produced by the isolates were identified as KPC-
2/4, NDM-1/5/7, VIM-1/4, IMP-1, OXA-48, and OXA-232. Nine isolates produced 2
carbapenemases, either OXA-48 in combination with NDM-1 (n ! 6) or KPC-2 in
combination with VIM-1 (n ! 3).
Detection of OXA-48, KPC, and NDM using the Resist-3 O.K.N. cassettes was carried
out according to the manufacturer’s protocol. Bacteria were grown for 18 h at 37°C on
Mueller-Hinton II agar plates (Oxoid), and a single colony was emulsified in 5 drops of
the lysis buffer. Cassettes were loaded with 3 drops of lysate and read within 5 min. Six
carbapenem-susceptible Gram-negative type strains (K. pneumoniae NCTC 9633, E. coli
NCTC 12241, Enterobacter cloacae NCTC 13380, Enterobacter aerogenes NCTC 9375,
Pseudomonas aeruginosa ATCC 27852, Acinetobacter baumannii ATCC 19606) were used
as negative controls. Eighteen additional Enterobacteriaceae isolates (K. pneumoniae
[n ! 8] or Klebsiella oxytoca [n ! 1], E. coli [n ! 4], E. cloacae [n ! 2] or E. aerogenes
[n ! 2], Serratia marcescens [n ! 1]) with phenotypic resistance to ertapenem but
without a known carbapenemase were also used as negative controls.
There was complete agreement between the carbapenemases detected by PCR and
the results obtained with Resist-3 O.K.N. (Table 1). The lateral flow device was able to
correctly identify and differentiate OXA, KPC, and NDM production among all CRE
species and enzyme variants tested, including those carrying more than one carbap-
TABLE 1 Detection of carbapenemase production using the Resist-3 O.K.N. assay
Isolate
Carbapenemase(s) carried
(no. of isolates)
Resist-3 O.K.N. result
OXA-48-like KPC-like NDM-like
Klebsiella pneumoniae OXA-48 (23) 23 0 0
OXA-48 " NDM-1 (4) 4 0 4
OXA-232 (6) 6 0 0
KPC-2 (8) 0 8 0
KPC-2 " VIM-1 (1) 0 1 0
NDM-1 (14) 0 0 14
VIM-4 (1) 0 0 0
Escherichia coli OXA-48 (1) 1 0 0
KPC-2 (3) 0 3 0
KPC-2 " VIM-1 (1) 0 1 0
NDM-1 (6) 0 0 6
NDM-5 (3) 0 0 3
NDM-7 (2) 0 0 2
VIM-1 (1) 0 0 0
Enterobacter cloacae OXA-48 " NDM-1 (2) 2 0 2
NDM-1 (2) 0 0 2
KPC-4 (2) 0 2 0
IMP-1 (1) 0 0 0
VIM-1 (4) 0 0 0
Enterobacter aerogenes KPC-2 (2) 0 2 0
NDM-1 (1) 0 0 1
Citrobacter koseri KPC-2 " VIM-1 (1) 0 1 0
Providencia stuartii NDM-1 (1) 0 0 1
VIM-1 (2) 0 0 0
Morganella morganii VIM-1 (1) 0 0 0
Proteus mirabilis VIM-1 (1) 0 0 0
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enemase. No cross-reactions were observed for strains with carbapenem resistance due
to IMP-1 or VIM-1/4 (Table 1) with any of the susceptible type strains or with the 18 CRE
that had no OXA, KPC, or NDM carbapenemase detectable by PCR (Fig. 1).
We found the Resist-3 O.K.N. assay to be 100% sensitive and specific in the detection
and differentiation of OXA-48, KPC, and NDM-like carbapenemases among CRE recently
referred to our laboratory. Although the assay does not currently extend to the
detection of VIM or IMP-like metallo-!-lactamases, the ability to detect 3 of the 5 most
prevalent and transmissible carbapenemases found worldwide is a significant advan-
tage. The ease of use, speed, and low cost (less than $15) of the cassettes make it
attractive as a diagnostic tool for use in the management of CRE outbreaks. Its role
either as a primary-screening, confirmatory, or rapid point-of-care test should be
assessed further, ideally prospectively in the setting of a polyclonal nosocomial CRE
outbreak.
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using the Resist-3 O.K.N. assay. NEG, negative; POS, positive.
Letter to the Editor Journal of Clinical Microbiology
April 2017 Volume 55 Issue 4 jcm.asm.org 1225
 on O
ctober 7, 2017 by guest
http://jcm
.asm
.org/
D
ow
nloaded from
 
 
 
515 
v) Direct detection of carbapenem resistance 
determinants in clinical specimens using 
immunochromatographic lateral flow devices 
 
 
 
 
 
 
516 
 
J Antimicrob Chemother
doi:10.1093/jac/dky095
Direct detection of carbapenem
resistance determinants in clinical
specimens using
immunochromatographic lateral flow
devices
David W. Wareham1,2*, Lynette M. Phee1
and Muhd Haziq F. Abdul Momin1
1Antimicrobial Research Group, Blizard Institute, Barts & The
London School of Medicine and Dentistry, Queen Mary University
of London, London, UK; 2Division of Infection, Barts Health NHS
Trust, London, UK
*Corresponding author. Blizard Institute, 4 Newark Street, London
E1 2AT, UK. Tel:!44-(0)20-7882-2317; Fax:!44-(0)20-7882-2181;
E-mail: d.w.wareham@qmul.ac.uk
Sir,
Accurate, rapid, affordable diagnostic tests are critically important in
tackling the problem of antimicrobial-resistant infections. Assays
that can be used for pathogen detection and drug susceptibility,
close to the point of care (POC), have themost potential to influence
clinical decisions, antimicrobial prescribing, stewardship and patient
outcomes.1,2 Considerable effort has been invested in the develop-
ment of assays for the rapid detection of bacterial sepsis and anti-
microbial resistance determinants. This includes genotypic (DNA
amplification/sequencing) and phenotypic assays targeted towards
bacterial strains such as the ESKAPE (Enterobacter, Staphylococcus,
Klebsiella, Acinetobacter, Pseudomonas, Enterococcus spp.) group of
organisms, but also for specific resistances to key antimicrobial
therapies.3
The need to detect resistance to carbapenems (ertapenem,
imipenem, meropenem) has received considerable attention.4
Once considered drugs of last resort in the treatment of
Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae), their
efficacy is now compromised by the global spread of carbapene-
mases (KPC, NDM, VIM, OXA). Carbapenemase genes are usually
carried on MDR plasmids that encode enzymes able to degrade or
destroy carbapenems andalsomany other b-lactamantibiotics.5
There are myriad methods for the detection of carbapenem re-
sistance genes and for carbapenem-resistant Enterobacteriaceae
(CRE). Recently a number of immunochromatographic lateral
flow cassettes have been developed (CORIS BioConcept, Gembloux,
Belgium) that enable 5min detection of KPC, NDM, VIM andOXA-48-
like carbapenemases directly from cultured bacterial colonies.6–10
Versions of the assay have been evaluated in simplex (KPC K-SeTVR ,
OXA-48K-SeTVR ) and multiplex (RESIST-3O.K.N.) forms across
different laboratories, with 100% sensitivity and specificity reported
when compared with molecular methods of detection.6–10 In lower
limit of detection (LLD) studies theminimum bacterial load required
in a sample is quoted as lowas 104–105cfu/mL.
Experience to date suggests that this technology could be well
suited and further adapted for use directly with clinical samples as
a POC test. Here we assessed the performance of the RESIST-
3O.K.N. card for the direct, simultaneous detection of KPC, NDM
andOXA-48-like carbapenemases in positive blood culture bottles.
Thirty carbapenem-resistant (meropenem MIC .4mg/L)
enterobacterial isolates (K. pneumoniae n"16, E. coli n"8,
Enterobacter cloacae n"4, Citrobacter koseri n"2) known to pro-
duce KPC-2 (n"8), OXA-48/181/232 (n"14), NDM-1/5/7 (n"12)
and VIM (n"2) b-lactamases (singly or in combination) were used
in the evaluation. Isolates were grown overnight at 37!C in 3mL of
Trypticase soy broth (TSB; Oxoid, Basingstoke, UK), then serially
diluted in PBS to a final concentration of 102 cfu/mL. Inocula were
quantified by viable bacterial counts plated using the Miles and
Misra technique on Mueller–Hinton II (MH II) agar. Inocula of
102 cfu were aliquoted into Aerobic (FA PlusTM) and Anaerobic
(SNTM) BacT/ALERT blood culture bottles (bioMe´rieux) followed by
the addition of 10mL of sterile heparinized horse blood (Oxoid).
Bottles were incubated aerobically on the BacT/ALERT system for
18h. Aliquots (0.1 and 0.5mL) were removed from bottles once
flagged positive (,10h) and centrifuged at 12000 rpm for 1min
(Biofuge, Heraeus). After discarding the supernatant, 10 drops of
lysis buffer (LY-A) were added to the deposit. Three drops of this
suspension were added to wells of RESIST-3O.K.N. cassettes and
results read within 15min. Bottles were subcultured to selective
mSuperCARBA agar (bioMe´rieux) to ensure viable growth of each
CRE in both blood culture bottles and that each still produced the
target carbapenemase.
All BacT/ALERT FA PlusTM and SNTM bottles spiked with isolates
known to produce OXA-48-like or KPC-2 carbapenemases were
positive following direct inoculation of the RESIST-3O.K.N. cards;
no additional bands were observed with either of the isolates co-
producing VIM. None of the isolates producing NDM carbapene-
mases gave positive bands on cards inoculated with preparations
made from blood culture bottles, despite each strain being
strongly positive when taken directly froma TSB culture. To investi-
gate anypossible inhibitory effects of the BacT/ALERT blood culture
base media on the growth of NDM carbapenemase producers, the
experiment with NDM-producing strains was repeated using bot-
tles supplemented additionally with 1mg/L meropenem and
0.1M ZnSO4. These were added to control for any growth effects
due to sequestration of antimicrobials or divalent cations by com-
ponents of the culturemedia or horse blood.
We found the RESIST-3O.K.N. triplex card to be compatible
with the BacT/ALERT blood culture media and highly sensitive
in the detection of KPC and OXA-48-like carbapenemases in
Enterobacteriaceae. This is in accordance with recent reports that
used single immunochromatographic assays (OXA-48K-SetVR ) for
the direct detection of OXA-370 and another blood culture system
(VersaTREKVR ; ThermoFisher, Waltham, MA, USA).10 We observed
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only very weak bands for NDM, in stark contrast to those for OXA-
48 and KPC, when applying a mixed KPC/OX-48/NDM culture.
Furthermore, the effects of the volume of blood culturemedia and
bottle used in incubation influenced the result. Weak positive NDM
bands were obtained using 100lL from BacT/ALERT FA PlusTM bot-
tles whilst tests using cultures from BacT/ALERT SNTM-inoculated
bottles were negative with 100lL of culture and only weakly posi-
tive on increasing the material to 500lL. This was despite supple-
mentation of bottles with meropenem and ZnSO4 to promote
growth and limit Zn starvation, which could be due to components
of the bacterial culture media or addition of horse blood.
Increasing the biomass further (.1.5mL) risksmaking the proced-
ure impractical for diagnostic laboratories as the volume exceeds
the capacity of most microcentrifuges. Direct detection of NDM
from positive blood culture sets will likely require an alternative
protocol or further enrichment of the inoculumbefore it can be rec-
ommended for diagnostic use in the detection of NDM.
Rapid identification of KPC- and OXA-48-like-mediated carbape-
nem resistance from positive blood culture appears to be possible
using the RESIST-3O.K.N. cassettes. This requires minimal technical
expertise and only access to a semi-automated blood culture sys-
tem, common to most diagnostic laboratories. Adaptation of the
test as a true POC test may be best pursued by applying it as a tool
to either aid patient screening for carriage of CRE or in the diagnosis
or empirical treatment of urinary tract infections. Successful identifi-
cation ofOXA-48directly frompre-incubated (2h) spiked stool sam-
ples has recently been reported with high sensitivity and a lower
limit of detection of 102cfu/mL.10 The same could be expectedwith
urine samples, for which the critical limit of 105 cfu/mL bacteria is
widely used as a diagnostic criterion to inform treatment.
Further evaluation of rapid immunochromatographic assays for
the detection of carbapenem-resistant infections should be under-
taken prospectively and in parallel with prevailing tests (e.g. PCR) to
assess their utility and economic viability in themanagement of CRE
carriage and infection using real-time patient samples in a setting
with a high prevalence of CRE infections. This, along with a cost–
benefit analysis, will promote theirmost effective and diligent use as
part of any strategy aimedat combatting antimicrobial resistance.
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